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ABSTRACT 
Bronchiectasis is a chronic respiratory condition with a wide spectrum of disease 
severity. There is a pressing need for randomised controlled trials in bronchiectasis 
to help guide management of this condition which is associated with increased 
morbidity and mortality. There is paucity of data in this respiratory condition but it 
is a rapidly progressive field. Most studies are conducted in more severe disease 
(colonised with Pseudomonas aeruginosa, 3 or more exacerbations/year, reduced 
lung function) as they experience more exacerbations which in turn reduces quality 
of life and increases mortality. However, the vicious cycle of bronchiectasis implies 
this is a progressive disease whereby infection leads to a destructive inflammatory 
response which destroys the mucociliary escalator which in turn leads to a build-up 
of stagnant mucus and further perpetuates the cycle by predisposing to further 
infection. Treatment strategies are being aimed at breaking different part of this 
vicious cycle and should aim to prevent exacerbations. A logical starting point for 
treatment could be in those with less severe disease and thereby hope to prevent 
progression to more severe disease. Yet, little is known about outpatient 
exacerbations which could be classed as less severe exacerbations of bronchiectasis.  
 
The aim of this thesis was to phenotype outpatient bronchiectasis exacerbations. In 
particular, the aim was to investigate the importance of bacterial load in these 
exacerbations to see whether they could have influence the diagnosis and 
management of outpatient exacerbations. There are few clinical endpoints in 
bronchiectasis that have been validated for use in bronchiectasis that could assess 
treatment response. Further endpoints are urgently needed to help assess randomised 
controlled trials which could investigate novel treatment options to guide evidence 
based management plans. This thesis also aimed to assess the incremental shuttle 
walk test, a marker of functional capacity, as a validated clinical endpoint for use in 
bronchiectasis. 
 
This thesis reported several clinical markers that could correlate with the 
Bronchiectasis Severity Index in a cohort of 207 patients with bronchiectasis. 
Sputum colour, 24 hr sputum volume, incremental shuttle walk test, parameters of 
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lung function, quality of life assessments, serum inflammatory markers and sputum 
inflammatory markers all correlated with Bronchiectasis Severity Index tertiles of 
increasing disease severity. Further work is necessary in a larger cohort to assess 
whether these clinical endpoints could be additive to the BSI in predicting hospital 
admission and 30-day mortality rates. 
 
This thesis examined 94 exacerbations of bronchiectasis that were all managed as an 
outpatient with 14 days of oral antibiotics based on previous sputum microbiology 
results. All clinical parameters assessed (sputum colour, spontaneous sputum 
volume, 24-hour sputum volume, the Leicester Cough Questionnaire score, the St 
George’s Respiratory Questionnaire score, FEV1 and FVC actual and predicted 
scores, serum inflammatory markers; white cell count, neutrophil count, erythrocyte 
sedimentation rate and C-reactive protein, sputum inflammatory markers 
myeloperoxidase and trends in neutrophil elastase) all deteriorated from baseline to 
start of exacerbation. Bacteriology was investigated and demonstrated an increase in 
culture positive sputum samples for pathogenic bacteria with a change in dominant 
pathogen in over 53% of samples. There was a 2-log increase in bacterial load 
CFU/ml from baseline to start of exacerbation overall but when sub-analysed, this 
was only present when the dominant pathogen changed, i.e. there was no increase in 
bacterial load if the dominant pathogen stayed the same. This is the first study to 
demonstrate a change in dominant pathogen leads to an increase in bacterial load. 
The clinical significance of a 1log or more rise in bacterial load was explored and 
found to be associated with increased severity markers of 10% or more decline in 
actual and predicted FEV1, 5% or more reduction in incremental shuttle walk test 
score, increase in 24hour sputum volume, increase in sputum inflammatory markers 
myeloperoxidase and neutrophil elastase, doubling of white cell count and 50% 
increase in neutrophil count at start of exacerbation. A rise of 1 or more log unit in 
bacterial count CFU/ml was also associated with a symptom complex of chest pain, 
increased sputum volume and the absence of headache. This symptom complex is 
more specific for a rise in bacterial load than either the British Thoracic Society or 
European consensus definition of an exacerbation. 
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Lastly, this thesis assessed the incremental shuttle walk test as a validated clinical 
endpoint for use in patients with bronchiectasis. Its reliability, validity and 
responsiveness were demonstrated with no change in incremental shuttle walk test 
over 6 months of clinical stability, correlation with other validated endpoints 
(including the St George’s Respiratory Questionnaire (SGRQ) total and activity 
score, the MRC dyspnoea score, the Bronchiectasis Severity Index score and 
physical activity duration and sedentary time recorded on activity monitors) and 
improvement with different antibiotic therapies for exacerbations and stable 
bronchiectasis with intravenous, oral and nebulised antibiotics. The minimum 
clinically important difference was found to a 5% improvement in walk distance as 
this took patient’s variable baseline functional capacity into account as well as 
correlating well with patients who had a clinically important improvement in SGRQ 
score (4 or more unit improvement). 
 
This thesis provides interesting results which require further investigation to help 
manage patients with bronchiectasis in the outpatient setting. Larger randomised 
controlled trials are needed to assess the clinical importance of a rise in bacterial 
load and to differentiate at which threshold colonisation becomes infection and 
requires treatment. This could ultimately lead onto randomised controlled trials that 
manage exacerbations based on bacterial load and symptoms, such as is currently 
the case in treating urinary tract infections. Once a rise in bacterial load has been 
further clarified, it could also provide insight into the duration of antibiotics needed 
in a cohort of patients that rely heavily on antibiotic therapy and antibiotic 
stewardship in a climate where there is a finite amount of available treatment 
options. Further external validation of the incremental shuttle walk test would 
strengthen its recommendation for use in routine clinical practice and research 
studies to assess response to existing and new therapies. 
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LAY SUMMARY 
Bronchiectasis is a progressive condition that affects the lungs and can range from 
mild to severe. Bronchiectasis causes patients to have a troublesome cough and 
produce thick sputum on a regular basis because the airways in the lungs are 
abnormally widened. There is a pressing need for research studies in bronchiectasis 
to help provide evidence based medicine to patients of this condition which is 
associated with increased mortality.  
 
Most studies are conducted in more severe disease as these patients are more 
affected daily with a poorer quality of life as they are prone to more frequent 
infections. However, bronchiectasis is a disease that can get worse with each 
infection as infections are thought to cause local damage to the airways, thereby 
studies should be directed at investigating less severe disease to prevent infections 
and the disease from getting worse. Little is known about infections of 
bronchiectasis in patients that can be treated in the community i.e. have less severe 
infections than those managed in the hospital.  
 
The aim of this thesis was to investigate patients with bronchiectasis that are 
managed in the community when they are well and when they are suffering from an 
infection related to their bronchiectasis. A further aim was to investigate if the 
number of bugs present in the sputum of patients during an infection was important. 
There are few assessments in bronchiectasis that have been studied that can reliably 
assess whether patients have responded to treatment. It is important to be able to 
determine if new therapies are helpful and so more assessments that can assess 
therapies are needed. This thesis also aimed to assess if the incremental shuttle walk 
test; a walking test that assesses a patient’s exercise capacity, can be used to 
accurately measure a patient’s response to treatment in bronchiectasis. 
 
This thesis reported several different tests that are not currently included in the 
Bronchiectasis Severity Index (BSI) – a scoring system that assesses disease 
severity, could associate with the BSI scores in a group of 207 patients with 
bronchiectasis. Sputum colour, 24 hr sputum volume, incremental shuttle walk test, 
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lung function, assessment of a patient’s quality of life and markers found in the 
blood and sputum all correlated with the BSI, i.e. there were worse test results for 
each assessment with higher (worse) BSI scores. Further work is necessary in a 
larger group of patients to investigate whether these additional tests could improve 
the BSI scoring system in predicting hospital admission and rates of death. 
 
This thesis examined 94 patients with bronchiectasis that suffered from a chest 
infection who were all managed out of hospital with a 14-day course of tablet 
antibiotics. All tests performed (sputum colour, volume of sputum collected the day 
before and in the morning of the visit, the Leicester Cough Questionnaire score, the 
St George’s Respiratory Questionnaire score, lung function tests, blood tests and 
sputum tests had all deteriorated during an infection compared to when the patient 
had performed them when they were well. Often the type of bug found in the 
sputum was different to what had previously been present in the patient’s sputum 
and it is thought that this change had led to a large increase in the number of overall 
bugs present in the sputum during an infection. This is important because the larger 
the number of bugs present, the worse the patient’s condition is likely to be. 
 
Lastly, this thesis assessed the incremental shuttle walk test. It was shown to be 
reliable; not change with time, valid; as good as other tests that assess exercise and 
responsive; test scores improved when patients were given treatments that we know 
improve their health (antibiotics). A 5% change in the test score was found to be the 
threshold at which point a patient is said to have experienced a change in condition. 
 
This thesis provides interesting results in patients with bronchiectasis that are 
managed out of hospital. Larger studies are needed to further investigate what an 
increase in sputum bugs means for the patient. Once this has been established, the 
way in which we diagnose infections and when and for how long we treat them may 
change. There is a limited number of different antibiotics available so it is important 
to only prescribe them when necessary. The incremental shuttle walk test needs to 
be tested in other centres to further strengthen its ability to assess response to new 
and existing treatments in bronchiectasis. 
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ABBREVIATIONS 
 
BSI  = Bronchiectasis Severity Index 
CFU  = Colony forming units  
COPD  = Chronic obstructive pulmonary disease 
CRP   = C-reactive protein 
ESR  = Erythrocyte sedimentation rate 
FEF25-75 = Forced expiratory flow at 25-75% 
FEV1  = Forced expiratory volume in 1 second 
FVC  = Forced vital capacity 
HRCT  = High resolution computer tomography 
IL-8  = Interleukin-8 
ISWT  = Incremental shuttle walk test 
LCQ  = Leicester Cough Questionnaire 
MPO  = Myeloperoxidase 
MRC   = Medical Research Council 
NE  = Neutrophil elastase 
SGRQ  = St George’s Respiratory Questionnaire 
WCC  = White cell count 
VO  =  Baseline visit 
VS  = Start of exacerbation visit 
VE  = End of exacerbation visit 
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1.0 Introduction 
1.1 Bronchiectasis 
Bronchiectasis is a term derived from the Greek words ‘bronkhia’ denoting the 
branches of the main bronchi and ‘ektasis’ meaning dilatation. The term 
‘bronchiectasis’ describes the condition it was named after in the most simplistic 
terms and with updates in modern day knowledge there are now clinical and 
radiological subdivisions within this condition.  
 
1.2 Background 
Bronchiectasis was first described by the French physician Rene Laennec, in 1819. 
He writes a chapter entitled ‘De la Dilatation des Bronches’ in his famous book ‘De 
l’ Auscultation Mediate ou Traite des maladies des poumons et du Coeur’ (Laennec, 
1819). He described how bronchioles can dilate to the width of a ‘crow’s feather, a 
goose quill, or even a finger’ and how these can abruptly regain their normal width 
or terminate in a ‘tortuous cul-de-sac’ or present as cavities capable of 
‘accommodating a hemp seed, a cherry pit, an almond kernel or even a walnut’ 
(Laennec, 1834 Lindskog, 1986). He also described how this dilatation of 
bronchioles would become permanent, in patients that were afflicted with ‘chronic 
mucous catarrh’, because of bulky sputum mass blocking the airways.  
 
This condition was further described by Sir William Osler in the late 1800s who is 
believed to have died from the complications of bronchiectasis himself but it wasn’t 
until 1922 that further detailed anatomical knowledge about bronchiectasis was 
discovered. Sicard and Forestier visualised the bronchial tree by injecting radio-
opaque materials like iodized oil alongside radiographic imaging – a procedure later 
known as bronchography (Sicard 1922, Joress 1944). This technique allowed the 
condition to be diagnosed at a much earlier stage and the presence, exact location 
and extent of disease could be detected. Thereafter, the most comprehensive 
descriptions were elucidated by Reid in 1950 when she examined the bronchograms 
and lung resections of 45 patients with a primary diagnosis of bronchiectasis. Reid 
classified the cases in three groups based on the predominate type of bronchial 
dilatation. Group I – ‘cylindrical’ type of bronchiectasis described by a uniform 
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appearance with slight dilatation with an abrupt ending, Group II – ‘varicose’ 
bronchiectasis is irregular forms of dilatation with sites of relative constriction and 
Group III – ‘saccular’ or cystic bronchiectasis described as balloon-like dilatation 
increasing towards the periphery of the lung – see Figure 1 (Reid, 1950). 
 
Figure 1. 
 
 
1.3 Pathophysiology 
The pathogenesis of bronchiectasis is poorly understood. Bronchiectasis is the 
permanent dilatation of airways in the context of chronic infection and inflammation 
(Barker 2002). The exact mechanism is not known but elastin in the airways is 
thought to be lost and in more advanced disease this is proceeded by loss of muscle 
and cartilage (Whitwell 1952). A predominantly neutrophilic inflammatory response 
in the airway lumen ensues (Ella 1994) but despite this immune response over two 
thirds of patients remain colonised with potentially pathogenic micro-organisms 
(Angrill 2002, Chalmers 2012). The driver for the persistent neutrophilic response is 
not known but infection is thought to play a role (Angrill 2001). It has been 
postulated that the increase in neutrophils is due to a failure of resolution of 
inflammation in addition to a persistent infective driver. Activated neutrophils 
produce neutrophil elastase, a protease that breaks down elastin, as well as other 
proteins like tumour necrosis factor - alpha (TNF-a), interleukin-8 (IL-8) and 
myeloperoxidase that are found to be high in airway inflammation (Angrill 2001). 
These proteins correlate with bacterial load (Chalmers 2012) and they together with 
bacterial products can cause structural damage and dilation of small airways. 
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1.3.1 Mucociliary clearance structure 
The mucociliary clearance system is part of the innate host defence system 
responsible for maintaining lung sterility. The passage of air from the pharynx to the 
alveoli where gas exchange occurs is via the respiratory tract. This tract is lined with 
a respiratory epithelium which serves to moisten and protect the airways. It 
comprises of columnar epithelial cells, goblet cells and basal cells. The columnar 
cells are ciliated, and function to move overlying mucus towards the oropharynx. 
The goblet cells contain membrane-bound mucous granules and secrete mucus to 
make up the epithelial lining fluid that maintains moisture and traps any airway 
pathogens or particulate matter. The basal cells can respond to areas of injury and 
differentiate into other cell types to maintain an intact epithelial lining (Figure 2). 
 
Figure 2. 
 
Figure 2. Left: normal epithelial lining, right: abnormal mucociliary escalator 
due to neutrophilic inflammatory response with mucus build up and dilated 
airway seen in bronchiectasis. 
 
The ciliated columnar epithelial cells are present in the respiratory tract as far 
distally at the 17th airway division. Each cell has about 200 cilia present on its 
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surface which are approximately 6µm long and 0.25µm in diameter (Greenstone & 
Cole 1985). In the respiratory tract, the cilia beat in a rhythmical continuous 
coordinated fashion in a two-layer system of fluid (Lucas & Douglas, 1934). The 
extent of the cilia lie in a watery solution called the periciliary fluid just beneath the 
thicker layer of mucus. To effectively move mucus along the tract with its 
associated trapped particles, the cilia perform two movements. The cilia have hooks 
on their tips which engage with the under surface of the mucus layer (Jeffrey & Reid 
1977). They then propel the mucus forward in the intended direction of travel by 
standing erect above the cell surface. After the ‘effective’ stroke the cilia return to 
their starting point by sweeping at right angles across the cell surface within the 
periciliary fluid termed the ‘recovery’ beat, so as not to engage the above mucus and 
cancel out the initial effective stroke. 
 
The secretory cells release mucins, defensins and lysozomes (antimicrobial agents), 
cytokines (immunomodulators) and protective molecules which integrate with water 
to form the thick mucus layer (epithelial lining fluid). This thick gel layer consists of 
97% water and 3% mucins. It functions to trap airway matter to expel it from the 
lungs. The airway mucus accumulates as it is transported through the larger airways 
and eventually it reaches the trachea and then the pharynx where it is unnoticeably 
swallowed. If, however there is a build-up of mucus then a cough is triggered to 
augment expectoration. 
 
The efficiency and integrity of the mucociliary escalator is essential in maintaining 
airway sterility. A deficient mucus layer or poor ciliary structure or function will 
allow a build-up of mucus that is exposed to the airways for longer. The airways 
will then be exposed to the pathogens or toxins held by the mucus and this will 
trigger a predominantly neutrophilic inflammatory response.  In bronchiectasis, the 
airways are permanently dilated and distorted with a resultant impaired mucociliary 
escalator (Figure 2).  
 
Each cilium consists of a central pair of filaments surrounded by nine additional 
pairs of filaments (A and B microtubules) in a circumferential design. This circular 
 23 
border is known as the axoneme and is surrounded by an extension of the cell 
membrane. The microfilaments join proximally to terminate in a basal body from 
which root fibres extend into the cell cytoplasm. Arising from midway up the basal 
body is the ‘basal foot’ and this points in the direction of travel of the effective 
stroke of the cilia, presumably to act as anchorage for the motile cilium. Each pair of 
outer microtubules has projections called nexin links to adjacent microfilaments and 
radial spokes attaching them to the inner central microfilament (Figure 3). The outer 
microfilament pairs slide over adjacent pairs by using energy gained from 
hydrolysing adenine triphosphate (ATP) in its outer projection dynein arms. The 
radial spokes limit movement but also transduce this into coordinated activity 
(Greenstone & Cole 1985). 
 
Figure 3. 
 
Figure 3. Classical structure of normal cilium (Adapted from Buchdahl et al, 
1988). 
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1.3.2 Abnormal ciliary structure 
The precise structure of the cilium is integral to maintaining its function. There are 
limited studies of ciliary abnormalities in bronchiectasis and are mainly limited to 
patients diagnosed with primary ciliary dyskinesia – an autosomal recessive 
condition that causes ultrastructural abnormalities of the cilia. The recognised 
abnormalities include the loss of the “9+2” formation, abnormalities in the 
orientation of the central microtubules, deficiencies or absence of the dynein arms 
and abnormalities of the nexin links between the pairs of peripheral microtubules 
(Sturgess et al, 1979 & Cowan et al, 2001). 
 
Tsang et al investigated the angle of central microfilament orientation in 133 
patients with bronchiectasis and in 59 control patients. 103 of these patients had 
idiopathic bronchiectasis and 6 had Kartagener’s. The central microfilament 
orientation angle correlates with reduced ciliary beat frequency and the presence of 
structural defects. They found a significant correlation with lower central 
microtubular orientation angle in patients with severe bronchiectasis (Forced 
expiratory volume in 1 second (FEV1) <60%, Forced vital capacity (FVC) <60% or 
more than 4 bronchiectatic lung lobes) p<0.05 (Tsang et al, 2005c). A second study 
by the same group in 152 stable patients with idiopathic bronchiectasis demonstrated 
slower ciliary beat frequency (p<0.05) and greater percentage of patients with 
central and peripheral microtubular defects than in control subjects (OR 14.4, 95% 
CI 5.6-36.8). There was no clinical correlation with a slower ciliary beat frequency 
but the percent of cilia with central microtubular defects correlated with 24hour 
sputum volume production (r=0.40, p=0.001) and FEV1 (r=.-0.24, p=0.01) 
suggesting a pathogenic role for central microtubular defects in idiopathic 
bronchiectasis (Tsang et al, 2005b).  
 
1.3.3 Abnormal ciliary function  
To move mucus effectively across the mucociliary escalator, cilia must beat at a 
normal rate, in a constant direction and in a co-ordinated fashion (Eliezer et al, 
1970). It is thought that cilia beat more slowly in bronchiectasis and it is due to the 
presence of purulent secretions (Rutland & Cole, 1981, Tsang et al, 1995b & Wilson 
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et al, 1986). Several factors affect ciliary function such as excessive release of 
inflammatory markers like elastase (Tegner et al, 1979) and exposure to toxic 
bacterial products (Wilson et al, 1985). 
 
1.4 Vicious Circle 
The airways of the respiratory tract are lined with a moist respiratory epithelium. 
This bears cilia – ‘hair like’ structures surrounded by mucus or epithelial lining 
fluid. Mucus traps foreign matter and pathogens in the airways and travels via the 
coordinated beating of the cilia up the airways towards the pharynx (Stanke 2015, 
Sleigh 1988). Here it is silently swallowed or coughed up to aid the expulsion of 
such sepsis-inducing material from the lower airways. The rhythmic co-ordinated 
action of the cilia action is referred to as the mucociliary escalator and in 
bronchiectasis where the airways are dilated and distorted this mucociliary escalator 
can break down. This leads to the build-up of mucus, which when lying stagnant can 
become prone to infection. Such infections, again cause an inflammatory response 
and again leads to further dilation and distortion of the airways. This theory is 
known as ‘the vicious circle’ and was initially coined by Cole et al and is 
demonstrated in figure 4 (Cole 1989). 
 
Figure 4. 
 
Figure 4. Schematic of Cole’s Vicious Circle. 
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1.5 Aetiology 
Bronchiectasis is a pathological endpoint of irreversibly damaged and dilated 
airways which can be associated with multiple different disease processes. All the 
different aetiologies can eventually result in the damage of the mucociliary escalator 
on the respiratory epithelium, build-up of mucus with colonisation and infection and 
subsequent inflammation. This further perpetuates the cycle causing dilation and 
distortion of the airways. Therefore, there is emphasis on identifying the primary 
insult to treat the underlying condition wherever possible.  
 
Investigating the aetiology is important in avoiding invasive, time-consuming and 
expensive tests in addition to guiding management. Pasteur et al investigated 150 
adult cases of bronchiectasis and found the underlying aetiology in 47% of cases. In 
15% of these cases the causative factor had important therapeutic and prognostic 
implications, such as allergic bronchopulmonary aspergillosis (ABPA) requiring 
treatment with steroids and common variable immune deficiency (CVID) with 
intravenous immunoglobulin therapy (Pasteur 2000). This rate was found to be 
higher at 56% in 136 cases of paediatric bronchiectasis (Li 2005). 
 
The rate of ‘idiopathic’ or no cause identified and different aetiological diagnoses 
can vary greatly between studies and this is probably due to different research 
techniques. The population of patients included can differ in age, socioeconomic 
background, background disease incidences, referral from secondary or tertiary 
centres and the range of investigations performed can vary greatly (Pasteur 2010). 
Table 1 shows the typical incidence of the different aetiologies and the supporting 
diagnostic features (Pasteur et al, 2010 & Pasteur et al, 2000). 
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Table 1. 
Aetiology Incidence Supporting features 
Idiopathic 41-53% • Exclusion	of	other	diagnoses	
Post infection 29-33% • History	of	previous	infection	e.g.	
pneumonia,	whooping	cough,	
measles,	tuberculosis	
• CT	changes	of	previous	infection	
e.g.	tuberculosis	
Immunodeficiency 
(agammaglobulinae
mia, CVID, IgA 
deficiency, IgG 
subclass deficiency) 
1-8% • Low	levels	of	either	IgA,	IgM,	
IgG	or	IgG	subclasses	(1-4)		
• Poor antibody response against 
Tetanus toxoid and the 
polysaccharide capsules of 
Streptococcus pneumoniae and 
Haemophilus influenzae type B  
• Recurrent	mucosal	infections	
with	encapsulated	organisms	
• Recurrent	upper	and	lower	
respiratory	tract	infections	with	
Streptococcus	pneumoniae,	
Haemophilus	influenzae	&	
Moraxella	catarrhalis	
Allergic 
bronchopulmonary 
aspergillosis  
1-7% • History	of	asthma	
• Raised	total	and	specific	IgE	to	
Aspergillus	
• Fleeting	infiltrates	on	chest	x-
ray	and	CT	
• Proximal	bronchiectasis	on	CT	
• Peripheral	blood	eosinophilia	
• Raised	Aspergillus	precipitins	
Connective tissue 3-6% • History	and	clinical	examination	
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disease characteristic	of	syndromes	
• Autoimmune	antibody	and	anti-
CCP	screen	
Aspiration or 
inhalation 
4% • History	consistent	with	
aspiration	
• Positive	findings	at	
bronchoscopy	e.g.	foreign	body	
or	mucus	plugging	
• Localised	bronchiectasis	
Cystic fibrosis 3% • Age	less	than	40yrs	old	
• History	of	malabsorption,	
steatorrhoea,	diabetes	and	male	
infertility	
• Persistent	isolation	of	
Staphylococcus	aureus	in	
sputum	
• Positive	for	cystic	fibrosis	
transmembrane	regulator	
receptor	TR	mutations	
• Positive	sweat	test	
Ciliary dysfunction 
 
2% • History	of	chronic	otitis	media,	
continuous	rhinitis,	infertility	
and	dextrocardia	
• Exhaled	nasal	nitric	oxide	test	
• Abnormal	ciliary	beat	pattern	
and	frequency	on	brushings	
from	two	separate	sites	
• Genetic	conditions	
Inflammatory 
bowel disease  
1% • History	of	malabsorption,	
weight	loss,	joint	pains,	
diarrhoea	
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• Diagnostic	colonic	biopsy	
Congenital  <1% • History	of	congenital	defects	of	
large	airways,	tracheobronchial	
or	oesophagobronchial	fistula,	
rib	malformations	or	
tracheobronchomegaly	
Table 1. Aetiologies of bronchiectasis with incidences and supporting diagnostic 
features. CT: computer tomography, CFTR: cystic fibrosis transmembrane 
regulator receptor. 
 
Previous infections suffered are a common precipitant for adult bronchiectasis such 
as bacterial pneumonia, whooping cough, mycoplasma and tuberculosis. Viral 
causes of bronchiectasis that cause permanent lung damage and subsequent 
bronchiectasis include adenovirus, measles virus, influenzae and respiratory 
syncytial virus. The closer the link of pulmonary infection to the development of 
chronic respiratory symptoms, the more likely the infection was the cause of the 
bronchiectasis. Studies suggest that patients are relatively good at identifying a 
significant respiratory infection that could be responsible and hence taking a detailed 
history is important in helping to limit unnecessary investigations (Nicotra et al, 
1995 & Wynn-Williams 1953). Sometimes however, an infection can proceed 
chronic symptoms by years and whilst this can make identifying the aetiology 
difficult, it is still possible (Lanning et al, 1980). 
 
Mycobacterium tuberculosis infection can precipitate bronchiectasis, often in a lobar 
or segmental distribution (Parker et al 1968), and the incidence depends on the 
population prevalence of the infection. Other mycobacterial species (non-
tuberculous mycobacteria, NTM) are ubiquitous environmental organisms and the 
environment has been proposed as the major source of NTM infection. The most 
common pathogens include Mycobacterium avium complex (MAC), Mycobacterium 
abscessus, and Mycobacterium chelonae. Opportunistic environmental mycobacteria 
can cause bronchial wall damage and hence bronchiectasis but patients with 
damaged lungs (including those already diagnosed with bronchiectasis) are also at a 
 30 
higher risk of contracting the infection with these opportunistic organisms in the 
first place. Patients with bronchiectasis are predisposed to NTM infection in either a 
localised or widespread distribution and can be isolated in sputum of up to 10% of 
bronchiectatic patients (Fowler et al 2006). Levin and colleagues have reported the 
presence of bronchiectasis and parenchymal nodules had an overall sensitivity of 
80% and specificity of 87% for positive MAC culture (Levin 2002). A meta-analysis 
by Chu and colleagues after searching the main databases including PubMed, 
Medline, Cochrane Library and EMBASE identified 8 studies reporting on NTM 
prevalence in 1492 patients with bronchiectasis (Chu et al, 2014). Using the random 
effect model they found the combined prevalence of NTM in the meta-analysis 
cohort to be 9.3%. They also reported increased combined NTM prevalence in those 
studies with 100 or more subjects, studies performed in 2002 and after, in Asian 
countries and in studies conducted retrospectively.  
 
The clinical significance of isolating mycobacteria in sputum is not known and these 
patients should be monitored and treatment considered when colonisation with 2 
positive sputum samples appears alongside a clinical (reduced lung function and 
infective symptoms) and radiological deterioration (rapid progression of disease, 
cavitating nodules, mucus plugging and tree in bud bronchiolitis) in the patient’s 
wellbeing. At this point you may well consider the picture has progressed from 
colonisation to infection. The different type of mycobacterial species (mycobacterial 
avium complex, mycobacterium kansasii, mycobacterium malmoense) may also 
influence the clinical picture and when to consider treatment (Pasteur et al 2010). 
For example, Mycobacterium avium complex, which is associated with infection of 
the middle lobe or lingular in women - termed ‘The Lady Windermere syndrome’, 
may develop bronchiectasis over several years (Reich & Johnson 1992). 
 
Primary defects in lung defences causing bronchiectasis in more commonly 
diagnosed in children unless the defect is subtle and not identified until adulthood. 
The more common defects include primary ciliary dyskinesia (PCD) and common 
variable immune deficiency (CVID) where antibody production and/or function is 
defective. The immune defects only constitute a small number of cases and as such, 
 31 
the exact immune defect tends to be poorly characterised. It is important to attempt 
to clarify the immune defect as administration of intravenous immunoglobulin G 
(IgG) therapy in CVID can help prevent infections and pneumonia but there is no 
consensus on the dose of IgG to administer or what trough levels to aim. There is no 
evidence that treatment prevents the progression of bronchiectasis. Additionally, in 
patients with immune deficiency the baseline specific antibody levels against 
capsular polysaccharides of S. pneumoniae should be measured. If found to be low, 
then 23 valent pneumococcal vaccine should be offered followed by rechecking 
antibodies levels 4-8weeks after. If patients do not mount an appropriate serological 
response then the 13-valent pneumococcal vaccine should be considered (Hill et al, 
2018). Primary ciliary dyskinesia is an autosomal recessive condition with 
structurally abnormal cilia. It is characterised by upper and lower respiratory tract 
infections, chronic sinopulmonary infections, bronchiectasis and loss of lung 
function. Male infertility and situs inversus (Kartagener’s syndrome) is also 
common (Hill et al, 2018). Diagnosis is made by measuring nasal nitric oxide in the 
first instance but analysing nasal brushings for ciliary beat frequency and pattern by 
either transmission electron microscopy or high speed video microscopy analysis, 
have high sensitivity and specificity also (Hill et al, 2018). 
 
Allergic bronchopulmonary aspergillosis (ABPA) is an important cause of 
bronchiectasis and should be identified because treatment can halt progression of 
lung damage. It can be diagnosed with deterioration on symptoms (exacerbations, 
increased sputum production, cough, wheeze and reducing lung function), 
serological testing (high total and specific IgE to Aspergillus fumigatus), immediate 
cutaneous reaction to Aspergillus (positive skin prick test >3mm) and new 
radiological changes (new pulmonary infiltrates and/or high attenuation mucus 
plugging, in the later stages, proximal bronchiectasis develops). ABPA is very often 
associated with asthma and it can be difficult to distinguish between the two as the 
above blood tests can be raised in both conditions, although usually to a lesser extent 
in asthma. Another diagnostic challenge with ABPA is that the bronchiectasis 
changes may be identified when the condition is quiescent and blood tests near the 
normal range. High resolution CT scan should help elucidate the cause as ABPA 
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causes predominantly central bronchiectasis in the upper lobes but can effect all 
lobes and in a peripheral distribution (Angus et al, 1994 & Mitchell et al 2000). 
 
Raised IgG to A. fumigatus, raised aspergillus precipitins (which can also be raised 
in other conditions such as aspergilloma and chronic pulmonary aspergillosis) and 
raised peripheral blood eosinophilia (which can be raised but normal levels do not 
rule out ABPA as there is no difference in counts between patients with aspergillus 
sensitisation and those with ABPA) should all be second line confirmatory tests 
(Hill et al, 2018). 
 
Aspiration of a foreign object can cause bronchiectasis because the secretions 
produced distal to the obstruction build up and can cause inflammation and 
structural wall damage. In the same manner, endobronchial tumours - benign or 
malignant can similarly cause distal bronchiectasis (Box et al, 1991 & Chiu 1973). 
There is benefit to removing the obstruction wherever possible with some 
improvement of the bronchiectasis (Mansour et al, 1998). 
 
Aspiration of gastrointestinal contents has been documented to cause bronchiectasis 
as has gastro-oesophageal reflux disease. There has been conflicting evidenced as to 
whether infection with Helicobacter pylori is causative (Tsang et al 1998b, Angrill 
et al 2006 & Gulhan et al 2007) but heart and lung transplant patients with 
documented oesophageal dysmotility and reflux were found to have bronchiectasis 
in a high frequency (Reid et al, 1990). 
 
Bronchiectasis is associated with many systemic disease entities. The most common 
being rheumatoid arthritis which is a chronic inflammatory disease -primarily 
affecting the joints but with extra-articular manifestations affecting the eyes, skin, 
heart and lungs.  Walker described an association with bronchiectasis in 3.1% of 516 
patients with rheumatoid arthritis (Walker, 1967).  A further study which 
investigated 77 patients with HRCT showed the most common pulmonary 
abnormality to be bronchiectasis in 30% of patients. Of these, 8% did not have any 
respiratory symptoms (Cortet et al, 1995). Whilst an association is well recognised, 
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the pathogenesis is not understood and there is no consensus on the prognosis of this 
specific subset of patients (Swinson et al 1997, McMahon et al 1993). De Soyza and 
colleagues recently investigated 147 patients with bronchiectasis and rheumatoid 
arthritis overlap syndrome (BROS) and found a higher mortality rate over a mean of 
48months when compared with idiopathic bronchiectasis (18% versus 9.3%), 
statistically but not clinically significant increase in bronchiectasis severity index 
scores (7.7 versus 7.1) and no difference in hospitalisation or exacerbations (De 
Soyza et al, 2017).  Systemic sclerosis, ankylosing spondylitis, systemic lupus 
erythematosus, relapsing polychrondritis, Marfan’s syndrome and Ehlers Danlos' 
syndrome are all conditions that have been known to have patients with 
bronchiectasis in their cohorts but studies are too few and too small for an 
association to be properly investigated (Pasteur et al, 2010). 
 
Cystic fibrosis (CF) is an important consideration when diagnosing bronchiectasis as 
both conditions can present with recurrent lower respiratory tract infections. Late 
first presentation of CF as an adult has been described and atypical presentations 
with respiratory symptoms in the absence of pancreatic failure or gastrointestinal 
symptoms has been known. A sweat chloride test and genetic testing for 
homozygosity of the CF transmembrane regulator mutation or heterozygosity for 
other mutations should be conducted (Pasteur et al, 2010). 
 
Obstructive airways disease is often seen in patients with bronchiectasis. Airway 
changes such as airway thickening and dilatation are seen on high resolution CT 
(HRCT) scan in patients with asthma. Features of bronchiectasis can also be seen 
with a higher frequency than in control subjects (Grenier et al, 1996). Bronchiectasis 
is strongly associated with patients with severe asthma and fixed airway obstruction 
and one study of asthmatic patients that excluded those with ABPA found varicose 
bronchiectasis in 60% of severe non-allergic type patients and cylindrical 
bronchiectasis in 50% of severe allergic type patients (Paganin et al, 1996). There 
have been no studies to date to investigate if asthma, independent of ABPA, is a 
cause of bronchiectasis.  
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Bronchiectasis has been found in patients with Chronic Obstructive Pulmonary 
Disease (COPD) (Patel et al, 2004, O’Brien et al, 2000) but documentation about 
smoking history and other causes of bronchiectasis has never been investigated 
thoroughly enough to establish whether COPD is causative of bronchiectasis or not. 
One study of patients with COPD demonstrated the isolation of Pseudomonas 
aeruginosa in sputum culture of patients with COPD are more likely to have 
bronchiectasis and that bronchiectasis was an independent risk factor for all-cause 
mortality in COPD (Mao et al, 2015). A meta-analysis of 6 studies in COPD 
patients reported a 54.3% prevalence of bronchiectasis comorbidity (range 25.6-
69%), patients were more likely to have exacerbations, worse lung function, 
increased colonisation with Pseudomonas aeruginosa and other potentially 
pathogenic microorganisms and a higher smoking history (Ni et al, 2015). A second 
meta-analysis of 14 studies in COPD patients reported patients with bronchiectasis 
comorbidity were more likely to have worse airway obstruction, increased 
colonisation with potentially pathogenic micro-organisms, increased exacerbations 
and mortality rates (Du et al, 2016).  
 
1.6 Clinical features 
Patients with bronchiectasis suffer from many different symptoms but the most 
commonly reported is cough. More than 90% of patient report cough and this can be 
productive of sputum on a daily basis for more than 75% of patients (Pasteur et al, 
2010). Approximately 5-8% of patients have a dry cough and the remaining patients 
produce sputum intermittently (Pasteur et al, 2010). Cough has been known to 
reduce a person’s quality of life as some find it irritating and others embarrassing. 
Thus, a specific questionnaire – The Leicester Cough Questionnaire has been 
validated to assess quality of life in patients with bronchiectasis who suffer from a 
cough (Murray et al, 2009).  
 
Sputum production can be assessed for volume and degree of purulence. Sputum 
should be collected over a 24hour period and measured or weighed. The amount of 
sputum produced can vary greatly among patients with some patient producing none 
and others producing copious amounts when clinically stable. Sputum production 
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can increase with infections but some patients find they are unable to expectorate 
when unwell. Sputum colour should also be assessed in patients with bronchiectasis. 
Increased sputum purulence is caused by neutrophilic inflammation with increased 
levels of myeloperoxidase and neutrophil elastase (Stockley et al, 2001). A study of 
141 patients’ sputum categorised sputum into mucoid, mucopurulent and purulent. 
They found increasing purulence correlated with colonisation and severity of 
radiological changes. Those with cystic or varicose bronchiectasis, as opposed to 
tubular bronchiectasis, tended to produce more purulent sputum (Murray et al, 
2009).  
 
Dyspnoea is a common symptom, present in three quarters of all cases. The degree 
of breathlessness correlates to the degree of FEV1 obstruction. Breathlessness is also 
found to correlate with the amount of sputum produced and radiological changes on 
HRCT (Smith et al, 1996 & Ellis et al, 1981). 
 
Haemoptysis can sometimes be an alarming clinical feature for patients but often is 
minor and accompanied by an infective exacerbation. It is present to some degree in 
approximately 50% of cases (Nicotra et al, 1995 & Warner 1935) but only 4% 
experience massive haemoptysis (>235mls) (Wynn-Williams 1953). Haemoptysis 
usually arises from aberrant blood vessels from bronchial arteries and should be 
monitored incase embolisation of the bleeding vessel is required. 
 
Chest pain is reported between 19% and 46.3% of patients with bronchiectasis 
(Nicotra et al, 1995 & King et al, 2006) can be pleuritic or musculoskeletal in 
nature. It can be poorly localised but one study found that 94.4% of chest pains 
reported in patients with bronchiectasis were described to be in the same area as the 
bronchiectatic lung (Munro et al, 1989). 
 
1.6.1 Clinical signs 
The most common clinical sign is audible coarse crackles on auscultation of the 
chest. Crackles tend to be typically heard at the lung bases but can be heard 
anywhere. There is poor correlation of the localisation of crackles with the 
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bronchiectatic lung underneath (Smith et al, 1996). Crackles are present in 
approximately 70% of cases and start in early inspiration. Wheeze has been reported 
in 34%, large airway rhonchi in 44% and finger clubbing can occur but this is an 
infrequent finding (Nicotra et al, 1995 & Wynn-williams et al 1953). Often the 
clinical examination can be unremarkable. 
 
1.6.2 Stable state 
Bronchiectasis is a chronic condition and patients will suffer periods of stability and 
periods of deterioration. A patient with bronchiectasis may well be symptomatic of 
the condition on a day-to-day basis experiencing the above named symptoms. They 
will, however, feel well in themselves and can function at their usual level of ability. 
Sputum from patients when they are ‘stable’ may well culture potentially pathogenic 
microorganisms as their lungs become colonised with bacteria due to the nature of 
the condition. They may not require antibiotics at this stage but should continue to 
perform chest physiotherapy regularly to prevent infections. 
 
There have been some studies which suggest there is ongoing chronic infection in 
patient during the stable state and hence the ongoing neutrophilic inflammatory 
response. Chalmers and colleagues have demonstrated that airway bacterial load 
correlates with airway inflammatory markers (Chalmers et al, 2012) and hence there 
has been further study into the effects of anti-inflammatory therapies in patients that 
are clinically stable to prevent further exacerbations (Wong et al, 2012, Altenburg et 
al, 2013, Serisier et al, 2013). Tunney and colleagues investigated bacterial load and 
taxonomy in patients that were clinically stable (no antibiotics for 4 weeks prior to 
recruitment). They found the bacterial load was similar during the stable state with 
that in patients who were experiencing an exacerbation. They also found multiple 
DNA sequences (15,000) that represented codes for 113 distinct microbial taxa, all 
of which were present in low abundance (Tunney et al, 2015). The latter studies are 
conflicting to the data found using the culture-based methodologies. The 16S studies 
however were carried out in a small number of bronchiectasis patients and larger 
studies are needed. 
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1.6.3 Exacerbations 
The British Thoracic Society (BTS) guidelines state an exacerbation is when a 
patient experiences an acute deterioration in their symptoms over the course of 
several days. They may experience more cough, increased sputum volume, 
increased sputum viscosity, an increase in the sputum purulence with or without 
increased breathlessness, wheeze, haemoptysis and/or systemic upset (figure 5). The 
BTS guidelines suggest prompt antibiotic treatment at times of an exacerbation to 
break the perpetual cycle of bronchiectasis and prevent further damage to the 
airways.  Studies have shown that exacerbations impact on a patient’s quality of life 
and the higher the number of exacerbations, the poorer the quality of life (Wilson et 
al, 1997). The BTS audit conducted nationally reports the number of exacerbations 
can vary anywhere from 0-12, depending on the severity of the bronchiectasis but 
the average number of bronchiectatic exacerbations of patients managed in 
secondary care is 2 (Hill et al, 2012).  
 
Figure 5. 
 
Figure 5. Exacerbations as defined by the British Thoracic guidelines (Pasteur et al, 2010) 
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Recently there has been a new European Consensus on the definition of an 
exacerbation, primarily produced for research purposes. It states an exacerbation is 
when a patient exhibits deterioration in three of more of the following key 
symptoms for at least 48hours: cough; sputum volume and/or consistency; sputum 
purulence; breathlessness and/or exercise tolerance; fatigue and/or malaise; 
haemoptysis AND a clinician determines that a change in bronchiectasis treatment is 
required (Hill et al, 2017). 
 
1.7 Sputum microbiology 
The lungs are not a sterile environment and studies suggest 75% of patients with 
bronchiectasis are colonised with potentially pathogenic microorganisms (Chalmers 
et al, 2012). Colonisation is a term defined by the BTS as the isolation of a pathogen 
on at least ‘3 separate occasions over a period of at least 3 months and at least two 
isolates 3 months apart over a year (Pasteur et al, 2010).  Colonisation can therefore 
become a chronic state of normality for a patient and does not necessitate treatment, 
unlike infection when the patient feels unwell with symptoms of an exacerbation 
(see above) usually in addition to fever, fatigue and systemic upset. The commonly 
isolated pathogens include Haemophilus influenzae, Pseudomonas aeruginosa, 
Staphylococcus aureus, Moraxella catarrhalis, Streptococcus pneumoniae and 
environmental mycobacteria (Figure 6).  
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Figure 6. 
 
Figure 6 to show the proportion of commonly cultured pathogens in 
bronchiectasis (Chalmers et al, 2012). 
 
1.7.1 Haemophilus influenzae 
Haemophilus influenzae is the most commonly cultured pathogen in patients with 
bronchiectasis (Barker et al, 2002 Chalmers et al, 2012). It is a gram negative 
coccobacillus, belonging to the Pasteurellaceae family. It colonises the nasopharynx 
as a commensal pathogen in up to 75% of normal adults and is a source of 
opportunistic infection, primarily causing lower respiratory tract infections (Murphy 
et al, 2001). There are 2 main categories of Haemophilus influenzae – capsulated 
and non-capsulated. The capsule is a major virulence factor that helps the pathogen 
evade phagocytosis and complement mediated lysis. The non-encapsulated types are 
thought to be less virile but are still capable of triggering a host inflammatory 
response. The non-encapsulated strains are often referred to as non-type-able 
Haemophilus due to the lack of capsular serotypes. The Hib vaccine offered 
routinely to children is directed against the capsulated HI type B strain and offers no 
protection against the non-encapsulated types. It has now been recognized that non 
typeable H. influenzae is a major cause of respiratory infection, which tends to be 
chronic and recurrent and includes sinusitis, otitis media, tonsillitis, pneumonia, 
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chronic bronchitis and systemic infection (Murphy 2001). Most bronchiectasis 
patients with chronic non-encapsulated infection can mount a highly effective 
humoral immune response that prevents systemic infection but there is some 
suggestion that they favour a predominant Th2 response compared with a 
predominantly Th1 response in healthy controls which may be important in the 
pathogenesis of bronchial infection (King et al, 2003). 
 
Colonies are small, round and convex and typically appear after 24hrs incubation in 
aerobic conditions enriched with 5% carbon dioxide at 37 degrees. The species 
appear negative on Gram staining as spherical, oval or rod shaped cells of less than 
1µm diameter. A study by Zhang and colleagues showed non-type-able 
Haemophilus influenzae can last up to 48hours or longer so sputum should be 
optimally cultured within 3hours of expectoration to maximise chances of isolating 
the pathogen prior to antibiotic use (Zhang et al, 2016). 
 
Haemophilus influenzae produces beta-lactamases, and it is also able to modify its 
penicillin-binding proteins, so it has gained resistance to the penicillin family of 
antibiotics. The choice of antibiotic and the duration of antibiotic therapy for 
treating exacerbations with H. influenzae infection are summarised in Table 2. 
 
1.7.2 Pseudomonas aeruginosa 
Pseudomonas aeruginosa is the second most commonly cultured pathogen in 
bronchiectasis behind Haemophilus influenzae and can be found in 24 - 33% of 
patients (Pasteur et al, 2000). It is a gram negative organism and although not as 
extensively investigated as it is in cystic fibrosis, it has been associated with 
increased morbidity and mortality in bronchiectasis. Patients colonised with 
Pseudomonas aeruginosa infection are likely to have more severe disease with a 
poorer quality of life, have accelerated lung function decline, are at risk of more 
frequent exacerbations and have increased mortality rates (Ho et al, 1998, Wilson et 
al, 1997, Evans et al, 1996, Martinez-Garcia et al, 2007 & Loebinger et al, 2009).  
 
Pseudomonas aeruginosa is a gram negative bacillus that is recognised for its 
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ubiquitous nature and ability to generate antibiotic resistant properties. It is often a 
multidrug resistant pathogen associated with severe sepsis including hospital 
acquired pneumonia and ventilator assisted pneumonia. It is an opportunistic 
pathogen with immunocompromised patients and those with chronic lung disease 
and illnesses at risk of serious infection. P. aeruginosa can be difficult to treat due to 
its protective antibiotic evading mechanisms. It can form a biofilm which consists of 
a community of cells irreversibly attached to a surface and to each other embedded 
in an extracellular substance exhibiting an altered phenotype (Donlan & Costerton, 
2002). Biofilms protect bacteria from adverse environmental factors by one or more 
mechanisms. These are poorly understood but thought to include the detachment of 
cells, production of endotoxin, increased resistance to the host immune system and 
provision of a niche environment for the generation of resistant organisms (Donlan 
& Costerton, 2002). P. aeruginosa can illicit quorum sensing which is the regulation 
of gene expression to adapt to its environment. It does this by producing small 
molecules called autoinducers. The extracellular accumulation of these molecules 
signal the bacteria to alter gene expression to control the expression of virulence 
factors and hence can rapidly adapt to its environment. 
 
Infection with P. aeruginosa has been demonstrated to cause more severe disease. 
There is therefore some suggestion that eradication of the pathogen when first 
isolated in sputum should be attempted before colonisation occurs. There are limited 
randomised controlled trials investigating the benefit and success of eradication. 
One study evaluating the effect of two weeks of ceftazidime and tobramycin 
followed by either nebulised tobramycin 300mg (Tobi®) or placebo twice daily for 
three months in 35 patients with bronchiectasis and a first growth of P. aeruginosa 
found the median time to recurrence of P. aeruginosa and the proportion of patients 
free of P. aeruginosa after 12 months follow up was significantly higher in the 
nebulised tobramycin group. The number of exacerbations, hospital admissions and 
the number of days in hospital were also significantly lower in the nebulised 
tobramycin group. Five patients in the nebulised tobramycin group discontinued 
treatment due to bronchospasm (Orriols et al, 2015). The definition of eradication 
has not yet been defined and it is not known whether eradication is superior to 
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reducing bacterial load or whether eradication is even achievable. The updated BTS 
guidelines recommend all patients with new growth of P. aeruginosa and clinical 
deterioration should be offered eradication therapy in the form of ciprofloxacin 
(500-750mg b.d. for 2 weeks) or second line beta lactam +/- an intravenous 
aminoglycoside for 2 weeks followed by nebulised colistin, gentamicin or 
tobramycin for 3 months (Hill et al, 2018).  
 
The existence of cross infection of pathogenic strains of Pseudomonas between 
patients has been documented in cystic fibrosis but there is limited evidence in 
bronchiectasis. De Soyza and colleagues investigated cross infection in a case series 
of 40 patients. 10 patients were followed up longitudinally for 4yrs. No predominant 
epidemic strain was found but certain strains found widely within the natural 
environment were also found in the patients attending the single adult bronchiectasis 
clinic and thus raising the possibility of environmental acquisition of the pathogen in 
bronchiectasis patients (Hill et al, 2018 & De Soyza et al, 2014).  
 
Pujana and colleagues used polymerase chain reaction bacterial fingerprinting to 
assess cross infection and 2 other studies by Mitchelmore and Hilliam used whole 
genome sequencing to further explore cross-infection of P. aeruginosa in 
bronchiectasis and all found a very small number of phenotypic heterogeneity within 
strains from individual patients but overall would not support the idea of significant 
cross infection with P. aeruginosa and suggest that larger longitudinal studies were 
necessary (Pujana et al 1999, Hilliam et al 2017 & Mitchelmore et al 2016).   
 
There is only 1 oral agent (ciprofloxacin) to treat P. aeruginosa, so if resistance or 
intolerance becomes problematic then treatment options are limited to intravenous 
regimes. However, in vitro resistance does not necessarily translate to in vivo 
resistance (Hill et al, 2018). New preparations of inhaled ciprofloxacin are being 
trialled in treatment on/off regimes that deposit the antibiotic at the site of infection 
thus potentially reducing issues with resistance and systemic side effects (De Soyza 
et al, 2018, Haworth et al, 2017, Cartlidge & Hill, 2017). The current recommended 
treatment regimens for P. aeruginosa exacerbation are described in Table 2. 
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1.7.3 Streptococcus pneumoniae 
Streptococcus pneumoniae is a gram positive facultative anaerobic member of the 
genus Streptococcus. It usually appears in pairs (diplococci), is haemolytic and non-
motile. It can be detected in up to 22% of patients with bronchiectasis (Angrill et al, 
2002) but is also a common cause of community acquired pneumonia and bacterial 
meningitis. S. pneumoniae can colonise the nasal cavity, sinuses and respiratory 
tract in healthy individuals but in susceptible patients it can spread and cause 
disease. It spreads by respiratory droplets via direct contact from person to person. It 
can also autoinoculate individuals carrying the bacteria in the upper respiratory tract.  
 
The pathogen has a polysaccharide capsule which acts as a virulence factor, helping 
it to evade phagocytosis and mechanical removal by mucus. The capsule is 
responsible for helping the pathogen to restrict autolysis by impairing bacterial 
opsonisation by both the alternative and classical complement pathways, masking 
subcapsular antigens and prevent binding of complement components to subcapsular 
components of complement activity. 
 
There are over 90 different serotypes of S. pneumococcus, each one with a different 
polysaccharide capsule.  There is a 23-valent pneumococcal vaccine targeted 
towards 23 different polysaccharide capsules. Widespread vaccination has led to the 
emergence of mutant strains expressing non-vaccine capsular serotypes and hence 
emphasises the importance of the capsule in affecting virulence (Hyams et al, 2010).  
 
Streptococcus pneumoniae appear as small 1-2mm round colonies that appear in 
pairs (diplococci), singularly or in short chains and are positive on Gram’s staining. 
The colour of the colonies depends on the degree of encapsulation of the strain of S. 
pneumoniae. It is good practice to culture the bacterial within 3 hours of sputum 
expectoration to maximise culture results. The choice of antibiotic and the duration 
of antibiotic therapy for treating exacerbations with S. pneumoniae infection are 
summarised in Table 2. 
 
1.7.4 Staphylococcus aureus 
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Staphylococcus aureus is not as commonly cultured in bronchiectasis as some of the 
other pathogens already mentioned (Cole, 1995). It is more commonly associated 
with cystic fibrosis and thought to stimulate the initial destructive inflammatory 
response that allows chronic Pseudomonas aeruginosa infection (Shah et al, 1999).  
Subsequently the rates of S. aureus culture are less frequent and thought to be due to 
anti-staphylococcal properties of P. aeruginosa (Machan et al, 1991). Shah and 
colleagues conducted a small study in patients with bronchiectasis colonised with S. 
aureus and found patients more likely to have ABPA or variants of cystic fibrosis.  
S. aureus is a gram positive, facultative anaerobe, round shaped bacterium of the 
family Staphylococcuceae. Its colonies are creamy-white or appear either singularly, 
in pairs or more commonly in clusters. It is part of the body’s normal flora and 
usually located on the skin, nose or respiratory tract. As a commensal organism is 
does not cause disease but can become more invasive and cause a whole range of 
illnesses. Apart from respiratory infections it can also cause skin infections 
including abscesses, cellulitis, impetigo and osteomyelitis, endocarditis and 
meningitis to name but a few.  
 
The treatment and duration of exacerbations caused by S. aureus are outlined in 
Table 2. More recently bacteraemia caused by this organism can be more concerning 
due to the increasing resistance patterns observed. Most strains are sensitive to 
methicillin (methicillin sensitive Staphylococcus aureus, MSSA) and therefore to 
more commonly used antibiotics but there is an increasing incidence of methicillin 
resistant Staphylococcus aureus (MRSA). Even more worryingly there has been an 
increase in hospital infections with vancomycin resistant Staphylococcus aureus and 
so these patients are usually isolated to contain the spread of resistant mutant strains. 
 
1.7.5 Moraxella catarrhalis  
Moraxella catarrhalis is an unencapsulated gram negative aerobic bacterium that 
appears as a diplococcus. Colonies are often small and yellow. M. catarrhalis can 
cause infections of the respiratory tract including bronchiectasis exacerbations, 
bronchopneumonia, COPD exacerbations as well as sinusitis, laryngitis, otitis media 
and infections of the eye, central nervous system and joints.  
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M. catarrhalis is more commonly acquired in childhood and can be present in up to 
75% of children as a resident commensal in the nasopharynx (Murphy et al, 2013).  
can be isolated in up to 20% of patients with bronchiectasis and its persistence 
within the respiratory system can be attributed to multiple factors. It can bind to host 
epithelial cells by its long range pili and outer membrane proteins including the 
trimeric autotransporters that allow short range binding. It can invade host cells and 
by remaining intracellularly can evade the host immune response. It is a hardy 
organism and can compete with commensal flora and exist under challenging 
nutritional conditions with the formation of micro-colonies and biofilms and can 
withstand the effects of human serum (de Vries et al, 2009).  
 
M. catarrhalis has rapidly acquired and spread beta-lactamase in the last 2-3 
decades and now clinical isolates appear to be resistant to one or more beta-lactam 
containing antibiotic in 95% of cases (Johnson et al, 2003). It has also been 
suggested that M. catarrhalis is also able to protect concomitant colonising 
pathogens from the effects of beta lactam containing antibiotics (Budhani & 
Struthers, 2008). There are currently no vaccines directed towards M. catarrhalis 
but several outer membrane proteins are under investigation as potential vaccine 
antigens. The treatment and duration of antibiotics for exacerbations caused by M. 
catarrhalis are outlined in Table 2. 
 
1.7.6 Other enteric gram negative organisms 
Other enteric gram negative pathogens including Klebsiella, Enterobacteriacea are 
of interest in bronchiectasis and studies have shown patients can be colonised with 
these potentially pathogenic microorganisms in the stable state (Angrill et al, 2001). 
They found patients colonised with these pathogens had an exaggerated 
inflammatory response with a clear association with bronchial bacterial load. They 
found poor correlations between bronchial and systemic inflammation but Chalmers 
and colleagues in 2013 demonstrated that increasing bacterial load was associated 
with increased bronchial and systemic inflammation which in turn led to an 
increased risk of further exacerbations (Chalmers et al, 2012). Commonly 
prescribed antibiotics for these pathogens are outlined in Table 2. 
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1.7.7 Table of commonly prescribed antibiotics for different microbial pathogens. 
 
Table 2. 
Pathogen 1st line 
treatment 
Length of 
treatment 
2nd line treatment Length of 
treatment 
Haemophilus 
influenzae 
-b lactamase 
negative 
Amoxicillin 
500mg TDS or 
Amoxicillin 
1G TDS or 
Amoxicillin 
3G BD 
14 days Doxycycline 100mg 
BD or Ciprofloxacin 
500mg or 750mg BD 
or Ceftriaxone 2G OD 
(IV) 
14 days 
Haemophilus 
influenzae 
-b lactamase  
positive 
Amoxicillin 
with 
clavulanic acid 
625mg TDS 
14 days Doxycycline 100mg 
BD or Ciprofloxacin 
500mg or 750mg BD 
or Ceftriaxone 2G OD 
(IV) 
14 days 
Pseudomonas 
aeruginosa 
Ciprofloxacin 
500mg or 
750mg BD 
14 days Monotherapy: 
intravenous 
Ceftazidime 2G TDS  
or  
Piperacillin with 
tazobactam 4.5G TDS 
or  
Aztreonam 2G TDS  
or  
Meropenem 2G TDS 
Combination therapy: 
The above can be 
combined with 
gentamicin or 
tobramycin or colistin  
14 days 
Streptococcus Amoxicillin 14 days Doxycycline 100mg 14 days 
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pneumoniae 500mg TDS BD 
Staphylococcus 
aureus 
-Methicillin	
sensitive	
Flucloxacillin 
500mg QDS 
14 days Clarithromycin 500mg 
BD  
or  
Doxycycline 100mg 
BD 
or  
Amoxicillin with 
clavulanic acid 625mg 
TDS 
14 days 
Staphylococcus 
aureus 
-Methicillin 
resistant 
Doxycycline 
100mg BD 
or 
Rifampicin 
(<50kg) 
450mg OD 
Rifampicin 
(>50kg) 
600mg OD 
or 
Trimethoprim 
200mg BD 
Or 
intravenous: 
Vancomycin 
1G BD 
Or  
Teicoplanin 
400mg OD 
14 days 
 
 
 
 
 
 
 
 
 
 
14 days 
Third line 
Linezolid 600mg BD 
 
 
 
 
 
 
 
 
 
Linezolid 600mg BD 
14 days 
 
 
 
 
 
 
 
 
 
 
14 days 
Moraxella 
catarrhalis 
Amoxicillin 
with 
clavulanic acid 
14 days Clarithromycin 500mg 
BD  
or  
14 days 
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625mg TDS Doxycycline 100mg 
BD 
or  
Ciprofloxacin 500mg 
or 750mg BD 
Coliforms e.g. 
Klebsiella, 
Enterobacter 
Ciprofloxacin 
500mg or 
750mg BD 
14 days Ceftriaxone 2G OD 
(IV) 
14 days 
Mixed normal 
flora 
(respiratory 
commensals) 
Amoxicillin 
500mg TDS 
14 days Clarithromycin 500mg 
BD 
14 days 
Table 2. 1st and 2nd line antibiotic regimes to treat commonly cultured 
pathogens in bronchiectasis. 
 
1.8 Epidemiology 
Bronchiectasis is a chronic respiratory condition that is diagnosed on high resolution 
CT scan (HRCT). HRCT is increasingly commonly used as a diagnostic tool as it 
becomes more widely available and so the incidence of bronchiectasis increases. 
There is a peak age of onset in adults in the mid-50s with more severe disease 
associated with increasing age (Chandrasekaran et al, 2018). In an ageing 
population, therefore, the prevalence of bronchiectasis will increase. There is a 
paucity of studies informing on the prevalence and incidence of bronchiectasis in the 
United Kingdom.  
 
Until the last decade it was widely believe the incidence of bronchiectasis was 
decreasing. It was thought to be an illness of the past due to improvement of 
effective treatment of childhood respiratory conditions, prevention of childhood 
respiratory conditions- particularly whooping cough and measles through 
vaccination, and the now effective eradication treatment regimens for pulmonary 
manifestations of Mycobacterium tuberculosis infection. 
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More recent data from Germany, USA and the UK have suggested there is an 
increasing prevalence of bronchiectasis with increasing hospitalisation and mortality 
(Seitz et al, 2007, Ringhausen et al, 2013 & Robert et al, 2013). The first large study 
investigating incidence and prevalence in the United Kingdom was performed by 
Quint and colleagues (Quint et al, 2016). They investigated prevalence, incidence 
and mortality over a nine-year period using a Clinical Practice Research Datalink 
(CPRD) – a large computerised database with longitudinal anonymised medical 
records in primary care. They found the incidence of bronchiectasis to be higher in 
women, something that has been long recognised but the cause for which remains 
unknown. They reported incidence levels increasing from 21.2/100,000 person-years 
in 2004 to 35.2/100,000 person-years in 2013 with a point prevalence increasing to 
566.1/100,000 in 2013. The incidence in men also similarly rose from 18.2/100,000 
person-years in 2004 to 26.9/100,000 person-years in 2013 with a point prevalence 
increasing to 485.5/100,000 in 2013. The incidence of bronchiectasis in both men 
and women increased with increasing age except in those that were over 80yrs old in 
both gender groups where the incidence was lower than in the age 70-79yr old age 
groups. The prevalence also increased with each increase in age decade remaining 
uncommon in the under-40s but up to 1% of the population in the elderly (aged 
³70yrs old) in 2013. The cause of increasing incidence and increased mortality is 
not known. It may be due to a change in the prevalence of causes of bronchiectasis 
i.e. less childhood infections but increased investigation of respiratory conditions in 
the older populations or the improved diagnosis rates with the use of CT or the 
improvement in diagnostic labelling with respect to other associated respiratory 
conditions. 
 
Quint and colleagues also investigated mortality rates in 11,862 individuals with 
bronchiectasis in England and Wales and showed mortality to be double that of the 
general population with age-adjusted mortality in women of 1437.7/100,000 
compared with 635.9/100,000 of the general population. Similarly, men with 
bronchiectasis had an age-adjusted mortality rate of 1914.6/100,000 compared with 
895.2/100,000. Bronchiectasis can co-exist or be associated with other chronic lung 
diseases such as COPD and asthma as well as other non-respiratory conditions such 
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as rheumatoid arthritis. Data on the co-existence of bronchiectasis is currently 
lacking. The cause of increased mortality is unknown and it is not known as to 
whether mortality is due to complications from   co-existing respiratory or other 
diseases or whether it results from bronchiectasis itself.    Further studies are needed 
to assess the impact of comorbidities on rates or mortality and the mechanisms of 
increased mortality in patients with bronchiectasis.  
 
The gender difference present in bronchiectasis has long since been reported with 
more women diagnosed with bronchiectasis than men (Pasteur et al, 2000, Nicotra 
et al, 1995, Weycker et al, 2005 and Shoemark et al, 2007). Again, the exact cause 
for this is unknown but several hypotheses have been postulated including 
sociological reasons; women are more likely to seek medical attention than men, 
women are more likely to be the primary carer for young children and therefore 
more likely to be exposed to repeated viral and bacterial infections and biological 
reasons; reduced muscle mass and strength would lessen the degree of chest 
expansion and therefore collapse compared to men, hormones present in the luteal 
phase of the menstrual cycle are thought to have an effect on airway reactivity and 
some diseases that are associated or causative of bronchiectasis such as rheumatoid 
arthritis and other connective tissue diseases are more common in women 
(Morrissey & Harper, 2004). Further work investigating the gender differences in 
patients with bronchiectasis is needed. 
  
1.9 Diagnosis 
1.9.1 Chest radiographs (Chest x-ray) 
Upon first recognition of the condition, the diagnosis was predominantly a clinical 
one as chest radiographs were insensitive for diagnosing bronchiectasis. The chest 
x-ray is usually normal unless patients have severe bronchiectasis and therefore a 
normal x-ray cannot exclude bronchiectasis.  Characteristic abnormalities on chest 
x-ray include crowding of the bronchi, parallel tram lines caused by the thickening 
and dilatation of bronchial walls, ring shadows represent end on dilated bronchi 
often associated with cystic bronchiectasis when 2cm or more in diameter and 
oligaemia resultant of lower pulmonary artery pressures.  Despite its poor sensitivity 
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for bronchiectasis and its poor inter – observer agreement, the chest x-ray is often 
the first imaging investigation performed as digital acquisition devices can provide 
images with improved visualisation of bronchiectatic airways behind the heart with 
the added potential of radiation dose reduction (Young et al 1991). 
Chest radiographs also have poor specificity for bronchiectasis with patient 
diagnosed with chronic obstructive pulmonary disease (COPD) also often displaying 
signs of thickened and dilated airways (tramlines and ring shadows) in hyper-
inflated lungs on chest x-ray. These changes can also be encountered in patients 
with asthma and lower respiratory tract infections (Lynch et al, 1993 & Cobientz et 
al, 1991). The British Thoracic Guidelines recommends a baseline chest radiograph 
for all patients but does not recommend its routine use in monitoring patients unless 
clinically indicated i.e. presence of new symptoms and even then, there is poor 
correlation between infective exacerbations and radiographic (Pasteur et al, 2010). 
 
1.9.2 Bronchograms 
In the 1920s a lipiodol substance was injected into the bronchopulmonary tree 
initially intra-tracheally and later via bronchoscopy immediately followed by chest 
radiograph to produce a bronchogram (Sicard et al, 1922 & Sergeant et al, 1923). 
This method allowed for more objective detection of bronchial dilatation but was 
not without its risks of allergy to contrast or anaesthetic and impairment of 
ventilation and diffusion, albeit temporarily. This imaging modality is one of the 
past now and has been superseded with more advanced imaging modalities such as 
computer tomography. 
 
1.9.3 High resolution computer tomography (HRCT) – Figure 7. 
Computer tomography (CT) is the gold standard imaging modality for the diagnosis 
and monitoring of bronchiectasis. The CT features are quite specific but the earliest 
abnormalities can be mild and merge with normality. Further confounders include 
age and cigarette smoking – both of which can cause bronchial abnormalities. One 
of the earliest signs of suppurative lung disease is bronchial wall thickening but this 
can be difficult to define and can also be seen in asthma and COPD so diagnosis of 
early or mild bronchiectasis can be contentious. 
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The characteristics of bronchiectatic airways on CT scan were first described by 
Naidich and colleagues to include: air-fluid levels, distended bronchi, linear arrays 
or clusters of cysts, dilated bronchi in the periphery of the lung and bronchial wall 
thickening (Naidich et al, 1982). Other radiological features that may be present in 
addition to those originally described by Naidich include emphysema, interlobular 
septal thickening (Sibtain et al, 2005) and a mosaic attenuation pattern due to small 
airways disease (Hansell et al, 1994). 
 
Reasons for poorer sensitivity with standard CT were explored and issues such as 
motion artefact (transmitted cardiac pulsations could mimic cystic bronchiectasis) 
and variations of disease such as mucoid impaction altering classical appearances of 
dilated bronchi were thought to contribute (Tarver et al, 1988). Sensitivity improved 
with the development of high resolution CT (HRCT) assessment of the bronchi in 
bronchiectasis and it was also proven to have minimal inter- and intra-observer 
variation with good reproducibility of bronchial wall circumference (Desai et al, 
1994). The BTS guidelines recommend the use of HRCT with the patient lying 
supine with breath holding at maximal inspiration. Standard protocol for scanning 
should be narrow collimation of 1.0mm slices taken at 10mm intervals to give the 
simplest and lowest radiation dose HRCT technique (Pasteur et al, 2010). 
 
HRCT imaging is now the gold standard investigation for diagnosing bronchiectasis 
with the defining feature being the presence of bronchial dilatation with the internal 
diameter of the bronchial lumen measuring greater than that of the adjacent artery 
often referred to as the signet ring sign, with the degree of bronchial dilatation 
typically categorised as cylindrical, varicose or cystic (Figure 7). The term 
cylindrical bronchiectasis is used when airways lie parallel to the plane of section 
and abnormal dilation is seen by a lack of normal tapering, producing a tramline 
(cylindrical) or flared appearance. Cylindrical bronchiectasis is the most common 
morphological pattern of bronchiectasis identified on CT. Constrictions along the 
length of the bronchiole can be termed varicose bronchiectasis and balloon cysts at 
the end of bronchioles can termed as cystic bronchiectasis. 
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Figure 7a. 
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Figure 7b. 
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Figure 7c. 
 
 
Figure 7. Radiological bronchiectasis a: cylindrical, b: varicose and c: cystic 
bronchiectasis. 
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1.9.4 Scoring systems on CT – Bhalla, Reiff and BRICS. 
HRCT is now established in the diagnosis of bronchiectasis but there had been no 
specific validated radiological score to assess severity until recently. Bhalla and 
colleagues designed a detailed radiological scoring system to quantify structural 
lung changes in cystic fibrosis using 9 categories:  number of lobes affected and 
segments involved; degree of bronchial dilatation; severity of bronchial wall 
thickening; extent of mucus plugging; presence or absence of sacculations; presence 
and number of bullae; presence of emphysema and number of lobes affected; 
collapse or consolidation; mosaic perfusion; air trapping (Bhalla et al, 1991). A 
modification of this score has been used in research studies (Eshed et al, 2007) but 
has not been validated for use in bronchiectasis.  The total range for the Bhalla score 
is from 3 to 25, with a lower score indicating more severe radiological 
bronchiectasis. This score was subdivided into mild (16-25), moderate (9-15), and 
severe (3-8). 
 
Reiff and colleagues subsequently developed a scoring system that described the 
site, type and extent of bronchiectasis whilst trying to establish if CT imaging could    
discriminate between idiopathic and other aetiological causes of bronchiectasis but 
found it to be of limited value. A modified Reiff score has been frequently used in 
studies gives a score ranging from 0-18 (mild:1-6, moderate: 7-12 and severe:13-18) 
based on the number of lobes affected (including the lingula) and the severity of 
bronchial dilatation compared to the adjacent vessel (0: no bronchiectasis; 1: 1-2x; 
2:  2-3x; 3: > 3x) (Reiff et al, 1995). 
 
Recently the Bronchiectasis Radiologically Indexed CT score (BRICS) was 
developed by Bedi and colleagues. This score used a multivariate analysis of the 
Bhalla score and its ability in predicted clinical markers that correlated with disease 
severity including FEV1 <50% predicted, sputum purulence and exacerbation 
requiring hospital admission.  Of the 9 categories of the Bhalla score only 2 (degree 
of bronchial dilatation and number of bronchopulmonary segments containing 
emphysema) categories were independently associated with the above markers of 
severity. These two radiological parameters were used to develop the BRICS 
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simplified score ranging from 0-5 where 1: mild, 2-3: moderate and ³3: severe 
disease.   The ROC values for the BRICS were 0.79 for percent predicted FEV1, 
0.71 for sputum purulence, and 0.75 for hospital admissions per year and 
significantly correlated with all 3 clinical severity parameters (p=0.004, p=0.008 and 
p=0.0001 respectively). The study was conducted in patients with only idiopathic or 
post-infective bronchiectasis with a previous minimal or none smoking history. It 
was externally validated (Bedi et al, 2018). 
 
Further studies investigating the use of HRCT severity scoring systems in other 
aetiologies are needed. In addition, long term studies investigating the role of CT 
and severity scoring as a means of disease monitoring are needed. 
 
1.10 Current management strategies 
The pathogenesis of bronchiectasis is poorly understood. Pulmonary pathology 
shows an excess of neutrophilic inflammation but despite this immune response, 
over two thirds of patients remain chronically infected with potential pathogenic 
microorganisms (Angrill et al, 2002). The driver for persistent neutrophilic airway 
inflammation in bronchiectasis is unknown, but infection is considered to play a 
major role (Chalmers et al, 2012). Paradoxically, there is failure of clearance of 
bacteria from the airways and this leads to a ‘vicious cycle’ of infection and 
inflammation in the airways as first described by Cole and colleagues (Cole et al, 
1989). The neutrophils and bacterial products cause structural damage and 
perpetuate the vicious cycle. Therapies are needed to break this vicious cycle and 
indeed antibiotics and anti-inflammatory agents have the potential for this (Sidhu et 
al, 2015). The goals of treatment in this chronic condition are to reduce cough and 
sputum volume, reduce sputum purulence, reduce the number of chest infections and 
improve the health-related quality of life. 
 
The management of bronchiectasis with specific aetiological diagnoses of allergic 
bronchopulmonary aspergillosis, connective tissue disease, rheumatoid arthritis, 
inflammatory bowel disease, gastro-oesophageal reflux disease, immune 
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deficiencies and cystic fibrosis should be targeted at the underlying condition and 
treated as per national guidelines. 
 
1.10.1 The role of vaccinations in bronchiectasis 
Influenza vaccinations are currently recommended on an annual basis for patients 
with chronic lung disease including bronchiectasis (Pasteur et al, 2010). There are 
no randomised controlled trials assessing the effect of influenza vaccination in 
bronchiectasis (Chang et al, 2007) but evidence reported in COPD, another chronic 
lung disease, in theory may be translatable. Influenza vaccination was found to 
reduce the number of exacerbations and the number of laboratory confirmed 
influenza infections in COPD patients 3 or more weeks after vaccination. There was 
no reported increase in exacerbations immediately after vaccination but there was 
transiently increased morbidity with arm redness and pain post-injection. Influenza 
vaccination had no impact on lung function, exercise tolerance, hospitalisation and 
mortality but the number of studies assessing some parameters (hospital admissions, 
death rates) was very small and so these conclusions have their limitations (Poole et 
al, 2006). 
 
There is limited evidence supporting the use of 23 valent pneumococcal vaccine to 
prevent exacerbations in bronchiectasis (Chang et al, 2009). One randomised 
controlled trial in COPD and bronchiectasis patient reported fewer exacerbations 
when pneumococcal vaccine was administered with influenza vaccines as opposed 
to influenza alone. There was no change in rates of pneumonia (Furumoto et al, 
2008). A Cochrane review of pneumococcal vaccines reports the 23-valent vaccine 
can prevent all cause pneumonia but results different depending on study site, adult 
population studied and which vaccine was assessed (Moberley et al, 2013). The 23-
valent pneumococcal vaccine is still offered in the UK, based on the evidence that, 
for adults between the ages of 65-74 with chronic lung disease, the 23-valent 
polysaccharide pneumococcal vaccine continues to provide short term protection 
against invasive pneumococcal disease and remains cost effective (Andrews et al, 
2012, JCVI 2012). The updated bronchiectasis guideline group recommends the 
pneumococcal vaccine is offered to all patients with bronchiectasis.  
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1.11 Management of exacerbations 
1.11.1 Role of oral antibiotics in exacerbations 
The British Thoracic Society (BTS) recommend sending sputum for bacteriological 
analysis but to start empirical antibiotics immediately for an exacerbation (Pasteur et 
al, 2010). The antibiotic recommended should be based on prior sputum 
microbiology but if no previous history is available, empirical amoxicillin (or 
clarithromycin in cases of penicillin allergy) should be started in addition to other 
supportive therapy. If patients fail to respond, then antibiotics could be amended 
based on the pathogen isolated and the antimicrobial sensitivities – Table 2. These 
recommendations are based predominantly on expert opinion (grade D). 
 
The evidence for oral antibiotic use in exacerbations is lacking, and even more so is 
the evidence for any particular agent. This may be due to the fact administration of 
antibiotics is so routine in treating chest infections. In an open labelled study, Hill et 
al investigated the response to oral antibiotics based on sputum purulence. All 
patients with mucoid (N=7) or mucopurulent (N=7) sputum had improved sputum 
purulence and/or clinical improvement when treated for an exacerbation with low 
dose amoxicillin 250mg t.d.s. for 14 days, compared to 16% in those with 
persistently purulent sputum (N=19). Of those that had treatment failure, 58% then 
responded to high dose amoxicillin 3g b.d for 14 days. This study demonstrates that 
higher doses of prolonged antibiotics may be needed for patients with more severe 
bronchiectasis.  
 
Chan et al (1996) and Lam et al (1989) investigated the use of quinolone antibiotics 
versus amoxicillin and reported better clinical and microbiological responses with 
the quinolones. These cohorts of patients had Pseudomonas aeruginosa in 41% and 
up to 32% respectively in the baseline sputum microbiology and further confirms 
the need for targeted antibiotic use. 
 
1.11.2 Inhaled antibiotics in exacerbations 
Traditionally exacerbations are treated with oral or intravenous antibiotics. The 
study by Bilton and colleagues studied the effect of adding nebulised tobramycin 
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300mg B.D. to a 2 week course of oral ciprofloxacin for exacerbations of 
bronchiectasis due to Pseudomonas aeruginosa10. They reported significant 
reductions in bacterial load in the treatment arm at day 7 which was maintained at 
the end of treatment (day 14) but with increased wheeze. There was no difference in 
clinical outcomes at day 14 or day 21. There is currently no recommendation to treat 
exacerbations with inhaled antibiotics (Bilton et al, 2006). 
 
1.11.3 Intravenous antibiotics in exacerbations 
The British Thoracic Society recommend the use of intravenous antibiotics when: 
the patient is unwell and requires hospital admission, if resistant organisms are not 
responsive to oral antibiotics or if patients fail to respond to oral therapy (usually in 
patients infected with Pseudomonas aeruginosa or other enteric Gram-negative 
organisms) (Pasteur et al, 2010). Evidence comparing oral with intravenous 
antibiotics is lacking and so this recommendation is only based on grade D 
evidence. 
 
Two small studies have been conducted with bronchiectasis patients investigating 
intravenous antibiotics but did not show any superiority in using intravenous 
antibiotics when compared with oral antibiotics (Levofloxacin 300mg B.D. versus 
Ceftazidime 1g T.D.S. (Tsang et al, 1999b) and amoxicillin 500mg T.D.S versus 
amoxicillin+clavulinc acid 750mg T.D.S versus amoxicillin+clavulanic acid 1.2g IV 
T.D.S (Mehta et al, 1991)) but highlighted the need for targeted antibiotic use. 
 
1.12 Stable state therapy 
1.12.1 Chest physiotherapy 
Clearance of pulmonary secretions is impaired in bronchiectasis. The expulsion of 
such stagnant secretions that are prone to infection is a key part of managing 
patients with bronchiectasis and is usually done with the aid of chest physiotherapy. 
There are different techniques of chest physiotherapy and these include the Active 
Cycle of Breathing Technique (ACBT), positive airway pressure adjuncts, 
oscillating positive airway pressure devices and postural drainage techniques.  
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Murray and colleagues demonstrated that twice daily chest physiotherapy improved 
volume of daily sputum expectorated, improved incremental shuttle walk test 
distance walked and cough related quality of life as assessed by the Leicester Cough 
Questionnaire (Murray et al, 2009b). A Cochrane review identified 7 small studies 
investigating different airway clearance techniques (ACT) in stable patients over a 
short-term (single sessions or 15-21days) and long-term (6months) period. It 
reported the effect of ACT on frequency of exacerbations is unknown and none of 
the included studies commented on time to next exacerbation or severity of 
exacerbations. There was low quality evidence to support that sputum expectoration 
is increased, quality of life is improved, some improvement in lung function, 
symptoms of breathlessness, cough and sputum production (Lee et al, 2015). The 
lack of randomised controlled trials comparing different techniques and the impact 
of ACT on patients experiencing an exacerbation mean no single technique of 
physiotherapy has been shown to be superior but the BTS guidelines recommend all 
patients with bronchiectasis should be referred to a dedicated respiratory 
physiotherapist (Pasteur et al, 2010) and a physiotherapy plan tailored to the 
individual’s needs and abilities should be suggested to help ensure compliance 
(Smith et al, 2017). 
 
Pulmonary rehabilitation and exercise training programmes have also been shown to 
be beneficial in several small studies with improvements in functional capacity, 
improvement in reported dyspnoea (Zanini et al, 2015 & Lee et al, 2014), health 
related quality of life (Mandal et al, 2012, Ong et al, 2011), fewer exacerbations 
with longer time to first exacerbation (Lee et al, 2014) but effects were not sustained 
at follow up visits after the rehabilitation programmes ended (Lee et al, 2014 & 
Newall et al, 2005). The BTS guidelines recommend pulmonary rehabilitation 
should be offered to patients that are functionally limited by breathlessness (Hill et 
al, 2018). 
 
Inspiratory muscle training (IMT) has been investigated by Newall and colleagues in 
a small (n=32) randomised controlled trial. Patients were randomised to either an 8 
week programme of pulmonary rehabilitation (PR) with IMT or 8 weeks of 
 62 
pulmonary rehabilitation with sham IMT or to the no intervention control group 
(Newall et al, 2005). They reported functional capacity improved in both 
intervention groups but quality of life was significantly better in the 8 weeks 
PR+IMT group. Exercise capacity deteriorated in the  PR+sham group at the 3 
month follow up but was maintained in the PR+IMT arm. Therefore IMT alone was 
not reported to increase exercise capacity or quality of life but may be useful in 
enhancing the longevity of the training effects. IMT should therefore be considered 
in conjunction with pulmonary rehabilitation for patients with bronchiectasis that are 
functionally limited by dyspnoea (Hill et al, 2018). 
 
31.12.2 Role of bronchodilators 
Prevalence of bronchiectasis in patients with COPD has been reported as high as 
69% and 43% in patients with asthma (Chalmers et al, 2017b). The BTS guidelines 
advocates all patients with bronchiectasis should be assessed for airway obstruction 
and reversibility. Bronchodilator therapy with b2 agonists +/- anticholinergics 
should be instituted where symptoms or lung function improves with therapy 
(Pasteur et al, 2010). There are no randomised controlled trials assessing 
bronchodilator therapy (Franco et al, 2003 & Lasserson et al, 2001) but in a small 
study (n=24) patients were given b2 agonist MDI treatment followed by b2 agonist 
nebulised therapy and then 24hrs later were given anticholinergic MDI treatment 
followed by anticholinergic nebulised therapy. 46% of patients were found to 
respond to one or both treatments with an improvement in FEV1 ³15% (Abu Hassan 
et al, 1999). There were similar responses to the b2 agonist (fenoterol) and the 
anticholinergic (ipratropium bromide). A randomised trial by Martinez and 
colleagues in 40 patients investigated combination therapy with formoterol-
budesonide 18/640mg versus budesonide 1600mg alone for 3months. There was a 
significant improvement in quality of life as assessed by SGRQ by 5.3units 
(p=0.0006), improvement in dyspnoea, cough and reduction in the number of rescue 
b2 agonist inhalations with the combination arm. There was no difference in lung 
function, sputum microbiology or exacerbation rate but fewer side effects with 
combination therapy, especially those associated with inhaled steroids (Martinez et 
al, 2012).  
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1.12.3 Role of muco-active therapies 
Regular chest clearance is regarded as key for all patients with clinically significant 
bronchiectasis. To aid this, there has been interest in treatments that improve 
mucociliary clearance and sputum expectoration. Hypertonic saline, mannitol, 
carbocysteine and DNase are the most studied agents but there are limited phase III 
trials in non-cystic fibrosis bronchiectasis patients.  Hypertonic saline and mannitol 
are hyperosmolar agents that improve airway hydration by inducing a liquid flux to 
the airway surface. This in turn helps to mobilise sputum.  
 
Hypertonic saline has been investigated in several small trials in bronchiectasis.  A 
study in 8 patients demonstrated the effect of isotonic 0.9% saline on sputum 
mobilisation by reporting increased sputum expectoration when using immediately 
prior to chest physiotherapy when compared to chest physiotherapy alone (Sutton et 
al, 1988). In a 4-way crossover study, 24 patients were randomised to one of the 
four arms: i) active cycle breathing technique (ACBT); ii) nebulised terbutaline and 
ACBT; iii) nebulised terbutaline, nebulised isotonic saline (IS) then ACBT; and iv) 
nebulised terbutaline, nebulised hypertonic 7% saline (HTS) then ACBT. The 
authors reported improved ease of sputum expectoration, reduced sputum viscosity 
and a small improvement in lung function with the use of inhaled HTS (7%) (Kellet 
et al, 2005). A second randomised single-blind study by the same group over a 
3month period in 28 patients comparing 7% HTS with 0.9% IS saline reported HTS 
had a significant improvement in quality of life as assessed by the St George’s 
Respiratory Questionnaire (p<0.05) and significant increase in FEV1 by 15% from 
baseline versus 1.8% with 0.9% IS (p<0.01) (Kellet et al, 2011). 
 
A randomised controlled trial investigating the effects of 6% HTS over 12 months 
was conducted, where 40 patients were randomised to receiving either once daily 
6% HTS or 0.9% IS (Nicolson et al, 2012). The authors found similar significant 
improvements in quality of life and lung function (FEV1 and FEF25-75) for both 
groups at 6 months but the improvement in FEV1 was not sustained at 12 months. 
There was a significant reduction in sputum colonisation from 60% in the IS group 
and 55% of HTS group at baseline to 15% in both groups at 12 months. There was 
 64 
no difference between the groups in any of the end points, including exacerbation 
frequency.  
 
The lack of large randomised trials on hypertonic saline preclude its 
recommendation for regular use in patients with bronchiectasis as there is some 
evidence to that suggests HTS may improve sputum clearance and quality of life but 
it remains unclear if this benefit is superior to that of IS use. The BTS guidelines 
suggest a trial of muco-active therapy could be considered in patients experiencing 
difficulty expectorating (Hill et al, 2018).  
 
Mannitol is a naturally occurring sugar thought to alter the osmotic gradient in the 
airways and thus change the properties of mannitol making it easier to expectorate. 
Inhaled mannitol has also been investigated with several small studies with mixed 
results of improved sputum expectoration (Daviskas et al, 1999 & Daviskas et al, 
2008), improvement in quality of life (Daviskas et al, 2003), no change in lung 
function and that it was well tolerated despite inducing cough (Daviskas et al, 2003, 
2005, 2008). In 2014, Bilton and colleagues conducted a larger multicentre double-
blind randomised controlled trial with 461 patients with excess sputum production 
and 2 or more exacerbations in the last 12 months were randomised to either 400mg 
mannitol b.d or low dose mannitol control b.d. (Bilton et al, 2014). They found the 
exacerbation rate did not significantly reduce on 400mg mannitol (p=0.3) but the 
time to next exacerbation did significantly lengthen (165days versus 124days, 
p=0.02). Quality of life as assessed by the St George’s Respiratory Questionnaire 
was also found to improve with mannitol (p=0.046) but there was no benefit in lung 
function or sputum bacteriological properties. Inhaled mannitol was well tolerated 
with similar adverse events experienced in both the mannitol and control group. As 
this mannitol study failed to reach its primary endpoint, it is unlikely to be used 
routinely in clinical practice.  
 
Mucolytics such as DNase, carbocysteine and bromhexine have also been 
investigated to enhance mucociliary clearance by changing the physiochemical 
properties of sputum. This reduction in sputum viscosity should allow easier 
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mobilisation. A Cochrane review identified only 3 studies (described below) 
assessing mucolytics in bronchiectasis patients (Crockett et al, 2001). Mucolytics 
remain a promising prospect for treatment but randomised controlled data is lacking 
to support any recommendations for regular use.  
 
The first study by Olivieri and colleagues, assessed bromhexine 30mg t.d.s versus 
placebo. They noted an improvement in ‘difficulty in expectoration’, an increase in 
sputum production and a significant reduction in cough. There was no change in 
lung function (Olivieri et al, 1991). Wills et al conducted a double blind randomised 
control trial studying human recombinant DNase (rhDNase) 2.5mg twice daily, 
2.5mg once daily, placebo twice daily or placebo once daily in 21 patients with 
bronchiectasis (Wills et al, 1996). They failed to show any improvement in lung 
function, dyspnoea or quality of life at the higher dose but did report a significant 
improvement in dyspnoea with low dose rhDNase. Influenza-like symptoms were 
reported in 4 subjects randomised to high dose rhDNase. O’Donnell and colleagues 
conducted a large double blind randomised control trial investigating rhDNase 
versus placebo twice daily for 24 weeks in 349 patients (O’Donnell et al, 1998). The 
authors reported a significant increase in protocol derived and non-protocol derived 
exacerbation rates when compared with placebo. They also reported a significant 
reduction in FEV1 compared with placebo (FEV1 decline -3.7% change vs  -1.7% in 
placebo    group) and as a consequence of this trial DNase is not recommended in 
the treatment of bronchiectasis (Pasteur et al, 2010). 
 
1.12.4 Role of inhaled corticosteroids 
A Cochrane review found limited small studies investigating the use of inhaled 
corticosteroids in bronchiectasis but no large placebo-controlled randomised 
controlled trials (Kapur et al, 2018). The small studies have suggested that inhaled 
corticosteroids can reduced sputum volume (Tsang et al, 2005, Elborn et al, 1992) 
and improve quality of life (Martinez et al, 2006) but they have not proven whether 
long-term treatment has any effect on lung function or exacerbation rates (Tsang et 
al, 1998). In addition, there is some concern with the use of single agent inhaled 
corticosteroid use in COPD due to the risk of pneumonia (Janson et al, 2013). Large 
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randomised controlled trials assessing benefit versus risk of these treatments must be 
conducted before their routine use can be recommended (Pasteur et al, 2010). 
 
1.12.5 Non-steroidal anti-inflammatories (NSAIDS) 
A Cochrane review identified only 1 small randomised double blinded controlled 
study comparing inhaled indomethacin 2.4micrograms, t.d.s for 14 days in 25 
patients with a variety of chronic lung diseases (8 bronchiectasis, 12 chronic 
bronchitis and 5 diffuse panbronchiolitis) with placebo (Pizzutto et al, 2010 & 
Tamaoki et al, 1992). Results showed an improvement in the amount of sputum 
expectorated and dyspnoea but no change in lung function. A second study of 9 
patients with stable bronchiectasis were given 4 weeks of oral 25mg oral 
indomethacin (t.d.s). Analysis showed no effect on airway bacterial load or sputum 
chemotaxis but there was marked reduction in peripheral blood neutrophil function 
with reduced chemotaxis and fibronectin degradation (Llewellyn-Jones et al, 1995). 
Larger randomised controlled trials to assess NSAIDs as potential anti-inflammatory 
agents are needed before they can be considered for routine treatment. 
 
1.12.6 Statins 
Statins are widely used in cardiovascular disease and have been shown to be 
associated with a 41% reduction in 30-day mortality in patients hospitalized with 
seasonal influenza. One of the pleotropic effects of statins is their anti-inflammatory 
property, which could have a role in breaking the vicious cycle of bronchiectasis. To 
date, only two randomised controlled trials has been conducted in patients with 
bronchiectasis. 60 patients were randomly allocated to either 80mg Atorvastatin 
once daily or placebo for 6 months. The authors reported a significant improvement 
in cough as assessed by the Leicester Cough Questionnaire with the intervention 
group (p=0.01) but also more adverse events (p=0.02) (Mandal et al, 2014).  
 
A randomised placebo cross over trial investigated atorvastatin 80mg daily for 3 
months in patients chronically infected with P. aeruginosa. Statin therapy did not 
improve the primary endpoint for improved cough assessed by the Leicester Cough 
Questionnaire. There were however significant improvements in the St. George’s 
 67 
Respiratory Questionnaire (5.6 Unit improvement) and a reduction in serum 
Interleukin-8, Tumour necrosis factor-alpha and Intercellular adhesion molecule-1 in 
the statin treated group (Mandal et al, 2017). Further randomised trials to assess 
their effect on exacerbation frequency are required.  
 
1.12.7 Others 
Because of the excess neutrophil burden in bronchiectasis, future studies are needed 
to assess novel therapies such as neutrophil elastase (NE) inhibitors and tumour 
necrosis factor alpha (TNFa) inhibitors but to date there has only been one small 
study on neutrophil elastase inhibitors and none in TNFa inhibitors.  
 
Stockley et al randomised 40 patients to receiving NE inhibitor AZD9668 60mg, 
b.d. (n=22) or placebo (n=16) for 4 weeks (Stockley et al, 2013). They reported a 
significant improvement in FEV1 of 100mls, slow vital capacity, plasma interleukin 
8 and post waking sputum interleukin 6. There was no significant improvement in 
quality of life, sputum weight or other lung function tests in the treatment group. 
AZD9668 seemed to be well tolerated with fewer adverse events reported than in the 
placebo arm. The most common complaint in the treatment arm was of headache 
7/22 compared with 2/16 in the placebo arm. These results are encouraging but 
larger studies of longer duration are needed. 
 
De Soyza and colleagues investigated CXCR2 antagonist AZD5069 80mg twice 
daily in a randomised double-blind placebo-controlled parallel-group trial for 28 
days in 52 patients with bronchiectasis. CXCR2 is a surface membrane receptor for 
Interleukin-8 which is partly responsible for neutrophil migration into the lungs. 
They reported a significant reduction in absolute percentage sputum neutrophil 
counts with AZD5069, but no difference was seen with the number of exacerbations 
or serum C-reactive protein levels. There were more discontinuation of treatment 
with AZD5069 but the compound was overall well tolerated (De Soyza et al, 2015). 
These results are encouraging but larger studies of longer duration are needed. 
 
1.12.8 Role of long term oral antibiotics 
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Studies have shown exacerbations reduce quality of life. It stands to reason then by 
reducing the number of exacerbations, quality of life should improve. Long term 
oral antibiotics have been investigated previously with the rationale that reducing 
bacterial load burden would reduce inflammation and hence allow the bronchial tree 
to repair/heal leading to fewer symptoms, exacerbations, and improved quality of 
life. The first studies were conducted in the 1950s and 1960s and mainly showed 
tetracyclines improved clinical outcome (reduced sputum volume and purulence), 
reduce exacerbation frequency but also lead to gastrointestinal side effects in 20-
30% or patients (MRC, 1957, Sobel et al, 1962 & Cherniack et al, 1959). Whilst 
tetracyclines reduced some bacterial species (S. pneumoniae, H. influenzae, S. 
aureus) it led to an increase in the culture of Pseudomonas aeruginosa (Dowling et 
al, 1960). One further study was conducted in 38 patients randomised to either high 
dose amoxicillin (3g, twice daily for 32weeks) or placebo found high dose 
amoxicillin led to significant clinical improvement with less severe exacerbations 
(Currie et al, 1990). There have been no large randomised controlled trials 
investigating the role of long-term non-macrolide oral antibiotics. In view of limited 
treatments, their use is only recommended in patients experiencing 3 or more 
exacerbations a year despite optimizing chest clearance techniques and treatment for 
comorbidities e.g. reflux or rhinosinusitis. Long term oral antibiotics are suitable 
particularly in patients colonised with potential pathogenic organisms, for example 
Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis, 
which have multiple suitable oral antibiotic preparations. The major limiting factor 
is that such long-term antibiotics have side effects and predominantly diarrhoea 
(Sobel et al, 1962 & Dowling et al, 1960). Further randomised controlled studies are 
required to assess the effect of long-term antibiotic use on the generation of 
resistance. 
 
1.12.9 Role of long term inhaled antibiotics 
Inhaled and nebulised antibiotic therapies target the airways directly and should 
thereby reduce systemic side effects. Several studies have investigated the role of 
long term nebulised antibiotics in the stable state and are summarised below. These 
key studies are also listed in table 3 (Sidhu et al, 2014). 
Author Study N Antibiotic Dose & Duration Microbiology Results Interpretation 
Lin et al, 
1997 
Randomised  16 Gentamicin  
Versus 
0.45% saline 
40mg, b.d, 3 days  Not recorded The gentamicin group led to a reduction in 
microbial load, sputum Myeloperoxidase 
(MPO) levels and sputum volume. There was 
improved Borg breathlessness score, peak 
expiratory flow rates and 6 min walk.  
Early proof of concept study showing 
inhaled antibiotics could reduce 
microbial burden and improve clinical 
outcomes. 
Barker 
et al, 
2000 
Randomised  74 Tobramycin  
Versus 
Placebo 
300mg, b.d, 4 weeks on 
treatment then 2 weeks off 
100% P. aeruginosa The tobramycin group at week 4 led to a 
significant reduction of sputum bacteria by 
4.54 log (10) cfu/g with tobramycin with no 
change in the placebo group, p<0.01. 
Tobramycin subjects also showed a 35% 
eradication rate at week 6, with no eradication 
in placebo. 
Tobramycin group had increased cough, 
wheeze, chest pain and breathlessness. 
Inhaled tobramycin over 4 weeks can 
eradicate P. aeruginosa in 35% - an 
outcome that is very different to the 
cystic fibrosis population. 
Wilson 
et al, 
2013 
Randomised 124 Ciprofloxacin (DPI) 
Versus 
Placebo  
32.5mg, b.d, 28 days 54% P. aeruginosa 
24% H. influenzae 
20% S. aureus 
7% S. pneumoniae 
6% M. catarrhalis 
4% K. pneumoniae 
6% P. mirabilis 
4% K. oxytoca 
There was a significant reduction in bacterial 
density for those on ciprofloxacin DPI with 
total sputum bacterial load at day 28 - end of 
treatment (EOT) (-3.62 log10 CFUg
-1 (range -
9.78–5.02 log10 CFUg
-1)) compared with 
placebo (-0.27 log10 CFUg
-1 (range -7.96–
5.25 log10 CFUg
-1)) (p<0.001). The counts 
increased thereafter until they were similar at 
day 84.  
14/40 subjects in the ciprofloxacin DPI group 
reported pathogen eradication at EOT vs 4/49 
in the placebo group (p=0.001). 
Inhaled ciprofloxacin improved 
bacterial clearance over 28 days and 
was well tolerated. 
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3/60 in ciprofloxacin vs 3/64 in placebo 
reported bronchospasm, 0/60 vs 5/64 reported 
cough and 1/60 vs 2/64 reported haemoptysis. 
No change in FEV1 or FVC for either group. 
No significant difference between the groups 
in sputum volume or colour. 
Drobnic 
et al, 
2005 
Randomised 
crossover 
study 
30 Tobramycin 
Versus 
Placebo  
300mg, b.d, 6 months 100% P. aeruginosa No effect on overall number of exacerbations, 
pulmonary function or health status. 
The tobramycin treated group had a reduced 
number of and length of hospital admissions 
(p<0.05). 
Significant reduction in P. aeruginosa 
bacterial load (p<0.05). 
Bronchospasm occurred in 10%.  
No significant increase in bacterial resistance. 
Inhaled tobramycin in patients with P. 
aeruginosa over 6 months led to a 
reduction in severity of admissions 
and with no impact on bacterial 
resistance. 
Serisier 
et al, 
2013b 
Randomised 42 Ciprofloxacin (DRCFI) 
Versus 
Placebo 
150mg ciprofloxacin for 
inhalation + 20mg free 
ciprofloxacin for 
inhalation, o.d., 24 weeks 
(3x 28days on/28days off) 
100% P. aeruginosa There was a mean reduction in P. aeruginosa 
bacterial density at day 28 of 4.2 log10 CFU/g 
with DRCFI compared to a mean reduction of 
0.08 with placebo (p=0.002). 
Time to first exacerbation was significantly 
delayed by DRCFI (134 days) when compared 
with placebo (58days). 
DRCFI was well tolerated with fewer 
respiratory related adverse events than 
placebo. Main treatment related adverse events 
included nausea, sinusitis, fatigue, headache 
and abnormal taste. 3 subjects in each arm 
developed an exacerbation – thought not to be 
related to treatment. 
In per protocol analysis inhaled 
ciprofloxacin led to a delayed first 
exacerbation in this 6 month study. 
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De 
Soyza et 
al, 2018 
Randomised 416 Ciprofloxacin (DPI) 
versus placebo 
32.5mg b.d. for 14 days 
on/14days off versus 
placebo 
OR 
32.5mg b.d. for 28 days on/ 
28 days off versus placebo   
Predefined bacterial 
culture including P. 
aeruginosa 
Ciprofloxacin DPI 14 days on/off significantly 
prolonged time to first 
exacerbation versus pooled placebo (median 
time >336 versus 186 days; hazard ratio 0.53, 
97.5% CI 0.36–0.80; p=0.0005). 
Ciprofloxacin DPI reduced the frequency of 
exacerbations compared with matching 
placebo by 39% (mean number of 
exacerbations 0.6 versus 1.0; incidence rate 
ratio 0.61, 97.5% CI 0.40–0.91; p=0.0061).  
There was no significant difference from 
placebo for the 28 days on/off treatment. 
The safety profile was favourable. 
Cyclical treatment with 14 days on 
and off with Ciprofloxacin DPI was 
well tolerated and led to reduced 
exacerbations and increased time to 
next exacerbation. The 14 day cyclical 
regimes were superior to the 28 day 
cyclical regimes which did not show 
any significant difference to treatment 
with placebo. 
Aksamit 
et al, 
2018 
Randomised 521 Ciprofloxacin (DPI) 
versus placebo 
32.5mg b.d. for 14 days 
on/14days off versus 
placebo 
OR 
32.5mg b.d. for 28 days on/ 
28 days off versus placebo   
Predefined sputum 
bacteria including P. 
aeruginosa 
There was a trend towards prolonged time to 
next exacerbation (ciprofloxacin DPI 14 days 
on/off: hazard ratio 0.87, 95.1% CI 0.62–1.21; 
p=0.397; ciprofloxacin DPI 
28 days on/off: hazard ratio 0.71, 99.9% CI 
0.39–1.27; p=0.051) but this was not 
statistically significant. 
There was a trend towards reduced 
exacerbation frequency in both active 
ciprofloxacin treatment groups (ciprofloxacin 
DPI 14 days on/off: incidence rate ratio 0.83, 
95.1% CI 0.59–1.17; p=0.2862; ciprofloxacin 
DPI 28 days on/off: incidence rate ratio 0.55, 
99.9% CI 0.30–1.02; p=0.0014.  
The overall exacerbation rate for the study was 
(mean±SD 0.6±0.9). 
The primary endpoints for this study 
were not achieved. There was no 
statistical difference between 
Ciprofloxacin DPI and placebo. 
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Ciprofloxacin DPI was well tolerated.  
Hawort
h et al, 
2017 
Randomised 582 Ciprofloxacin (ARD -
3150, pulmaquin) 
nebulised versus 
placebo 
150mg ciprofloxacin for 
inhalation + 60mg free 
ciprofloxacin for 
inhalation, o.d., 48 weeks 
(6x 28days on/28days off) 
100% P. aeruginosa Ciprofloxacin treatment led to a clinically 
significant increase in the time to next 
exacerbations requiring antibiotics.  
There was also a significant reduction in the 
frequency of protocol defined exacerbations 
(irrespective of whether antibiotics were 
prescribed).  
No difference in time to next protocol defined 
exacerbation.  
There was significantly reduced sputum P. 
aeruginosa bacterial density. with 
ciprofloxacin. 
Similar rates of adverse evcnts/serious adverse 
events between the ciprofloxacin and placebo 
group.  
Nebulised Ciprofloxacin in 28 day 
on/off regime for 6 cycles reduced the 
number of protocol defined 
exacerbations but not the time to next 
protocol defined exacerbation in 
patients colonised with P. aeruginosa. 
It was well tolerated. 
Orriols  
et al, 
1999 
 Randomised 
open labelled 
study 
15 Ceftazidime + 
tobramycin 
Versus 
Symptomatic treatment  
1g, b.d &  
100mg b.d, 1 year  
100% P. aeruginosa In the active group the mean number of 
admissions and length of admission were 
significantly lower than symptomatic 
treatment. 
No change in FEV1 or FVC for overall 
exacerbation frequency for either group. 
No significant increase in bacterial resistance. 
This small study supports that long 
term inhaled antibiotics reduce the 
severity of exacerbations.  
Murray 
et al, 
2011 
Randomised 
single blinded 
study 
65 Gentamicin  
Versus 
0.9% Saline 
80mg, b.d, 1 year 48.1% P. aeruginosa 
40.7% H. influenzae 
7.4% S. aureus 
3.4% S. pneumoniae 
 
The gentamicin group led to                           1. 
Increased ETT 95m 
2. Leicester Cough Questionnaire 81% had 
1.3U improvement or greater vs. 20% placebo  
3. SGRQ 82.5% had 4U improvement or 
greater vs. 19.2% placebo  
This 1 year study supports long term 
inhaled antibiotics reduce total 
number of exacerbations and time to 
first exacerbation. Treatment, 
however, has to be continuous for its 
ongoing efficacy. 
 73 
4. Increased time to next exacerbation 
(Gentamicin 120d (87-162) vs. Saline 61.5d 
(20-7-122.7)) 
5. Decreased exacerbations (Gent 0(0-1) vs. 
Saline 1.5(1-2)) 
6. No significant effect on antimicrobial 
resistance 
There was however in the gentamicin group, 
1. No effect 24hr volume, FEV1, FVC, 
FEF25/75 
2. 21.9% (7 of 32 patients) reported 
bronchospasm and received adjunctive 
nebulised β2 agonist treatment. Despite this, 
two patients (6%) required withdrawal from 
the study (one at month 3 and one at month 6) 
Treatment needs to be continuous for its on-
going efficacy. 
Hawort
h et al, 
2014 
Randomised, 
double-blind 
144 Colistin versus placebo 
(0.45% saline) 
1million I.U. via ineb b.d, 
6months 
100% P. aeruginosa Primary endpoint of time to next exacerbation 
showed no difference between Colistin and 
placebo (p=0.11).  
Time to next exacerbation based on adherence 
recorded by the I-neb was delayed in the 
Colistin arm; 168days versus 103days 
(p=0.038). 
P.aeruginosa density reduced after 4 
(p=0.001) and 12 weeks (p=0.008). 
SGRQ scores improved after 26weeks 
(p=0.006). 
No Colistin resistant strains of P. aeruginosa 
Primary endpoint of time to next 
exacerbation was not achieved. 
In treatment adherent patients (took 
medication more than 80% of the 
time) there was a significant delay in 
time to next exacerbation. 
Overall well tolerated with no issues 
of resistance with continuous therapy. 
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identified, no difference in treatment emergent 
pathogens between the groups. 
No difference in FEV1, sputum weight or 
adverse events. 
Barker 
et al, 
2014 
Randomised 266 
 
 
 
 
 
 
274 
Aztreonam versus 
placebo 
 
 
 
 
 
Aztreonam versus 
placebo 
75mg o.d. for 16 weeks (2x 
4weeks on/4 weeks off) 
 
 
 
 
 
75mg o.d. for 16 weeks (2x 
4weeks on/4 weeks off) 
Chronic colonisation 
with gram negative 
organisms 
 
 
 
 
 
Chronic colonisation 
with gram negative 
organisms 
Primary endpoint of change from baseline 
Quality of Life-Bronchiectasis Respiratory 
Symptoms scores (QOL-B-RSS) was not 
significantly different between active and 
placebo arms. 
There was a statistically significant difference 
in QOL-B-RSS but the 4.6unit change was not 
thought to be clinically relevant. 
In both studies treatment adverse events and 
discontinuations from treatment were more 
common in the Aztreonam group. 
No improvement in respiratory 
symptoms; time to first exacerbation 
not prolonged; more treatment-related 
adverse events; more discontinuations 
with treatment than placebo  
 
Table 3. Inhaled antibiotic studies in stable bronchiectasis  
 
 
 
 
 
The studies to date show encouraging preliminary data that long term inhaled 
antibiotics can reduce the bacterial burden and improve clinical outcomes (Drobnic 
et al, 2005; Serisier et al, 2013b; Orriols et al, 1999 & Murray et al, 2011).  New 
phase 3 trials have shown in randomised controlled trials that long-term dry powder 
for inhalation preparations of Ciprofloxacin may have effects of reducing 
exacerbation frequency and prolonging the time to next exacerbation but results are 
not consistent. RESPIRE-1 and RESPIRE-2 are identical trials in different cohorts. 
In RESPIRE-1, De Soyza and colleagues reported increased time to next 
exacerbation (p=0.0005) and reduced frequency of exacerbations (p=0.0061) with a 
14day on/off regime but did not see this effect with the 28day on/off treatment arms 
(p=0.065 and p=0.89 respectively) (De Soyza et al, 2018). 24.5% of all isolates at 
baseline had increased minimum inhibitory concentrations (MICs) for ciprofloxacin 
and the number of patients that cultured pathogens with increased MICs during 
treatment was higher with ciprofloxacin than with placebo (14days: 20.4%, 28days: 
26.3% and pooled placebo: 12.3%). If taking into account any pathogens with 
increased MICs including at baseline and End of Study (8weeks after trial, EOS) the 
percentages increase to 54%, 53.9% and 36.2% for 14day, 28day and pooled 
placebo respectively. At EOS, there was less than 10% of elevated MIC pathogens 
for the ciprofloxacin arms and 2.2% in the placebo arms suggesting resistance off 
treatment was not maintained. The clinical consequences of elevated MICs require 
further investigation as subgroup analysis did not show reduced efficacy in those 
patients with elevated MICs at baseline. RESPIRE-2, Aksamit and colleagues 
(2018) did not show an increase in time to next exacerbation (14day: p=0.40, 28day: 
p=0.05) or reduction in exacerbation frequency (14day: p=0.29, 28day: p=0.0014). 
RESPIRE-2 did not meet its primary endpoints.   
 
2 further phase 3 trials (ORBIT-3 and ORBIT-4) are underway and preliminary 
results only have been published in abstract format reporting 28day on/off cycles of 
ciprofloxacin reduced frequency of protocol derived exacerbations but not increased 
time to next protocol defined exacerbation (Haworth et al, 2018). Overall 
inhaled/nebulised ciprofloxacin appears to be well tolerated. 
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A meta-analysis by Brodt and colleagues in 12 trials (including most of those listed 
above in addition to unpublished trials) evaluating the efficacy and safety of inhaled 
antibiotics in 1264 patients with bronchiectasis reported inhaled antibiotics were 
more effective at reducing sputum bacterial load, sputum bacterial eradication and 
reducing exacerbations than placebo or symptomatic treatment (Brodt et al, 2014). 
 
There has been a longstanding debate whether these treatments should be 14-day or 
28-day, on and off or continuous (Murray et al, 2011, Haworth et al, 2014, Serisier 
et al, 2013b, De Sozya et al, 2018, Aksamit et al, 2018, Haworth et al, 2017 & 
Barker et al, 2014). The theory for the on-off regimen was to reduce the 
development of microbial resistance. The long term antibiotic studies to date have 
not shown that continuous antibiotics lead to bacterial resistance affecting patient 
care (Drobnic et al, 2005; Orriels et al, 1999, Murray et al, 2011 & Haworth et al, 
2014). It is likely that inhaled therapy will be predominantly used in patients 
colonised with more complex pathogens such as Pseudomonas aeruginosa where 
there are limited or no long term suitable oral therapies. The limiting factors to date 
using these therapies are they have significant cost to their use and are all currently 
unlicensed. In addition, such therapies can cause bronchospasm and breathlessness 
and around 10% of patients will have to discontinue therapy despite the addition of 
inhaled or nebulised bronchodilator therapy because of these symptoms (Barker et 
al, 2000; Drobnic et al, 2005 & Murray et al, 2011, Brodt et al, 2014).  
 
An alternative approach in patients with very severe bronchiectasis is the 
consideration for regular planned eight weekly courses of intravenous antibiotic 
therapy. A small study showed that this treatment improved patients’ symptoms 
with reduced antibiotic burden, cough and improved health status and reduction of 
systemic inflammation (Mandal et al, 2013).  Randomised controlled trials are 
however needed to explore this further.  
 
1.12.10 Role of Macrolides 
There has been a growing interest in newer therapies for bronchiectasis to break the 
‘vicious cycle’. These include anti-inflammatory and anti-infective therapies. It is 
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likely such treatments are not needed for patients with mild bronchiectasis who have 
few symptoms when clinically stable and have few chest infections. The largest 
anti-inflammatory therapies studied to date are the macrolides. In addition to 
antibacterial properties, macrolides are thought to have immunomodulatory and 
anti-inflammatory properties. Over recent years, several studies have been done 
assessing the role of long term macrolides in stable bronchiectasis.  
 
Tsang et al performed a randomised double blind placebo controlled study showing 
an improvement in lung function and sputum volume reduction in patients treated 
with 8 weeks of 500mg b.d erythromycin (Tsang et al, 1999). It did not show a 
difference in microbial load or inflammatory markers but the majority of patients 
were colonised with Pseudomonas aeruginosa. 
 
Wong et al confirmed these findings in the Effectiveness of Macrolides in patients 
with Bronchiectasis using Azithromycin to control Exacerbations (EMBRACE) trial 
(Wong et al, 2012). This was a randomised double-blind placebo controlled trial of 
141 patients randomised to either taking azithromycin 500mg three times a week or 
placebo for 6 months. They showed a significant reduction in the rate of event-based 
exacerbation from 1.57 in the placebo group to 0.59 with the azithromycin group.  
There was no statistically significant difference in lung function or quality of life. 
Macrolide resistance testing was not routinely undertaken in this study but 4% in the 
azithromycin group had macrolide resistant Streptococcus pneumoniae at 6 months. 
 
The Bronchiectasis and long term Azithromycin Treatment (BAT) study in 83 
bronchiectasis patients with 3 or more exacerbations in the past year were 
randomised to either 250mg azithromycin once daily or placebo for 1 year 
(Altenburg et al, 2013). Results showed a significant decrease in exacerbation 
frequency in the azithromycin group with a longer time to first exacerbation during 
treatment. FEV1 and FVC improved with azithromycin, as did quality of life as 
assessed by SGRQ. Sputum microbiology was similar at baseline and at 1 year but 
macrolide resistance was recorded in 88% of the isolates tested (53 of 60 pathogens 
tested in 20patients in the azithromycin arm) compared with 26% (29 of 112 
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pathogens tested from 22 patients) in the placebo group during treatment. Adverse 
reactions were reported, mainly gastrointestinal symptoms, but these were not 
severe enough to discontinue treatment. 
 
The Bronchiectasis and Low dose Erythromycin Study (BLESS) investigated the 
effect on exacerbations rates and resistance rates post 1-year therapy with low dose 
erythromycin (Serisier et al, 2013). Patients were randomised to low dose 
erythromycin or placebo for 48 weeks. Results showed a significant reduction in 
exacerbation frequency, reduced FEV1 decline but an increase in macrolide 
resistance. Erythromycin was well tolerated with no significant adverse effects. In 
the literature, there is evidence of increased risk of cardiac death due to prolonged 
QTc and arrthymias with the use of macrolides (Ray et al, 2012). No difference in 
QTc values or arrthymias was reported at this low dose, in the BLESS trial. 
Erythromycin increased the proportion of macrolide resistant oropharyngeal 
streptococci. 
 
There is debate whether macrolides are anti-infective, anti-inflammatory or both. All 
three studies showed in comparison to placebo, macrolide therapy reduced 
exacerbations (Wong et al, 2012; Altenburg et al, 2013 & Serisier et al, 2013). It is 
clear that it was not dependent on the macrolide chosen or the frequency of delivery. 
Reducing exacerbations is key to improving the morbidity of bronchiectasis and 
these studies support the long-term use of macrolides. There are however concerns 
with macrolides concerning their toxicity in a middle age and elderly cohort. The 
concerns are the risk of non-tuberculous mycobacteria, cardiovascular mortality and 
pneumococcal resistance to macrolides (Adjemian et al, 2012 & Olivier et al, 2003). 
In bronchiectasis, macrolide resistance in this group would make the treatment of 
non-tuberculous mycobacteria very difficult to treat. This is of major concern 
because non-tuberculous mycobacteria are isolated in 5-10% of cases in Europe but 
30-40% cases in the US (Adjemian et al, 2012 & Olivier et al, 2003). Recent 
reviews have shown that macrolide use can increase cardiovascular mortality, which 
would be concern to a middle and elderly aged cohort (Ray et al, 2012 & Schembri 
et al, 2013). It has been shown in these studies that there is a significant increase in 
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pneumococcal resistance to macrolides (Altenburg et al, 2013 & Serisier et al, 
2013). It is not known however whether this has any clinical significance. In the 
studies to date up to one year, these have not been of any clinical significance.  
 
1.13 Stepwise management of bronchiectasis 
Exacerbations should be treated with antibiotics based on previous sputum culture. 
If patients are experiencing 3 or more exacerbations in a year, which is considered 
to be a marker of disease severity then the above stable treatments should be 
considered. The updated BTS guidelines have suggested a stepwise management 
plan as demonstrated in figure 8. 
Figure 8. 
 
Figure 8.  The stepwise management recommended in patients with 3 or more exacerbations per year. PA: Pseudomonas 
aeruginosa, PPM: potentially pathogenic microorganisms. 
1.14 Monitoring of disease 
Antibiotics and chest physiotherapy are the accepted forms of treatment for 
exacerbations of bronchiectasis but there are no randomised placebo-controlled trials 
examining the efficacy of treatment. Validated endpoints to assess response to 
treatment has been investigated by Murray and colleagues. They investigated several 
endpoints (24hr sputum volume, forced expiratory volume in one second (FEV1), 
forced vital capacity (FVC), incremental shuttle walk test, qualitative sputum 
microbiology, white cell count, erythrocyte sedimentation rate, C-reactive protein 
(CRP) and St George’s Respiratory Questionnaire (SGRQ)) after 14days of 
intravenous antibiotics for patients colonised with P. aeruginosa and other 
potentially pathogenic microorganisms. They found all clinical markers improved 
with treatment irrespective of pathogenic organism except for FEV1 and FVC. They 
reported the most responsive markers to include 24hr sputum volume (reduced by 
>50% in 80% of all cases), sputum bacterial clearance (in 78.1% of all cases), CRP 
with more than 75% reduction in 62.5% of all cases and health related quality of life 
score as measured by the St George’s Respiratory Questionnaire (SGRQ) improved 
by the minimum clinically important difference or more (4 or more units) in 89.7% 
of all cases. They found 24hr sputum volume, CRP and SGRQ scores all improved 
independent of bacterial clearance (Murray et al, 2009c).  
 
Phase 3 research studies (Haworth et al, 2014; Wong et al, 2012; Serisier et al, 
2013) are using time to next exacerbation or exacerbation frequency as primary 
endpoints but these have not been validated endpoints for use in bronchiectasis. 
Several questionnaires assessing quality of life have been validated for use as 
endpoints in bronchiectasis including The Leicester Cough Questionnaire, The St 
George’s Respiratory Questionnaire, Quality of Life-Bronchiectasis and Short form-
36. A meta-analysis of 38 studies was performed by Spinou and colleagues to assess 
their psychometric properties and the strength of their associations with other 
clinical endpoints. They reported good test-retest ability and moderate to good 
internal consistency. The authors reported health-related quality of life scores 
correlated better with subjective clinical endpoints such as degree of dyspnoea and 
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fatigue then objective measures of exercise capacity, FEV1 and radiological extent 
of bronchiectasis on CT scan (P<0.0001 for all endpoints) (Spinou et al, 2016). 
 
There are no studies in bronchiectasis comparing different monitoring schedules in 
stable disease of bronchiectasis or correlated strategies to outcomes. Factors 
associated with increased risk of exacerbations, hospitalisations and mortality in 
bronchiectasis include age, body mass index, past history of exacerbations and or 
hospitalisations, persistent infection, especially with P. aeruginosa, dyspnoea as 
measured on the MRC scale, radiological extent of disease and FEV1 and so it 
would be understandable to monitor these variables in addition to quality of life as 
these tools may assess components of health status in bronchiectasis not measured 
using other outcomes (Spinou et al, 2016). The time intervals of monitoring are not 
known but all patients with bronchiectasis should undergo routine monitoring 
tailored to their disease severity in order to identify disease progression, pathogen 
emergence and modify treatment where necessary (Hill et al, 2018). 
 
These variables have recently been incorporated into two severity scoring systems – 
the Bronchiectasis Severity Index (BSI) (Chalmers et al, 2013) and the FACED 
score (Martinez-Garcia et al, 2014).  These scoring systems appear to be comparable 
but the BSI has higher sensitivity for predicting those at further risk of exacerbation 
(McDonnell et al, 2016). Studies have also suggested that the existence of 
comorbidity can increase severity and therefore the bronchiectasis aetiology and 
comorbidity index (BACI) was produced and whilst it appears to have a higher 
predictive power for 5year mortality when used in conjunction with the BSI score, 
its role in the monitoring of disease is yet unknown (McDonnell et al, 2016b). 
 
The new bronchiectasis guideline group (Hill et al, 2018) recommend certain 
criteria necessitating specialist input in secondary care for monitoring of patients. 
These include severity markers of 3 or more exacerbations/year, colonisation with P. 
aeruginosa, non-tuberculous mycobacteria or methicillin-resistant S. aureus 
colonisation (MRSA), deteriorating lung function, patients receiving any method of 
long-term antibiotic delivery and patients with diagnoses of rheumatoid arthritis, 
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immune deficiency, inflammatory bowel disease, primary ciliary dyskinesia, ABPA 
or patients with advanced disease and considering transplantation. 
 
1.15 Aims 
There were three main aims for this thesis. 
1) To phenotype stable patients with bronchiectasis. 
2) To investigate the importance of sputum bacterial load on outpatient 
exacerbations of bronchiectasis. 
3) To evaluate validated clinical endpoints in bronchiectasis. 
To investigate the first aim patients with bronchiectasis were recruited when 
clinically stable. Currently disease severity is assessed according to the 
Bronchiectasis Severity Index (BSI) score. This study investigated different clinical 
and laboratory markers to see if they correlated with the bronchiectasis severity 
score to see if disease severity can be further explored with markers not included in 
the original BSI score. 
 
The second aim was investigated by designing a study where patients with 
bronchiectasis were assessed when clinically stable, at start of exacerbation and after 
14 days of oral antibiotic therapy.  Clinical, bacteriological and inflammatory 
markers were all assessed at each time point including quantitative microbiology to 
assess the importance of a rise in bacterial load has on outpatient exacerbations of 
bronchiectasis. 
 
There is a lack of validated clinical endpoints in bronchiectasis. Different endpoints 
have been validated for use in bronchiectasis but the none of these assess functional 
capacity. There are no randomised controlled trials assessing the different clinical 
endpoints.   In order to investigate this third aim, a study was designed to validate 
the incremental shuttle walk test for use in bronchiectasis.  
 
 
 
 
 
 
 
 
 
 
Chapter 2: 
Material and Methods 
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2.0 Material and methods 
2.1 Ethical approval 
 
Ethical approval was granted by the West of Scotland Research ethics service, REC 
reference 13/WS/0230. All patients provided informed written consent and were 
recruited from a single centre. 
 
2.2 Patient recruitment 
All patients aged 18years and older with a radiologically confirmed diagnosis of 
bronchiectasis were eligible for inclusion in the separate studies. For all the studies 
reported in this thesis patients with clinical and radiological bronchiectasis were 
included but those with a primary diagnosis of chronic obstructive pulmonary 
disease, poorly controlled asthma, active sarcoidosis, active lung malignancy or 
active pulmonary mycobacterial disease were excluded. 
 
A clinical diagnosis of bronchiectasis included patients with a history of chronic 
cough with daily sputum production who had previously experienced exacerbations 
or bronchiectasis requiring antibiotics. All patients attended a dedicated 
bronchiectasis clinic in a tertiary centre – The Royal Infirmary of Edinburgh. 
 
A radiological diagnosis of bronchiectasis was defined as a high resolution computer 
tomography scan preformed within the last 5years which was reported by a trained 
radiologist and demonstrated bronchial dilatation, defined as a wider luminal 
diameter of a bronchus in respect to the neighbouring bronchial artery. 
 
Patients were required to be clinically stable with no exacerbations requiring 
antibiotics or oral corticosteroid prescription and no changes to regular respiratory 
medications in the preceding 6 weeks. For exacerbations, patients phoned the 
clinical research fellow when they felt they were having an exacerbation and if the 
fellow thought antibiotic treatment was warranted then they were reviewed and 
entered into the study. When patients were recalled due to an exacerbation, only the 
first exacerbation after the clinically stable visit was included. 
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2.3 Sputum 
2.3.1 Sputum volume 
Patients were asked to provide two sputum samples whenever attending a clinical 
visit. The first was a ‘Spontaneous sputum’ sample which was all sputum 
expectorated within the first 4 hours of rising from bed on the day of the visit. 
Sputum was collected in a sterile, transparent container. The second sample was a 
‘24-hour sputum’ collection which included all the sputum expectorated for the full 
24hour period the day before the clinical visit. Again, sputum was collected in a 
sterile transparent container. 
 
2.3.2 Sputum colour 
All sputum samples were graded for sputum colour using a validated sputum colour 
chart (Murray et al, 2009). Mucoid sputum was graded a 1, mucopurulent sputum 
was graded a 2 and purulent sputum was graded a 3 or 4 depending on the colour 
with increasing purulence awarded a higher number (Figure 1). 
 
Figure 1. 
 
Figure 1. Sputum colour chart (Murray et al, 2009) 
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2.4 Bacteriology 
2.4.1   Quantitative bacteriology 
Sputum samples were processed as quickly as possible after receipt. Sputum was 
prepared by adding an equal volume of 0.1% dithiothreitol to at least 1millilitre of 
fresh sputum. Samples were vigorously vortexed to produce a liquefied and 
homogenised sample. The sample was then serially diluted with 0.85 % saline to 
achieve dilutional factors of 10-1 and 10-4. 100microlitres aliquots of diluted sputum 
of concentrations x10-2 and x10-4 were then inoculated across the surface of different 
culture media and spread using a sterile hockey stick spreader (Pye et al, 1995). 
Three different culture plates were used at each of the two dilutions: Pseudomonas 
isolation agar (Difco) which is selective for Pseudomonal species, chocolate blood 
agar with bacitracin (Oxoid) and horse blood agar (Oxoid). The plates were 
incubated for 48 hours at 37oC in an aerobic incubator except for the chocolate 
blood agar plates which were incubated at 37oC for 48 hours in a 5% carbon dioxide 
enriched incubator. Colony forming units for each different pathogen identified were 
counted at 48 hours and the bacterial count was calculated as follows: Number of 
colony forming units x 2 x 10 x dilutional factor to give the number of colony 
forming units per millilitre (CFU/ml). 
 
The remainder of the fresh sputum was ultra-centrifuged at 30000g for 90 minutes at 
4oC to produce a pellet and supernatant (Hill et al, 1999). The soluble portion was 
aspirated into small aliquots and stored at -70oC until it was defrosted thoroughly at 
room temperature for further analysis. 
  
2.4.2 Qualitative bacteriology 
Pathogens were identified using Gram stain and specific standardised identification 
tests for the more commonly identified pathogens are outlined below. 
 
2.4.2.1 Gram stain 
Ten microliters of fresh sputum was smeared across a glass slide using a sterile 
10ml sterile loop. An equal volume of sterile saline was added to the slide and the 
sputum was spread thinly across the slide. The slide was air dried and heat fixed by 
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passing through an open flame until the moisture had evaporated. Methylviolet was 
added and left for one minute before rinsing the slide with deionised water. Iodine 
was then added and left for a further minute before rinsing with deionised water 
again. Acetone was subsequently added as a decolourising agent followed by rinsing 
with deionised water. A counter stain of basic fuschin was then used to flood the 
slide for one minute before rinsing with deionised water. The slide was air dried 
before observing under oil immersion at low (x100) and high (x1000) magnification. 
The bacterial cell colour was described as pink (gram negative) or purple (gram 
positive) and the morphology (rods or cones) was noted to help identification.  
 
2.4.2.2 Haemophilus influenzae  
These colonies appear small, round and convex on chocolate blood agar plates 
which have been incubated at 37oC with 5% carbon dioxide, usually visible after 
24hours (figure 2a). Gram staining shows gram negative spherical, oval or rod-like 
cells of less than 1µm diameter. Further identification of H. influenzae was carried 
out using X and V factors, which also helped distinguish them from H. 
parainfluenzae. One colony was gently lifted with a sterile loop and emulsified in 
distilled water to produce a light suspension. 100µl of this suspension was then 
inoculated onto nutrient agar and spread evenly with a sterile hockey stick spreader. 
Three filter paper discs ‘X’ – containing protoporphyrin IX and haemin, ‘V’ – 
containing nicotinamide adenine dinucleotide and ‘XV’ –containing both the above, 
were placed on the agar plate at equidistant from each other with a minimum of 
3.5cm between the discs (Figure 2b). Plates were incubated for 24 hours at 37oC and 
examined for growth around each disc as per table 1. 
 
Table 1. 
Factor Haemophilus influenzae Haemophilus parainfluenzae 
X Negative  Negative 
V Negative  Positive 
XV Positive Negative 
Table 1. Test results for growth around the respective discs for H. influenzae 
and H. parainfluenzae. 
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Figure 2a. 
 
Figure 2b. 
 
Figure 2. Haemophilus influenzae, a) classical appearance of colonies on 
chocolate blood agar, b) positive XV identification test. 
 
2.4.2.3 Pseudomonas aeruginosa  
Morphological identification of Pseudomonas aeruginosa included several  
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characteristics. The colony appearance varied but the most common type is a large, 
oval convex shape with a rough appearance on primarily Pseudomonas isolation 
agar plates (figure 3a) but in mucoid strains the colonies coalesce and appear gel 
like (figure 3b). Colonies may have a greeny-blue appearance due to production of 
pyocyanin or yellow due to the production of pyoverdin.  Pseudomonal species can 
have a characteristic smell of aminoacetophenone. Not all strains produce the 
pigment pyocyanin and hence further identification can be carried out using the 
commercially available API20NE kits (biomerieux UK limited, Basingstoke, 
Hampshire) according to manufacturer’s instructions. This includes the sterile 
emulsification of potential colonies with 2mls of 0.85% sterile saline. The 
suspension (approximately 0.5McFarland standard) is then added to dehydrated 
substances present on the API20NE strip of microtubules (figure 3c). Strips are 
incubated for 24 hours before the addition to reagents an interpretation of reactions 
(as per manufacturer’s instructions) prior to potential further incubation for 24 
hours. The resultant biochemical reaction profile is converted into an octal profile 
number and decoded using the Analytical Profile Index (API database Vn6.0, 
APILAB software Vn3.3.3, Apilab Plus; biomerieux). 
 
Figure 3a. 
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Figure 3b. 
 
Figure 3c. 
 
Figure 3. Pseudomonas aeruginosa; a) classic colonies on Pseudomonas isolation 
plate, b)mucoid Pseudomonas isolated in the lab, c)API20NE commercial test 
kit. 
 
2.4.2.4 Streptococcus pneumoniae 
Streptococcus pneumoniae colonies are primarily grown on horse blood agar and 
appear white, 1-2mm in diameter with a depressed centre and raised edges giving 
them the classic draughtsman appearance with underlying haemolysis (figure 4a). 
They appear positive on Gram staining and morphologically spherical, either in 
pairs, chains or clusters. Further identification is carried out but assessing the 
sensitivity of the colony to ethylhydrocupreine hydrochloride (optochin test). The 
ethylhydrocupreine hydrochloride containing optochin disc causes lysis of 
Streptococcus pneumoniae and so is placed on a horse blood agar plate that has been 
freshly inoculated with Streptococcus pneumoniae colonies using a sterile wire loop 
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to gently lift the colonies and streak across the plate. The plate is incubated for 24 
hours at 37oC in enriched 5% carbon dioxide conditions. A positive result was 
defined as ³ 5mm radius of growth inhibition around the optochin disc (Figure 4b). 
 
Figure 4a. 
 
Figure 4b. 
 
Figure 4. Streptococcus pneumoniae; a) classic appearance of Streptococcus 
pneumoniae, b) positive optochin test 
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2.4.2.5 Moraxella catarrhalis 
The primary isolation media used to Moraxella species is horse blood agar, on 
which their appearance is grey, white or yellowy opaque colonies that are 1-3mm 
big and convex in shape (figure 5a). On chocolate blood agar, they can appear 
pinkish brown and difficult to distinguish from Neisseria gonorrhoea (figure 5b). 
They stain negative on Gram staining and appear as cocci, approximately 0.6-
1.0mm diameter. Further clarification on identity can sought with the positive 
oxidase reaction. Filter paper was soaked in the test reagent N, N, N‟, N‟-tetra-
methyl-p-phenylenediamine dihydrochloride. A sterile wooden stick was used to 
select one colony and rub it onto the pre-soaked filter paper. A positive result was 
confirmed with the development of a blue colour, indicating oxidase production 
within ten seconds. A negative result was indicated by an absence of colour. 
 
Figure 5a. 
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Figure 5b. 
 
Figure 5. Moraxella catarrhalis; a) classical appearance on horse blood agar, b) 
pinky-brown colonies on chocolate blood agar. 
 
2.4.2.6 Staphylococcus aureus 
Colonies of Staphylococcus aureus are opaque and creamy white or yellow-orange 
in colour (figure 6a). They are primarily grown on horse blood agar and stain 
positive on Gram staining. They are cocci which can occur singularly, in pairs or in 
clusters. Further identification is confirmed using the commercially available 
Dryspot Staphytect Plus kit. This is a latex slide agglutination test where blue latex 
particles coated with both porcine, fibrinogen and rabbit IgG together with specific 
polyclonal antibodies raised against capsular polysaccharide of Staphylococcus 
aureus are dried onto the test reaction area. A second test control area contains blue 
latex particles sensitised with non-reactive globulin and acts as a negative control. 
An emulsion of test colonies and sterile saline is made and the suspension added to 
each test area with the addition of reagents as per manufacturer’s instructions. A 
positive test results in the agglutination and clumping of the suspension (figure 6b). 
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Figure 6a. 
 
Figure 6b. 
 
Figure 6. Staphylococcus aureus; a) classical appearance on horse blood agar, 
b) negative control test on the left and positive agglutination reaction on the 
right. 
 
2.4.2.7 Enterobacteriaceae 
These pathogens were selected from horse blood agar (figure 7a) and chocolate 
blood agar containing bacitracin (figure 7b). They can appear as single colonies or 
adopt a gel-like appearance when mucoid. The cells stain Gram negative and appear 
as rods on microscopy. Further identification of these pathogens is with a negative 
oxidase test as described above and then with the commercially available API20E 
(bioMerieux UK, Limited, Basingstoke, Hampshire). The preparation for this test 
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strip is similar to that described for the API20NE kit described above, except it is 
only incubated for 24 hours at 30oC (figure 7c).  
Figure 7a. 
 
Figure 7b. 
 
Figure 7c.  
 
Figure 7. Enterobacteriaceae; a) classical appearance on horse blood agar, b) 
classical appearance on chocolate blood agar with bacitracin, c) API20E 
commercial test kit. 
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2.4.2.8 Mixed normal flora 
There can be an abundance of mixed commensal organisms resident in the 
pharyngeal area and throughout the bronchial tree when no one pathogen is 
predominantly present. The appearance of mixed normal flora or respiratory 
commensals can appear on horse blood agar and chocolate blood agar containing 
bacitracin plates (figure 8). 
Figure 8. 
 
Figure 8. Mixed normal flora on horse blood agar 
 
2.5 Sputum inflammatory marker assays 
Sputum was prepared as earlier described and sputum sol frozen until required for 
inflammatory assays. Soluble sputum specimens were thawed at room temperature 
ready for use. 
 
2.5.1 Myeloperoxidase 
Myeloperoxidase (MPO) activity in the sputum was measured as a surrogate marker 
for the neutrophilic inflammatory response. MPO was measured from the sputum 
sol phase by a chromogenic substrate assay (Calbiochem). All reagents and samples 
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were first brought to room temperature. The test samples and standards were diluted 
in phosphate buffered solution as per manufacturer’s instructions. 25µl of test 
sample or standard was added to each well of a 96 well microliter plate (Costar®). 
25µl of tetramethybenzidine (TMB, Sigma) was also added to each well. The plate 
was incubated for 5 minutes at 25oC. The reaction was stopped with the addition of 
50µL of sulphuric acid to each well. The absorbance from each well was measured 
using a dual wavelength of 450nm and 560nm. A standard curve from the MPO 
standard results was formed and test sample results were interpolated from this 
curve and expressed as mg/ml. The MPO concentration for each standard and 
sample was determined in duplicate and the mean result determined for each.  
 
2.5.2 Neutrophil elastase 
Sputum neutrophil elastase was measured as a surrogate marker of the neutrophilic 
inflammatory response. Neutrophil elastase was measured spectrophotometrically as 
the rate of change of optical density. The chromogenic synthetic substrate 
methoxysuccinyl-ala-ala-pro-val-paranitroanilide (MeoSAAPVpNa 4-(2-
hydroxyethyl)- 1-piperazineethanesulfonic acid) (Sigma) whilst not specific for 
neutrophil elastase can be used to detect it. Firstly, a standard curve for the rate of 
change in optical density by incubating the chromogen with known quantities of 
human neutrophil elastase is formed (Sigma Aldrich). Both the standards and test 
samples are diluted in 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 
buffer solution. 40µL of standard or sample were added to a 96 well microtiter plate 
(Costar®). 40µl of MeoSAAPvn was added to each well and samples read 
immediately at 405nm, 37ºC for a minimum of thirty minutes with readings every 
two minutes. The rate of change in optical density is converted into elastase activity 
and expressed in units per milligram. The elastase concentration for each sample and 
standard was assessed in duplicate and the mean determined for each. 
 
2.5.3 Interleukin-8 
Interleukin-8 concentrations were assessed as a marker of neutrophil chemotaxis. 
The sputum sol phase from previously frozen samples stored at -70oC was used and 
samples were first brought down to room temperature. The commercially available 
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specific enzyme linked immunosorbent assay (ELISA, R+D systems, Abingdon, 
UK) that has previously validated for use in sputum (Stockley & Bayley, 2000) was 
performed according to manufacturer’s instructions. 
2.6 Systemic inflammation 
Venous blood (15mls) was collected and analysed for full blood count (FBC), 
erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), urea & 
electrolytes (U&Es). The normal ranges for the most pertinent markers are: white 
cell count 4-11 x109/L; ESR for males (age/2) mm/hr and for females (age + 10/2) 
mm/hr; CRP <5 mg/L, urea 2.5-6.6 mmol/L and creatinine 60-120umol/L. 
 
5mls of blood was centrifuged at 750g for 10 minutes and the supernatant collected 
and stored at -70oC for measuring pro and anti-inflammatory cytokines and 
chemoattractants by cytometric bead array (BDTM Cytometric Bead Array Kits). The 
cytometric bead array was performed according to manufacturer’s instructions and 
measured Human interleukin (IL) IL-12p70, TNFa, IL-10, IL-6, IL-1b and IL-8. 
 
2.7 Quality of life assessments 
2.7.1 The Leicester Cough Questionnaire (LCQ) 
This 19-item questionnaire assesses 3 domains including physical (8 items), 
psychological (7 items) and social (4 items). The questionnaire predominantly 
assesses the impact of participant’s cough severity on health related quality of life 
by assessing symptoms over the preceding 2 weeks. It has been validated for use in 
bronchiectasis (Murray et al, 2009d) and issues a score ranging from 3 to 21 with a 
lower score indicating greater impairment of health status due to cough. The 
minimum clinically important difference (MCID) is 1.3 units (Birring et al, 2003). 
 
2.7.2 St George’s Respiratory Questionnaire (SGRQ) 
This 50-item questionnaire investigates the components of symptoms (8 items), 
activity (16 items) and impact (26 items) on health related quality of life. Unlike the 
LCQ, it assesses multiple respiratory symptoms over the preceding 4 weeks. It has 
been validated for use in bronchiectasis (Wilson et al, 1997b). The total score can 
range from 0 to 100 with a higher score indicating greater impairment of health  
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status. The minimum clinically important difference is 4 units (Wilson et al, 1997b). 
 
2.8 Spirometry 
Patients were asked to perform spirometry according to standardised guidelines 
(Miller et al, 2005). Forced expiratory volume in 1 second (FEV1) was measured as 
the maximal expired air in 1 second after taking a maximal breath in. Forced vital 
capacity (FVC) was measured as the total expired volume of air with maximal effort 
after taking a maximal breath in. Both FEV1 and FVC results were expressed in 
litres (L) and as percent of predicted values for the patient’s sex, age and height. The 
test was conducted using the MicroMedical Microloop ML3535 device (Viasys 
Healthcare) and calculated FEV1/FVC ratio and mid expiratory forced expiratory 
flow (FEF25-75) results were also calculated from the same manoeuvres and 
recorded. All patients performed three manoeuvres that were within 10% of each 
other and the highest result was recorded. All patients had performed spirometry 
before as part of routine clinical practise and were aware of how to perform the test. 
 
2.9 Incremental shuttle walk test 
The ISWT was performed according to standard test procedure (Singh et al, 1992). 
The patient is asked to walk a 10-metre shuttle course with the walking speed 
controlled using pre-recorded audio signals. Each of the twelve incremental levels 
last one minute. The pre-recorded audio signals beep progressively faster so that 
more distance is covered at each level. The test continues until the participant is 
unable to complete the shuttle in the designated time (0.5metres or further from the 
marker at the time of the audio signal) or the patient becomes too breathless. The 
distance completed is recorded. Patients were instructed to walk at a steady pace 
aiming to turn around at each end of the course at the sound of the audio signal. All 
were advised to continue to walk until they felt unable to maintain the required 
speed without becoming unduly breathless. At the start and end all patients had their 
heart rate, oxygen saturations and dyspnoea score according to the modified BORG 
dyspnoea scale (Borg, 1982) in accordance with standardised guidelines recorded 
(2002). The MCID has been proposed as 35m (Lee et al, 2014c) but successful 
completion of distance walked in our study was recorded in increments of 10m. 
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Chapter 3: 
Stable state bronchiectasis: BSI and beyond in outpatients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 102 
3.1 Severity scoring systems 
Bronchiectasis is a condition with relatively little research investigating its 
pathophysiology and the mechanism of its natural progression compared with 
chronic obstructive pulmonary disease, lung cancer and asthma. Therefore, until 
recently there was no accepted model to grade the severity of bronchiectasis and 
patients were routinely classified as ‘mild’, ‘moderate’ and ‘severe’ but there was no 
officially accepted definition for this. Other respiratory conditions have robust 
scoring systems to help guide treatment appropriately to those most at risk and with 
a poorer prognosis (Lange et al, 2012, Chalmers et al, 2010 & du Bois et al, 2011). 
 
There is a great need for severity scoring systems to stratify patients and allocate 
limited resources appropriately. There are new treatments being investigated for the 
management of bronchiectasis, such as long term macrolide use but these are not 
without their limitations; risk of microbial resistance, toxicity, healthcare costs and 
treatment burden (Wong et al, 2012, Serisier et al, 2013 & Altenburg et al, 2013). 
Therefore, it would be appropriate to identify those with more severe disease who 
might benefit most from such novel therapies. 
 
The two new scoring systems in bronchiectasis are the Bronchiectasis Severity 
Index (BSI) (Chalmers et al, 2013) which can identify patients at risk of future 
hospitalisation, exacerbation and mortality. The FACED Score (Martinez-Garcia et 
al, 2014) classifies the severity of bronchiectasis according to prognosis.  
 
The Bronchiectasis Severity Index incorporates 9 variables including; age, body 
mass index, FEV1 % predicted, hospital admission in the previous year, number of 
exacerbations in the last year, MRC dyspnoea score, Pseudomonas aeruginosa 
colonisation, colonisation with other microorganisms and radiological severity. The 
BSI grades bronchiectasis with a minimum score of 0 being very mild to 26 being 
very severe. The scores are classified into tertiles where 0-4 is thought of as a low 
score, 5-8 as intermediate and 9 is high – Table 1.  
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FACED score incorporates 5 dichotomised variables including FEV1 % predicted, 
Age, Presence of chronic Colonization by Pseudomonas aeruginosa, radiological 
Extension and Dyspnoea. The overall sum of scores can range from 0 to 7 points 
where 0-2 points is classified mild bronchiectasis, 3-4 points is moderate 
bronchiectasis and overall 5-7 points is classified as severe bronchiectasis – Table 1. 
 
Several studies comparing the two scores report that they are comparable at 
predicting mortality and assessing severity in regards to its prognosis (Ellis et al, 
2016 & Minov et al, 2015). The FACED score is easier and less time consuming but 
the BSI has perhaps been more comprehensively studied to show it can predict 
hospital admissions as well as mortality and was found to differentiate the number 
of exacerbations and quality of life between the different severity classifications 
(McDonnell et al, 2016). These are all well recognised primary endpoints in 
bronchiectasis and important considerations for future research. Both scores have 
been validated, the FACED was internally validated and the BSI was externally 
validated. 
 
The FACED score was later amended to construct the E-FACED score which was a 
9-point severity scoring system adding in the number of severe exacerbations to its 
existing FACED score (Martinez-Garcia et al, 2017). Its predictive capacity for 
exacerbations was high with Area under the receiver operator curve (AUC) of 0.82 
for 2 or more exacerbations in 1 year and 0.87 for 1 exacerbation in 1 year. Its 
predictive all cause and respiratory mortality capacity was like that of the original 
FACED score. The E-FACED score was externally validated in 651 patients from 6 
different Latin America centers. The overall sum of the dichotomised scores can 
range from 0 to 9 points where 0-3 points is classified mild bronchiectasis, 4-6 
points is moderate bronchiectasis and overall 7-9 points is classified as severe 
bronchiectasis – Table 1. 
 
Both the BSI and E-FACED scores are clinically based. We know that patients 
diagnosed with bronchiectasis can have multiple comorbidities and that these 
comorbidities can be causative or synergistic with the presence of bronchiectasis 
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(Leroy et al, 2014).  Those that can cause bronchiectasis e.g. COPD and rheumatoid 
arthritis are known to cause a more severe phenotype of bronchiectasis with 
increased mortality despite treatment of the underlying condition (Hurst et al, 2015, 
Perry et al, 2017). It is also known that certain comorbidities that can independently 
occur alongside bronchiectasis such as cardiovascular disease, mental health illness, 
gastro-oesophageal reflux disease and some malignancies can be major contributing 
factors for hospital admissions and increase the healthcare utilisation and cost 
burden (Joish et al, 2013, Gale et al, 2012, Lee et al, 2014b, Mandal et al, 2013b, 
Olveira et al, 2013, Chung et al, 2015).  
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Table 1. 
BSI FACED E-FACED 
% predicted 
FEV1 
>80%    (0) 
50-80% (1) 
30-49% (2) 
<30%    (3) 
% 
predicted 
FEV1 
³50%(0) 
<50%(2) 
% 
predicted 
FEV1 
³50%(0) 
<50%(2) 
Age <50        (0) 
50-69     (2) 
70-79     (4) 
80+        (6) 
Age ³70    (0) 
<70    (2) 
Age ³70    (0) 
<70    (2) 
P. aeruginosa Yes        (3) 
No          (0) 
P. 
aeruginosa 
Yes    (1) 
No     (0) 
P. 
aeruginosa 
Yes    (1) 
No     (0) 
Radiological 
³3lobes or 
cystic 
Yes        (1) 
No          (0) 
Radiologic
al >2lobes 
Yes    (1) 
No     (0) 
Radiologic
al severity 
Yes    (1) 
No     (0) 
MRC 
dyspnoea 
1-3         (0) 
4             (2) 
5             (3) 
mMRC 
Dyspnoea  
0-2     (0) 
3-4     (1) 
mMRC 
Dyspnoea  
0-2     (0) 
3-4     (1) 
Hospital 
admissions 
Yes        (5) 
No          (0) 
  1 hospital 
admission 
in last year 
Yes    (2)  
No      (0) 
No. of 
exacerbations 
0             (0) 
1-2         (0) 
³3          (2) 
    
Body mass 
Index 
<18.5     (2) 
18.5-25  (0) 
26-29     (0) 
³30        (0) 
    
Other micro-
organism 
Yes        (1) 
No          (0)  
    
Table to show the individual variables for each scoring system and the points 
assigned to each. BSI: Bronchiectasis Severity Index. FEV1: forced expiratory 
volume in 1 second, P. aeruginosa: Pseudomonas aeruginosa, mMRC: modified 
Medical Research Council 
 
Neither prognostic score (Bronchiectasis severity index or the E-FACED score) 
incorporated the presence of comorbidities to assess its impact on mortality. 
McDonnell and colleagues constructed the Bronchiectasis Aetiology Comorbidity 
Index (BACI) designed to predict the 5-year mortality of comorbidity diagnoses 
(metastatic malignancy, COPD, inflammatory bowel disease, iron deficiency 
anaemia, asthma, peripheral vascular disease, haematological malignancy, cognitive 
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impairment, chronic liver disease, diabetes, pulmonary hypertension and ischaemic 
heart disease). They found the BACI predicted mortality, hospital admissions, 
exacerbations and health-related quality of life across all BSI risk groups 
(P<0.0001). The hazard ratio (95% CI) for death conferred by a one point increase 
in the BACI score was 1.18 (1.14 - 1.23), p<0.0001. When the BACI score was used 
in conjunction with the BSI, the combined model was superior overall in predicting 
5-year mortality with AUC (95% CI) 0.83 (0.79 – 0.87) (McDonnell et al, 2016b). 
Depending on the relative contribution of each comorbidity to future risk patients 
can be stratified as low risk score:0 (Estimated 5 year mortality risk 3.5%, Estimated 
risk of hospitalisation for severe exacerbation 11.7% over 5 years), intermediate risk 
score 1-5 (Estimated 5 year mortality risk 11.7%, Estimated risk of hospitalisation 
for severe exacerbation 14.8% over 5 years) and high risk with a score of 6 or more 
(Estimated 5 year mortality risk 34.9%, Estimated risk of hospitalisation for severe 
exacerbation 36% over 5 years).  
 
Bronchiectasis is known to be characterised with dilated and distorted airways. The 
leads to a buildup of stagnant sputum because of the resultant impaired mucociliary 
escalator. This sputum can become infected and a neutrophilic inflammatory 
response ensues. Previous studies have suggested that an increase in bacterial load 
can cause an increase in airways inflammation and a greater risk of exacerbations 
(Chalmers et al, 2012). The neutrophilic inflammatory response is thought to be a 
key component in potentiating the ‘vicious circle’ of lung damage in bronchiectasis 
(Dente et al, 2015) and is part of the cycle that novel treatments that reduce 
inflammation could be active. For example, there is recent growing interest in the 
use of macrolide therapy for their anti-inflammatory and not necessarily their anti-
microbial properties (Wong et al, 2012, Serisier et al, 2013 & Altenburg et al, 
2013). 
 
Further work in 381 stable patients with bronchiectasis had sputum analysed for 
neutrophil elastase. The authors found neutrophil elastase levels were associated 
with the bronchiectasis severity index score (r=0.49, p<0.0001) but was not 
independently associated with mortality rates during a 3yr follow up period. 
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Neutrophil elastase did correlate with Medical research council dyspnoea score 
(r=0.34, p<0.0001), FEV1 % predicted (r=0.33, p<0.0001), radiological extent of 
bronchiectasis (r=0.29, p<0.0001). Within the 3yr follow up period elevated 
neutrophil elastase levels were found to associate with higher rates of exacerbation 
and decline in FEV1 (P<0.0001). The authors found neutrophil elastase to rise in 
exacerbations and have good discrimination for severe exacerbations and all-cause 
mortality (Chalmers et al, 2017). 
 
Elevation of systemic inflammatory markers such as CRP, white cell count and 
Erythrocyte sedimentation rate have been found to correlate with disease severity 
and lung function in clinically stable patients with bronchiectasis (Wilson et al, 
1998). Further work by Hsieh and colleagues investigated the role of high sensitivity 
CRP in stable patients and found it significantly correlated with high resolution 
computer tomography (HRCT) severity scores of bronchiectasis as assessed by 
Brody and colleagues and with oxygen saturation levels.  
 
The Bronchiectasis Severity Index has been demonstrated to be able to predict 
mortality, hospitalization, future exacerbations and quality of life in stable patients 
with bronchiectasis based on several clinical parameters. The ongoing inflammatory 
response present in patients with bronchiectasis, perhaps because of chronic 
infection and the importance of the neutrophilic inflammatory response in its 
pathogenesis might indicate that sputum and serum inflammatory markers may be 
additive to the clinical parameters in assessing severity and predicting mortality. 
 
The BSI incorporates 9 clinical parameters in its severity score; age, body mass 
index, FEV1 % predicted, hospital admission in the previous year, number of 
exacerbations in the last year, MRC dyspnoea score, Pseudomonas aeruginosa 
colonisation, colonisation with other microorganisms and radiological severity. 
Other clinical parameters of sputum colour, quantitative bacteriology and distance 
walked in incremental shuttle walk test (ISWT) are also important when assessing 
severity of bronchiectasis.  
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Murray and colleagues demonstrated that sputum colour predicted bacterial 
colonisation (Murray et al, 2009) and Chalmers and colleagues demonstrated that 
airways bacterial load was associated with airway inflammation. They also noted 
that in stable patients there was a direct relationship between airway bacterial load 
and risk of subsequent exacerbations and severe exacerbations.  
 
In previous work the ISWT was found to deteriorate with exacerbations and 
improve with treatment. It correlated with other validated markers of severity 
including the St George’s Respiratory Questionnaire assessment of quality of life. 
The ISWT was validated as a useful clinical endpoint in bronchiectasis and the 
minimum clinical important difference was a change of 5% (Cartlidge et al, 2018).  
 
This chapter aims to investigate whether serum and sputum inflammatory markers in 
addition to sputum colour, distance walked in ISWT and quantitative bacteriology 
are important in assessing disease severity of clinically stable patients and aim to see 
if these clinical endpoints correlated with the Bronchiectasis Severity Index. 
 
3.2 Methodology 
3.2.1 Ethics 
Ethical approval was granted by the West of Scotland Research ethics service, REC 
reference 13/WS/0230. All patients provided informed written consent and were 
recruited from a single centre. 
 
3.2.2 Recruitment and study design 
Patients that were clinically stable (no antibiotic therapy for over 6 weeks for an 
exacerbation prior to selection) were recruited from a dedicated outpatient 
bronchiectasis clinic in a tertiary hospital (Royal infirmary of Edinburgh). Patient 
aged 16years and over with radiologically evident bronchiectasis on High 
Resolution Computer Tomography (HRCT) scan were invited to join and attend a 
consultation where the below tests were performed. Bronchiectasis severity score 
(BSI) was calculated for each individual patient according to previous clinical data 
recorded in routine clinic appointments. All patients underwent the tests below and 
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results analysed for each of the three severity groups ‘BSI 0-4 mild’, ‘BSI 5-8 
moderate’ and ‘BSI ³9 severe’.  
 
3.2.3 Blood inflammatory markers 
Venous blood sampling was taken to monitor full blood count, urea and electrolytes, 
Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).  
 
3.2.4 Sputum inflammatory markers 
Whole sputum samples were also centrifuged to produce supernatants on which 
myeloperoxidase (MPO), neutrophil elastase (NE) and interleukin – 8 (IL-8) were 
tested. MPO (Steinman et al, 1972) was assayed using a chromogenic substrate 
assay (Stockley et al, 2000), free neutrophil elastase (NE) (Buttle et al, 1990) was 
measured by spectrophotometry with a  synthetic substrate (methoxysuccinyl-Ala-
Ala-Pro-Val paranitroanilide; Sigma, Gillingham, UK) were tested as per standard 
protocol (Hill et al, 1999, Hill et al, 2000) and interleukin – 8 (IL-8) assayed using 
commercially available specific ELISAs (R&D Systems, Oxford, UK). 
 
3.2.5 Sputum 
Sputum colour was graded according to a visual colour chart rating. Mucoid sputum 
was rated 1, mucopurulent rated as 2 and purulent sputum rated as 3 or 4 depending 
on colour (Murray et al, 2009]). 24hour sputum volume was recorded by asking 
patients to expectorate solely into a universal container for 24hours. Qualitative and 
quantitative microbiology was performed on all samples. 
 
3.2.6 Incremental shuttle walk test 
The test was performed according to standard test procedure [Singh et al, 1992] and 
consisted of a 10-metre shuttle course on a flat surface with the walking speed 
controlled using pre-recorded audio signals. The test continues until the participant 
is unable to complete the shuttle in the designated time or the patient decides to stop 
due to symptoms (e.g. breathless, leg fatigue). The distance completed within the 
timeframe was recorded. The successful completion of distance walked in our study 
was recorded in increments of 10m.  
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3.2.7 Qualitative and quantitative microbiology (Murray et al, 2011) 
For analysis culture results were grouped as either positive for ‘Pseudomonas 
aeruginosa’, ‘potentially pathogenic microorganisms’ (Haemophilus influenzae, 
Moraxella catarrhalis, Streptococcus pneumoniae, Staphylococcus aureus) or ‘other 
gram negatives’ (Enterobacter, Escherichia coli, Klebsiella pneumoniae, 
Stenotrophomonas maltophilia, Serratia marcescens, Proteus mirabilis, 
Acinetobacter baumannii, Achromobacter xylosoxidans, Citrobacter freundii and 
Aeromonas hydrophila) and ‘mixed normal flora’ (no dominant pathogen cultured 
or presence of respiratory commensal flora only). 
 
3.2.8 Lung function 
We measured pre-bronchodilator forced expiratory volume in 1 second (FEV1), 
forced vital capacity (FVC) and ratio FEV1:FVC by spirometry according to 
standardized guidelines [ATS guidelines]. Patients were asked to take three attempts 
and the best results were recorded. All patients have previously performed 
spirometry as part of routine clinical practise. 
 
3.2.9 Quality of Life 
Health related quality of life assessments were assessed by the St George’s 
Respiratory Questionnaire. Quality of life was also assessed by evaluating the 
impact of cough by completing The Leicester Cough Questionnaire. 
 
3.2.10 Statistical analysis 
All data were analysed using Graphpad prism version 5.0a (Graphpad software, San 
Diego, CA, USA). For demographic and clinical variables, data are presented as 
median (interquartile range) for continuous variables and n (%) for categorical 
variables unless specified otherwise. A P value <0.05 was considered statistically 
significant for each analysis. Comparison of changes between groups was performed 
by Analysis of Variance (ANOVA) statistical test or by using the Kruskal-Wallis 
test if data was not normally distributed. 
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3.3 Results  
3.3.1 Cohort 
229 patients signed consent forms to take part in the study. Patients were over 
recruited to compensate for dropouts. 208 patients were contactable and proceeded 
to a baseline visit. Of the remaining 21 patients 13 were either not contactable again 
to arrange a visit or there was not a suitable time for baseline visit due to ill health or 
recent exacerbation. 1 patient died before attending baseline visit and 7 patients 
changed their mind about taking part. 
 
1 of the 208 patients that completed a baseline visit dropped out during the study 
and so is not included in the results analysis. Baseline characteristics are displayed 
below in table 2. The relatively small number of patients on long term antibiotic 
therapy is a reflection of local departmental practice and not of cohort severity. Of 
the 207 patients that continued with the study 74 had a BSI score 0-4, 79 had a BSI 
score 5-8 and 54 had a BSI score of 9 or above. Aetiological data is shown in table 
3. 
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Table 2. 
Characteristic Total patients 
Number 207 
Age (yrs) (mean, (SD) ) 65.79 (10.6) 
Female 110 (53) 
Current smokers 
Ex-smokers 
Never 
9 (4) 
83 (40) 
115 (56) 
BMI Kg/m2 (mean, (SD)) 29.09 (35.54) 
COPD 
Asthma 
Interstitial lung disease 
Lung cancer 
Pulm. Hypertension 
Inactive ABPA 
IHD 
Other cancers 
35 (17) 
23 (11) 
3 (1) 
2 (1) 
1 (1) 
21 (10) 
14 (7) 
22 (11) 
LTOT 2 (1) 
Inhaled steroid 
Dose (mean, (SD)) 
Oral steroid 
Dose (mean, (SD)) 
Nebulised bronchodilators   
Long-term oral antibiotics 
Long-term inhaled antibiotics 
Cyclical IV antibiotics 
23 (11) 
211mcg (104.4) 
12 (6) 
7.7mg (5.3) 
7 (3) 
4 (2) 
7 (3) 
1 (0.5) 
Forced Expiratory volume 1s mean (SD) 
%pred Forced Expiratory volume 1s mean (SD) 
Bronchiectasis severity score (mean, (SD) 
Bronchiectasis Severity Index 0-4, 5-8, ³9 
2.03 (0.77) 
78.6 (24.0) 
6.7 (4.2) 
74, 79, 54 
Table to show the baseline characteristics of the 207 stable patients recruited. N 
(%) or as otherwise stated. BMI: body mass index, COPD: chronic obstructive 
pulmonary disease, ABPA: allergic bronchopulmonary aspergillosis, IHD: 
ischaemic heart disease, IV: intravenous and LTOT: long term oxygen therapy. 
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Table 3. 
Aetiology Number of patients (%) 
Idiopathic 92 (44) 
Post infectious 55 (27) 
COPD 9 (4) 
Inflammatory bowel disease 7 (3) 
Immunoglobulin deficiency 9 (4) 
Allergic bronchopulmonary aspergillosis  13 (6) 
Connective tissue disease 7 (3) 
Aspiration or inhalation or GORD 15 (7) 
Table to show the N (%) of patients with different aetiologies of bronchiectasis. 
COPD: chronic obstructive pulmonary disease, GORD: gastric oesophageal 
reflux disease. 
 
3.3.2 Serum inflammatory markers results 
There was a significant association between increasing BSI severity group and white 
cell count (WCC), neutrophil count, Erythrocyte sedimentation rate and C-reactive 
protein whilst clinically stable. The median x109/L (IQR) WCC for groups 0-4, 5-8 
and ³9 was 6.3 (5.3-7.9), 6.9 (5.5-8.7) and 7.9 (6-9.95), p=0.0084. The median 
x109/L (IQR) for neutrophil counts for groups 0-4, 5-8 and ³9 was 3.5 (2.6-4.8), 
3.98 (3.2-6.2) and 5.2 (3.5-5.7), p=0.0013. The was also increasing ESR mm/hr 
levels with increasing severity; 11 (16-17), 12 (7-18) and 17 (8-28.8) respectively, 
p=0.0065. CRP for group 0-4 was 3mg/L (1-7); group 5-8 was 3mg/L (1-8.6) and 
group 9 or above was 7mg/L (2.5-22.5), p=0.0045 – see Figure 1. 
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Figure 1. 
						A.  
  
  
Figure 1. Blood inflammatory markers in clinically stable patients with 
bronchiectasis in ‘mild, 0-4’ ‘moderate, 5-8’ and ‘severe, ³9’ Bronchiectasis 
Severity Index groups shown as boxplot with median (IQR), whiskers of 5-95% 
CI and dots of outliers. A: White cell count p= 0.0084, B: Neutrophil count 
p=0.0015, C: Erythrocyte sedimentation rate p=0.0065, D: C-reactive protein 
p=0.0045, ***p<0.001. 
 
 
WCC
BS
I 0
-4
BS
I 5
-8
BS
I ≥
9
2
4
8
16
32
BSI severity score
W
hi
te
 c
el
l c
ou
nt
 x
10
9 /
L
                   ***
NEUT
BS
I 0
-4
BS
I 5
-8
BS
I ≥
9
1
2
4
8
16
32
BSI severity score
N
eu
tro
ph
il 
co
un
t x
10
9 /
L
                   ***
ESR
BS
I 0
-4
BS
I 5
-8
BS
I ≥
9
1
2
4
8
16
32
64
128
BSI severity score
E
ry
th
ro
cy
te
 S
ed
im
en
ta
tio
n 
R
at
e 
(m
m
/h
r)                    ***
CRP
BS
I 0
-4
BS
I 5
-8
BS
I ≥
9
1
2
4
8
16
32
64
128
256
BSI severity score
C
 - 
R
ea
ct
iv
e 
pr
ot
ei
n 
(m
g/
L)
                   ***
B. 
C. D. 
 115 
3.3.3 Sputum inflammatory markers results 
Free neutrophil elastase (NE), myeloperoxidase (MPO) and interleukin-8 (IL-8) was 
investigated in groups as per increasing BSI severity score. NE median (IQR) results 
for groups 0-4, 5-8 and ³9 were 2569 UG/ml (1408-6191), 2600 UG/ml (1915-
3404) and 3238 UG/ml (2013-11552) respectively, p=0.076. MPO median (IQR) 
results for groups 0-4, 5-8 and ³9 were 1719 UG/ml (859-4718), 1125 UG/ml (399-
3096) and 2521 UG/ml (1159-9544) respectively, p=0.002. IL-8 median (IQR) 
results were 14976 pg/ml (3815-26466), 13257 pg/ml (6324-30975) and 11848 
pg/ml (5935-31455) respectively, p=0.6. There was no association with NE and IL-
8. There was statistical significance with MPO –figure 2. 
 
Figure 2.  
 
 
Figure 2. Sputum inflammatory markers in clinically stable patients with 
bronchiectasis in ‘mild, 0-4’ ‘moderate, 5-8’ and ‘severe, ³9’ Bronchiectasis 
Severity Index groups shown as boxplot with median (IQR), whiskers 5-95% 
CI and dots of outliers, A: Neutrophil elastase #p=0.076, B: Myeloperoxidase 
**p=0.01, C: Interleukin - 8 #p= 0.57. 
 
3.3.4 Sputum characteristics 
There were associations with increasing 24hr sputum volume and with increasing 
sputum purulence but not with spontaneous sputum volume (sputum collected 
within 4hrs of waking) with higher BSI scores – see Figure 3. 
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Figure 3. 
 
Figure 3. Sputum properties in clinically stable patients with bronchiectasis in 
‘mild, 0-4’ ‘moderate, 5-8’ and ‘severe, ³9’ Bronchiectasis Severity Index 
groups shown as boxplot with median (IQR), whiskers 5-95% CI and dots of 
outliers. A: 24hr sputum volume p=0.02, B: Spontaneous sputum p=0.76, C: 
Sputum colour p= 0.0008, *p<0.05, ***p<0.001, #p>0.05. 
 
3.3.5 Incremental shuttle walk test 
The distance walked in the incremental shuttle walk test was significantly lower in 
the progressive BSI tertiles of severity. In BSI group 0-4 the median (IQR) ISWT 
distance was 470m (365-580m), for group 5-8 was 350m (260-485m) and for those 
with a score of 9 and over had deteriorated to 250m (95-365m), p<0.0001 – figure 4. 
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Figure 4. 
 
Figure 4. Incremental shuttle walk test in clinically stable patients with 
bronchiectasis in ‘mild, 0-4’ ‘moderate, 5-8’ and ‘severe, ³9’ Bronchiectasis 
Severity Index groups shown as boxplot with median (IQR), whiskers 5-95% 
CI and dots of outliers, ***p<0.0001. 
 
3.3.6 Bacteriology 
Quantitative bacteriology was performed on all sputum samples. There was an 
increase in bacterial load with increasing severity of BSI from groups 0-4, 5-8 and 
³9 with median (IQR) counts of 0 CFU/ml (0 - 9.3x106), 0.1x105 CFU/ml (0 – 7.4 
x106) and 1.27x107 CFU/ml (0.02 x106 – 1.0 x108) respectively, p<0.0001 –figure 5. 
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Figure 5. 
 
Figure 5. Bacterial load in stable patients with bronchiectasis in ‘mild, 0-4’ 
‘moderate, 5-8’ and ‘severe ³9’ Bronchiectasis Severity Index groups shown as 
boxplot with median (IQR), whiskers 5-95% CI, dots of outliers, ***p<0.0001. 
 
3.3.7 Lung function tests results 
Forced expiratory volume in 1 second (FEV1), percent predicted of FEV1 (% FEV1), 
forced vital capacity (FVC), percent predicted FVC (%FVC), forced expiratory flow 
at 25-75% (FEF25-75) and percent predicted of FEF25-75 (%FEF25-75) was tested in all 
patients. There was an association with all markers of lung function and increasing 
severity across the BSI groups, p<0.0001 – see figure 6. Median (IQR) for each BSI 
group 0-4, 5-8 and ³9 for FEV1: 2.32L (1.8 - 2.9), 1.86L (1.4 - 2.4) and 1.48L (1.1 – 
2.1); %FEV1: 90% (75 - 100), 81% (64 - 98) and 60.5% (48 – 78); FVC: 3.4L (2.7 – 
4.1), 3.0L (2.4 – 3.6) and 2.6L (2.0 – 3.1); % FVC: 101% (88 - 117), 99% (84 - 114) 
and 79% (65 - 97); FEF25-75: 1.5L (0.9 – 2.7), 1.0L (0.6 – 1.7) and 0.67L (0.44 – 
1.2); %FEF25-75: 46% (28.8 – 73.3), 36% (22 - 55) and 25% (16 - 40) respectively. 
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Figure 6. 
 
Figure 6. Lung function tests in clinically stable patients with ‘mild, 0-4’ 
‘moderate, 5-8’ and ‘severe, ³9’ Bronchiectasis Severity Index groups shown as 
boxplot with median (IQR), whiskers 5-95% CI, dots of outliers. A: FEV1 (L) 
B: % predicted FEV1, C: FVC (L), D: % predicted FVC, E: FEF25-75, F: % 
predicted FEF25-75, ***P<0.0001. 
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3.3.8 Quality of life results 
The Leicester Cough Questionnaire (LCQ) assesses quality of life based on the 
impact of cough severity across the domains of physical, psychological and social 
items. The St George’s Respiratory Questionnaire (SGRQ) assesses quality of life 
based on symptoms, activity and psychosocial impact. The median (IQR) of LCQ 
results for each BSI tertile were: 19 (16-20), 18 (14-20) and 16 (13-19) respectively. 
The median (IQR) for the SGRQ for each group was: 26 (17-37), 28.5 (16-44) and 
44 (31-66) respectively. Both quality of life assessments correlated with BSI 
severity; SGRQ: p<0.0001 and the LCQ: p=0.01 – see figure 7. 
 
Figure 7. 
 
Figure 7. Quality of life in clinically stable patients with bronchiectasis in ‘mild, 
0-4’ ‘moderate, 5-8’ and ‘severe, ³9’ Bronchiectasis Severity Index groups 
shown as boxplot with median (IQR) and 5-95% CI, A: Leicester Cough 
Questionnaire (LCQ), *p=0.01, B: St George’s Respiratory Questionnaire 
(SGRQ), ***p<0.0001. 
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3.4 Discussion 
The bronchiectasis severity index score is internationally validated for predict 30-
day mortality rate and hospitalisation. Work from this thesis supports that in 
addition the BSI links with sputum purulence, 24hr sputum volume, quantitative 
bacterial load, lung function, functional capacity, quality of life, sputum and serum 
inflammatory markers. These other endpoints have been shown to be of importance 
previously but have not to date been linked with the Bronchiectasis Severity Index.  
 
Sputum colour was investigated by Murray et al in stable patients with 
bronchiectasis. They reported good reliability of sputum colour between patients and 
clinician and that it was predictive of bacterial colonisation (p<0.0001). They also 
reported independent factors associated with sputum purulence were bacterial 
colonisation, radiological varicose or cystic bronchiectasis, FEV1 less than 80% 
predicted and diagnosis of bronchiectasis aged less than 45yrs old (Murray et al, 
2009).  
 
Bacterial load has been evaluated with conflicting evidence in the literature. Tunney 
and colleagues reported that bacterial load did not change with exacerbations 
although they did not measure bacterial load during clinical stability and during an 
exacerbation in the same patients and their study on exacerbations was small (n=14) 
(Tunney et al, 2013). Chalmers and colleagues reported there was a direct 
relationship between bacterial load and the severity of exacerbations and risk of 
subsequent exacerbations. They linked bacterial load with airways inflammation and 
systemic inflammation when assessing both inpatients and outpatient exacerbations. 
Furthermore, they reported the reduction of bacterial load with short and long term 
antibiotic therapy (Chalmers et al, 2012).  
 
Lung function in bronchiectasis has not been very well characterised in 
bronchiectasis. A study by Guan and colleagues have reported in 142 stable patients 
that the variables associated with a 50% or lower FEV1 were radiological severity 
(p<0.01), presence of Pseudomonas aeruginosa (p<0.01) and the presence of 
symptoms for 10 or more years (p=0.01). They also noted differences in FEV1 and 
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FVC between exacerbations and convalescence in a small subgroup (p<0.05). 
Martinez-Garcia and colleagues also investigated FEV1 decline in 76 stable patients. 
They also found accelerated decline in function to be associated with more severe 
exacerbations, the presence of Pseudomonas aeruginosa in sputum and systemic 
inflammation (Martinez-Garcia et al, 2007).   
 
The ISWT is an objective measurement of functional capacity and has been 
previously shown to remain stable in patients with clinical stability i.e. no change to 
medications and no exacerbation 6 months apart (Mandal et al, 2014). It has also 
been shown to improve with long-term nebulised antibiotics (Murray et al, 2011) 
and anti-inflammatory treatment (Mandal et al, 2014). Work from this thesis 
demonstrated that the ISWT mean distances deteriorated significantly with 
increasing severity of BSI. Work from this thesis has validated the ISWT as a 
clinical endpoint in bronchiectasis and found a 5% difference in distance walked to 
be the minimum clinically important difference (MCID) (See chapter 5) (Cartlidge 
et al, 2018).   
 
The Leicester Cough Questionnaire (LCQ) and the St George’s Respiratory 
Questionnaire (SGRQ) have both been validated as clinical endpoints for use in 
bronchiectasis (Murray et al, 2009d Wilson et al, 1997b). The MCID for the LCQ is 
1.3units and for the SGRQ is 4units.  
 
Previous studies have shown the importance of airway inflammation and its 
correlation with higher bacterial loads and subsequent increased risk of exacerbation 
and with severe exacerbations (Chalmers et al, 2012). Airway inflammatory markers 
have also been shown to improve with the use of long-term antibiotic use (Murray et 
al, 2011 and Chalmers et al, 2012) They also reported on the increased airways 
inflammation present with patients colonised with Pseudomonas aeruginosa and in 
those with more severe radiological bronchiectasis (Chalmers et al, 2012). Elevation 
of Neutrophil elastase, a product of activated neutrophils has been investigated by 
Chalmers and colleagues and was found to be associated with the bronchiectasis 
severity index score (r=0.49, p<0.0001) but was not independently associated with 
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mortality rates. The authors found neutrophil elastase to rise in exacerbations and 
have good discrimination for severe exacerbations and all-cause mortality (Chalmers 
et al, 2016). 
 
Relatively little is known about systemic inflammation in patients with 
bronchiectasis due to the paucity of studies in this area. A study by Wilson et al in 
87 stable bronchiectasis patients investigated the correlation of inflammatory 
markers with radiological severity, lung function, sputum bacteriology and health 
related quality of life as assessed by the SGRQ. They reported patients have raised 
inflammatory markers when clinically stable and that inflammatory markers 
correlate with disease severity; WCC, neutrophil count, ESR and CRP all correlated 
with radiological severity, WCC and CRP correlated with total SGRQ scores 
(Wilson et al, 1998). 
 
3.5 Significance 
There have been no prior studies linking the BSI with sputum purulence despite its 
importance in recognising severity. This is the first study to show increasing sputum 
purulence, a very quick and easy assessment, links with increasing severity of BSI. 
The role of quantitative bacteriology has been debated in the literature but this study 
supports the notion that increasing bacterial load is associated with increased 
severity of bronchiectasis. The most commonly research lung function parameter is 
FEV1 and variables associated with its decline have been investigated. The BSI 
already incorporates percent predicted FEV1 as part of its severity scoring system 
but as this can be affected by other respiratory conditions that patients with 
bronchiectasis might have such as asthma and COPD, the other measures of lung 
function were explored. This is the first study to find all parameters of actual and 
predicted FEV1, FVC and FEF 25-75 correlated with worsening severity of 
bronchiectasis as assessed by the BSI. Functional capacity in bronchiectasis has not 
been well studied in bronchiectasis and has only recently been validated in this 
respiratory condition (Cartlidge et al, 2018). This study has shown that the ISWT 
links with BSI severity in stable patients. The LCQ and SGRQ are validated clinical 
endpoints in bronchiectasis. This is the first study to show the LCQ measurement of 
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quality of life links with BSI severity scoring. Lastly, the BSI is a very clinical tool 
and does not incorporate any laboratory endpoints that assess inflammation. This 
study demonstrates that markers of serum inflammation –WCC, Neutrophil count, 
ESR and CRP all increase with worsening severity of bronchiectasis as assessed by 
the BSI. The changes in the serum inflammatory markers, whilst statistically 
significant are small and therefore of questionable clinical significance. 
 
3.6 Limitations  
The BSI score has already been externally validated and predicts mortality and 
hospitalization. This study reiterates the current literature findings that this scoring 
system is robust in this outpatient cohort. Several clinical markers are already 
included in the BSI but this study shows additional markers like exercise tolerance 
(ISWT) and sputum colour correlate well with it. Due to the small number of 
patients in this study, the added value of these endpoints to BSI to predict 30-day 
mortality and hospitalisation could not be explored.  
 
3.7 Conclusion 
The Bronchiectasis Severity Index stratifies patients into tertiles and has been shown 
to predict 30day mortality and hospitalization. The authors have shown the BSI 
scoring of severity to also link with other endpoints of increasing sputum purulence, 
24hr sputum volume, bacterial load, functional capacity as assessed by the ISWT, 
quality of life, lung function parameters of FVC and FEF25-75 in addition to FEV1, 
and serum inflammatory markers. Further work is needed to assess whether these 
clinical endpoints could be additive or independent to the BSI in predicting 30-day 
mortality and future hospitalisation. 
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Chapter 4: 
Defining the characteristics of outpatient exacerbations 
4.1 Introduction to exacerbations 
Bronchiectasis is a chronic respiratory condition where patients suffer from a daily 
cough, sputum production and breathlessness. It is a heterogeneous condition with 
multiple aetiologies and the severity of the condition can range from mild to severe. 
Patients can suffer from recurrent exacerbations which necessitates treatment; 
mainly in the form of short term antibiotics and chest physiotherapy. Patients can 
however also suffer from daily symptoms when clinically stable that do not 
necessitate acute treatment but for which long term treatments such as anti-
inflammatories, prophylactic antibiotics, mucolytic therapy could be explored. As 
with any chronic progressive lung disease the distinction between the patient’s 
baseline, albeit far off a healthy person’s baseline with an exacerbation can be 
blurred and hence the decision to treat can be difficult.  
 
The British Thoracic Guidelines defined an exacerbation as an acute deterioration 
(usually over several days) with worsening local symptoms (cough, increase sputum 
volume or change of viscosity, increased sputum purulence with or without 
increasing wheeze, breathlessness, haemoptysis) and/or systemic upset (Pasteur et 
al, 2010). There has recently been a European consensus led by Hill and colleagues 
to define an exacerbation for use in clinical research trials. They concluded an 
exacerbation to be when a patient exhibits a deterioration in three of more of the 
following key symptoms for at least 48hours: cough; sputum volume and/or 
consistency; sputum purulence; breathlessness and/or exercise tolerance; fatigue 
and/or malaise; haemoptysis AND a clinician determines that a change in 
bronchiectasis treatment is required (Hill et al, 2017). 
 
Exacerbations meeting these criteria treated as outpatients are less severe and treated 
with oral antibiotic therapy. The British Thoracic Society guidelines recommends 
that intravenous antibiotic therapy should be considered when patients are 
particularly unwell, have resistant organisms or have failed to respond to oral 
therapy (Pasteur et al, 2010). 
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There are a paucity of studies investigating outpatient exacerbations of 
bronchiectasis and the mechanism underpinning this needs further study.  
 
The role of quantitative bacteriology and bacterial load in exacerbations of 
bronchiectasis is unclear with previous literature offering different views. Chalmers 
and colleagues suggest bacterial load in the stable state directly correlates with 
markers of airway inflammation and the risk of subsequent exacerbations and severe 
exacerbations. They also suggested that intravenous antibiotics reduced bacterial 
load in addition to airway and systemic inflammation. Tunney et al investigated 
bacterial load using quantitative microbiology as well as 16S rDNA pyrosequencing 
and found similar communities of microbial taxa (113 distinct microbial taxa) were 
present in low abundance when clinically stable, start of exacerbation and after 
treatment. The clinical significance of these numerous taxa in low abundance is 
unclear. To further investigate the role of bacterial load we aimed to perform 
qualitative and quantitative microbiology on patients sequentially at stable baseline, 
start and end of exacerbation in the same patients. The hypothesis is that an 
exacerbation with a rise in bacterial load of 1 or more log unit in colony forming 
units per ml would lead to a more severe exacerbation. 
 
This chapter aims to provide further guidance on the phenotype of outpatient 
exacerbations and to investigate the significance of bacterial load rise in 
exacerbations of bronchiectasis. 
 
4.2 Clinically unstable patients 
94 of the 207 patients that completed a baseline visit went on to have an 
‘exacerbation’ during the length of the study. The study did specify that patients 
should be seen for their first exacerbation after their baseline visit in the study and 
that subsequent exacerbations would not be included. Due to the length of the study 
(2 years) and the limitations (patients could only be seen during working hours) 
there will undoubtedly have been patients that sought medical advice from their 
general practitioner, emergency services or started rescue medications at home.  
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Patients completed all tests at a ‘baseline’ visit (Visit 0, V0) when clinically well 
and free from any exacerbating symptoms or antibiotic use in the last 6 weeks. The 
results were recorded and patients were then encouraged to get in touch when they 
felt they had symptoms of an exacerbation. A suitable time would be arranged (often 
the same day but occasionally the next day) and the patient would return for a ‘Start 
of exacerbation’ visit (Visit start, VS) and repeat all tests. The patient would be 
issued with a 14-day prescription of antibiotics, according to sensitivities of any 
previous microbiological sputum results, as per unit guidelines. After 14 days 
patients would return for an ‘End of exacerbation’ visit (Visit end, VE) and repeat 
all tests and to ensure clinical recovery. 
 
4.3 Methodology 
4.3.1 Ethics 
Ethical approval was granted by the West of Scotland Research ethics service, REC 
reference 13/WS/0230. All patients provided informed written consent and were 
recruited from a single centre. 
 
4.3.2 Study design 
Patients were recruited from a routine bronchiectasis clinic in a single tertiary 
specialist centre. Patients over the age of 16 with clinically evident bronchiectasis, 
previously diagnosed by high resolution computer tomography (CT) scan. Patients 
were asked to attend for three visits –baseline (VO), start of exacerbation (VS) and 
end of exacerbation (VE). Patient were asked to attend an outpatient appointment 
when clinically stable (no antibiotic use in the last 6 weeks) where baseline 
assessments (see below) were performed. They were then given a dedicated phone 
number for the clinical researcher and advised to phone when they felt they were 
experiencing an exacerbation. After discussion, if the clinical fellow thought 
antibiotics were warranted then the patients were seen for the second visit. All 
assessments were repeated and a prescription for 14 days of antibiotics as per their 
previous microbiology results was given. After 14 days patients re-attended for the 
final visit and assessments were repeated. 
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4.3.3 Incremental shuttle walk test 
The test was performed according to standard test procedure (Singh et al, 1992) and 
consisted of a 10-metre shuttle course on a flat surface with the walking speed 
controlled using pre-recorded audio signals. The test continues until the participant 
is unable to complete the shuttle in the designated time or the patient decides to stop 
due to symptoms (e.g. breathless, leg fatigue). The distance completed within the 
timeframe was recorded. The successful completion of distance walked in our study 
was recorded in increments of 10m.  
 
4.3.4 Lung function 
We measured pre-bronchodilator forced expiratory volume in 1 second (FEV1), 
forced vital capacity (FVC) and ratio FEV1:FVC by spirometry according to 
standardized guidelines [ATS guidelines]. Patients were asked to take three attempts 
and the best results were recorded. All patients have previously performed 
spirometry as part of routine clinical practise. 
 
4.3.5 Sputum 
Sputum colour was graded according to a visual colour chart rating. Mucoid sputum 
was rated 1, mucopurulent rated as 2 and purulent sputum rated as 3 or 4 depending 
on colour (Murray et al, 2009). 24hour sputum volume was recorded by asking 
patients to expectorate solely into a universal container for 24hours. Qualitative and 
quantitative microbiology was performed on all samples at baseline, pre- and post 
14 days of antibiotics. 
 
4.3.6 Qualitative and quantitative microbiology (Murray et al, 2011) 
For analysis culture results were grouped as either positive for ‘Pseudomonas 
aeruginosa’, ‘potentially pathogenic microorganisms’ (Haemophilus influenzae, 
Moraxella catarrhalis, Streptococcus pneumoniae, Staphylococcus aureus) or ‘other 
gram negatives’ (Enterobacter, Escherichia coli, Klebsiella pneumoniae, 
Stenotrophomonas maltophilia, Serratia marcescens, Proteus mirabilis, 
Acinetobacter baumannii, Achromobacter xylosoxidans, Citrobacter freundii and 
Aeromonas hydrophila) and ‘mixed normal flora’ (no dominant pathogen cultured 
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or presence of respiratory commensal flora only). 
 
4.3.7 Sputum inflammatory markers 
Whole sputum samples were also centrifuged to produce supernatants on which 
myeloperoxidase (MPO), neutrophil elastase (NE) and interleukin – 8 (IL-8) were 
tested. MPO (Steinman et al, 1972) was assayed using a chromogenic substrate 
assay (Stockley et al, 2000), free neutrophil elastase (NE) (Buttle et al, 1990) was 
measured by spectrophotometry with a  synthetic substrate (methoxysuccinyl-Ala-
Ala-Pro-Val paranitroanilide; Sigma, Gillingham, UK) were tested as per standard 
protocol (Hill et al, 1999, Hill et al, 2000) and interleukin – 8 (IL-8) was assayed 
using commercially available specific ELISAs (R&D Systems, Oxford, UK). 
 
4.3.8 Blood inflammatory markers 
Venous blood sampling was taken to monitor full blood count, urea and electrolytes, 
Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).  
 
4.3.9 Statistical analysis 
All data were analysed using Graphpad prism version 5.0a (Graphpad software, San 
Diego, CA, USA). For demographic and clinical variables, data are presented as 
median (interquartile range) for continuous variables and n (%) for categorical 
variables unless specified otherwise. A P value <0.05 was considered statistically 
significant for each analysis. Comparison of changes within a group i.e. before and 
after treatment was calculated using Wilcoxon signed rank test and we compared 
categorical data between groups was calculated using the χ2 test. 
 
4.4 Results 
4.4.1 Baseline characteristics 
The 94 patients with exacerbations within the study that completed a start of 
exacerbation and end of exacerbation visit, had the following characteristics (Table 
1) and aetiology (Table 2): 
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Table 1. 
Characteristic Exacerbations No exacerbations 
Number 94 113 
Age (yrs) (mean, (SD)) 65.76 (9.9) 65.82 (11.2) 
Female 51(54) 59 (52) 
Current smokers 
Ex-smokers 
Never 
2 (2) 
35 (37) 
57 (61) 
7 (6) 
48 (42) 
58 (51) 
BMI Kg/m2 (mean (SD)) 32.39 (53.79) 26.33 (4.96) 
COPD 
Asthma 
Interstitial lung disease 
Lung cancer 
Pulm. Hypertension 
Inactive ABPA 
IHD 
Other cancers  
13 (14) 
16 (17) 
0 
2 (2) 
0 
11 (12) 
5 (5) 
7 (7) 
22 (19) 
7 (6) 
3 (3) 
0 
1 (1) 
10 (9) 
9 (8) 
15 (13) 
LTOT 0 2 (2) 
Inhaled steroid 
Dose (mean, (SD)) 
Oral steroid 
Dose (mean, (SD)) 
Nebulised bronchodilators   
Long-term oral antibx 
Long-term inh antibx 
Cyclical IV antibiotics 
16 (17) 
216mcg (118mcg) 
2 (2) 
10mg (7mg) 
2 (2) 
2 (2) 
5 (5) 
1 (1) 
7 (6) 
200mcg (70.7mcg) 
10 (9) 
7.2mg (5.1mg) 
5 (4) 
2 (2) 
2 (2) 
0 
Bronchiectasis severity 
FEV1 
% pred FEV1 
6.9 (4.4) 
2.02 (0.75) 
79.2 (24.9) 
6.5 (4.1) 
2.05 (0.79) 
77.5 (24.6) 
Baseline characteristics of patients that did and did not present with an exacerbation. 
N (%) unless otherwise stated. Body mass index (BMI), Chronic obstructive 
pulmonary disease (COPD), Allergic bronchopulmonary aspergillosis (ABPA), 
Ischaemic heart disease (IHD), Long term oxygen therapy (LTOT), inhaled antibiotics 
(inh antibx) and forced expiratory volume in 1 second (FEV1). 
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Table 2. 
 
Table to show the N (%) of patients with different aetiologies of bronchiectasis. 
COPD: chronic obstructive pulmonary disease, GORD: gastric oesophageal 
reflux disease. 
 
4.4.2 Lung function 
4.4.2.1 Forced expiratory volume in 1 second (FEV1) 
94 patients performed spirometry at baseline and start of exacerbation. 93 patients 
performed spirometry at the end of an exacerbation. Results are outlined in table 3. 
 
 
 
 
 
 
 
Aetiology Exacerbation 
N (%) 
No exacerbation 
N (%) 
Idiopathic 37 (39) 56 (50) 
Post infectious 29 (31) 26 (23) 
COPD 1 (1) 8 (7) 
Inflammatory bowel 
disease 
2 (2) 5 (4) 
Immunoglobulin 
deficiency 
4 (4) 5 (4) 
Allergic 
bronchopulmonary 
aspergillosis  
6 (6) 6 (5) 
Connective tissue 
disease 
4 (4) 3 (3) 
Aspiration or inhalation 
or GORD 
11 (12) 4 (4) 
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Table 3. 
	 Baseline	(VO)	
	FEV1	Litres	(L)	
Start	of	
exacerbation	(VS)	
FEV1	Litres	(L)	
End	of	
exacerbation	(VE)	
FEV1	Litres	(L)	
No.	of	values	 94	 94	 93	
25%	
percentile	
1.425	 1.290	 1.435	
Median		 1.975	 1.825	 1.920	
75%	
percentile	
2.443	 2.273	 2.360	
Table to show the change in forced expiratory volume in 1 second (FEV1) in 
patients when stable (VO) and with an exacerbation (VS and VE). 
 
The median value for FEV1 at baseline as 1.98L which reduced by 150ml to 1.83L 
at start of exacerbation. Following a 14-day course of antibiotics the median FEV1 
increased by 95ml to 1.92L. Patient’s FEV1 median value at the end of exacerbation 
was 55mls short of the median baseline value. 
 
A Wilcoxon paired t test analysis was performed. The reduction in FEV1 from 
baseline visit (VO) to start of exacerbation (VS) was statistically significant 
(P<0.0001). The increase in FEV1 from start of exacerbation to end of exacerbation 
was also statistically significant (P<0.001). The median FEV1 at end of exacerbation 
was also found to be significantly lower than initial baseline tests (P=0.03). See 
figure 1 for schematic.  
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Figure 1.
 
Boxplot (median, IQR with whiskers 5-95% percentile) to show the change in 
forced expiratory volume in 1 second (FEV1) from baseline (VO) to start of 
exacerbation (VS) to end of exacerbation (VE). Significance, *p<0.05, 
***p<0.001. 
 
4.4.2.2 Percentage of predicted forced expiratory volume in 1 second (% FEV1) 
94 patients performed spirometry at baseline and start of exacerbation. 93 patients 
performed spirometry at the end of an exacerbation. Results for percent predicted of 
FEV1 are outlined in table 4. 
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The median value for percentage of predicted FEV1 was 81% at baseline. This 
reduced to a median value of 78% at the start of exacerbation. After a course of 
antibiotics, the median value for percent predicted remained the same at 78%. There 
was a 3% reduction in the median percent predicted of FEV1 at the end of 
exacerbation when compared with baseline values.  
 
Table 4. 
Table to show the change in percent predicted of FEV1 in patients when stable 
(VO) and with an exacerbation (VS and VE). 
 
The reduction in percent predicted FEV1 from baseline to start of exacerbation was 
statistically significant when analysed using a paired Wilcoxon statistical analysis 
(P=0.0002). There was also a statistically significant increase in percent predicted 
FEV1 from start of exacerbation to end of exacerbation with the mean increasing 
from 75.9% to 77.8%, although the median values remained the same. There was no 
significant difference from baseline values to end of exacerbation and may suggest 
that patients returned to baseline level (Figure 2). 
 
	 Baseline	(VO)	
%	predicted		
FEV1	(%)	
Start	of		
exacerbation	(VS)		
%	predicted	FEV1	
(%)	
End	of		
exacerbation	(VE)	
	%	predicted	FEV1	
(%)	
No.	of	values	 94	 94	 93	
25%	
percentile	
62.00	 58.75	 63.50	
Median		 81.00	 78.00	 78.00	
75%	
percentile	
97.25	 92.50	 92.00	
 136 
Figure 2. 
 
Boxplot (median, IQR with whiskers 5-95% percentile) to show the change in 
percent predicted in FEV1 (%) from baseline (VO) to start of exacerbation (VS) 
to end of exacerbation (VE). Significance, **p<0.01, ***p<0.001, #p>0.05. 
 
4.4.2.3 Forced vital capacity (FVC) 
94 patients performed spirometry at baseline and start of exacerbation. 93 patients 
performed spirometry at the end of an exacerbation. Results are outlined in table 5. 
The median forced vital capacity at baseline level is 2.96L. This decreases by 240ml 
at start of exacerbation. After 14 days of antibiotics the median FVC increases by 
200mls to 2.92L. The end of exacerbation median value is 40mls less that the initial  
baseline level. 
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Table 5. 
 
Baseline (VO) 
FVC (L) 
Start of 
exacerbation (VS) 
FVC (L) 
End of 
exacerbation 
(VE) FVC (L) 
No. of values 94 94 93 
25% 
percentile 2.288 2.120 2.385 
Median  2.960 2.720 2.920 
75% 
percentile 3.843 3.463 3.680 
Table to show the change in forced vital capacity (FVC) in patients when stable 
(VO) and with an exacerbation (VS and VE). 
 
Figure 3.  
 
Boxplot (median, IQR with whiskers 5-95% percentile) to show the change in 
forced vital capacity (FVC) from baseline (VO) to start of exacerbation (VS) to 
end of exacerbation (VE). Significance, ***p<0.001. 
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Statistical analysis shows a significant reduction in FVC from baseline to start of 
exacerbation. 14 days of antibiotics results in a significant improvement but not 
enough to reach initial baseline level. There remains a significant difference 
between baseline and end of exacerbation forced vital capacity (Figure 3). 
 
4.4.2.4 Percentage predicted forced vital capacity (% FVC) 
94 patients performed spirometry at baseline and start of exacerbation. 93 patients 
performed spirometry at the end of an exacerbation. Results for percent predicted of 
forced vital capacity are outlined in table 6. 
 
The median value for percent predicted of forced vital capacity at baseline was 
99.5%. This reduced by 7.5% to 92% when patients self-presented with an 
exacerbation of bronchiectasis. Following therapy, the percent predicted increased 
by 3%. There remained a 4.5% reduction in percent predicted FVC at end of 
exacerbation when compared with baseline.  
 
Table 6. 
Table to show the change in percent predicted of forced vital capacity (FVC) 
when stable (VO) and with an exacerbation (VS and VE). 
  
 
Baseline (VO) 
% predicted FVC 
(%) 
Start of 
exacerbation (VS) 
% predicted FVC 
(%) 
End of 
exacerbation (VE) 
% predicted FVC 
(%) 
No. of values 94 94 93 
25% Percentile 82.75 75.00 81.00 
Median 99.50 92.00 95.00 
75% Percentile 114.0 106.0 107.0 
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Figure 4. 
 
 
Boxplot (median, IQR with whiskers 5-95% percentile) to show the change in 
percent predicted forced vital capacity (FVC) from baseline (VO) to start of 
exacerbation (VS) to end of exacerbation (VE). Significance,**p<0.01, 
***p<0.001. 
 
There is a significant reduction in the percent predicted forced vital capacity at start 
of exacerbation when compared with baseline (P<0.0001). The percent predicted 
significantly improves at end of exacerbation with treatment (P=0.002) but does not 
reach initial levels with a significant reduction remaining when compared with 
baseline results (P=0.002). See figure 4. 
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4.4.2.5 Forced expiratory flow25-75 (FEF25-75) 
93 patients performed spirometry at baseline and start of exacerbation. 91 patients 
had FEF25-75 measured at start and 93 at end of exacerbation. The reduced number 
of results was due to equipment failure. Results for forced expiratory flow25-75 and 
percent predicted FEF25-75 are outlined in table 7 and table 8. 
 
Forced expiratory flow25-75 measures the volume expired in mid expiration when 
maximally breathing out. Results showed a small reduction of 50mls in volume 
expired at start of exacerbation when compared with baseline. This reduction 
disappeared at the end of exacerbation with median values of 1.07L expired at both 
baseline and end of exacerbation. The results did not reach statistical significance. 
 
Similarly, the percent predicted FEF25-75 reduced from 37% at baseline to 36% at 
start of exacerbation. After treatment with 14 days of antibiotics, the percent 
predicted median value was 35%. The results did not reach statistical significance.  
 
Table 7. 
 
Baseline (VO) 
FEF25-75 (L) 
Start of 
exacerbation (VS) 
FEF25-75 (L) 
End of exacerbation 
(VE) 
FEF25-75 (L) 
No. of values 93 91 93 
25% percentile 0.6050 0.5900 0.6250 
Median 1.070 1.020 1.070 
75% percentile 1.695 1.510 1.600 
P value compared 
with VO  
0.9 0.2 
P value compared 
with VS   
0.07 
Table to show the change in forced expiratory flow25-75 (FEF25-75) when stable 
(VO) and with an exacerbation (VS and VE). 
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Table 8. 
 
Baseline (VO) 
% predicted 
FEF25-75 
Start of 
exacerbation (VS) 
% predicted 
FEF25-75 
End of exacerbation 
(VE) 
% predicted 
FEF25-75 
No. of values 93 91 93 
25% percentile 21.00 22.00 24.50 
Median 37.00 36.00 35.00 
75% percentile 58.50 52.00 56.00 
P value compared 
with VO  
0.9 0.3 
P value compared 
with VS   
0.1 
Table to show the change in percent predicted forced expiratory flow25-75 
(FEF25-75) when stable (VO) and with an exacerbation (VS and VE). 
 
4.4.3 Sputum characteristics 
All patients were asked to provide a spontaneous sputum sample within 4 hours of 
waking in the morning and a 24-hour sputum collection from the preceding 24hours 
of their appointment. 
 
4.4.3.1 Sputum colour 
Sputum was analysed for its colour and graded according to a standardised colour 
chart. The colour was awarded a number of 1 to 4 with 1 being awarded to clear or 
grey sputum and the number increasing with increasing purulence (see sputum 
purulence colour chart – 2= light yellow or light green, 3/4= dark 
yellow/green/brown colour).  
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89 patients provided a spontaneous sputum sample at baseline. 94 patients provided 
a spontaneous sputum sample at start of exacerbation and 84 at end of exacerbation. 
At baseline the median colour of spontaneous sputum was grade 2. This increased to 
a median colour of grade 3 at start of exacerbation which then returned to a baseline 
median value of grade 2 at the end of exacerbation.  
 
There was a significant increase in sputum colour from baseline to start of 
exacerbation. This reduced back to baseline level at the end of exacerbation 
(P<0.0001) with no significant difference in sputum colour seen from baseline to 
end of exacerbation (P=0.2) – see figure 5. 
 
Figure 5. 
 
Boxplot (median, IQR with whiskers 5-95% percentile) to show the change in 
sputum colour from baseline (VO) to start of exacerbation (VS) to end of 
exacerbation (VE). Significance, ***p<0.001, #p>0.05. 
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4.4.3.2 Sputum purulence  
Sputum colour grade was divided into three groups with grade 1 classed as mucoid, 
grade 2 classed as mucopurulent and grades 3 and 4 classed as purulent. 
Mucopurulent was the predominant sputum grade at baseline. Sputum at the start of 
exacerbation were more purulent with less mucoid samples than baseline. At the end 
of exacerbation, the predominant grade was mucopurulent.  
 
Figure 6. 
 
Bar chart to show the change in sputum purulence from baseline (VO) to start 
(VS) and end of exacerbation (VE). 
 
4.4.3.3 Spontaneous sputum volume 
Spontaneous sputum produced within 4hrs from waking on the morning of each visit 
was measured. Results are shown in figure 7. Spontaneous sputum production 
changed with exacerbation. There was a median of 2mls produced by patients at 
baseline. This increased to 4mls at start of exacerbation visits (P<0.0001) and 
reduced back to 2mls at end of exacerbation (P<0.001). There was no difference in 
the amount of spontaneous sputum produced between baseline and end of 
exacerbation.  
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Figure 7. 
 
Boxplot (median, IQR with whiskers 5-95% percentile) to show the change in 
spontaneous sputum volume from baseline (VO) to start of exacerbation (VS) 
to end of exacerbation (VE). Significance, ***p<0.001, #p>0.05. 
 
4.4.3.4 24-hour sputum volume 
Patients were asked to collect all sputum expectorated in a collection pot over a 
period of 24-hours prior to each clinic visit. This is particularly arduous for patients 
and at times the clinic visit (especially start of exacerbation visit) was arranged at 
short notice. Therefore 78 patients provided a 24-hour sample at baseline, 59 at start 
of exacerbation and 76 at end of exacerbation. Results are shown in figure 8. 
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Figure 8.
Boxplot (median, IQR with whiskers 5-95% percentile) to show the change in 
24hr sputum volume from baseline (VO) to start of exacerbation (VS) to end of 
exacerbation (VE). Significance, *p<0.05, **P<0.01, #p>0.05. 
 
24-hour sputum volume increased from 5mls at baseline to 10mls at start of 
exacerbation (P=0.003). It significantly reduced with treatment to 6.5mls at the end 
of exacerbation (P=0.001). There was no difference in 24-hour sputum production 
between baseline and end of exacerbation. 
 
4.4.4 Medical research council (MRC) breathlessness score 
Patients with bronchiectasis often report breathlessness as a symptom. The MRC 
breathlessness score is a scale of 1-5 based on the degree of breathlessness- see 
below (Bestall et al, 1999). 
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MRC BREATHLESS SCORE 
1 Not troubled by breathlessness, except on strenuous exercise 
2 Breathless when hurrying on the level or walking up an incline 
3 Walks slower than most on the level, stops after walking 1 mile or 15mins 
4 Stops for breath after 100yards or few minutes walking on level ground 
5 Breathless when dressing/undressing, unable to leave the house 
 
The range of MRC scores appointed at each visit are depicted in figure 9. The most 
commonly occurring score at baseline is MRC score 1. There is an increase in the 
number of patients reporting MRC scores of 3, 4 and 5 at start of exacerbation. The 
pattern of MRC scores at end of exacerbation are similar to baseline scores. 
 
Figure 9. 
 
Barchart to show the pattern of Medical Research Council Dyspnoea scores 
(MRC) levels 1-5 at different visits VO: baseline, VS: start of exacerbation, VE: 
end of exacerbation with increasing severity from level 1 to 5. 
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Paired statistical analysis of the MRC scores at different visits is shown in figure 10. 
The median MRC score at baseline, start of exacerbation and end of exacerbation 
was 2. The mean value increased from 2.3 at baseline to 2.7 at start of exacerbation 
(P=0.007). It then reduced to 2.4 (P=0.01) at end of exacerbation which was not 
significantly different from baseline (P=0.6). 
 
Figure 10. 
 
Boxplot (median, IQR with whiskers 5-95% percentile) to show the change in 
MRC breathlessness score from baseline (VO) to start of exacerbation (VS) to 
end of exacerbation (VE). Significance, *p<0.05, **P<0.01, #p>0.05. 
 
4.4.4.2 Subanalysis of MRC score 
MRC scores 1 and 2 represent relatively mild breathlessness and 3, 4 and 5 are for 
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more symptomatic breathlessness at the start of exacerbation when compared with 
baseline scores although just failed to reach conventional statistical significance. 
There was no difference between start and end of exacerbation and no difference 
between baseline and end of exacerbation (Tables 9a, 9b & 9c). 
 
Table 9a. 
 
 
 
 
 
P=0.054 
Table 9b. 
 
 
 
 
P= 0.2 
 
Table 9c. 
 
 
 
 
P= 0.5 
Chi squared results of change in MRC results from 9a: stable (VO) to start 
(VS), 9b: start to end of exacerbation (VE), 9c: stable to end exacerbation. 
 
4.4.5 Quality of life  
4.4.5.1 The Leicester cough questionnaire  
The Leicester cough questionnaire (LCQ) is a validated questionnaire shown to 
assess the impact of cough on quality of life in patients with bronchiectasis. The 
LCQ gives a score that range from 3 to 21. The lower the score the poorer the 
quality of life. All patients were required to complete a questionnaire at each visit. 
Results are shown in table 10 and figure 11. 
 
 
 
MRC 1-2 MRC 3-5 
VO 61 33 
VS 48 46 
 MRC 1-2 MRC 3-5 
VS 48 46 
VE 56 38 
 MRC 1-2 MRC 3-5 
VO 61 33 
VE 56 38 
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Table 10. 
  VO Total LCQ VS Total LCQ VE Total LCQ 
Number of values 92 91 94 
25% Percentile 15.00 10.00 12.00 
Median 18.00 14.00 17.00 
75% Percentile 20.00 17.00 19.25 
Table to show the change in Leicester Cough Questionnaire (LCQ) Units when 
stable (VO) and with an exacerbation (VS and VE). 
 
Figure 11. 
 
Boxplot (median, IQR with whiskers 5-95% percentile) to show the change in 
Leicester Cough Questionnaire (LCQ) from baseline (VO) to start of 
exacerbation (VS) to end of exacerbation (VE). Significance, **p<0.01, 
***P<0.001. 
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There is a significant decrease in LCQ from baseline to start of exacerbation.  There 
is a significant improvement in scores at the end of exacerbation visit post 14 day 
course of antibiotics.  There remained a difference between baseline and end of 
exacerbation suggesting patients did not feel fully recovered. The minimum 
clinically important difference in score is 1.3 units.  This would suggest that patients 
felt clinically worse at start of exacerbation and improved at the end of exacerbation.  
 
4.4.5.2 The St George’s Respiratory Questionnaire (SGRQ) 
The St George’s Respiratory Questionnaire assess quality of life and gives a score 
ranging from 0 to 100. The higher the score the poorer the quality of life. The 
minimum clinically important difference is 4 units. See table 11 and figure 12 for 
results. 
 
Table 11. 
  VO Total SGRQ VS Total SGRQ VE Total SGRQ 
Number of values 92 91 94 
25% Percentile 18.00 23.00 20.00 
Median 29.50 34.00 34.00 
75% Percentile 48.50 52.00 51.00 
Table to show the change in the St George’s Respiratory Questionnaire 
(SGRQ) Units from stable (VO) to start and end of exacerbation (VS and VE). 
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Figure 12. 
 
Figure to show the median value (IQR) St George’s Respiratory Questionnaire 
(SGRQ) scores as baseline (VO), start of exacerbation (VS) and end of 
exacerbation (VE). Wilcoxon analysis **p<0.01, ***p<0.0001. 
 
There is a significant worsening in SGRQ quality of life score at start of 
exacerbation (median 36 (25-36)) when compared with baseline (median 28 (18-
44)) (P<0.00001). The median then reduced significantly with 14 days of antibiotics 
at end of exacerbation (median 34 (20-51.75)) (p=0.003).  
 
4.4.6 Qualitative bacteriology 
4.4.6.1 Bacterial culture results 
Patients were asked to provide a spontaneous sputum sample produced within 4 
hours of waking to perform quantitative and qualitative microbiological analysis. 
Out of 94 patients with exacerbations, 93 samples were analysed at baseline, 90 
samples at start of exacerbation and 90 at the end of exacerbation. 
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The predominant pathogens cultured included Haemophilus influenzae, 
Pseudomonas aeruginosa, Streptococcus pneumoniae, Staphylococcus aureus, 
Moraxella catarrhalis, Enterobacter, Escherichia coli, Klebsiella pneumoniae, 
Serratia marcescens, Proteus mirabilis, Acinetobacter baumannii, Achromobacter 
xylosoxidans, Aeromonas hydrophila, citrobacter freundii, Stenotrophomonas 
maltophilia, mixed normal flora, and occasionally there was no growth. Some 
patients were not expectorating sputum despite feeling unwell. 
 
In order to analyse the data, the pathogens were placed into the four following 
groups:  
• MNF/No growth - mixed normal flora, no growth and no sputum 
expectorated 
• Potentially pathogenic microorganisms (PPM) - Haemophilus influenzae, 
Streptococcus pneumoniae, Staphylococcus aureus and Moraxella 
catarrhalis 
• Pseudomonas aeruginosa (PA) 
• Other gram negative organisms - Enterobacter, Escherichia coli, Klebsiella 
pneumoniae, Stenotrophomonas maltophilia, Serratia marcescens, Proteus 
mirabilis, Acinetobacter baumannii, Achromobacter xylosoxidans, 
citrobacter freundii and Aeromonas hydrophila 
• 61% of patients at baseline had sputum that cultured a pathogen. Of these, 
25% cultured more than 1 microorganism.  
• 79% of patients at start of exacerbation had sputum that cultured a pathogen. 
Of these, 30% cultured multiple pathogens. 
 
47% of patients at the end of exacerbation had sputum that cultured a pathogen. Of 
these, 17% cultured multiple microorganisms –figure 13. The pathogens cultured at 
each visit are represented in pie-charts 14a, 14b and 14c. 
 
 
 
 
 153 
Figure 13. 
 
Increase in % of patients that cultured a pathogen at start of exacerbation. 
 
Figure 14a. 
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Figure 14b. 
 
Figure 14c. 
 
Piecharts to show the proportion of different microorganisms cultured 14a) 
Out of a total 108 results at baseline (VO), 14b) Total 113 results at start of 
exacerbation (VS) and 14c) A total of 97 results at end of exacerbation (VE). 
MNF: mixed normal flora, PA: Pseudomonas aeruginosa, PPM: other 
potentially pathogenic microorganisms. 
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There were significantly more patients with sputum samples that grew mixed normal 
flora or that had no sputum at baseline when compared with patients at the start of 
exacerbation. There were therefore more patients that had sputum that cultured a 
pathogen at the start of exacerbation than there was at baseline (P=0.009). 
 
There was a significant increase in the number of samples that cultured mixed 
normal flora or had no sputum at the end of 14 days of antibiotics when compared 
with the start of exacerbation. There was therefore a significant reduction in the 
number of samples that cultured any pathogen (P=0.0001). 
 
There was a similar trend when comparing sputum sample results at baseline and 
end of exacerbations with more sputum samples culturing pathogens at baseline and 
more samples confirming mixed normal flora or no growth at end of exacerbation 
(P=0.047). 
 
4.4.6.2 Change in bacterial species cultured with exacerbation 
Culture results from individual patients were analysed. There was a 57% overall 
change in the dominant pathogen cultured when comparing start of exacerbation 
with baseline culture results. Of these, a small proportion of results saw a switch to 
growing mixed normal flora (4%) and a much larger proportion (53%) saw a 
different pathogen being cultured (figure 15). At the end of exacerbation there was a 
much bigger switch to mixed normal flora (36%) when compared with start of 
exacerbation, as you might expect after a 14-day course of antibiotics and 23% 
switch to a different pathogen. There was a 34% switch of pathogen from baseline to 
end of exacerbation with a smaller 29% switch to mixed normal flora from baseline 
to end of exacerbation and this might be accounted for by a persistent change in 
bacteria isolated at start of exacerbation. The changes from VO to VS were 
statistically significant when compared with the change in bacterial culture to either 
MNF or different pathogen from VS to VE and from VO to VE (P<0.01). 
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Figure 15. 
 
                               
Figure to show the change in proportions of different microorganisms cultured 
at each time point baseline (VO), start of exacerbation (VS) and end of 
exacerbation (VE). MNF: mixed normal flora. 
 
4.4.6.3 Change in the number of pathogens isolated with exacerbation 
There was a 33% increase in the number of culture results that isolated more 
pathogens at visit start than at baseline visit for the same patient (P<0.0001). In 55% 
of cases the number of isolates remained the same. At the end of exacerbation 47% 
of culture plates isolated fewer numbers of pathogens than when cultured at start of 
exacerbation for the same patient (P<0.0001). Results are outlined in figure 16 and 
table 12. 
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Figure 16. 
 
 
  
Figures to show the change in numbers of pathogens cultured per patients from 
baseline (VO) to start of exacerbation (VS) top, start to end of exacerbation 
(VE) middle and from baseline to end of exacerbation bottom. 
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Table 12.  
Table to show the change in the number of pathogens cultured per patient with 
exacerbation with chi squared results. 
 
4.4.7 Quantitative microbiological analysis 
4.4.7.1 Bacterial load 
Sputum samples were diluted and plated out as per protocol. After 48 hours of 
incubation the plates were analysed and bacteria identified. Individual colony 
forming units (CFU) were counted to ascertain the bacterial load. Results are 
presented in table 13 and figure 17. 
 
The median bacterial count is 6.7 x 105 CFU at baseline. This increases to 1.2 x 107 
at start of exacerbation and returns to a median value of 0 CFU at the end of 
exacerbation visits. 
 
 
 
 
 
 
 Visit start (VS) Visit end (VE) 
Change in the 
number of 
pathogens 
cultured 
compared 
with VO 
33% of patients cultured more 
pathogens ↑ 
34% of patients cultured less 
pathogens ↓  
P value <0.0001 <0.0001 
Change in the 
number of 
pathogens 
cultured 
compared 
with VS 
 47% of patients cultured less 
pathogens ↓  
P value  <0.0001 
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Table 13. 
 
Bacterial load VO 
(CFU/ml) 
Bacterial load VS 
(CFU/ml) 
Bacterial load VE 
(CFU/ml) 
Number of values 93 90 90 
25% Percentile 0 1.8 x 105 0 
Median 6.7 x 105 1.2 x 107 0 
75% Percentile 9.22 x 107 2.213 x 108 3 x 106 
Table to show the change in bacterial load (CFU/ml) from baseline (VO) to 
start (VS) and end of exacerbation (VE). 
 
Figure 17. 
 
Boxplot (median, IQR with whiskers 5-95% percentile) to show the change in 
bacterial load (CFU/ml) from baseline (VO) to start of exacerbation (VS) to end 
of exacerbation (VE). Significance, *p<0.05, **P<0.01, ***p<0.001. 
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There was a significant 1.5 log increase in bacterial load from baseline to start of 
exacerbation (P=0.04). The effect of 14 days of antibiotic treatment also 
significantly reduces the bacterial load (P<0.0001). Bacterial load is reduced below 
baseline level at the end of antibiotic treatment (P=0.007).  
 
4.4.7.2 Bacterial load when the dominant pathogen changes 
57% of patients had a different sputum pathogen cultured at start of exacerbation 
(VS) when compared with their baseline visit (VO) sputum results – see figure 14. 
The bacterial load was analysed in these patients – figure 18 and table 14. 
 
Figure 18. 
 
Boxplot (median, IQR with whiskers 5-95% percentile) to show the change in 
bacterial load (CFU/ml) when sputum microbiology changes at exacerbation, 
from baseline (VO), start of exacerbation (VS) and end of exacerbation (VE). 
Significance, *p<0.05, ***p<0.001, #p>0.05. 
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Table 14.  
Table to show the change in bacterial load in exacerbation when sputum 
microbiology changes. 
 
There is a 1.5 log increase in bacterial load when a change in pathogen is detected 
on sputum culture microbiology. The bacterial load significantly increased from a 
median value of 2.7 x 105 CFU/ml to 3.2 X 107 CFU/ml on exacerbation (P=0.02). 
This value reduces to 0 CFU/ml at the end of exacerbation and after 14days of 
antibiotics (P=0.0001). There is no difference between baseline bacterial load and 
that at the end of exacerbation. 
 
4.4.7.3 Bacterial load when the dominant pathogen is unchanged. 
In 43% of patients that experienced an exacerbation, the sputum microbiology did 
not differ from baseline to start of exacerbation. The changes in bacterial load was 
analysed in this subset of patients and presented in figure 19 and table 15. 
 
 
 
 
 
 
 
 
 
 
  VO Bacterial load 
(CFU/ml) 
VS Bacterial load 
(CFU/ml) 
VE Bacterial load 
(CFU/ml) 
Number of values 51 51 49 
25% Percentile 0 1.2 x106 0 
Median 2.7 x 105 3.2 x107 0 
75% Percentile 6.0 x107 1.0 x109 3.6 x106 
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Figure 19. 
 
Boxplot (median, IQR with whiskers 5-95% percentile) to show the change in 
bacterial load (CFU/ml) when sputum bacteriology is unchanged at 
exacerbation from baseline (VO), start of exacerbation (VS) and end of 
exacerbation (VE). Significance, **p<0.01, #p>0.05. 
 
Table 15. 
Change in bacterial load (CFU/ml) from baseline (VO), start (VS) to end of 
exacerbation (VE) when sputum bacteriology is unchanged at exacerbation. 
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  VO Bacterial load 
(CFU/ml) 
VS Bacterial load 
(CFU/ml) 
VE Bacterial load 
(CFU/ml) 
Number of values 38 38 38 
25% Percentile 0.0 0.0 0.0 
Median 6.3 x105 7.0 x105 0.0 
75% Percentile 1.5 x108 7.4 x107 1.7 x106 
**P	<	0.01 
#P	=	0.9 # 
** 
** 
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There is no significant change in bacterial load in this subset of patients with a 
median value of 6.3 x105 CFU/ml on baseline and 7.0 x 105 CFU/ml at start of 
exacerbation. There is significant reduction in bacterial load after 14 days of 
antibiotics at the end of exacerbation when compared with baseline levels (P=0.007) 
and start of exacerbation levels (P=0.002). 
 
4.4.7.4 Change in dominant pathogen associated with a ³1log rise in bacterial load? 
A change in dominant pathogen is associated with an increase in bacterial load from 
baseline to start of exacerbation in these patients. To further assess the rise in 
bacterial load, results were analysed to see if there was a significant difference 
between the number of patients that had a 1 or more log rise in bacterial load 
depending on whether the dominant pathogen changed. Results are outlined below: 
 
Table 16. 
 Dominant Pathogen 
changed 
Dominant pathogen 
unchanged 
³1Log rise in bacterial 
CFU/ml 
29 8 
£1Log rise in bacterial 
CFU/ml 
22 30 
Table to show the significance of ³1Log rise in bacterial load when dominant 
pathogen changes. 
 
There was a significantly higher proportion of patients that had a 1 or more log rise 
in bacterial load if the dominant pathogen on sputum culture had changed at start of 
exacerbation then if the dominant pathogen had not changed (P=0.0007). 
 
4.4.8 Blood inflammatory markers 
Blood was taken from each patient at every visit. Bloods were analysed for full 
blood count, urea and electrolytes, liver function tests and inflammatory markers 
erythrocyte sedimentation rate and C-reactive protein. Important markers of 
infection and inflammation are shown in the figures below and table 17. 
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4.4.8.1 White cell count (WCC) 
There was a significant increase in WCC from baseline (VO) to start of exacerbation 
(VS). There was a significant reduction in white cell count after 14 days therapy of 
antibiotics with no significant change between baseline and end of exacerbation 
which could imply the white cell count had returned to baseline (Figure 20). 
 
Figure 20. 
 
Boxplot (median, IQR with whiskers 5-95% percentile) to show the change in 
White Cell Count (WCC) from baseline (VO), start of exacerbation (VS) and 
end of exacerbation (VE). Significance, ***p<0.001, #p>0.05. 
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4.4.8.2 Neutrophil count 
There was a significant increase in neutrophil count at start of exacerbation which 
decreased again after 14 days of treatment. There was no difference in neutrophil 
count between baseline and end of exacerbation (Figure 21). 
 
Figure 21. 
 
Boxplot (median, IQR with whiskers 5-95% percentile) to show the change in 
Neutrophil count (neuts) from baseline (VO), start of exacerbation (VS) and 
end of exacerbation (VE). Significance, ***p<0.001, #p>0.05. 
 
4.4.8.3 Erythrocyte sedimentation rate (ESR) 
There was a significant increase in ESR from baseline (VO) to start of exacerbation 
(VS). There was a significant reduction from VS to end of exacerbation (VE). There 
was no significant change between baseline and end of exacerbation (Figure 22). 
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Figure 22.  
 
Boxplot (median, IQR with whiskers 5-95% percentile) to show the change in 
Erythrocyte sedimentation rate (ESR) from baseline (VO), start of 
exacerbation (VS) and end of exacerbation (VE). Significance, ***p<0.001, 
*p<0.05, #p>0.05.  
 
4.4.8.4 C-reactive protein (CRP) 
There was a significant increase in CRP from baseline to start of exacerbation, rising 
from a median 3.0 to 9.0 mg/L. There was a significant reduction from VS to end of 
exacerbation (VE). There was no significant change between baseline and end of 
exacerbation with median of 3.0 and 3.0mg/L respectively (Figure 23). 
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Figure 23. 
 
Boxplot (median, IQR with whiskers 5-95% percentile) to show the change in 
C-reactive protein (CRP) from baseline (VO), start of exacerbation (VS) and 
end of exacerbation (VE). Significance, ***p<0.001, #p>0.05. 
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Table 17. 
INFLAMMATORY 
MARKER 
VALUE BASELINE 
(VO) 
VISIT 
START 
(VS) 
VISIT 
END 
(VE) 
White cell count 
x 109/L 
25% 
Percentile 
5.3 6.3 5.5 
 Median 6.8 8.0 6.6 
 75% 
Percentile 
8.5 9.9 8.2 
Neutrophil count 
x 109/L 
25% 
Percentile 
3.0 4.0 3.0 
 Median 4.1 5.0 4.1 
 75% 
Percentile 
5.3 7.1 5.5 
Erythrocyte 
sedimentation rate 
mm/hr 
25% 
Percentile 
7.0 8.8 7.0 
 Median 13.0 16.5 14.0 
 75% 
Percentile 
19.0 32.8 25.0 
C- reactive protein 
mg/L 
25% 
Percentile 
1.0 3.0 1.0 
 Median 3.0 9.0 3.0 
 75% 
Percentile 
8.0 38.0 7.5 
Table to show the change in blood inflammatory markers from baseline (VO) 
to start of exacerbation (VS) and end of exacerbation (VE). 
 
There was a significant increase in all the infection and inflammatory markers 
analysed (WCC, Neutrophils, ESR & CRP). All markers significantly improved 
with treatment. There was no significant change between pre-infection and post 
treatment markers, suggesting levels had gone back to baseline. 
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4.4.9 Sputum inflammatory markers 
4.4.9.1 Myeloperoxidase 
 
Myeloperoxidase levels significantly increased from baseline to start of 
exacerbation. Levels reduced after 14 days of antibiotics to a level significantly 
lower than baseline levels – see figure 24 and table 18 for median (IQR) values. 
 
Table 18. 
 
VO MPO (UG/ML) VS MPO (UG/ML) VE MPO (UG/ML) 
Number of values 85 77 84 
25% Percentile 405.0 726.5 0.0 
Median 1279 2462 682.5 
75% Percentile 4626 8356 1935 
Table to show the change in myeloperoxidase (MPO) levels from baseline (VO) 
to start (VS) and end of exacerbation (VE). 
 
Figure 24. 
 
Boxplot (median, IQR with whiskers 5-95% percentile) to show the change in 
Myeloperoxidase (MPO) from baseline (VO), start of exacerbation (VS) and 
end of exacerbation (VE). Significance, *p<0.05, ***p<0.001. 
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4.4.9.2 Neutrophil elastase (NE) 
Neutrophil elastase levels increased from a median level of 2788µg/ml at baseline to 
3728µg/ml but this increase was not statistically significant. Results significantly 
reduced after 14 days of antibiotics to 2200µg/ml, significantly lower than pre-
infection baseline levels (figure 25, table 19). 
 
Figure 25. 
 
Boxplot (median, IQR with whiskers 5-95% percentile) to show the change in 
Neutrophil elastase (NE) from baseline (VO), start of exacerbation (VS) and 
end of exacerbation (VE). Significance, **p<0.01, ***p<0.001, #p>0.05. 
 
Table 19. 
 VO NE (UG/ML) VS NE (UG/ML) VE NE (UG/ML) 
Number of values 87 78 85 
25% Percentile 1913 2194 0.0 
Median 2788 3728 2200 
75% Percentile 6983 11429 3532 
Table to show the change in neutrophil elastase (NE) levels from baseline (VO), 
start (VS) and end of exacerbation (VE). 
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4.4.9.3 Interleukin 8 (IL-8) 
There was no significant change in IL-8 level from baseline to start of exacerbation. 
There was a significant reduction in IL-8 after 14 days of antibiotics when compared 
with start of exacerbation and pre-infection baseline levels (figure 26, table 20). 
 
Figure 26. 
 
Boxplot (median, IQR with whiskers 5-95% percentile) to show the change in 
Interleukin-8 (IL-8) from baseline (VO), start of exacerbation (VS) and end of 
exacerbation (VE). Significance, *p<0.05, #p>0.05. 
 
Table 20. 
 
VO IL8 
Pg/ml 
VS IL8 
Pg/ml 
VE IL8 
Pg/ml 
Number of values 88 76 80 
25% Percentile 4903 5753 0.0 
Median 16308 14271 8416 
75% Percentile 32361 24408 24517 
Table to show the change in Interleukin-8 (IL-8) levels from baseline (VO) to 
start and end of exacerbation (VS and VE). 
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4.5 Sub-analysis 
A change in the dominant pathogen cultured caused a significant rise in bacterial 
load of more than 1 log CFU. A sub-analysis was carried out to see whether a 1 or 
more log rise in bacterial CFU was significant in causing increased inflammation or 
worsening of clinical parameters compared with a bacterial load rise of less than 1 
Log unit CFU.  
 
4.5.1 Clinical parameters 
Patient results were split into two groups depending on the bacterial load change 
from baseline to start of exacerbation. The two groups (³ log increase in bacterial 
load and <1log rise) were compared to see if there was any difference in the change 
of clinical parameters with infection (table 21). 
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Table 21. 
VO VS ³1 LOG ­ BL <1 LOG ­ BL 
P 
VALUE 
FEV1 (L) -0.06 (-0.2 – 0.045) -0.10 (-0.168 – 0.01) 0.9 
>200mls or >12% 14/38 14/52 0.05 
>5% 20/38 24/52 0.67 
>10% 16/38 11/52 0.04* 
>15% 9/38 8/52 0.42 
>20% 4/38 7/52 0.75 
% FEV1 (%) 4.2 (-1.9 – 13.8) 3.6 (-0.77 – 7.77) 0.7 
>5% 18/38 22/52 0.67 
>10% 16/38 11/52 0.04* 
>15% 9/38 8/52 0.42 
>20% 4/38 6/52 1.0 
FVC (L) -0.185 (-0.44 – 0.01) -0.21 (-0.43 - 0) 0.91 
>200mls or >12% 19/38 29/52 0.67 
>5% 22/38 31/52 1.0 
>10% 14/38 19/52 1.0 
>15% 12/38 9/52 0.13 
>20% 6/38 7/52 0.7 
% FVC (%) -4.355 (-0.96 – 17.7) -6.155 (-1.21 – 12.83) 0.75 
>5% 18/38 30/52 0.40 
>10% 13/38 18/52 1.0 
>15% 12/38 10/52 0.22 
>20% 6/38 7/52 0.7 
LCQ (Units) -4.0 (-6.75 - -1) -3.0 (-5.75 - -1) 0.8 
LCQ ³1.3unit ¯ 28/38 35/52 0.64 
SGRQ (Units) 2.0 (-3 – 14.5) 3.0 (-5 - 13) 0.6 
SGRQ ³4units ­ 17/38  24/52 1.0 
24hr sputum vol. 
(mls) 
0.0 (-5 - 10) 0.0 (-4.75 – 3.75) 0.3 
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24hr sp. >50%­ 19/38 12/52 0.01 
24hr sp. >100%­ 15/38 10/52 0.05 
Spont. sputum vol. 
(mls) 
2.0 (0 – 4.5) 1.0 (-1 - 3) 0.04* 
Spont sp. >50% ­ 22/38 27/52 0.6 
Spont sp. >100% ­ 21/38 26/52 0.67 
Sputum colour 
(Units) 
1.0 (0 - 1) 1.0 (0 - 1) 0.3 
ISWT (m) -60m (-105 - -10) -30 (-80 - 5) 0.08 
ISWT ³ 5% ¯ 28/38 27/52 0.049* 
Table to show the median (IQR) difference in clinical parameters or number of 
patients with specified change in parameters based on bacterial load (BL) rise 
in 38 patients with ³1 Log unit rise in bacterial load (BL) (CFU/ml) and 52 
patients with <1 Log rise in CFU/ml from baseline to start of exacerbation. 
FEV1:forced expiratory volume in 1 second, FVC: forced vital capacity, LCQ: 
Leicester cough questionnaire, SGRQ: St George’s Respiratory Questionnaire, 
ISWT: Incremental shuttle walk test. 
 
There were similar reductions in FEV1 between the two groups. 60mls in those with 
higher bacterial load rise and 100mls in the less than 1 log CFU rise group. 
However, there were significantly more patients with a 10% or more reduction in 
FEV1 and %predicted FEV1 in the group with 1 or more unit rise in bacterial load 
(p=0.04). There was no significant difference between the groups in term of change 
in quality of life scores. There was a significant increase in the volume of 
spontaneous sputum production on exacerbation in the higher bacterial load group 
(P=0.04) but this was not seen in the 24-hour collection of sputum production or 
change in sputum colour. There was an overall larger reduction in exercise tolerance 
in the group with 1 or more unit log rise in bacterial load (60m versus 30m) but this 
did not reach statistical significance. However, there was significant difference in 
the number of patients that had an overall 5% reduction or greater in their exercise 
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tolerance between the groups with more people with reduced exercise tolerance by 
5% or more in the 1 or more log unit rise in bacterial load group (74% versus 52%), 
p=0.049. 
 
The improvement in lung function following antibiotics was small in both groups 
(50mls vs 60mls). There were small and similar improvements in both the Leicester 
Cough Questionnaire and the St George’s Respiratory Questionnaire between the 
two groups. There was no difference between the two groups in the change in 
sputum colour or volume expectorated from start to end of exacerbation (Table 22). 
 
Table 22. 
VS VE ³1 LOG ­ BL <1 LOG ­ BL P VALUE 
FEV1 (L) 0.05 (-0.03 – 0.15) 0.06 (-0.07 – 0.14) 0.6 
FVC (L) 0.07 (-0.01 – 0.23) 0.10 (-0.01 – 0.28) 0.9 
LCQ (Units) 2.0 (0 - 5) 2.0 (0 – 4) 0.8 
SGRQ (Units) -1.0 (-6.5 – 5.5) 0.0 (-9.75 - 6) 0.9 
24Hr sputum vol. 
(mls) 
0.0 (-10 – 3.5) 0.0 (-7.25 - 5) 0.3 
Spont. sputum vol. 
(mls) 
-1.0 (-4 – 0.5) -1.0 (-3 - 1) 0.4 
Sputum colour 
(Units) 
-1.0 (-1 - 0) -1.0 (-1 - 0) 0.4 
ISWT (m) 70 (25 – 100) 30 (10 – 85) 0.056 
Table to show the median (IQR) differences in clinical parameters from start 
(VS) to end of exacerbation (VE) based on bacterial load rise at start of 
exacerbation. FEV1:forced expiratory volume in 1 second, FVC: forced vital 
capacity, LCQ: Leicester cough questionnaire, SGRQ: St George’s Respiratory 
Questionnaire, ISWT: Incremental shuttle walk test. 
 
4.5.2 Blood inflammatory markers VO to VS 
Both groups reported a rise in serum inflammatory markers but there was a 
significant difference between the two groups when assessing the degree of rise in 
white cell count and neutrophil count. Those with a 1 or more log unit rise in WCC 
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were more likely to double the white cell count or greater (11% versus 0%) (p=0.02) 
and increase the neutrophil count by 50% or more (45% versus 23%) (p=0.04).  
 
There were similar increases in erythrocyte sedimentation rate between the two 
groups (p=0.9). There was a median increase in the CRP by 6 units in the higher 
bacterial load group compared to 2 units in the lower bacterial load rise but these 
results were not significant P=0.6 – see table 23.  
 
Table 23. 
VO VS ³1 LOG ­ BL <1 LOG ­ BL P VALUE 
WCC (x109/L) 5.05 (2.67 – 7.3) 3.7 (0.78 - 7) 0.08 
>25%­ 23/38 20/52 0.05 
>50%­ 12/38 9/52 0.1 
>100%­ 4/38 0/52 0.02* 
Neutrophil 
(x109/L) 
1.475 (0.22 – 3.53) 0.78 (-0.46 – 2.19) 0.03* 
>25%­ 21/38 18/52 0.05 
>50%­ 17/38 12/52 0.04* 
>100%­ 8/38 7/52 0.3 
ESR (mm/hr) 3.0 (-2 - 17) 3.0 (0 - 8) 0.9 
>25%­ 18/38 23/52 0.8 
>50%­ 17/38 19/52 0.5 
>100%­ 12/38 8/52 0.07 
CRP (mg/L) 5.0 (-0.5 - 29) 2.0 (0 -11) 0.5 
>25%­ 20/38 29/52 0.8 
>50%­ 20/38 26/52 0.49 
>100%­ 20/38 24/52 0.26 
Table of median (IQR) differences or number of patients with specified change 
in blood markers, depending on the degree of bacterial load (BL) rise (CFU/ml) 
from baseline (VO) to start of exacerbation (VS). WCC: White cell count, ESR: 
Erythrocyte sedimentation rate, CRP: C-reactive protein. *p<0.05. 
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There were similar improvements in the blood inflammatory markers after 14 days 
of antibiotics. The C-reactive protein results improved significantly more in the 
higher bacterial load rise group P=0.04. See table 24 for full results. 
 
Table 24. 
VS VE ³1 LOG ­ BL <1 LOG ­ BL P VALUE 
WCC (x109/L) -1.0 (-3.2 – 0.1) -0.60 (-2.32 – 0.73) 0.3 
Neutrophil 
(x109/L) 
-0.79 (-2.53 –0.24) -0.36 (-2.13 – 0.86) 0.2 
ESR (mm/hr) -1.0 (-15 - 2) -2.0 (-10 - 2) 0.9 
CRP (mg/L) -8 (-49 - 0) 0.0 (-11 - 0) 0.04* 
Table to show the median difference (IQR) in blood markers from start to end 
of exacerbation, depending on the degree of bacterial load rise at start of 
exacerbation. WCC: White cell count, ESR: Erythrocyte sedimentation rate, 
CRP: C-reactive protein. *p<0.05. 
 
4.5.3 Sputum inflammatory markers  
4.5.3.1 Myeloperoxidase (MPO) 
There was a median (25th, 75th percentile) increase in MPO levels of 601µg/ml (238,  
2834µg/ml) from baseline to start of exacerbation in the subset of patients whose 
bacterial load rose ³1Log CFU. In the group of patients whose bacterial load 
changed <1Log CFU the median change was an overall decrease in 
myeloperoxidase by 61µg/ml CFU (-2695, 3166µg/ml) (P=0.04). 
 
The median change of MPO of the two groups - ³1Log rise in CFU and <1Log rise 
CFU after 14days of antibiotics (VS to VE) was an overall decrease of MPO by 
1248µg/ml (-3743, 93.5µg/ml) and 712µg/ml (-5852, 0.0µg/ml) respectively. There 
was no difference between the two groups (P=0.7). The median (IQR) values at VO, 
VS and VE for each of the two subgroups are reported in table 25. 
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4.5.3.2 Neutrophil elastase (NE) 
The change in neutrophil elastase from baseline to start of exacerbation significantly 
differed between the two groups. Those with a ³1Log rise in bacterial CFU had a 
median increase of 437µg/ml (-62.5, 11250µg/ml) compared with 0.0µg/ml (-4489, 
1394µg/ml) P=0.04 in the group with a less than 1 log increase in bacterial load. 
 
There was a median decrease in neutrophil elastase levels after 14 days of antibiotics 
at the end of exacerbation visit (VS to VE) of 584µg/ml (-11136, 344µg/ml)) in the 
group with a higher bacterial load rise (³1Log CFU) and decrease of 1100µg/ml (-
3750, 0.0µg/ml) in the group with <1Log bacterial load rise, P=0.8. The median 
(IQR) values at VO, VS and VE for each of the two subgroups are reported in table 
25. 
 
4.5.3.3 Interleukin – 8 (IL-8) 
There was no significant change in IL-8 levels from baseline to start of exacerbation 
(see figure 26 and table 20). In the subgroup analysis, there was no difference in IL-
8 change between the higher and lower change in bacterial load groups (P=0.5). The 
median change was an overall decrease of 2833µg/ml (-17801, 24827µg/ml) in the 
³1Log CFU and decrease of 5414µg/ml (-16234, 4373µg/ml) in the <1Log CFU 
group.  
 
At the end of exacerbation both groups responded to 14 days of antibiotic treatment 
with a decrease in IL-8 levels. There was a median reduction of 2565mg/ml in the 
³1Log rise in CFU group and 1736mg/ml in the <1Log rise in CFU group, P=0.5. 
The median (IQR) values at VO, VS and VE for each of the two subgroups are 
reported in table 25. 
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Table 25. 
Marker ³1log rise <1log rise 
 VO VS VE VO VS VE 
25th percentile MPO 0.0 745.8 315.0 785.0 692.0 0.0 
Median MPO 
(µg/ml) 
990.5 2803 798.0 1609 2307 593.0 
75th percentile MPO 2846 11427 4582 6545 6938 1651 
P value VOÞVS 0.0006***  0.8  
P value VSÞVE  0.018*  0.0004*** 
P value VOÞVE 0.86 <0.0001*** 
25th percentile NE 338.0 2284 1692 1879 2044 0.0 
Median NE (µg/ml) 2725 3350 2538 2850 3819 2000 
75th percentile NE 5267 32116 4871 6869 5485 2850 
P value VOÞVS 0.028*  0.97  
P value VSÞVE  0.06  0.0005*** 
P value VOÞVE 0.9 0.0006*** 
25th percentile IL-8 4048 5358 4285 5049 5322 0.0 
Median IL-8 (pg/ml) 12306 16816 9813 18921 13883 5685 
75th percentile IL-8 34025 28334 25746 31200 21598 22175 
P value VOÞVS 0.99  0.09  
P value VSÞVE  0.095  0.35 
P value VOÞVE 0.1 0.08 
Table to show the median, 25th and 75th percentile values for sputum 
inflammatory markers MPO: myeloperoxidase, NE: neutrophil elastase, IL-8: 
interleukin-8. P values calculated using the Wilcoxon t-test for the subgroups 
³1log rise and <1log rise in bacterial load at start of exacerbation. VO: 
baseline, VS: start of exacerbation, VE: end of exacerbation. *P<0.05, 
***p<0.001.  
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4.5.4 Symptoms 
At the start of exacerbation only, patients were asked to report any new symptoms 
they experienced. Most patients (91%) reported increased or new cough. There were 
changes in sputum characteristics on exacerbation with 78% of patients reporting 
increased sputum volume and 72% of patients reporting increased sputum 
purulence. 79% of patients reported feeling more breathless than usual.  See table 26 
for full results. Symptoms were also analysed to see if there was a difference 
between patients with a ³1 log rise in bacterial load CFU and those that had a less 
than 1 log rise. Both groups had a similar distribution of symptoms except those in 
the higher bacterial load category were more likely to develop pleuritic chest pain 
(p=0.04) –  table 26.  
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Table 26. 
 N=92 
Total 
exacerbations 
n (%) 
N=37 
1 Log 
BL n (%) 
 
N=52 
<1 Log BL 
n (%) 
 
P 
value 
Worsening Cough  84 (91) 35 (95) 45 (87) 0.3 
Increased sputum 
volume 72 (78) 31 (84) 35 (67) 0.09 
Increased sputum 
purulence 69 (75) 31 (84) 34 (65) 0.08 
Breathlessness  73 (79) 30 (81) 39 (75) 0.6 
Fatigue  71 (77) 29 (78) 37 (71) 0.5 
Fever  40 (43) 17 (46) 19 (37) 0.4 
Chest pain 36 (39) 19 (51) 15 (29) 0.046* 
Wheeze 48 (52) 20 (54) 23 (44) 0.4 
Stridor  2 (2) 0 (0) 1 (2) 1.0 
Haemoptysis 9 (10) 2 (5) 7 (13) 0.3 
Sore throat  35 (38) 14 (38) 19 (37) 1.0 
Coryzal symptoms – 
nose/ears 50 (54) 19 (51) 27 (51) 1.0 
Headaches  41 (45) 13 (35) 25 (52) 0.3 
Myalgia 39 (42) 16 (43) 21 (40) 0.8 
Rigors  34 (37) 14 (38) 20 (38) 1.0 
Diarrhoea&Vomiting 11 (12) 4 (11) 5 (10) 1.0 
Table to show the different symptoms patients experienced on start of 
exacerbation. 2 patients did not complete symptom questionnaires. 3 patients 
did not have either a start or an end sputum load calculated. Results presented 
as N (%). Chi squared analysis to see if patients with 1 or more log unit rise in 
bacterial load were more likely to present with each symptom. 
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Taking the univariate results into account, clinically important symptoms and those 
with a p value less than 0.3 were included in a multivariate backward logistic 
regression to see if they were predictive of a 1 or more log unit rise in bacterial load. 
Cough was not included because sputum volume and purulence (surrogate markers 
of cough) were included. Results shown in table 27 demonstrate chest pain, increase 
in sputum volume and the absence of headache are more likely to be associated with 
an increase in bacterial load at start of exacerbation. 
 
Table 27. 
SYMPTOM ODDS RATIO (OR) 95% CI P value 
Chest pain  3.95 1.42-10.97 0.008* 
Haemoptysis 0.22 0.04-1.31 0.096 
Headache 0.33 0.12-0.92 0.034* 
Increase in sputum 
purulence 
2.76 0.90-8.49 0.08 
Increase in sputum 
volume 
3.18 1.01-10.07 0.049* 
Table to show the odds ratio with 95% confidence intervals (CI) of each 
symptom in the multivariate backward logistic regression model. The 
dependent variable was a 1 log unit rise in bacterial load. 
 
Guidelines in COPD have recommended antibiotics for exacerbations based on the 
simple Anthonisen criteria of 3 patient reported symptoms of increased sputum 
volume, increased sputum purulence and increased dyspnoea. Similarly, the British 
Thoracic Society (BTS) guidelines have a similar definition of an exacerbation 
including increased sputum purulence, increased sputum volume or viscosity and 
increased cough and/or wheeze and/or dyspnoea and/or systemic upset (figure 5). 
Symptom complexes were assessed to see if they are more likely to affect bacterial 
load rise with exacerbations - table 28. There was a statistically significant 
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likelihood of having a 1 or more log unit rise in bacterial load CFU/ml if patients 
developed the triad of symptoms (cough, increased sputum volume, increased 
sputum purulence) at start of exacerbation (p=0.005). There was also a significant 
likelihood of having a 1 or more unit rise in bacterial load if the patients had the 
above triad of symptoms as well as chest pain (p=0.0004) – see table 28. Taking the 
multivariate results into account, the symptom complex of chest pain, increased 
sputum volume without headache was also significantly more likely to predict a rise 
in bacterial load. There was no significant difference, when assessed by chi square, 
in the likelihood of having symptom complex of ‘increased cough, sputum volume 
and purulence’ than having ‘chest pain, increased sputum volume without headache’ 
with a 1 or more log unit rise in bacterial load, p=0.17. 
 
Table 28. 
SYMPTOMS 
N=92 
Total 
exacerbations 
n (%) 
N=38 
1 Log BL 
n (%) 
 
N=52 
<1 Log BL n 
(%) 
 
P value 
↑Cough + ↑sp. Vol + 
↑sp. Purulence 
51 (55) 27 (73) 22 (42) 0.005 
↑Cough + ↑sp. Vol + 
↑sp. Purulence + 
chest pain 
20 (22) 15 (41) 4 (8) 0.0004 
↑sp. Vol + chest pain 
- headache 
11 (12) 9 (24) 2 (4) 0.0073 
↑Purulent sp. AND 
↑Cough OR ↑sp. Vol 
65 (71) 29 (78) 32 (62) 0.1 
↑Purulent sp. + chest 
pain 
26 (28) 16 (43) 9 (17) 0.009 
↑sp.Vol + chest pain 28 (30) 18 (47) 9 (17) 0.0027 
Table to show if symptom complexes were more likely to be associated with a 1 
or more log unit rise in bacterial load CFU/ml. Analysis performed by chi-
squared. Sp: sputum. 
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The different definitions of an exacerbation along with the outcome from the above 
multivariate model were used to assess the sensitivity, specificity, positive and 
negative predictive values of a 1 or more log unit rise in bacterial load for each 
symptom complex. The model from the multivariate analysis results need to be 
externally validated before comparison with accepted definitions by either the 
British Thoracic Society or European Respiratory Society can be made to see if it 
has improved specificity. Sensitivity, specificity, positive and negative predictive 
values from this cohort for different symptom complexes are shown in Table 29. 
 
Table 29. 
SYMPTOM COMPLEX Sensitivity Specificity 
 
Positive 
predictive 
value 
Negative 
predictive 
value 
British Thoracic Society 
definition 
71% 58% 55% 73% 
European Respiratory 
Society consensus 
definition 
95% 10% 43% 71% 
↑sp. Vol + chest pain - 
headache 
24% 96% 82% 63% 
↑Purulent sp. AND 
↑Cough OR ↑sp. Vol 
76% 38% 48% 69% 
↑Purulent sp. + chest 
pain 
42% 83% 64% 66% 
↑sp. Vol  + chest pain  47% 83% 66% 68% 
Table to show the sensitivity, specificity, positive and negative predictive values for 
each symptom complex. British thoracic society definition: worsening of cough, 
increased sputum volume or viscosity, increased sputum purulence with or without 
increasing wheeze, breathlessness, haemoptysis. The European consensus: 
deterioration in three of more of: cough; sputum volume or consistency; sputum 
purulence; breathlessness and/or exercise tolerance; fatigue and/or malaise; 
haemoptysis. Sp: sputum. 
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4.5.5 Virology 
Many patients reported symptoms that could be attributable to viral infection - 54% 
of patients reported developing coryzal symptoms of runny or blocked nose and 
blocked ears, 37% developed a sore throat, 43% of patients reported myalgia, 44% 
reported headache and 11% reported new diarrhoea and/or vomiting (table 26). 
 
Patients that developed an exacerbation had a viral throat swab sent for routine 
virology. 90 viral throat swab tests were performed and of these, 16 (18%) were 
reported as positive for viral infection. The viruses detected are outlined in table 30. 
 
Table 30. 
Virus No. of positive results 
Rhinovirus 12 
Influenza A 2 
Influenza B 1 
Parainfluenza 1 
Table of positive viral results from 16 of total 90 exacerbations tested. 
 
Results were analysed to see if positive viral infection affected the bacterial load 
cultured on sputum microbiology. There was no significant difference in the number 
of viral positive samples between the higher ³1 log bacterial CFU rise and < 1Log 
rise in bacterial CFU groups, p=0.6 – see table 31. 
 
Table 31. 
 Positive for viral 
infection 
Negative for viral 
infection 
³1 log rise in bacterial 
load CFU 
5 32 
<1 log rise in bacterial 
load CFU 
10 42 
Table to show that the detection of viruses had no impact on bacterial load, Chi 
squared analysis, p=0.6. 
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4.6 Discussion 
Exacerbations are currently subjectively defined based on symptoms. The British 
Thoracic Society (BTS) Guidelines defined an exacerbation as an acute deterioration 
(usually over several days) with worsening local symptoms (cough, increase sputum 
volume or change of viscosity, increased sputum purulence with or without 
increasing wheeze, breathlessness, haemoptysis) and/or systemic upset (Pasteur et 
al, 2010). The recent European consensus led by Hill and colleagues concluded an 
exacerbation to be when a patient exhibits a deterioration in three of more of the 
following key symptoms for at least 48hours: cough; sputum volume and/or 
consistency; sputum purulence; breathlessness and/or exercise tolerance; fatigue 
and/or malaise; haemoptysis AND a clinician determines that a change in 
bronchiectasis treatment is required (Hill et al, 2017). Treatment in the form of 
antibiotics is given based on BTS definition in the outpatient setting with no 
immediate access to blood test results to check inflammatory markers or chest x-
rays to investigate for consolidation. 
 
This study investigated exacerbations of bronchiectasis that could be managed on an 
outpatient basis to see if the exacerbations could be phenotyped and the role of 
quantitative sputum bacteriology and its implications explored further. 94 Patients 
were recruited whilst clinically stable. These patients performed baseline tests to 
measure pulmonary function, exercise tolerance, quality of life and blood and 
sputum inflammatory markers. Patients were asked to return when they felt they 
were experiencing an exacerbation to repeat the tests and receive a prescription for 
14days of oral antibiotics based on previously sputum microbiology. Patients 
returned after 2 weeks to repeat all investigations again. 
 
Based on the subjective definition of exacerbation, patients that thought they were 
experiencing an exacerbation had a significant reduction in lung function tests, 
increase in blood inflammatory markers, reduced exercise tolerance and a reduction 
in quality of life as assessed by the Leicester Cough Questionnaire and the St 
George’s Respiratory Questionnaire at start of exacerbation when compared with 
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baseline results. Sputum myeloperoxidase and free neutrophil elastase were also 
significantly elevated but interleukin-8 did not significantly change.  
 
The sputum microbiology showed that more patients cultured a pathogen in their 
sputum at the start of exacerbation compared to baseline and they were also more 
likely to culture multiple pathogens. There was an increase in the number of positive 
culture results for Pseudomonas aeruginosa, other gram negative pathogens and 
other potentially pathogenic microorganisms with a reduction in culture negative 
results or those that cultured mixed normal flora at start of exacerbation. There were 
significantly more culture results that grew a different dominant pathogen from that 
which was cultured at baseline for the same patient. A dominant pathogen was 
defined as the pathogen with the highest bacterial load if more than 1 microorganism 
was identified. 
 
Quantitative sputum bacteriology also showed that there was a significant around 2 
log increase in the bacterial load from a mean baseline of 105 colony forming units 
(CFU) to 107 CFU at start of exacerbation. If the dominant pathogen cultured were 
to change at visit start then this was more likely to be associated with a 1 or more 
log rise in bacterial load (p=0.02). If the dominant pathogen did not change then 
there was no significant rise in bacterial load from baseline to start of exacerbation 
(p=0.9). A small number of patients (n=12) tested positive for a virus at start of 
exacerbation, the majority of these were diagnosed as rhinovirus, but the latter did 
not impact on bacterial load rise. 
 
Lastly, the implications of a 1 or more unit log rise in bacterial load in a clinical 
setting was explored. A bacterial load rise of 1 or more log CFU was associated with 
a deterioration of 10% in actual and predicted FEV1. It was also significantly 
associated with an increase in volume of spontaneous sputum expectorated. Blood 
inflammatory markers were also investigated and an increase in bacterial load of 1 
log unit or more was significantly associated with a 100% rise in white cell count 
and a 50% increase in neutrophil count. It was also associated with an increase in 
sputum inflammatory markers myeloperoxidase and neutrophil elastase when 
 188 
compared with those with a less than 1 log unit rise in CFU. Out of all those that had 
a 1 or more log unit rise in bacterial load 79% had a change in dominant pathogen 
(p=0.0006). The presence of viruses did not have an impact on bacterial load. 
 
Patients presented with various symptoms as outlined in table 24. A univariate 
analysis showed ‘chest pain’ to be significantly associated with a 1 or more unit rise 
in bacterial load on exacerbation. A multivariate backward logistic regression 
analysis showed chest pain as well as an increase in sputum volume and the absence 
of headache to be associated with a 1 or more log unit rise in bacterial load CFU/ml. 
Patients presenting with a combination of symptoms can also help differentiate a 
rise in bacterial load. The results from the multivariate model identified increase in 
sputum volume, the presence of chest pain and the absence of headache to be much 
more specific for a rise in bacterial load count than either of the BTS or ERS 
consensus definitions for exacerbation. The addition of chest pain to either increased 
sputum purulence or to increased sputum volume increased the specificity for 
recognising a rise in bacterial load of 1 or more log units. ‘Chest pain’ is a symptom 
absent from both the British thoracic society and ERS consensus definitions.  
 
National definitions such as those described above by the BTS and ERS consensus 
definition do not discriminate between inpatient and outpatient exacerbations and 
are largely based on grade D expert opinion alone. There is a paucity of studies 
investigating outpatient exacerbations of bronchiectasis. Symptoms associated with 
a rise in bacterial load in this outpatient cohort are chest pain, increase in 24hr 
sputum volume and the absence of headache. This symptom complex has a high 
specificity but lower sensitivity. Therefore, it may be more productive to use this to 
help exclude disease rather than to diagnose it as a higher proportion of patients that 
did not have this triad of symptoms did not have a rise in bacterial count above 1 log 
unit. 
 
This study showed exacerbations to be associated with a rise in bacterial load but 
this conflicts with the study by Tunney and colleagues (2013) who investigated 
bacterial load and bacterial community present in a small number of patients (n=12) 
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with an exacerbation who were treated with intravenous antibiotics. They found 
bacterial loads at start of exacerbation to be similar to when clinically stable and that 
there was only a limited shift in microbial taxa. This was a small study in a more 
severe cohort of patients and could reflect the difference. Cox et al also investigated 
bacterial load and found no change in bacterial communities or change in bacterial 
load from baseline, start and end of exacerbation. This cohort of patients were more 
severe than the patients in this thesis with a higher percentage of patients culturing 
Pseudomonas (45%). They, therefore are more likely to have had more 
exacerbations and antibiotics in the past which could account for the change in 
resident bacteria. The study was also small examining only 13 paired baseline and 
exacerbation samples (Cox et al, 2017). Results from this outpatient cohort reveals 
the rise in bacterial load to be attributable to a change in primary dominant pathogen 
and this could be a result of them being a relatively antibiotic naive population. 
There was no change in bacterial load at start of exacerbation if the dominant 
pathogen remained the same as that which was cultured at the baseline visit when 
patients were clinically stable. There is evidence that would support the change in 
bacterial communities as a result of certain bacteria e.g. Pseudomonas and 
Haemophilus (Cox et al, 2017). To the best of our knowledge this is the first study 
to demonstrate the importance of a change in dominant pathogen and could have 
implications for the way we investigate and treat exacerbations. 
 
The hypothesis that a 1 or more log unit rise in bacterial load would be associated 
with a more severe exacerbation was investigated. This study highlighted that there 
is increased sputum volume and purulence as well as poor quality of life in all 
patients that experienced an exacerbation but there did not appear to be an 
association with increased bacterial load rise of 1 or more log unit in CFU/ml. 
However, there was a significant association with a rise in bacterial load of 1 or 
more log units and reduction in distance walked by 5 or more percent in the 
incremental shuttle walk test - a test that objectively measures functional capacity. It 
was also associated with a 10% or more reduction in both lung function parameters 
actual FEV1 and %predicted FEV1 as well as volume of spontaneous sputum 
expectorated. As expected both groups in the subanalysis (1 or more log unit rise 
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and less than 1 log unit rise in bacterial load) improved with antibiotic therapy and 
there was little to differentiate the improvement apart from a greater reduction in c-
reactive protein in the higher bacterial load group (p=0.049). 
 
4.7 Limitations 
There were several limitations to this study. This study was based on outpatient 
exacerbations and therefore were less severe and did not require hospital admission. 
The applicability of these results and conclusions will require further investigation 
for inpatients and severe exacerbations. Patients were asked to telephone when they 
experienced an exacerbation during normal working hours, thus some exacerbations 
will have been missed. 
 
Standardised qualitative and quantitative microbiology techniques were used but not 
molecular microbiology techniques such as 16S rDNA pyrosequencing. A study by 
Tunney et al and Cox et al suggested there was poor overall agreement between 
standard microbiology and 16S rDNA pyrosequencing. They found 150,000 
sequences from 40 sputum samples and reported the majority of them were from 
taxa present in low abundance and that the community present did not change from 
stable, to start of exacerbation or indeed after treatment with antibiotics.   
 
4.8 Significance  
This study investigating outpatient exacerbations may have implications for the way 
we investigate and treat outpatient exacerbations. If higher bacterial loads lead to 
more severe exacerbations, then there could be an argument for assessing the need 
for intravenous antibiotics based on bacterial load. Antibiotic choice is currently 
prescribed based on previous microbiology data but if the dominant pathogen 
changes at start of exacerbation then how we treat exacerbations may require further 
investigation.  
 
4.9 Conclusion 
In this cohort of outpatient exacerbations of bronchiectasis there was a 2-log 
increase in bacterial load as well as a deterioration in lung function, exercise 
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tolerance, quality of life and an increase in sputum and serum inflammatory markers 
at start of exacerbation. Those with a 1 or more log unit rise in bacterial load count 
at start of exacerbation can exhibit more severe characteristics, present with 
symptom complexes including chest pain but not headache and are likely to have a 
change in the dominant pathogen. Exacerbations do lead to a rise in bacterial load 
and that this is due to a change in dominant pathogen.  
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Chapter 5: 
Validating the incremental shuttle walk test 
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5.1 – The Incremental Shuttle Walk Test (ISWT)  
Bronchiectasis is a chronic lung condition where patients commonly experience 
exacerbations and progression of disease. The mainstay of treatment consists of 
antibiotics and chest physiotherapy but novel therapies are being assessed to break 
the vicious circle of bronchiectasis. 
 
There is an urgent need for objective endpoints to assess progress and response to 
treatment in bronchiectasis. 24-hour sputum volume, microbial clearance, C-reactive 
protein, quality of life assessed by the SGRQ (Wilson et al, 1997b) and the LCQ 
(Murray et al, 2009d) have been found to be useful clinical endpoints (Murray et al, 
2009c). New therapies are continually being investigated in bronchiectasis to break 
the vicious circle of disease and need evaluation. ‘Exacerbation frequency’ or ‘time 
to next exacerbation’ is now the endpoint of choice used in phase 3 randomised 
controlled trials (Haworth et al 2014, Fan et al, 2015, Wong et al, 2012, Serisier et 
al, 2013) but there was uncertainty on the definition of what an exacerbation is. 
Recently, a European Consensus statement was published to try define what an 
exacerbation is for use in clinical research (Hill et al, 2017). 
 
24-hour sputum volume is thought to be inaccurate and unreliable. It is onerous and 
often embarrassing for the patient to collect. In clinical practice this test is poorly 
complied with and therefore difficult to interpret. In addition, it takes, by definition 
24 hours to assess response.  
 
Microbial clearance has been used to assess response to antibiotic treatment but 
often in clinical practice only qualitative analysis has been performed. Quantitative 
microbiological analysis has currently only been carried out in phase 2 trials 
(Serisier et al 2013b). The lungs, once thought to be sterile, are now theorised to 
contain lung microbiota and the presence of microorganisms cultured could 
represent colonisation or infection. Some facilities offer quantitative microbiological 
analysis but a change in bacterial load is not universally thought to increase with 
exacerbations or decrease with treatment (Tunney et al, 2013 & Cox et al, 2017). 
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A subset of patients routinely culture mixed normal flora or respiratory commensals 
on sputum qualitative culture at the start of exacerbation. Microbial clearance would 
not be a suitable endpoint for these patients or in those that cannot expectorate. In 
addition, microbial culture takes at least 24 hours to perform so results are not 
readily available at the bedside. 
 
C-reactive protein (CRP) can be useful in patients with a significant systemic 
response to infection but the degree of inflammatory response in patients cannot be 
predicted and is often varied. It is less useful in those without a systemic response to 
infection and is of limited value in patients that are clinically stable. As such, it has 
not been used to assess longitudinal decline in bronchiectasis or any long-term 
therapies for bronchiectasis. CRP is a relatively non-specific marker of 
inflammation which can often lag behind the clinical picture.  
 
Several quality of life questionnaires have been validated for use in bronchiectasis; 
SGRQ, (Wilson et al, 1997b) LCQ (Murray et al, 2009d), Bronchiectasis health 
questionnaire (Spinou et al, 2017) & the Quality of life questionnaire-bronchiectasis 
(QOL-B) (Quittner et al, 2014 & Quittner et al, 2015). These are more subjective 
outcome measures incorporating patient self-assessment and reporting. The 
questionnaires can be cumbersome for the patient to complete and time-consuming 
for the clinician to analyse. 
 
A validated endpoint that is reliable, quick and easy to perform would help evaluate 
existing and new therapies. The incremental shuttle walk test is an assessment of 
functional exercise capacity and the previous two chapters in this thesis have shown 
that ISWT correlates well with disease severity and deteriorates with exacerbation 
and improves after treatment. Taking these interesting findings into account, 
coupled with the fact there is currently no validated marker of functional capacity in 
bronchiectasis, the aim of this chapter is to assess if the ISWT could be a reliable 
indicator of longitudinal decline in bronchiectasis and whether it could be used to 
measure response to treatment by validating it for use in bronchiectasis. 
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Improving exercise tolerance and preventing deconditioning is an important 
therapeutic goal in chronic respiratory disease (Palange et al, 2000). Therefore, as 
part of the long-term outpatient management for COPD, patients are routinely 
referred for pulmonary rehabilitation to improve exercise tolerance and capacity. 
The incremental shuttle walk test has been tested in chronic obstructive lung disease 
(COPD) (Singh et al, 1992), cystic fibrosis (Bradley et al, 2000), interstitial 
pneumonias (Eaton et al, 2005) and advanced cancers (Booth et al, 2001). A study 
performed in 372 patients with COPD were asked to perform the incremental shuttle 
walk test (ISWT) before and after completing a 7 week pulmonary rehabilitation 
course. They found the minimum clinically important difference (MCID) to be 
47.4m with patients also recognising an additional benefit in their COPD state when 
able to walk a further 78.7m (Singh et al, 2008). 
 
It has also been used to assess the effect of interventions on exercise capacity and 
response to new therapies such as antibiotics (Murray et al, 2011), chest 
physiotherapy (Murray et al, 2009b) and pulmonary rehabilitation (Mandal et al, 
2012) in bronchiectasis. A randomised crossover trial of 20 patients with 
bronchiectasis underwent 3 months of chest physiotherapy followed by a 3 month 
period of no physiotherapy after a 1 month washout period. They found a 
statistically significant improvement in the distance walked in the ISWT by 40m in 
the treatment group (p=0.001) (Murray et al, 2009b). Patients with bronchiectasis 
can also present with fatigue and breathlessness and improving exercise capacity 
might help alleviate these symptoms in this chronic respiratory disease. Another 
study in patients with bronchiectasis and limited exercise tolerance showed an 
increase in ISWT by 56.7m (p=0.03) after 8 weeks of pulmonary rehabilitation and 
the improvement was sustained 12 weeks post the end of pulmonary rehabilitation 
(80m) when compared with controls (p=0.04) (Mandal et al, 2012). The incremental 
shuttle walk test was also used to assess the impact of inspiratory muscle training in 
addition to pulmonary rehabilitation. 32 patients were randomised to either 1) 
pulmonary rehabilitation with inspiratory muscle training, 2) pulmonary 
rehabilitation with sham inspiratory muscle training or 3) control group for eight 
weeks. The authors found pulmonary rehabilitation improved the ISWT 
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significantly by 124.5m with inspiratory muscle training and 96.7m without. The 
was no significant difference between the groups (p=0.22) (Newall et al, 2005). 
 
A small study conducted in patients with bronchiectasis investigated the MCID in 
this patient group. 37 patients were asked to perform the ISWT pre- and post- an 
eight week exercise programme. They found the MCID to be 35m (AUC 0.88, 95% 
CI 0.73-0.99)) using the Anchor based method and 37m using the distribution 
method. They concluded that small changes in the ISWT score were likely to 
represent clinically important benefits (Lee et al, 2014c). 
 
The above studies show that the incremental shuttle walk test has been used in 
bronchiectasis but it has never to date been fully validated for use. The incremental 
shuttle walk test is a relatively inexpensive test, easy to perform and quick to 
analyse. A validated endpoint to objectively assess a patient’s functional status 
would be helpful to see if patients have responded to treatment and returned to their 
baseline physical capability, and whether like COPD patients, they could benefit 
from pulmonary rehabilitation or other forms of exercise in the long-term 
management of chronic disease. 
 
5.2 – The validation process 
5.2.1 Incremental shuttle walk test  
The ISWT was performed according to standard test procedure (Singh et al, 1992). 
The patient is asked to walk a 10-metre shuttle course on a flat surface with the 
walking speed controlled using pre-recorded audio signals. There are twelve 
incremental levels with each level lasting one minute. The pre-recorded audio 
signals beep progressively faster so that more distance is covered at each level. The 
test continues until such a time that the participant is unable to complete the shuttle 
in the designated time (0.5metres or further from the marker) at the time of the audio 
signal) or the patient becomes too breathless to continue. The distance completed is 
recorded. All patients were instructed to walk at a steady pace walk aiming to turn 
around at each end of the course at the sound of the audio signal. All were advised 
to continue to walk until they felt unable to maintain the required speed without 
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becoming unduly breathless. At the start and end of the ISWT all patients had their 
heart rate, oxygen saturations and dyspnoea score according to the modified BORG 
dyspnoea scale (Borg, 1982) in accordance with standardised guidelines (2002).  
 
The MCID has been proposed as 35m but successful completion of distance walked 
in this study was recorded in increments of 10m. Difference in ISWT walked 
between visits are presented in groups of ‘deterioration/no change’, ‘1-29m’, ‘30-
59m’, ‘60-89m’ and ‘³90m’. As baseline distance varied amongst patients, the 
percentage change in ISWT distance was also calculated and presented in groups of 
‘deterioration’, ‘no change’, ‘0-4.99%’, ‘5-9.9%’ and ‘³10%’ change. 
 
5.2.2 Study design 
In order to validate the incremental shuttle walk test as a useful endpoint in 
bronchiectasis, the reliability, validity and responsiveness needs to be demonstrated. 
The minimum clinically important difference (MCID) was also investigated. 
 
Each section was assessed separately by using several studies as outlined below. 
Every patient in each of the studies had previously performed the ISWT as part of 
routine clinical practice and was familiar with how the test was conducted and so a 
practice test was not necessary. 
 
The reliability of the ISWT was assessed by inviting 30 sequential patients, a 
number thought to be acceptable to the researchers with bronchiectasis (varying 
severity), to complete the incremental shuttle walk test 6 months apart when they 
were clinically stable. There was no change made to their medical management of 
bronchiectasis during this time. 
 
The validity of the ISWT was assessed by correlating the distance walked by 
patients with the SGRQ scores – a validated marker of quality of life that assess 
activity as one of its scoring domains. ISWT results were correlated with SGRQ 
total scores and SGRQ activity scores in 94 patients at three different time points: 
when clinically stable, at start of an exacerbation and at the end of an exacerbation 
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after 14 days of oral antibiotics treatment, prescribed according to previous 
microbiology results. 
 
In a substudy, 49 patients of the above cohort were asked to wear an activity 
monitor continuously for a period of 8 days, only removing to bath or shower. Data 
from the physical activity monitors were correlated with the ISWT to assess 
functional capacity. ISWT results were also correlated with MRC breathlessness 
scores (Bestall et al, 1999) and BSI scores (Chalmers et al, 2014) to assess disease 
severity. 
  
To assess responsiveness, the ISWT was performed in patients that were treated 
with either short-term (14 days) intravenous or oral antibiotic therapy for an 
exacerbation of bronchiectasis. A repeat analysis from a previous study assessing 
the impact of long-term nebulised gentamicin twice a day for 12months compared 
with placebo (0.9% saline) on the ISWT was performed (Murray et al, 2011).  
 
30 patients that required intravenous antibiotic therapy for an acute exacerbation of 
bronchiectasis were asked to perform the test pre- and post- 14 days of antibiotic 
therapy. These patients had to meet the criteria for receiving intravenous antibiotics 
which included having failed oral treatment, a severe exacerbation necessitating 
inpatient stay or sputum microbiology results necessitating an intravenous agent to 
be administered (Pasteur et al, 2010). 
 
94 patients that required oral antibiotic therapy for an acute exacerbation of 
bronchiectasis that could be managed on an outpatient basis were asked to perform 
the test pre (Visit start, VS) and post 14 days of antibiotic therapy (Visit end, VE). 
Antibiotic choice was guided by previously microbiology results. These patients 
also performed the ISWT when clinically stable at least 30 days pre-exacerbation 
(Baseline visit, V0). 
 
In the long-term nebulised antibiotic group, 30 patients with bronchiectasis who 
were treated with nebulised gentamicin 80mg, b.i.d. for 12 months performed the 
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ISWT prior to starting treatment and at 12months. 30 patients that were treated with 
12 months of nebulised 0.9% saline performed the ISWT similarly (Murray et al, 
2011). 
 
5.2.3 The minimum clinically important difference 
The anchor method was used to determine the minimum clinically important 
difference using a 4 or more unit rise in SGRQ as a clinically significant 
improvement of quality of life (Wilson et al, 1997b). The 1-year gentamicin study 
(Murray et al, 2011) was reanalysed to assess the area under the curve (percent 
change of ISWT with a 4 or more-unit improvement in total SGRQ). This study was 
selected as there was significant improvement of 1-year nebulised gentamicin 
compared with the group that received nebulised saline. 
 
5.2.4 Lung function 
Pre-bronchodilator Forced expiratory volume in 1 second (FEV1), Forced vital 
capacity (FVC) and ratio FEV1:FVC by spirometry as per standardised protocols 
(Miller et al, 2005). Patients were asked to take three attempts and the best results 
were recorded. All patients have previously performed spirometry as part of routine 
clinical practise. 
 
5.2.5 Sputum 
Sputum colour was recorded according to a visual colour chart rating. Mucoid 
sputum was rated 1, mucopurulent rated as 2 and purulent sputum rated as 3 or 4 
depending on colour (Murray et al, 2009). 24hour sputum volume was recorded by 
asking patients to expectorate solely into a universal container for 24hours. 
Qualitative and quantitative microbiology was performed on all samples pre- and 
post 14 days of antibiotics. 
 
5.2.6 Statistical analysis 
All data were analysed using Graphpad prism version 5.0a (Graphpad software, San 
Diego, CA, USA). For demographic and clinical variables, data are presented as 
median (interquartile range) for continuous variables and n (%) for categorical 
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variables unless specified otherwise. Comparison of changes within a group i.e. 
before and after treatment was calculated using Wilcoxon signed rank test. We 
compared categorical data between groups with the χ2 test. A P value <0.05 was 
considered statistically significant for each analysis. A Bland-Altman test was used 
to show repeatability over time with bias and 95% limits of agreement calculated 
and intraclass correlation coefficient calculated. Correlations were assessed using 
the Spearman correlation. An unpaired t test was used to calculate the change from 
baseline to 12months in ISWT between patients assigned gentamicin and nebulised 
saline with results displayed as mean difference (95% confidence interval). 
 
5.3 Results 
5.3.1 Reliability 
30 patients were asked to perform the incremental shuttle walk test when clinically 
stable and then repeat the test in 6 months’ time. No changes were made to their 
medical management. The aetiology of their bronchiectasis varied from 70% 
idiopathic, 13% post infection, 13% autoimmune disease and 3% IgG2 subclass 
deficiency. Their baseline characteristics are outlined below in table 1. 
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Table 1. 
Characteristics  
Age 59.1 (11.4) 
Female 47% 
Smoking 60% never 
40% ex-smoker 
0% current 
FEV1 
Predicted FEV1 
2.2L (0.9) 
73.9% (24.5) 
FVC 
Predicted FVC 
3.2L (1.1) 
86.4% (25.6) 
Sputum microbiology 40% potentially pathogenic 
microorganisms 
57% mixed normal flora 
3% no sputum 
Inhaled/ 
oral corticosteroids 
60% 
7% 
COPD 0% 
Asthma 5.7% 
Long-term antibiotics 3% 
Results presented as mean (SD) or % of patients. FEV1: forced expiratory 
volume in 1 second, FVC: forced vital capacity, COPD: chronic obstructive 
pulmonary disease. 
 
At the first visit, patients walked a median distance of 390m. 6 months later patients 
were recalled and the test was performed again in an identical manner. A median 
distance of 400m was walked. There was no significant difference in the distance 
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walked in these clinically stable patients (see table 2 and figure 1). The median 
change in distance walked was 0m (-25m – 50m) with median percentage change 
0% (-4.9% - 18.2%). 
 
Table 2. 
Table to show the median and interquartile ranges of distances walked in 30 
clinically stable patients with bronchiectasis. 
 
Figure 1. 
 
Barchart of mean (SEM) to show there is no significant difference in distance 
(m) walked after 6 months in clinically stable patients with bronchiectasis. 
ISWT: incremental shuttle walk test, #p>0.05. 
Value Baseline distance (m) 6-month distance (m) 
25% Percentile 225.0 260.0 
Median 390.0 400.0 
75% Percentile 462.5 480.0 
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A Bland-Altman plot showed a bias of 1.38m and 95% limits of agreements from -
188m to 185m (see figure 2). The intraclass correlation coefficient was calculated to 
be 0.85 (95% CI 0.68-0.93, p<0.001). 
 
Figure 2 
 
Figure 2. Bland-Altman figure of 30 stable patients that completed the ISWT 6 
months apart. The difference versus average distances walked are shown. The 
middle line represents the mean bias (-1.4). The upper and lower dashed lines 
represent the limits of agreement (95% confidence intervals -188.4 – 185.6). 
 
5.3.2 Validity 
 
To assess the validity of the incremental shuttle walk test, it needs to be comparable 
with other already validated markers of function in bronchiectasis. To assess this, 
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their St George’s Respiratory Questionnaire (SGRQ) results which has already been 
validated for use in bronchiectasis (Wilson et al, 1997b). The SGRQ scores 
‘activity’ as part of its evaluation and hence correlations between ‘Total SGRQ’ and 
‘Activity SGRQ’ with the ISWT were assessed.  
 
The SGRQ changed with exacerbations: the median values at baseline for SGRQ 
were 28 (18-44) to 36 (25-36) at visit start (p<0.0001). The median then reduced to 
34 (20-51.75) at visit end (p=0.003) – see figure 3. The degree of change was 
analysed per patient. There was a median increase of 4 points in SGRQ score from 
baseline to start of exacerbation. There was a median reduction of 2 points in SGRQ 
score from start to end of exacerbation - figure 4. 
 
Figure 3. 
 
Figure to show the median value (IQR) St George’s Respiratory Questionnaire 
(SGRQ) scores as baseline (VO), start of exacerbation (VS) and end of 
exacerbation (VE). Wilcoxon analysis **p<0.01, ***p<0.0001. 
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Figure 4. 
 
Figure to show the actual change in St George’s Respiratory Questionnaire 
(SGRQ) value (units) from clinically stable bronchiectasis to start (VO-VS) and 
then from start to end of exacerbation (VS-VE). 
 
Similarly, the ISWT median distance deteriorated from baseline to start of 
exacerbation and then improved following antibiotic treatment. Median values for 
distance walked at baseline (370m), start of exacerbation (330m) and end of 
exacerbation (350m) are shown below. There was a reduction of 40m walked from 
baseline to start of exacerbation. Patients were then given 14 days of antibiotics and 
the median distance walked improved by 50m. See figures 5 & 6. 
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Figure 5. 
 
Boxplot of median (IQR) with whiskers 5-95% percentiles of distance walked at 
baseline (VO), start of exacerbation (VS) and end of exacerbation (VE) in 94 
patients. ISWT: incremental shuttle walk test. 
 
Figure 6. 
 
Figure to show the median (IQR) change with 5-95 percentile whiskers (m) in 
incremental shuttle walk (ISWT) distance walked with exacerbation (VO-VS) 
and after treatment (VS-VE). Wilcoxon analysis, ***P<0.001. 
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ISWT distance can be variable and is dependent on many factors including physical 
fitness. The percentage change in ISWT was analysed and found to drop by a 
median value 11.1% from baseline to the start of exacerbation. After 14 days of oral 
antibiotics, it improved by 16.3% (see figure 7). 
 
Figure 7. 
 
Boxplot of median (IQR) percentage change (%) with 5-95% whiskers in 
incremental shuttle walk test (ISWT) from baseline to start of exacerbation 
(VO-VS) and from start to end of treatment (VS-VE). Wilcoxon analysis, 
***p<0.001. 
 
To further illustrate validity of the ISWT, the distance walked was correlated with 
actual SGRQ scores and then the change in ISWT was correlated with change in 
SGRQ score – see figures 8 & 9. The percentage change in ISWT was also 
correlated with change in SGRQ score (figure 10). 
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Figure 8. 
 
Figure to show the correlation between ISWT (m) and SGRQ scores in 282 
events (94 patients at 3 different time points). R= -0.60, p<0.0001. 
 
Figure 9. 
 
Figure to show the correlation between change in ISWT (m) and change in 
SGRQ scores (vo-vs and vs-ve), n=188. R=-0.33, p<0.0001. 
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Figure 10. 
 
Scatter plot to show the correlation between percentage change (%) in 
Incremental shuttle walk test (ISWT) and change in St George’s Respiratory 
Questionnaire (SGRQ) scores from baseline to start of exacerbation (vo-vs) and 
start to end of exacerbation (vs-ve), n= 188. R=-0.35, P<0.0001. 
 
The ‘Activity’ component of the SGRQ changed with exacerbations: the median 
(IQR) values at baseline were 33 (17 - 54) to 42 (18 - 66) at visit start (p=0.002). 
The median then reduced to 38.5 (12 - 60.25) at visit end (p=0.009). The degree of 
change was analysed per patient. There was a median change of 0 (-1 - 13) units in 
Activity score from baseline to start of exacerbation. There was a median reduction 
of 6 (-14.5 - -6) units in activity score from start to end of exacerbation (p=0.002). 
See figures 11&12. 
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Figure 11. 
 
Figure to show the median (IQR) with whiskers 5-95percentile values for 
activity scores at baseline (VO), start of exacerbation (VS) and end of 
exacerbation (VE) in 94 patients with bronchiectasis. **p<0.01. 
 
Figure 12. 
 
Figure to show the median (IQR) change in Activity component (units) with 
exacerbation (VO-VS) and after treatment (VS-VE). **p<0.01. 
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To further assess the validity of the ISWT, the distance walked was correlated with 
actual activity scores and then the change in ISWT was correlated with change in 
activity score – see figures 13&14. The percentage change in ISWT was also 
correlated with change in activity score (figure 15). Results were calculated using 
the Spearman’s correlation. 
 
Figure 13. 
 
Figure to show the correlation between Activity scores and Incremental shuttle 
walk test (ISWT) in 94 patients at 3 different time points (n=282). R= -0.64, 
p<0.0001. 
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Figure 14. 
  
Figure to show the correlation between change in ISWT and change in Activity 
scores (vo-vs and vs-ve), n=188. R=-0.30, p<0.0001. 
 
Figure 15. 
 
Figure to show the correlation between percentage change (%) in ISWT and 
actual change in activity scores from baseline to start of exacerbation (vo-vs) 
and start to end of exacerbation (vs-ve), n= 188. R=-0.27, P=0.0004. 
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A subset of patients were asked to wear an activity monitor for 1 week n=49. The 
average time spent being active and sedentary per day during this recorded time was 
correlated with ISWT distance walked at the start of the week. Correlations are 
shown below. 
 
Figure 16. 
 
Figures to show the correlation of Incremental shuttle walk test (ISWT) 
distance (m) with average physical activity duration (minutes) (above) and time 
spent sedentary (minutes) (below). R=0.42, p=0.004 and r=-0.48, p=0.0007. 
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Other parameters assessed include ‘measured sleep’ r=0.11, p=0.5; ‘moderate 
activity’ r=0.40, p=0.006; ‘vigorous activity’ r=0.13, p=0.4; ‘measured active 
energy expenditure’ r=0.35, p=0.02; ‘number of steps’ r=0.33, p=0.03 and ‘Average 
metabolic equivalent (METs)’ r=0.38, p<0.01. 
 
To assess correlation with markers of severity the ISWT distance walked at each 
visit; baseline (VO), start of exacerbation (VS) and end of exacerbation (VE) was 
correlated with the MRC score for breathlessness recorded at each visit. Results 
showed a strong negative Spearman’s correlation R=-0.59, p<0.0001. 
 
ISWT scores at baseline were correlated with the bronchiectasis severity index (BSI) 
score calculated for each patient. Spearman’s correlation was calculated to show R=-
0.44, p<0.0001 (see below). 
 
Figure 17. 
 
Figure to show correlation between incremental shuttle walk test distance (m) 
at baseline by 94 clinically stable patients with bronchiectasis with their 
corresponding Bronchiectasis Severity Index (BSI) score. 
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5.3.3.1 Responsiveness – Intravenous therapy 
30 patients were given intravenous antibiotics for exacerbations of bronchiectasis as 
per the BTS guidelines (Pasteur et al, 2010). Their baseline characteristics are 
displayed below: 
 
Table 3. 
Characteristics  
Age yrs (mean, SD) 62.4 (11.4) 
Female 47% 
Smoking 70% never 
30% ex-smoker 
0% current 
Inhaled/ 
oral corticosteroids 
24/30 
3/30 
COPD 2/30 
Asthma 13/30 
Long-term antibiotics 3/30 
Sputum microbiology Pseudomonas 8/30 
Other PPM 18/30 
Mixed normal flora 5/30 
Table to show the baseline characteristics of 30 patients with bronchiectasis 
including gender, smoking, medications, comorbidities and microbiology. PPM: 
Other potentially pathogenic microorganisms. 
 
Patients were assessed at the beginning and end of intravenous therapy to ensure that 
improvement with intravenous therapy had occurred. The table below demonstrates 
an improvement in sputum colour assessed as per colour chart (Murray et al, 2009) 
and sputum volume, blood inflammatory markers and sputum bacterial clearance. 
 216 
There was an improvement in FVC and %predicted FVC but no difference in FEV1 
or %predicted FEV1. 
 
Table 4. 
 Day 0 Day 14 P value 
Sputum colour 3.7 2.1 <0.0001 
24hr volume 26.8mls 6.5mls <0.0001 
FEV1 (L) 1.58 1.65 0.09 
%FEV1 pred. 56.6% 59.3% 0.1004 
FVC (L) 2.53 2.84 0.002 
%FVC pred. 72.7% 81.1% 0.0009 
WCC x109/L 10.1 7.8 0.0004 
ESR x109/L 29.1 22.2 0.0026  
CRP (units) 22.5 4.7 <0.0001 
PA 8/30 2/30 0.0003 
Other PPMs 18/30 1/30 0.0001 
MNF 5/30 17/30 0.0001 
No growth 0 6/30 0.0001 
yeasts 0 2/30 0.0210 
Table to show biochemical, microbiological and clinical response to 14 days 
intravenous antibiotic therapy. FEV1: forced expiratory volume in 1 second, 
FVC: forced vital capacity, WCC: white cell count, ESR: erythrocyte 
sedimentation rate, CRP: C-reactive protein, PA: Pseudomonas aeruginosa, 
PPMs: potentially pathogenic miceoorganisms, MNF: mixed normal flora. 
 
At the start of exacerbation, patients were walking a median distance of 265m. After 
14 days of intravenous therapy, the overall median distance walked improved by 
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70m to 335m (see table 5 and figure 18). The median change per patient after 14 
days of IV antibiotics was 32.5m (-12.5-90) and percentage improvement was 11.9% 
(-3.7 – 38.9%). 
 
Table 5. 
Table to show distance walked pre- and post- intravenous antibiotic therapy. 
 
Figure 18. 
 
Barchart of mean (SEM) of Incremental shuttle walk test (ISWT) distance (m) 
pre and post 14 days of intravenous therapy. Wilcoxon analysis, **p<0.01. 
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Day 14 
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Change in 
distance (m) 
% change 
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25% Percentile 137.5 190.0 -12.5 -3.7 
Median 265.0 335.0 32.5 11.9 
75% Percentile 395.0 450.0 90 38.9 
**P=0.004 
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5.3.3.2 Responsiveness - Oral therapy 
94 patients attended for exacerbations that were managed on an outpatient basis with 
oral antibiotics. To ensure the patient had a genuine exacerbation, they were 
clinically assessed when stable and then again when developing an exacerbation – 
both before treatment was initiated and after completion. Baseline characteristics of 
the 94 patients are shown below. 
 
Table 6. 
  
Age  65.6 (10.7) 
Female 54% 
Smoking 62% never 
36% ex-smoker 
2% current 
Inhaled/ 
oral corticosteroids 
70% 
2% 
COPD 14% 
Asthma 49% 
Long-term antibiotics 7% 
Sputum microbiology Pseudomonas 13% 
Other PPM 76% 
Mixed normal flora 20% 
Table to show baseline characteristic of 94 patients with bronchiectasis. COPD: 
chronic obstructive pulmonary disease, PPM: potentially pathogenic 
microorganisms. 
 
To ensure patients had responded to oral therapy, various clinical parameters were 
measured both before and after treatment. The table below shows that after 14 days 
of oral therapy patients had improved inflammatory markers, lung function, sputum 
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production and increased microbial clearance of potentially pathogenic organisms 
and more culture of mixed normal flora. 
 
Table 7. 
 Day 0 Day 14 P value 
Sputum colour 2.6 2.0 <0.0001 
24hr volume 13mls 8.7mls 0.01 
FEV1 (L) 1.90 1.96 0.0009 
%FEV1 pred. 75.8% 77.7% 0.007 
FVC (L) 2.85 2.97 <0.0001 
%FVC pred. 91.4% 94.9% 0.002 
WCC x109/L 9.4 7.3 0.0003 
ESR x109/L 25.6 19.6 0.01 
CRP (units) 29.9 8.5 <0.0001 
PA 12/90 12/90 1.0 
Other PPMs 71/90 31/90 0.0001 
MNF 19/90 37/90 0.004 
No growth 0/90 10/90 0.001 
yeasts 0/90 1/90 0.3 
Table to show clinical markers at start and end of oral antibiotic therapy in 94 
patients treated for an exacerbation of bronchiectasis. FEV1: forced expiratory 
volume in 1 second, FVC: forced vital capacity, WCC: white cell count, ESR: 
erythrocyte sedimentation rate, CRP: C-reactive protein, PA: Pseudomonas 
aeruginosa, PPMs: potentially pathogenic miceoorganisms, MNF: mixed 
normal flora. 
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Patients walked a median distance of 370m on the incremental shuttle walk test 
when clinically stable at the baseline visit. At start of exacerbation the median 
distance walked was 330m (P<0.0001). After oral antibiotic therapy, prescribed 
according to available previous microbiology results, the median distance improved 
to 350m (P<0.0001). The distance walked at baseline did not differ from the 
distance walked after oral therapy, suggesting patients may have returned to their 
baseline level of function (see table 8 & figure 5). The median change (IQR) in 
distance walked from VO to VS was -40m (-100 – 0) with a median percentage 
reduction of 11.1% (-33.1% - 0%). The median change from VS to VE was 50m (10 
– 85) with a median percentage improvement of 16.3% (3.1% – 33.3%). 
 
Table 8. 
Table to show the ISWT distance walked pre- and post- oral antibiotic therapy. 
 
5.3.3.3 Responsiveness - Nebulised therapy 
30 patients were randomly assigned to nebulised gentamicin therapy or placebo 
(nebulised saline). They performed an incremental shuttle walk test at baseline and 
repeated it at 12months of therapy. Median distances walked at each time point are 
displayed in the table below. The median difference (IQR) walked between baseline 
and 12months for the Gentamicin group was 70m (40 -160m) with a percentage 
median improvement (IQR) of 18.5% (11.1 – 45.7). There was a marked 
improvement in the Gentamicin group compared with the saline group with a mean 
difference of 90.4m (95% CI 40.76 – 140m, p=0.0006) and mean % difference 
34.7% (95% CI 12.56 – 56.79, p=0.003) table 9 and figure 19. 
 
 
 
 
 
Value VO VS VE 
25% Percentile 252.5 180.0 210.0 
Median 370.0 330.0 350.0 
75% Percentile 540.0 510.0 530.0 
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Table 9. 
Table to show the difference in distances walked (median, IQR) after 12months 
of either Gentamicin or placebo therapy (0.9% saline). 
 
Figure 19. 
 
Boxplots (median, IQR with 5-95 percentile whiskers) of Incremental shuttle 
walk test (ISWT) distance (m) improvement with nebulised Gentamicin b.d. 
therapy but not with nebulised 0.9% saline. ***p<0.001, #p>0.05. 
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Value Nebulised Gentamicin Nebulised saline 
 Baseline End of therapy Baseline End of therapy 
25% Percentile 270.0 360.0 257.5 267.5 
Median 350.0 510.0 345.0 415.0 
75% Percentile 530.0 690.0 450.0 530.0 
***P <0.0001 
#P = 0.5 
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5.3.4 ISWT threshold for use as an objective clinical endpoint 
The minimum clinical important difference (MCID) has been found to be 35m in a 
small study conducted in patients with bronchiectasis (Lee et al, 2014c). Our study 
measured ISWT distance walked in completion of increments of 10 metres. 
Therefore, in order to clarify what threshold of ISWT improvement is required to 
define a positive response we looked at the percentage of patients that had different 
metre and percentage improvements. We then investigated to see what level of 
improvement correlated best with clinically significant improvements in SGRQ 
score (4 or more unit improvement in overall score). 
 
3.7% of those on long term nebulised therapy, 20.5% on short term oral antibiotic 
therapy and 33.3% on short term intravenous antibiotic therapy for acute 
exacerbation had deteriorated or had 0m improvement in ISWT distance. The trend 
is understandable as the sickest of patients would have been requiring 2 weeks of 
intravenous antibiotic therapy. 7.4% on nebulised, 15.9% on oral and 16.6% on 
intravenous antibiotics had an improvement between 1-29m. 25.9% of patients on 
nebulised therapy, 15.9% on oral therapy and 6.7% of patients on intravenous 
therapy had a 30-59m improvement. 14.8% on nebulised therapy, 22.7% of those on 
oral therapy and 16.7% on intravenous improved between 60-89m. 48.1% of 
patients on 12months nebulised therapy had a 90m or more improvement. 25% and 
26.7% of patients on oral and intravenous respectively had a 90m or more 
improvement – see figure 20. 
 
If a threshold of 30m was used then this would have included 65.5% of all the 
patients (on nebulised, oral and intravenous therapy). If a threshold of 60m was 
used, then this would include 50% of all patients.  
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Figure 20. 
 
Barchart to show the percentage of patients with different metre incremental 
shuttle walk test (ISWT) improvements groups by medical therapy; nebulised, 
oral, intravenous and all therapies together. 
Patients have different baseline functional capacity due to many factors incl. age, 
fitness, weight and comorbidities. An arbitrary metre improvement in ISWT might 
therefore underestimate improvement. To assess improvement whilst considering 
differing abilities, the percentage improvement in ISWT distance was investigated. 
 
Figure 21 shows the different categories of improvement – ‘deteriorated’, ‘no 
change’, ‘1-4.99%’, ‘5-9.99%’ and ‘³10%’ improvement within the three treatment 
groups. There was no deterioration in the group receiving nebulised gentamicin 
twice daily. 13.6% and 26.6% or those on oral and intravenous antibiotic therapy 
respectively had a deterioration in the ISWT distance walked after 2 weeks of 
therapy. 3.7% of nebulised patients, 6.8% of oral and 6.6% of intravenous antibiotic 
patients had no change (0m) in the ISWT distance walked. Those that had a 1-4.99% 
improvement included 0% of nebulised patients, 10.2% of those on oral treatment 
and 6.7% of those in intravenous antibiotics. For patients on nebulised therapy 
14.8% had a 5-9.99% improvement and 81.5% had a more than 10% improvement. 
Out of the patients on oral antibiotics, 8% and 61.3% had a 5-9.99% and >10% 
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improvement respectively. For patients on intravenous therapy 10% had a 5-9.99% 
improvement in ISWT distance and 50% had a ³10% improvement. 
 
Figure 21. 
 
Barchart of the percentage of patients with different percentage improvement 
in incremental shuttle walk test (ISWT) by medical therapies. 
 
5.3.5 Correlation of ISWT improvement with clinical improvement in SGRQ score 
The minimum clinically important difference in SGRQ score is defined as 4 or more 
units. To further assess what the threshold of ISWT improvement is required to 
show when patients had clinically improved, we looked at the proportion of patients 
that had clinically significant improvements in SGRQ scores with therapy. 110 
patients that had completed 14days of oral antibiotics or nebulised Gentamicin 
therapy also completed the SGRQ both pre- and post- treatment. Figure 22 shows 
the percentage of patients with a 4 or more unit rise in SGRQ scores with different 
categories of metre improvement in ISWT. If a threshold of 30m was taken to be an 
arbitrary cut off level, then 13.2% of all patients assessed that improved more than 
30m also had a clinically significant improvement in SGRQ score. If a threshold of 
60m was taken as the threshold, then 16.3% of these patients had a significant 
improvement in quality of life. In each metre improvement group, there were 
significantly more patients that did not have a significant improvement in SGRQ 
score than those that did. 
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Figure 22. 
 
Figure to show the percentage of patients with a 4 or more unit rise in St 
George’s Respiratory Questionnaire (SGRQ) score after antibiotic therapy 
within each incremental shuttle walk test (ISWT) metre improvement group; 
deterioration/no change, 0-29m, 30-59m, 60-89m and ³90m. 
Figure 23 shows the percentage of patients that had a 4 or more unit improvement in 
SGRQ score when patients were separated by percent improvement in ISWT after 
antibiotic therapy. The figure shows more patients had significant improvements in 
SGRQ score in the groups 5-9.99% and ³10% than those who did not – 60%:40% 
and 62.5%:37.5% respectively. If a threshold of 5% improvement in ISWT distance 
walked after antibiotic therapy was used 62.2% of patients will also have 
significantly improved when measuring quality of life as assessed by SGRQ. If a 
threshold of ³10% was used, then 62.5% of patients were captured that also reached 
the MCID for SGRQ improvement. 
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Figure 23. 
 
Figure to show the percentage of patients with a 4 or more unit rise in St 
George’s Respiratory Questionnaire (SGRQ) score after antibiotic therapy 
within each incremental shuttle walk test (ISWT) percentage improvement 
group; deterioration, no change, 1-4.99%, 5-9.99% and ³10%. 
 
A clinically useful test would be when we could achieve at least 50% of patients 
having a 4unit or more improvement in SGRQ or more – see table 10. Using data 
from exacerbations, a 5% improvement or greater in ISWT would represent the 
MCID. Although all patients receiving antibiotic therapy improved, Erythrocyte 
Sedimentation Rate only improved in the group that had a 5% or more improvement 
in the ISWT (p<0.0005). Both groups had improved C reactive protein (change from 
Day 0 to day 14 after antibiotic in less than 5% improvement group p=0.004 and in 
more than 5% improvement group was p<0.0001), but the group that had 5% or 
more improvement had a greater reduction in C reactive protein, p=0.007.  
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Table 10. 
% improvement in 
ISWT group 
% of 110 patients 
% with SGRQ 
improvement 
(³4units) within 
the group 
Average SGRQ 
change 
(Units) 
Deterioration 10.9% 25% -2.08 
0.1-1% 6.4% 42.8% -1.67 
1.1-2.4% 1.8% 50% -5.5 
2.5% - 4.9% 6.4% 42.8% 5.29 
5-9.9% 9% 60% -8.28 
10-19.9% 25.5% 53.6% -6.86 
> 20% 40% 68.1% -9.86 
Table 10: Percentage of patients with different percent improvements in ISWT, 
after treatment with oral and nebulised antibiotics for exacerbations (data not 
available in 14), with their average change in SGRQ score (a reduction of 4 or 
more units is a clinically significant difference). 
 
The area under the curve for percentage ISWT change with a 4 unit improvement in 
SGRQ was calculated to be 0.79 (0.66-0.91, p=0.001). If a 2% improvement in 
ISWT was picked this had 92% sensitivity but 42% specificity. A 5% improvement 
had 92% sensitivity and 50% specificity. A 7.5% improvement had 88% and 58% 
respectively and a 10% improvement had 83% and 62% respectively. 
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5.4 Discussion 
There has been an urgent need for an objective, validated clinical endpoint to assess 
response to existing and new therapies that prevent exacerbations and declining 
health status in patients with bronchiectasis. Current clinical endpoints routinely 
used in the management of patients with bronchiectasis each have their limitations. 
24-hour sputum volume is thought to be inaccurate, unreliable and onerous. In 
clinical practice, this test is poorly complied with and difficult to interpret. 
Microbial clearance has been used to assess response to antibiotic treatment but 
often in clinical practice only qualitative microbiological analysis is performed and 
as patients are often chronically infected, this endpoint is difficult to interpret. 
Quantitative microbiological analysis has been carried out in phase 2 studies 
(Serisier et al, 2013b) but not for phase 3 studies to date (Haworth et al, 2014). In 
addition, there is controversy whether there is a change of microbial load with 
antibiotics (Tunney et al, 2013). C-reactive protein (CRP) can be useful in patients 
with a significant systemic response to infection. The degree of inflammatory 
response, however is highly variable among patients (Murray et al, 2009c). As such, 
it has not been used to assess longitudinal decline in bronchiectasis or any long-term 
therapies for bronchiectasis. Several quality of life questionnaires have been 
validated for use in bronchiectasis; SGRQ (Wilson et al, 1997b), LCQ (Murray et 
al, 2009d), Bronchiectasis health questionnaire (Spinou et al, 2017) & the Quality of 
life questionnaire-bronchiectasis (QOL-B) (Quittner et al, 2014 Quittner et al, 2015) 
but all are subjective outcome measures with patient self-assessment and reporting. 
The questionnaires can be cumbersome for the patient to complete and time-
consuming for the clinician to analyse. For phase 3 studies, time to first exacerbation 
or mean exacerbations is used (Fan et al, 2015, Wong et al, 2012, Serisier et al, 
2013). There has been debate about the definition of an exacerbation. A European 
Consensus statement has now been published that defines an exacerbation for use in 
clinical research (Hill et al, 2017). 
 
Previous research by Carmargo and colleagues in patients with bronchiectasis has 
shown the ISWT to be reliable and represent functional capacity. 75 patients 
underwent cardiopulmonary exercise testing (CPET), two ISWT 30 minutes apart 
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while physical activity levels (steps per day) and dyspnoea score were recorded. 
ISWT significantly correlated with peak load (r=.82), VO2 (r=.72), steps per day 
(r=.61) and dyspnoea (r=.69). Greater desaturation was achieved with ISWT than 
with CPET (Carmargo et al, 2009). 
 
The incremental shuttle walk test has previously been used in studies of patients 
with bronchiectasis to assess the effect of interventions e.g. chest physiotherapy 
(Murray et al, 2009b) and pulmonary rehabilitation (Mandal et al, 2012, Newall et 
al 2005) but to date it has not been validated for use as an objective clinical endpoint 
in bronchiectasis. The main findings of this study support the ISWT to be reliable, 
valid and additionally, responsive to therapy (both short-term and long-term) in a 
large cohort of patients with bronchiectasis and therefore supports its use as an 
objective clinical endpoint. 
 
The reliability was assessed over a 6-month period as the proposal would be to use 
the ISWT to assess both short or long-term therapies. At each time period, patients 
were stable and had not required antibiotic therapy for at least 28 days. The ISWT 
was found to be repeatable, in line with previously reported findings (Alves de 
Camargo et al, 2014). 
 
The validity of the ISWT was supported with good correlations with both the total 
and activity SGRQ scores. The SGRQ was chosen as it is already validated for use 
in bronchiectasis and specifically measures activity as one of its domains. The 
correlation would never be perfect as the ISWT is an objective measure of exercise 
capacity whilst the SGRQ is a self-filled questionnaire but despite this remains 
strong with an R value of -0.6 (P<0.0001). In a sub group, there was a moderate 
correlation with sedentary and physically active duration time measured by activity 
monitors and further supports the proposal that the ISWT correlates well with other 
markers of exercise capacity. Overall there has been demonstration of at least 
moderate validity with the ISWT.  
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Disease severity can provide important prognostic information and the ISWT was 
found to moderately correlate with the Bronchiectasis Severity Index which might 
suggest its use in measuring severity although we acknowledge there are other 
factors that would influence a patient’s ISWT score (e.g. fitness level, weight, 
comorbidity etc.) and therefore suggest serial measurements to show improvement 
or decline in ISWT score are more valuable than a one-off result. Furthermore, 
patients will all have differing baseline functional capacity so when the response to 
different treatments (short-term oral, short-term intravenous and long-term 
nebulised) was assessed the change in metres and percentage change was analysed. 
 
This study used the response to therapies known to work in bronchiectasis and 
included patients treated with oral antibiotics and a more severe group receiving 
intravenous antibiotic therapy. Objective assessments showed patients did improve 
with short term antibiotic therapy and similarly there were significant improvements 
in ISWT. The third group chosen was the previously published study assessing the 
effectiveness of nebulised gentamicin over 1 year to assess the ISWT with effective 
long term therapy. Patients felt better with nebulised gentamicin therapy and there 
was a reduction in overall exacerbations compared with the group that received 
nebulised 0.9% saline therapy. There was similarly a significant improvement in the 
ISWT (in the gentamicin arm) over 1 year (Murray et al, 2011). 
 
This study assessed to see whether there was a threshold of improvement in ISWT 
that could be used for future studies. For at least a 30m improvement, overall 66% 
of patients had met this improvement but if a higher threshold of at least 60m 
improvement was chosen, overall 50% met this improvement. Considering the 
overall biochemical and microbiological improvement it was difficult to appreciate 
that 50% of patients had not improved. A percentage improvement may however be 
more reliable and would take account of the variable baseline ISWT scores and 
functional capacity of patients. If a threshold of at least 5% improvement in ISWT is 
used, this would capture 73% overall (60% of those that received intravenous 
antibiotics, 69% of those that received oral antibiotics for 2 weeks and 96% of those 
that received inhaled gentamicin for 12m).  If a threshold of at least 10% 
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improvement in ISWT is used, this would capture 63% overall (50% of those that 
received intravenous antibiotics, 61% of those that received oral antibiotics for 2 
weeks and 81% of those that received inhaled gentamicin for 12m). Furthermore, 
both 5% and 10% improvement in ISWT groups had much higher percentage of 
patients with a clinically significant improvement in SGRQ outcomes (62.2% and 
62.5% of patients with 4 or more unit improvements in SGRQ respectively) to 
further imply a percentage improvement that accounts for baseline function captured 
a group of patients that had truly clinically improved as opposed to using an 
arbitrary metre improvement with low numbers of patients that had met the 
minimum clinically important difference in SGRQ score. A percentage 
improvement in ISWT is a more reliable method of predicting clinical improvement 
than an arbitrary distance improvement. Using at least a 5% improvement in score 
as this captured 73% of our total cohort of patients, where the disease severity was 
mixed. 
 
The area under the curve showed that the % ISWT was at least moderate value in 
predicting a 4 or more-unit improvement in SGRQ. As the cut-off rose, the 
sensitivity fell and specificity improved. For the MCID, the authors proposed that at 
least 50% should have a 4 or more-unit improvement in SGRQ and using a 
threshold of 5% ISWT improvement this was achieved when treating exacerbations 
of bronchiectasis.  The authors would therefore recommend a MCID of 5% change 
in ISWT to be used as an objective endpoint for assessing response to new and 
existing therapies. 
 
There were limitations to the study that included the lack of a placebo arm when 
assessing the response to therapy. Whilst this could have strengthened the impact of 
the responsiveness of ISWT to therapy, it would not have been ethical to withhold 
an effective treatment. To provide a similar dual arm situation, the Gentamicin trial 
was reanalysed which included a placebo arm. Gentamicin was also shown to be an 
effective therapy with a concomitant improvement in ISWT over 12months (Murray 
et al, 2011). The patients included in each subsection had varying degrees of 
severity of bronchiectasis with milder patients in the reliability and oral antibiotic 
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substudies. There were more severe patients in the studies investigating the area 
under the curve MCID and in the response to intravenous and nebulised antibiotics. 
Therefore, the applicability of these findings may require further investigation in 
patients with very severe bronchiectasis and further external validation in multi-
centred studies is needed. 
 
Previous research by Carmarco and colleagues in patients with bronchiectasis has 
shown the ISWT to be reliable (Carmarco et al, 2014) and the incremental shuttle 
walk test has previously been used to assess the effect of interventions e.g. chest 
physiotherapy (Murray et al, 2009b) and pulmonary rehabilitation (Mandal et al, 
2012, Newall et al, 2005) on patients with bronchiectasis but to date it has not been 
validated for use as an objective clinical endpoint in bronchiectasis. 
 
In conclusion, this study has confirmed the ISWT to be reliable, valid and 
responsive to change in patients with bronchiectasis. At least a 5% improvement in 
ISWT would be a useful objective endpoint to assess therapies in bronchiectasis. 
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Bronchiectasis is a chronic respiratory condition, characterised by dilated airways 
which give rise to destruction of the mucociliary escalator, the build-up of stagnant 
mucus and subsequently infection and inflammation which further destroy the 
airways. It has comparatively little research investigating it compared to other 
respiratory conditions such as asthma, chronic pulmonary obstructive disease and 
lung cancer. However, strides in bronchiectasis research have been made in the last 
two decades.  
 
There is a multifactorial cause for its increasing incidence including; the increased 
use of the more commonly accepted diagnostic tool of computer tomography 
scanning which is the gold standard imaging modality for bronchiectasis; the 
increased awareness of distinction between bronchiectasis and other chronic lung 
conditions and the fact the ageing population are experiencing more hospital 
admissions and suffering from more respiratory infections like pneumonia which are 
a recognised cause for bronchiectasis. There is a recognised increased morbidity and 
mortality rate associated with bronchiectasis and this coupled with its increasing 
incidence makes bronchiectasis a respiratory condition of increasing research 
interest with a relative lack of evidence base for managing it.  
 
There is a paucity of studies investigating patients with bronchiectasis that are 
largely managed in the community. Most new randomised controlled trials focus on 
cohorts with increased severity markers such as colonisation with Pseudomonas 
aeruginosa, poor lung function, repeated exacerbations and hospital admissions. 
Bronchiectasis is a progressive condition with newer therapies targeting the vicious 
cycle to prevent further progression of disease. It is therefore important to be 
manage the condition well, even in its less severe form. 
 
This thesis aims to investigate patients with bronchiectasis that can be managed on 
an outpatient basis. The first chapter aimed to characterise these patients in their 
stable state before phenotyping their exacerbations in the clinically unstable state. 
The final chapter investigates validated endpoints in bronchiectasis which are vital 
to assessing treatment response in clinical practice as well as in research studies. 
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Recently, there have been two severity scoring systems developed to assess disease 
severity in bronchiectasis. The Bronchiectasis Severity Index score and the FACED 
score are two multidimensional scoring systems which categorise patients into low, 
medium and high severity brackets. The Bronchiectasis Severity Index (BSI) grades 
patients with bronchiectasis from a minimum score of 0 (very mild) to 26 (very 
severe) (Chalmers et al, 2016). The scores are classified into tertiles where 0-4 is a 
low score, 5-8 as intermediate and ³9 is high score. The BSI incorporates 9 
variables; age, body mass index (BMI), FEV1 % predicted, hospital admission in the 
previous 2 years, number of exacerbations in the last year, MRC dyspnoea score, 
Pseudomonas aeruginosa colonisation, colonisation with other microorganisms and 
radiological severity. The BSI has been externally validated and shown to predict 
30-day mortality and hospital admission rate and is also associated with the risk of 
future exacerbations and quality of life. 
 
The FACED score is a slightly less complex scoring system incorporating only 5 
variables including FEV1 % predicted, Age, Presence of chronic Colonization by 
Pseudomonas aeruginosa, radiological Extension and Dyspnoea. The overall sum of 
scores can range from 0 to 7 points where 0-2 points is classified mild 
bronchiectasis, 3-4 points is moderate bronchiectasis and overall 5-7 points is 
classified as severe bronchiectasis. The FACED score was later amended to a 9-
point E-FACED score to include number of exacerbations in its severity scoring 
system.  
 
 Both scoring systems are comparable but the BSI was found to predict hospital 
admissions and differentiate the number of exacerbations and quality of life between 
the different severity tertiles.  
 
The study in chapter one successfully recruited 208 patients that were clinically 
stable, i.e. no prescribed antibiotics or steroids for exacerbations in the last 6 weeks 
or any change to their regular respiratory medications. Of the 207 patients that 
continued with the study 74 had a BSI score 0-4, 79 had a BSI score 5-8 and 54 had 
a BSI score of 9 or above. 
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Each patients underwent a range of tests including quality of life questionnaires 
(The Leicester Cough Questionnaire and the St George’s Respiratory 
Questionnaire), the incremental shuttle walk test, providing sputum for assessment 
of colour and 24 hour volume, sputum for quantitative bacteriological analysis, 
sputum for inflammatory marker assays of myeloperoxidase, neutrophil elastase and 
interleukin 8, blood for inflammatory serum analysis of primarily white cell count, 
neutrophil count, erythrocyte sedimentation rate and c-reactive protein and lung 
spirometry to assess forced expiratory flow in 1 second, forced vital capacity and 
mid expiratory flows with actual and % predicted values. 
 
Results showed that increasing bronchiectasis severity index tertile correlated well 
with the LCQ assessing quality of life as a result of cough, the SGRQ assessing 
quality of life including activity and the incremental shuttle walk – a validated 
marker of functional capacity. There was also significant correlations of the BSI 
score with increased sputum colour (purulence), 24-hour sputum volume and 
bacterial load in sputum. Analysis of sputum colour and volume is quick and easy to 
assess and already part of routine practice. This thesis has investigated the 
importance of bacterial load but there is conflicting results in the literature and 
hence requires further analysis.  
 
The bronchiectasis severity index score also significantly correlated with all serum 
inflammatory markers, sputum myeloperixodase and all measured parameters of 
lung function but not with sputum neutrophil elastase or sputum interleukin -8. The 
above clinical endpoints have been previously investigated and found to be clinical 
importance in bronchiectasis: 
 
The Leicester Cough Questionnaire (LCQ) (range 3-21, 3 most severe cough 
severity) and the St George’s Respiratory Questionnaire (SGRQ) (range 0-100, 100 
most severe) have both been validated as clinical endpoints for use in bronchiectasis 
(Murray et al, 2009d Wilson et al, 1997b). The MCID for the LCQ is 1.3units and 
for the SGRQ is 4units.  
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The ISWT is an objective measurement of functional capacity and has been 
previously shown to remain stable in patients with clinical stability i.e. no change to 
medications and no exacerbation 6 months apart (Mandal et al, 2014). It has also 
been shown to improve with long-term nebulised antibiotics (Murray et al, 2011) 
and anti-inflammatory treatment (Mandal et al, 2014).  
 
Sputum colour was reported to have good reliability between patients and clinician 
and found to be predictive of bacterial colonisation (p<0.0001). Independent factors 
associated with sputum purulence were found to be bacterial colonisation, 
radiological severity with varicose or cystic bronchiectasis, FEV1 less than 80% 
predicted and diagnosis of bronchiectasis aged less than 45yrs old (Murray et al, 
2009).  
 
Chalmers and colleagues reported there was a direct relationship between bacterial 
load and the severity of exacerbations and risk of subsequent exacerbations. They 
linked bacterial load with airways inflammation and systemic inflammation when 
assessing both inpatients and outpatient exacerbations. Furthermore, they reported 
the reduction of bacterial load with short and long term antibiotic therapy (Chalmers 
et al, 2012).  
 
Wilson and colleagues reported patients with bronchiectasis have raised 
inflammatory markers when clinically stable and that inflammatory markers 
correlate with disease severity; WCC, neutrophil count, ESR and CRP all correlated 
with radiological severity, WCC and CRP correlated with total SGRQ scores 
(Wilson et al, 1998).  
 
Airway inflammation has been shown to correlate with higher bacterial loads and 
subsequent increased risk of exacerbation and with more severe exacerbations 
(Chalmers et al, 2012). Inflammatory markers have been reported to be increased in 
patients colonised with Pseudomonas aeruginosa and in those with more severe 
radiological bronchiectasis (Chalmers et al, 2012). Elevation of Neutrophil elastase 
was found to be associated with the bronchiectasis severity index score (r=0.49, 
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p<0.0001) but was not independently associated with mortality rates. The authors 
found neutrophil elastase to rise in exacerbations and have good discrimination for 
severe exacerbations and all-cause mortality (Chalmers et al, 2016). Airway 
inflammatory markers have been shown to improve with the use of long term 
antibiotic use (Murray et al, 2011 and Chalmers et al, 2012) 
 
Lung function (50% or lower FEV1) was associated with increased radiological 
severity (p<0.01), presence of Pseudomonas aeruginosa (p<0.01) and the presence 
of symptoms for 10 or more years (p=0.01) (Guan et al, 2014). Martinez-Garcia also 
found accelerated decline in FEV1 to be associated with more severe exacerbations, 
the presence of Pseudomonas aeruginosa in sputum and systemic inflammation 
(Martinez-Garcia et al, 2007).   
 
These results showed that in addition to the existing 9 variables included in the 
severity score, these other clinically relevant endpoints with the exception of 
inflammatory marker interleukin-8 might be valuable in assessing disease severity. 
The sample size was not large enough to investigate whether these clinical endpoints 
could also help predict mortality in this cohort but larger studies investigating these 
endpoints in conjunction with the Bronchiectasis Severity Index would be 
interesting to see if its predictive ability could be more sensitive although 
acknowledging this might make the scoring system more complex.  
 
The next study investigated outpatient exacerbations of patients with bronchiectasis 
to further help phenotype this patient cohort. Patients were invited to call the 
dedicated clinical research fellow if they felt they were experiencing an exacerbation 
of their disease during normal working hours Monday to Friday, 9am to 5pm. They 
would be seen as soon as possible and undergo a series of tests before being issued 
with a 14 day prescription for antibiotics based on their previous sputum culture 
results. Patients then re-attended after completing the treatment course to repeat the 
same series of tests. 
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Results showed that all clinical markers including FEV1 and FVC actual and 
predicted values, sputum colour, spontaneous and 24hour sputum volume and MRC 
dyspnoea scores all deteriorated when patients experienced an exacerbation. There 
was a 4 unit deterioration in LCQ score (MCID 1.3 units) and 4.5 units deterioration 
in SGRQ score (MCID 4 units) in keeping with literature that report exacerbations 
reduce quality of life.  
 
This cohort of outpatient exacerbations, which by the virtue of being able to be 
managed on an outpatient basis could be classed as less severe all had significant 
rises in serum inflammatory markers (WCC, neutrophils, ESR and CRP). In 
addition, there was also evidence of significant increase in sputum inflammatory 
marker myeloperoxidase and a trend towards an increase in neutrophil elastase. All 
markers of inflammation improved with short term antibiotics for 14 days. 
 
Quantitative microbiology results revealed culture of pathogens commonly 
associated with bronchiectasis including: Haemophilus influenzae, Pseudomonas 
aeruginosa, Streptococcus pneumoniae, Staphylococcus aureus, Moraxella 
catarrhalis, Enterobacter, Escherichia coli, Klebsiella pneumoniae, Serratia 
marcescens, Proteus mirabilis, Acinetobacter baumannii, Achromobacter 
xylosoxidans, Aeromonas hydrophila, citrobacter freundii, Stenotrophomonas 
maltophilia, mixed normal flora, and occasionally there was no growth. There was 
significantly more growth of pathogenic organisms and of multiple pathogens 
cultured by patients at the start of exacerbation when compared with baseline. 10% 
of culture results grew Pseudomonas aeruginosa at baseline and whilst this did not 
vary much at start of exacerbation (12%) and end of exacerbation (12%), there was 
significantly more growth of potentially pathogenic microorganisms and less mixed 
normal flora with exacerbation.  
 
Interestingly, there was a 57% overall change in the dominant pathogen cultured at 
start of exacerbation with baseline culture results. The overall median bacterial 
count at baseline was 6.7 x 105 CFU/ml. This increases significantly by 2log units to 
1.2 x 107 CFU/ml at start of exacerbation and returns to a median value of 0 CFU/ml 
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at the end of exacerbation visits. This 2-log unit rise in bacterial load is not seen if 
the dominant pathogen remains the same but only if it changes (p=0.02). There was 
a significant higher proportion of patients that had a 1 or more log rise in bacterial 
load if the dominant pathogen on sputum culture had changed then if the dominant 
pathogen had not changed (P=0.0007). This is the first study to demonstrate a 
change in dominant pathogen leads to a rise in bacterial load. 
 
To further investigate the importance of a rise in bacterial load, patients results were 
sub analysed to detect any clinical differences between those that had a 1 or more 
log unit rise in CFU/ml in bacterial load at start of exacerbation and those that 
didn’t.  There were significantly more patients with a 10% or more reduction in 
FEV1 and %predicted FEV1 in the group with 1 or more unit rise in bacterial load 
(p=0.04), a significant increase in the volume of spontaneous sputum production on 
exacerbation in the higher bacterial load group (P=0.04) but this was not seen in the 
24-hour collection of sputum production or change in sputum colour. There was an 
overall larger reduction in exercise tolerance in the group with 1 or more unit log 
rise in bacterial load (60m versus 30m) but this was not significant. However, there 
was significantly more patients with an overall 5% reduction in their exercise 
tolerance in the 1 or more log unit rise in bacterial load (74% versus 52%), p=0.049. 
 
There was some evidence to support the presence of increased inflammation in those 
with a higher bacterial load count as has already been previously described in the 
literature (Chalmers et al, 2012) with patients in this cohort more likely to have a 
doubling of their white cell count (p=0.02) and an increase in 50% of their 
neutrophil count on exacerbation (p=0.04). There was also a significantly higher 
increase in myeloperoxidase and neutrophil elastase levels with a 1 or more log unit 
rise in bacterial load on exacerbation. 
 
The respiratory symptoms that patients reported on start of exacerbation were well 
recognised symptoms of exacerbations with 91% reporting worsening cough, 78% 
reporting increased sputum volume, 72% reporting increased sputum purulence and 
79% reporting worsening breathlessness. The group with a higher rise in bacterial 
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load were more likely to develop chest pain, have increased sputum volume and 
deny any headache. This symptom complex was more specific with a high positive 
predictive value for recognising a rise in bacterial load of 1 or more log units than 
either of the British Thoracic Society or European Respiratory Society consensus 
definitions of exacerbations but it lacked sensitivity. 
 
Lastly, the effect of viruses on exacerbations of bronchiectasis was explored. Of the 
94 outpatient exacerbations, 90 had a viral throat swab performed. 16 of these were 
positive for common recognised viruses such as rhinovirus and influenza. There was 
no significant difference in the number of viral positive samples between the higher 
³1 log bacterial CFU rise and < 1Log rise in bacterial CFU groups, p=0.6 suggesting 
viruses do not affect bacterial load in bronchiectasis exacerbations, although the 
number of positive viral samples were small in this cohort (18%). 
 
These 94 outpatient exacerbations revealed deterioration in all clinical markers from 
baseline. All clinical markers improved with a 14 day course of antibiotics. 
Bacteriology results in this cohort demonstrated the change in microbial flora and 
bacterial load on the start of exacerbation in addition to the clinical importance of a 
demonstrable rise in bacterial load of 1 or more log units in CFU/ml. The way in 
which exacerbations of bronchiectasis is currently defined based largely on expert 
opinion of symptomology may not be the most accurate method to employ in a 
society where antibiotic guardianship becomes increasingly paramount. This study 
has demonstrated that there may be a case for more objective treatment of 
exacerbations, such as those employed when treating urinary tract infections; 
positive urine culture with bacterial load above a certain threshold coupled with 
classical symptoms. Further larger studies are required to explore the clinical 
consequences of an increase in bacterial load and the threshold at which colonisation 
becomes infection and requires treatment. 
 
All clinical markers improved with a 14 day course of antibiotics. The optimum 
duration of antibiotic therapy has not been explored in large randomised controlled 
trials. Patients with bronchiectasis often have chronically colonised airways and 
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after repeated courses of antibiotics may have pathogens with multiple resistant 
profiles. These patients may require a longer course of antibiotics but in patients 
with common pathogens and a lower bacterial load signalling a less severe 
exacerbation may improve sufficiently with a shorter course of antibiotics. 
Randomised controlled trials are needed to assess the optimum length of treatment. 
 
In order to assess response to treatment there needs to be robust validated endpoints 
to measure. The first two chapters showed how all the clinical markers assessed 
(sputum colour, spontaneous sputum volume, 24-hour sputum volume, lung function 
parameters, LCQ score, SGRQ score, ISWT score, serum markers of inflammation 
and sputum markers of inflammation) all correlated with bronchial severity index 
scores and deteriorated from baseline levels when patients experienced an 
exacerbation. Some of these endpoints have already been validated for use in 
bronchiectasis but each have their limitations. 
 
Sputum colour is thought to be useful in assessing severity but it has not been 
validated for use as an endpoint. 24-hour sputum volume is poorly complied and 
therefore often inaccurate and difficult to interpret. Microbial clearance has been 
used to assess response to antibiotic treatment but would not be a suitable endpoint 
in patients that culture mixed normal flora and in those that are unable to 
expectorate. Qualitative analysis is not usually performed in clinical practice and has 
currently only been carried out in phase 2 trials (Serisier et al 2013b). Qualitative or 
quantitative microbial culture takes at least 24 hours to perform so results would not 
be readily available. 
 
Serum inflammatory markers have not been validated for use as endpoints and they 
rely on patients mounting a significant systemic response to infection. As such, it 
may be of limited use in patients that are clinically stable. There has been some 
interest in sputum inflammatory markers such as neutrophil elastase which is 
considered to increase with bacterial load but again, none have been validated for 
use in bronchiectasis as a useful endpoint. 
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Several quality of life questionnaires have been validated for use in bronchiectasis; 
SGRQ, (Wilson et al, 1997b) LCQ (Murray et al, 2009d), Bronchiectasis health 
questionnaire (Spinou et al, 2017) & the Quality of life questionnaire-bronchiectasis 
(QOL-B) (Quittner et al, 2014 & Quittner et al, 2015). These are more subjective 
outcome measures incorporating patient self-assessment and reporting. The 
questionnaires can be cumbersome for the patient to complete and time-consuming 
for the clinician to analyse. 
 
The results in the first two chapters showed some interesting findings with the 
incremental shuttle walk test. This is the only marker of functional capacity tested 
and hence can provide insight into how exacerbations can physically impact on the 
body. In the first chapter, the ISWT correlated well with the BSI, demonstrating 
reducing exercise capacity with increasing severity. In the second chapter, the ISWT 
deteriorated significantly with exacerbation and improved with treatment. In 
addition, a reduction in 5% of ISWT walk distance was associated with a 1 or more 
log unit rise in bacterial count CFU/ml. In this growing field of bronchiectasis 
research more validated clinical endpoints are required to fully assess existing and 
new therapies. Therefore, the third chapter assesses the incremental shuttle walk test 
as a validated clinical endpoint for use in patients with bronchiectasis. 
 
In order to validate the incremental shuttle walk test the reliability, validity, and 
responsiveness of the test were investigated. For reliability, 30 patients completed 
the ISWT 6 months apart when clinically stable. There was no significant change in 
distance walked (390m versus 400m) over 6 months (p=0.48) and a Bland-Altman 
plot showed a mean bias of -1.38m with a calculated intraclass coefficient to be 0.85 
(p<0.001).  
 
Validity was assessed by correlating ISWT distance walked with total and activity 
components of the SGRQ score in 94 patients at three different time points 
(clinically stable, start of exacerbation and end of exacerbation, n=282). There was a 
reduction in ISWT distance walked at start of exacerbation and similarly there was 
an increase in SGRQ scores with exacerbation (the higher the score, the bigger the 
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impairment in quality of life). A Spearman’s correlation between the two indices 
was highly significant, R=-0.60, p<0.0001. Similarly, the correlation between the 
activity component and ISWT distance walked was also highly significant, R= -0.64, 
p<0.0001. 
 
A subset of patients were asked to wear an activity monitor for 1 week n=49. The 
average time spent being active and sedentary per day was recorded and shown to 
moderately correlate with ISWT; physical activity duration (R=0.42, p=0.004) and 
sedentary time (R=-0.48, p=0.0007). Further correlations with other markers of 
disease severity; MRC dyspnoea score (R=-0.59, p<0.0001) and bronchiectasis 
severity index score (R=-0.44, p<0.0001) were strong. 
 
Responsiveness of the ISWT to intravenous, oral and nebulised therapy was 
demonstrated. 30 patients were given intravenous antibiotics for exacerbations of 
bronchiectasis as per the BTS guidelines (Pasteur et al, 2010). The patients showed 
overall clinical improvement and the ISWT improved from 2656m to 335m 
(p=0.004) with an overall median percentage improvement of 11.9% (-3.7 – 38.9%). 
94 patients were treated with oral antibiotics for an exacerbation. The median 
change in distance walked from baseline to start of exacerbation was a significant 
reduction of 40m. After 14 days of oral antibiotics there was a significant median 
improvement in ISWT distance of 50m or 16.3%. 
 
30 patients were previously treated with nebulised gentamicin or placebo (nebulised 
saline) for 12 months (Murray et al, 2011). Reanalysis of the results showed the 
median difference (IQR) for the Gentamicin group was 70m (40 -160m) with a 
percentage median improvement (IQR) of 18.5% (11.1 – 45.7). There was a marked 
improvement in the Gentamicin group compared with the saline group with a mean 
difference of 90.4m (95% CI 40.76 – 140m, p=0.0006) and mean % difference 
34.7% (95% CI 12.56 – 56.79, p=0.003). 
 
The minimum clinical important difference (MCID) has been found to be 35m in a 
small study conducted in patients with bronchiectasis (Lee et al, 2014c). As patients 
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can have different baseline functional exercise capacity, an arbitrary metre distance 
might under-report improvement in those with poor functional reserve and over 
report improvement in patients that have good cardiovascular reserve. A percentage 
improvement would take a patient’s baseline capability into account. A 5% 
improvement in ISWT captured 73% of all patients that responded to some type of 
antibiotic therapy. There was also a higher proportion (62.2%) of patients that had a 
significant (more than 4 unit) improvement in SGRQ score in those that had a 5% or 
more improvement in ISWT.   
 
The minimum clinically important difference was recommended to be a 5% 
improvement in ISWT as this had a moderate ability to predict a 4 or more unit 
improvement in SGRQ score. The ISWT is an objective test of functional capacity 
and a 5% improvement in distance walked has been demonstrated as a validated 
clinical endpoint for use in patients with bronchiectasis. Further studies assessing 
the external validation of a 5% improvement in ISWT would now be necessary 
before this clinical endpoint can be routinely used in clinical practice and research 
studies. 
 
 
 
 
 
 
 
Future work 
This thesis has characterised a cohort of bronchiectasis patients that are usually 
managed as outpatients in their clinically stable state and when unwell with an 
exacerbation of bronchiectasis. All exacerbations were managed as outpatients and 
so the phenotype of outpatient exacerbations including the clinical importance of 
assessing bacterial load in this cohort was further clarified.  
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Quantitative and qualitative microbiology was performed according to conventional 
microbiological culture techniques. DNA sequence based molecular methods have 
identified a complex and diverse polymicrobial community exists in the lungs but 
the clinical implications of such detailed assessment is not completely understood. 
The role of lung microbiota in the pathogenesis and progression of bronchiectasis 
remains poorly understood but this thesis highlights the potential of higher bacterial 
loads in the unstable, exacerbation state for a more severe phenotype of 
exacerbation. Further work examining the implication of higher bacterial loads in 
the stable state in the progression of disease is needed and whether antimicrobial 
therapy would benefit patients with high loads of colonising bacteria. In addition, 
further studies comparing conventional microbiological techniques with molecular 
microbiology techniques including 16S DNA is required to gain a better 
understanding of the comprehensive cross sectional analysis of bacterial isolation 
within the airways.   
 
A 1 log unit rise or more in bacterial load was explored in this thesis as a significant 
increase in bacterial load that is known to have increased airway and systemic 
inflammation, however further work is required to determine the exact threshold of 
change that is clinically important in terms of differentiating, if possible, between 
colonisation and infection and between mild and severe disease.  
 
The implications of bacterial load could be explored even further. Currently, the 
optimum duration of antibiotic treatment is unknown and a 14day course is 
recommended based on expert opinion in the British Thoracic Society guidelines. If, 
lower bacterial loads are predictive of less severe exacerbations, as implied by the 
work in this thesis, then a shorter course of antibiotics may be prudent in those with 
a lesser rise in bacterial load. Randomised controlled trials are required to explore 
this further. 
 
The work contained in this thesis reported a change in dominant pathogen was 
causative of a 1 log unit rise in bacterial load on start of exacerbation. Currently, 
empirical antibiotic treatment for exacerbations is recommended based on any 
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previously available sputum microbiology results. This thesis suggests the way we 
treat exacerbations requires further investigation as empirical antibiotics based on 
previous microbiology might not work in all patients and highlights the importance 
of sending sputum for bacterial culture prior to starting empirical antibiotic therapy 
and of reviewing patients for clinical improvement.  
 
Ultimately, randomised controlled trials assessing different management strategies 
based on quantitative bacterial load and qualitative microbiology results are needed 
and further investigation on inpatients (a more severe cohort) is required to assess 
the translatability of the results presented in this thesis.  
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Abstract 
Introduction: Bronchiectasis is a common condition and is likely to be 
underestimated, as bronchiectasis is now a recognized problem complicating other 
chronic lung diseases such as severe asthma, severe COPD and advanced pulmonary 
fibrosis. In more advanced bronchiectasis there is a vicious cycle of excess 
neutrophilic airways inflammation and chronic infection of the airways. This leads 
to the clinical syndrome including a chronic productive cough and recurrent chest 
infections.  
Areas covered: This review provides an overview of the current pharmacotherapy 
options available and the potential future perspectives for treatment in adult patients 
with idiopathic or post infective bronchiectasis. A PUBMED search for all phase III 
and above trials on current therapies focusing on optimizing airway dilatation and 
treatments to break the vicious cycle of infection and inflammation were sought. 
These therapies include antibiotics, anti-inflammatory and mucoactive therapies 
alongside chest physiotherapy. Landmark phase II studies were also included.    
Expert opinion: Current practice has predominantly been based on treatment advised 
from national guidelines that are mainly grade D expert opinion. Randomised 
controlled trials are greatly needed to improve practice of evidence based medicine. 
 
 
 
Article Highlights 
 
With the advent of CT, bronchiectasis is being increasingly recognized as an 
important clinical condition. 
The treatments recommended depend on disease severity. 
For milder disease, there should be a focus on education, regular chest 
physiotherapy, keeping up to date with influenza and pneumococcal vaccinations 
and receiving prompt antibiotics for infections. 
For more severe patients, the above is essential with the additional consideration 
of a long-term antibiotic and/or a long term anti-inflammatory agent. 
Large randomised controlled trials are needed. 
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Introduction 
Bronchiectasis is a common chronic debilitating respiratory condition1,2. The gold 
standard for diagnosing bronchiectasis is using computed tomography of the chest as 
opposed to the bronchogram. Using modern imaging, the true prevalence is not 
known but we have over 750 patients with clinically significant bronchiectasis 
monitored in secondary care in Edinburgh, UK with a population around 480,000.  
 
There are numerous causes of bronchiectasis with post-infection bronchiectasis 
being the commonest at 29-42% but no cause identified in 30-53% cases3. These can 
both lead to patients having daily cough, sputum production and recurrent chest 
infections3,4.  
 
The pathogenesis of bronchiectasis is poorly understood. Pulmonary pathology 
shows an excess of neutrophilic inflammation but despite this immune response, 
over two thirds of patients remain chronically infected with potential pathogenic 
microorganisms5,6. The driver for persistent neutrophilic airway inflammation in 
bronchiectasis is unknown, but infection is considered to play a major role.6 
Paradoxically, there is failure of clearance of bacteria from the airways and this 
leads to a ‘vicious cycle’ of infection and inflammation in the airways as first 
described by Cole and colleagues4. The neutrophils and bacterial products cause 
structural damage and perpetuate the vicious cycle. Therapies are needed to break 
this vicious cycle and indeed antibiotics and anti-inflammatory agents have the 
potential for this. The goals of treatment in this chronic condition are to reduce 
cough and sputum volume, reduce sputum purulence, reduce the number of chest 
infections and improve the health related quality of life. 
 
This review will provide an overview on current pharmacotherapy and future 
perspectives in adult patients with clinically significant idiopathic and post infection 
bronchiectasis alone, as the management is the same. The review, however, does not 
cover the treatment of bronchiectasis due to active allergic bronchopulmonary 
aspergillosis, active sarcoid, cystic fibrosis and immunoglobulin deficiencies, which 
have their own disease specific treatments. We have included phase III and IV 
studies but where little evidence is available important phase II studies have also 
been included.  
 
1. Antibiotics in exacerbations - Table 1 
1.1 Role of oral antibiotics in exacerbations 
When patients present with exacerbations, the British Thoracic Society (BTS) 
recommend sending sputum for bacteriological analysis but to start empirical 
antibiotics immediately3. The antibiotic recommended should be based on prior 
sputum microbiology but if no previous history is available, empirical amoxicillin 
(or clarithromycin in cases of penicillin allergy) should be started in addition to 
other supportive therapy. Antibiotics can be modified if patients fail to respond and 
this should be based on the pathogen isolated and the antimicrobial sensitivities. 
These recommendations are based predominantly on expert opinion (grade D) 3. 
 270 
 
The evidence for oral antibiotic use in exacerbations is lacking, and even more so is 
the evidence for any particular agent. This may be due to the fact administration of 
antibiotics is so routine in treating chest infections. The length of optimal antibiotic 
treatment is still unknown and the British Thoracic Society recommend 14 days of 
antibiotics based on grade D evidence3. Below, we have presented some of the 
studies where oral antibiotics have been studied in bronchiectasis that could 
potentially guide management. 
 
In an open labelled study, Hill et al investigated the response to oral antibiotics 
based on sputum purulence7. Antibiotics were given for exacerbations or in stable 
patients with intermittent mucopurulent or purulent sputum or in patients with 
persistent purulent sputum. All patients with mucoid (N=7) or mucopurulent (N=7) 
sputum had improved sputum purulence and/or clinical improvement when treated 
for an exacerbation with low dose amoxicillin 250mg t.d.s for 14 days, compared to 
16% in those with persistently purulent sputum (N=19). Of those that had treatment 
failure, 58% then responded to high dose amoxicillin 3g b.d for 14 days. This study 
demonstrates that higher doses of prolonged antibiotics may be needed for patients 
with more severe bronchiectasis.  
 
Chan et al investigated the use of ciprofloxacin versus amoxicillin in a randomised 
double blind trial with 42 patients8. Over a 7 day period they showed ciprofloxacin 
to have a better clinical response with reduced sputum volume, reduced purulence 
and higher bacterial eradication. Lam et al showed similar results with ofloxacin 
versus amoxicillin over 10 days with better microbiological clearance and clinical 
response with ofloxacin9. These cohorts of patients had Pseudomonas aeruginosa in 
41% and up to 32% respectively in the baseline sputum microbiology and further 
confirms the need for targeted antibiotic use. 
 
1.2 Is there an additional role for inhaled antibiotics in exacerbations? 
Traditionally exacerbations are treated with oral or intravenous antibiotics. The 
study by Bilton and colleagues studied the effect of adding nebulised tobramycin to 
a 2 week course of oral ciprofloxacin for exacerbations of bronchiectasis due to 
Pseudomonas aeruginosa10. This double blind randomised controlled trial of 53 
patients showed those treated concomitantly with inhaled tobramycin had a 
statistically significant reduction in bacterial density at day 7, which was maintained 
at day 14. There was however, no difference in clinical outcomes at day 14 (end of 
antibiotic treatment) and day 21 (one week after antibiotic treatment finished). 
Adverse events were common in both treatment arms with 22/26 in the 
tobramycin/ciprofloxacin arm and 26/27 in the placebo/ciprofloxacin arm reporting 
adverse events including wheeze, cough, dyspnoea, headache, fatigue and nausea. 
Only wheeze was reported at higher frequency in the tobramycin/ciprofloxacin arm 
with 24% of patients affected, compared to none in the placebo group. The wheeze 
did not seem to be predicted by the measurement of acute changes in FEV1 
measured 30mins post initial treatment and there was no significant difference in 
FEV1 between the two groups at day 7 and day 14. In view that there was no added 
efficacy with nebulized tobramycin and there were more side effects, this study does 
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not support the routine addition of nebulized tobramycin for treatment of 
exacerbations due to Pseudomonas aeruginosa. 
 
1.3 Role of intravenous antibiotics in exacerbations  
There have only been limited studies in bronchiectasis exploring the efficacy of 
intravenous antibiotic therapy. As such the following recommendations by the BTS 
are based on grade D evidence only: Intravenous antibiotics should be considered if 
the patient is unwell and requires hospital admission, if resistant organisms are not 
responsive to oral antibiotics or if patients fail to respond to oral therapy (usually in 
patients infected with Pseudomonas aeruginosa or other enteric Gram-negative 
organisms)3.  
 
Tsang et al compared a 10 day course of oral levofloxacin with intravenous 
ceftazidime. They showed significant improvement in bacterial eradication rates, 
sputum volume, purulence, cough and dyspnoea scores in both groups11.  
 
As further evidence in bronchiectasis is lacking, we looked at trials conducted in 
large cohorts of patients that had bronchiectasis amongst other respiratory 
conditions. Brambilla et al studied lower respiratory tract infections (mainly patients 
with a pneumonia or exacerbation of chronic bronchitis and bronchiectasis), which 
showed similar clinical response rates to parenteral therapy with either co-amoxiclav 
or cefuroxime12. Both drugs had similar rates of clearance in sputum microbiology 
and adverse reaction rates. Mehta et al conducted a comparative study in patients 
with lower respiratory tract infections, of which 59% of the cohort had 
bronchiectasis13. They showed oral amoxicillin, oral co-amoxiclav and intravenous 
co-amoxiclav to have similar clinical and radiological improvement but co-
amoxiclav to be superior in clearing bacteria from sputum (45% with co-amoxiclav 
vs. 8% with amoxicillin). 
 
Overall there is a lack of trials exploring intravenous therapy in bronchiectasis. It 
seems pragmatic to follow the BTS guidelines3. Further studies are needed to 
explore which patients would benefit from intravenous as opposed to oral 
antibiotics, which intravenous agents to use and the optimal duration. 
 
2.  Stable state therapy 
2.1 Role of airway bronchodilators 
Airflow obstruction is frequently observed in bronchiectasis. Approximately 30% of 
patients with bronchiectasis have concomitant asthma or chronic obstructive 
pulmonary disease (COPD) and the role of b2 agonist (both short and long acting) 
and anticholinergic therapy have been well described in these conditions. There are 
no randomised controlled trials that have investigated the effect of short and long 
acting b2 agonists or anticholinergics in bronchiectasis14-16.  
 
Abu Hassan et al studied 24 bronchiectasis patients (asthmatic patients were 
excluded)14. Patients were given inhaled fenoterol 400micrograms by metered dose 
inhaler (MDI). Lung function was assessed at baseline and 30 minutes after 
inhalation. Patients were then given fenoterol 5mg via nebuliser and repeat lung 
function was repeated 30 minutes later. The study was repeated 24 hours later with 
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ipratropium bromide 40micrograms by MDI and with ipratropium bromide 
500micrograms via nebuliser. 45.8% patients responded to one or both 
bronchodilators (>15% improvement in FEV1), 12% responded to fenoterol alone 
and 12% to ipratropium alone14.  
 
In the stable state, regarding bronchodilator therapy, the BTS guidelines recommend 
assessment for airway obstruction and reversibility in all patients3. Inhaled therapy 
should be instituted when symptoms or lung function improves on b2 agonist and/or 
anti-cholinergic therapy. Randomised controlled trials are needed to further assess 
the role of long term long acting b2 agonists and anticholinergics in bronchiectasis. 
 
2.2 Role of mucoactive therapies 
Regular chest clearance is regarded as key for all patients with clinically significant 
bronchiectasis3. To aid this, there has been interest in treatments that improve 
mucociliary clearance and sputum expectoration. Hypertonic saline, mannitol, 
carbocysteine and DNase are the most studied agents but there are limited phase III 
trials in non-cystic fibrosis bronchiectasis patients.   
 
Hypertonic saline and mannitol are hyperosmolar agents that improve airway 
hydration by inducing a liquid flux to the airway surface. This in turn helps to 
mobilise sputum.  
 
In a small study by Kellett et al 24 patients were randomised to one of the 4 arms: 1) 
active cycle breathing technique (ACBT), 2) nebulised terbutaline and ACBT, 3) 
nebulised terbutaline, nebulised isotonic saline then ACBT and 4) nebulised 
terbutaline, nebulised hypertonic saline then ACBT17. They described improved ease 
of sputum expectoration, reduced sputum viscosity and a small improvement in lung 
function with the use of inhaled hypertonic saline (7%).  More recently Kellett et al 
conducted a small randomised single blind trial of 28 patients where patients were 
given either nebulised 7% hypertonic saline or 0.9% isotonic saline for 3 months18. 
They reported those treated with hypertonic saline had a significant increase in 
FEV1 by 15% from baseline compared to an increase of 1.8% with 0.9% isotonic 
saline (p<0.01). There was a significant (p<0.05) improvement in the quality of life 
of patients as assessed by the St George’s Respiratory Questionnaire (SGRQ).  
 
A randomised controlled trial by Nicolson et al investigated the effects of inhaling 
6% hypertonic saline on quality of life and respiratory function19. 40 patients were 
randomised to receiving either 6% hypertonic saline (HTS) or 0.9% isotonic saline 
(IS) once daily for 12 months. They found both groups to demonstrate similar 
significant improvements in quality of life (as assessed by SGRQ), significant 
improvement in FEV1 and FEF25-75 for both groups at 6 months but this was not 
sustained at 12 months for FEV1. There was a significant reduction in sputum 
colonisation from 60% in the IS group and 55% of HTS group at baseline to 15% in 
both groups at 12 months. There was no difference between the groups in any of the 
endpoints including exacerbation frequency. There were 3 adverse events in the 
HTS group (chest tightness due to underlying exacerbation, transient hypertension 
not requiring treatment and fast atrial fibrillation) with only 1 patient electing to 
cease treatment. There were no adverse events in the IS group. Larger randomized 
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controlled studies are needed before the routine use of hypertonic saline can be 
advocated. 
 
A Cochrane review on the use of mannitol in bronchiectasis identified only 2 small 
randomised studies and several non-randomised studies20. Daviskas et al reported 
doubling of tracheobronchial clearance 75 minutes after inhalation of 400mg 
mannitol when compared with coughing and inspiratory manoeuvres alone21. Lung 
function did not significantly change and mannitol was well tolerated despite the 
induction of cough22-24. An optimum dose of 480mg of mannitol induced most 
sputum clearance but must be administered twice daily in order to achieve sustained 
effects23. Quality of life was improved by a reduction of 12.4units in the SGRQ 
(four units being the minimal clinically important difference) 24. 
 
More recently a phase III randomised study was conducted by Bilton et al to assess 
the efficacy and safety of dry powdered mannitol25. Patients were randomised to 
inhale 320mg mannitol (n=231) or placebo (n=112) twice daily for 12 weeks. The 
mannitol treated group reported improved sputum expectoration and in a subgroup 
study (n=82) mannitol subjects showed less small airway mucus plugging on HRCT 
at 12 weeks compared to placebo (p=0.048). There was no statistical difference 
between the groups (p = 0.304) for total SGRQ score - Mannitol -3.4 points (95% 
CI: -4.81 to -1.94) versus placebo -2.1 points (95% CI: -4.12 to -0.09)). Compliance 
rates were high and mannitol was well tolerated with similar adverse events to 
placebo. A larger controlled study is now required to investigate the long-term 
effects of mannitol on pulmonary exacerbations and antibiotic use. 
 
Mucolytics such as DNase, carbocysteine and bromhexine have also been 
investigated to enhance mucociliary clearance by changing the physiochemical 
properties of sputum. This reduction in sputum viscosity should allow easier 
mobilisation. A Cochrane review identified only 3 studies (described below) 
assessing mucolytics in bronchiectasis patients26. Mucolytics remain a promising 
prospect for treatment but randomised controlled data is lacking to support any 
recommendations for regular use.  
 
The first study by Olivieri et al, assessed bromhexine 30mg t.d.s versus placebo27. 
They noted an improvement in ‘difficulty in expectoration’, an increase in sputum 
production and a significant reduction in cough. There was no change in lung 
function. Wills et al conducted a double blind randomised control trial studying 
human recombinant DNase (rhDNase) 2.5mg twice daily, 2.5mg once daily, placebo 
twice daily or placebo once daily in 21 patients with bronchiectasis28. They failed to 
show any improvement in lung function, dyspnoea or quality of life at the higher 
dose but did report a significant improvement in dyspnoea with low dose rhDNase. 
Influenza-like symptoms were reported in 4 subjects randomised to high dose 
rhDNase. O’Donnell et al conducted a large double blind randomised control trial 
investigating rhDNase versus placebo twice daily for 24 weeks in 349 patients29. 
The authors reported a significant increase in protocol derived and non-protocol 
derived exacerbation rates when compared with placebo. They also reported a 
significant reduction in FEV1 compared with placebo (FEV1 decline -3.7% change 
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vs  -1.7% in placebo    group) and as a consequence of this trial DNase is not 
recommended in the treatment of bronchiectasis3.  
 
2.3 Role of corticosteroids - Table 2 
Oral steroids have long since been used in difficult to treat asthma by limiting local 
and systemic inflammation. There are currently no randomised controlled studies 
that have investigated the role of oral corticosteroids in bronchiectasis. 
 
A Cochrane review identified limited studies for the use of inhaled corticosteroids in 
bronchiectasis30. Tsang et al demonstrated in a double-blind placebo controlled trial 
that 4 weeks of inhaled corticosteroids (ICS) reduce sputum inflammatory markers 
Interleukin (IL)-1, IL-8, leukotriene (LT)B4 and total neutrophil count31. There was 
no reduction in exacerbation frequency, sputum volume, bacterial density or lung 
function. A further study by the same group randomized 86 patients to inhaled 
fluticasone or placebo for 12 months and showed a statistically significant reduction 
(20%) in sputum volume in those receiving inhaled fluticasone and in a sub analysis 
there appeared to be a particular benefit to patients colonised with Pseudomonas 
aeruginosa32 .  
 
Elborn et al conducted a small placebo controlled double blind 6 week crossover 
study examining inhaled beclometasone diproprionate33. They showed a significant 
reduction (18%) in sputum volume and small improvements in FEV1 and peak 
expiratory flow rates. The clinical significance of this small improvement in FEV1 
and peak flow rates is unknown. Martinez et al showed that the use of high dose ICS 
over 6 months improved quality of life in bronchiectatic patients34.  
 
Combination therapy with inhaled corticosteroid and long acting b2 agonists may 
also have a role in bronchiectasis. Martinez-Garcia et al showed combination 
therapy with budesonide-formoterol inhalers was more efficacious than high dose 
budesonide alone. The double blind randomised study reported statistically 
significant improvement in symptoms and health related quality of life in the 
combination group. In addition, there were fewer side effects with combination 
therapy, especially those associated with inhaled steroids35. 
 
The above studies suggest inhaled corticosteroids reduce sputum volume and 
improve health related quality of life. The studies however have not proven whether 
long term treatment has any impact on exacerbations. In addition, there have been 
concerns about the long-term use of inhaled corticosteroids in patients with COPD 
with regards to pneumonia risk36. Before advocating long term treatments, the 
benefits must outweigh the potential risks. At this current time, the routine use 
cannot be recommended3. Large randomized controlled studies are needed. 
 
2.4 Other potential anti-inflammatory treatments 
2.4.1 NSAIDS: There are no randomised controlled trials assessing the efficacy of 
oral NSAIDS in bronchiectasis. A Cochrane review identified only 1 small 
randomised double blinded controlled study comparing inhaled indomethacin 
2.4micrograms, t.d.s for 14 days in 25 patients with chronic lung disease (8 
bronchiectasis, 12 chronic bronchitis and 5 diffuse panbronchiolitis) with 
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placebo37,38. Results showed an improvement in the amount of sputum production 
and dyspnoea as assessed by the Borg’s score but no change in lung function. 
Another small study of 9 stable bronchiectasis patients included the treatment of 4 
weeks of oral indomethacin therapy (25mg, t.d.s). Analysis showed marked 
reduction in peripheral blood neutrophil function with reduced chemotaxis and 
fibronectin degradation but no change in airway bacterial load or sputum 
chemotaxis39. Larger randomised controlled trials are needed to assess the use of 
NSAIDs as potential anti-inflammatory agents before they can be considered for 
routine treatment. 
 
2.4.2 Statins: Statins are widely used in cardiovascular disease and have been 
shown to be associated with a 41% reduction in 30-day mortality in patients 
hospitalized with seasonal influenza40. One of the pleotropic effects of statins is their 
anti-inflammatory property, which could have a role as a novel, non-antibiotic 
treatment in bronchiectasis. There are no randomised controlled trials that have been 
conducted evaluating their routine use in bronchiectasis but this could be a potential 
anti-inflammatory therapy for the future. 
 
2.4.3 Others: Because of the excess neutrophil burden in bronchiectasis, future 
studies are needed to assess novel therapies such as neutrophil elastase (NE) 
inhibitors and tumour necrosis factor alpha (TNFa) inhibitors but to date there has 
only been one small study on neutrophil elastase inhibitors and none in TNFa 
inhibitors.  
 
Stockley et al randomised 40 patients to receiving NE inhibitor AZD9668 60mg, 
b.d. (n=22) or placebo (n=16) for 4 weeks41. They reported a significant 
improvement in FEV1 of 100mls, slow vital capacity, plasma interleukin 8 and post 
waking sputum interleukin 6. There was no significant improvement in quality of 
life, sputum weight or other lung function tests in the treatment group. AZD9668 
seemed to be well tolerated with fewer adverse events reported than in the placebo 
arm. The most common complaint in the treatment arm was of headache 7/22 
compared with 2/16 in the placebo arm. These results are encouraging but larger 
studies of longer duration are needed. 
 
2.5 Role of antibiotics in the stable state 
2.5.1 Role of long-term oral antibiotics  
Studies have shown that recurrent exacerbations lead to a poorer quality of life in 
bronchiectasis. One of the key aims of management of bronchiectasis is improving 
quality of life in these patients. Several studies have investigated long term 
antibiotic therapy in stable patients with the aim of reducing exacerbation frequency 
and thereby improving quality of life.  
 
The key studies investigating long term oral antibiotics are outlined in Table 3. In 
the infancy of this condition, randomised controlled trials assessed the impact of 
long-term tetracyclines and penicillins. The Medical Research Council42 conducted 
a randomised controlled trial of 122 patients over the course of a year. Patients were 
randomised to 2g penicillin, 2g tetracycline or 2g lactulose (placebo). Findings 
reported tetracyclines to be more effective than penicillin in reducing symptoms and 
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sputum volume with less days confined to bed and less days off work. A further 
randomised trial by Sobel and colleagues assessed for adverse reactions with long-
term antibiotics and found 27% of patients treated with tetracyclines developed side 
effects and predominantly diarrhoea43. 
 
Cherniack and colleagues assessed the long-term impact of 2g oral tetracycline/day 
vs. 1g oral penicillin/day vs. 2g oral oleandomycin/penicillin combination vs. 
placebo over a period of at least 3 months (extending up to 22months) on 
exacerbation frequency in patients with chronic bronchitis and bronchiectasis44. 
They reported fewer lower respiratory tract illnesses with tetracyclines compared to 
either placebo or penicillin alone and that penicillin alone was not more effective 
than placebo. The combination treatment was also better at reducing exacerbation 
frequency than placebo. A similar study by Dowling and colleagues assessing the 
effect of the same 4 arms on sputum microbiology over a period of at least 3 months 
(extending up to 31 months) showed that whilst tetracyclines reduced the presence 
of H. influenzae, S. pneumoniae and S. aureus there was an increase in 
Pseudomonas species45. 
 
Currie et al showed a reduction in exacerbation severity, but not frequency, with 
high dose amoxicillin (3g, b.d) administered over a 32 week period when compared 
with placebo46. They also reported a reduction in sputum purulence, volume and less 
time confined to bed or off work. 
 
Whilst these studies are old, we thought it prudent to include them here, as there has 
been increasing use of simpler antibiotics such as amoxicillin and doxycycline in 
clinical practice. In addition, there is a lack of randomised controlled trial data on 
non-macrolide antibiotics in stable bronchiectasis. 
 
2.5.2 Role of macrolide therapy - Table 4 
In addition to antibacterial properties, macrolides are thought to have 
immunomodulatory and anti-inflammatory properties. Over recent years, several 
studies have been done assessing the role of long term macrolides in stable 
bronchiectasis. Here we outline the key trials and summarise them in Table 4. 
 
Tsang et al performed a randomised double blind placebo controlled study showing 
an improvement in lung function and sputum volume reduction in patients treated 
with 8 weeks of 500mg b.d erythromycin47. It did not show a difference in microbial 
load or inflammatory markers but the majority of patients were colonised with 
Pseudomonas aeruginosa. 
 
Wong et al confirmed these findings in the Effectiveness of Macrolides in patients 
with Bronchiectasis using Azithromycin to control Exacerbations (EMBRACE) 
trial48. This was a randomised double-blind placebo controlled trial of 141 patients 
randomised to either taking azithromycin 500mg three times a week or placebo for 6 
months. They showed a significant reduction in the rate of event-based exacerbation 
from 1.57 in the placebo group to 0.59 with the azithromycin group.  There was no 
statistically significant difference in lung function or quality of life. Macrolide 
resistance testing was not routinely undertaken in this study but 4% in the 
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azithromycin group had macrolide resistant Streptococcus pneumoniae at 6 months. 
 
More recently the Bronchiectasis and long term Azithromycin Treatment (BAT) 
study in 83 bronchiectasis patients with 3 or more exacerbations in the past year 
were randomised to either 250mg azithromycin once daily or placebo for 1 year49. 
Results showed a significant decrease in exacerbation frequency in the azithromycin 
group with a longer time to first exacerbation during treatment. FEV1 and FVC 
improved with azithromycin, as did quality of life as assessed by SGRQ. Sputum 
microbiology was similar at baseline and at 1 year but macrolide resistance was 
recorded in 88% of the isolates tested compared with 26% in the placebo group. 
Adverse reactions were reported, mainly gastrointestinal symptoms, but these were 
not severe enough to discontinue treatment. 
 
The Bronchiectasis and Low dose Erythromycin Study (BLESS) investigated the 
effect on exacerbations rates and resistance rates post 1-year therapy with low dose 
erythromycin50. Patients were randomised to low dose erythromycin or placebo for 
48 weeks. Results showed a significant reduction in exacerbation frequency, 
reduced FEV1 decline but an increase in macrolide resistance. Erythromycin was 
well tolerated without any evidence of significant adverse effects. In the literature, 
there is evidence of increased risk of cardiac death due to prolonged QTc and 
arrthymias with the use of macrolides51. However, no difference in QTc values or 
arrthymias was found at this low dose, in the BLESS trial. Erythromycin increased 
the proportion of macrolide resistant oropharyngeal streptococci. 
The potential long term use of macrolides is discussed in the expert opinion section. 
2.6.3 Role of long term inhaled antibiotics 
Nebulised antibiotic therapies target the airways directly and should thereby reduce 
systemic side effects. Several studies have investigated the role of long term 
nebulised antibiotics in the stable state and are summarized below. These key 
studies are also listed in Table 5. 
 
The initial proof of concept study by Lin et al showed the acute efficacy of inhaled 
gentamicin over 3 days and led the way for long term antibiotics studies in the stable 
state52. They assessed the effect of inhaled gentamicin on airway neutrophil activity 
and mucus hypersecretion in 28 stable patients with bronchiectasis. Patients were 
randomised to inhaled gentamicin 40mg b.d or 0.45% saline bd. No baseline 
microbiology was recorded. In the gentamicin arm, they reported reduced sputum 
myeloperoxidase, reduced bacterial load and sputum volume. In addition, they 
reported improved breathlessness, exercise tolerance and peak expiratory flow rates.  
 
Barker et al administered nebulised tobramycin 300mg b.d versus placebo to 
patients colonised with Pseudomonas aeruginosa53. There was a significant 
reduction in bacterial density at week 4 and eradication in 35% of patients at week 6 
(2 weeks after completing treatment). However, 70% of patients in the tobramycin 
arm reported respiratory side effects compared to 51% of placebo patients. Of the 
adverse effects reported in the tobramycin arm, 12 out of the 15 that reported 
increased cough, 3 out of the 6 that reported wheeze, 3 out of the 7 that reported 
chest pain, 3 out of the 12 that reported breathlessness adverse effects were thought 
to be due to the tobramycin itself. 
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Recently, Wilson and colleagues studied the effects of inhaled ciprofloxacin dry 
powder for inhalation (DPI) 32.5mg twice daily versus placebo for 28 days in a 
randomised double-blind study54. Their primary end point of bacterial load showed a 
reduction in sputum bacterial load in treatment arm patients at day 28 but that 
bacterial counts increased thereafter in the 56 day follow up. The treatment was well 
tolerated as only 3 out of the 60 recruited patients in the treatment arm reported 
bronchospasm, 0 out of 60 reported cough and 1 out of 60 reported haemoptysis.    
 
To investigate nebulised therapy as a longer-term therapy Drobnic et al administered 
nebulised tobramycin 300mg b.d in a randomised trial over 6 months55. They found 
a significant reduction in number and length of hospital admissions, reduced 
bacterial density and no increase in bacterial resistance. No difference in 
exacerbation frequency, lung function or quality of life (QofL) was detected and 
bronchospasm was reported in 10% of patients. 
 
Serisier and colleagues conducted a multicentre phase II double-blind placebo-
controlled randomised trial assessing the effects of regular intermittent treatment 
with dual release ciprofloxacin for inhalation (DRCFI) containing liposomal 
ciprofloxacin, in a subset of bronchiectasis patients infected with Pseudomonas 
aeruginosa56. Patients received 3 treatment cycles of 28 days on and then 28 days 
off treatment (liposomal ciprofloxacin versus placebo). They reported a significant 
reduction in bacterial count on day 28 when compared with placebo and also 
reported bacterial counts trended back up to baseline during treatment off periods 
but only 1/22 patient in the placebo group and 5/20 patients in the treatment group 
finished the 3 cycle trial. There was a significant delayed time to first exacerbation 
but only in a per protocol analysis. Systemic adverse events were similar in both 
arms but pulmonary adverse events were lower in the DRCFI group.  
 
Similarly, Orriols et al showed treatment with nebulised therapy (ceftazidime and 
tobramycin) over 1 year was effective in reducing hospital admissions and length of 
hospital stay with no increase in antibiotic resistance57.  Murray et al conducted a 
randomised trial investigating the use of long term nebulised gentamicin 80mg twice 
daily vs. 0.9% saline in bronchiectatic patients irrespective of baseline 
microbiology58. The researchers were blinded but patients were not. Main study 
findings were a reduction in bacterial density, reduced sputum purulence, greater 
exercise capacity and fewer exacerbations. Time to first exacerbation was also 
increased and there was an improvement in cough and quality of life as assessed by 
Leicester Cough Questionnaire and St George’s Respiratory Questionnaire 
respectively. 30.8% eradication in those with Pseudomonas infection and 92.8% 
eradication in those infected with other pathogens was reported. All markers 
returned to baseline 3 months post cessation of treatment suggesting the need for 
continuous therapy or less than 3 months off therapy for sustained efficacy. 
 
The potential long term use of inhaled antibiotics is discussed in the expert opinion 
section. 
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3.  Conclusions 
There is a distinct lack of randomised controlled trials in this common chronic 
condition. Considering this, many of the recommended treatments are based on 
expert guidance. In clinical practice the mainstay of treatment is airways chest 
clearance using chest physiotherapy, optimizing the airways with short and long 
acting bronchodilators +/- inhaled corticosteroid, preventing exacerbations (with 
vaccinations and consideration of a long-term antibiotic) and prompt treatment of 
exacerbations. Future studies are needed to improve the evidence of the role of 
existing and new therapies.  
 
4. Expert opinion and future perspectives 
Bronchiectasis was first described in 1819 and despite this the field has been 
hampered by the lack of randomised controlled trials. In a PUBMED search October 
2013 there were 151 randomised controlled trials in bronchiectasis compared with 
5,754 in lung cancer. In light of this, the recommendations regarding treatment are 
largely based on expert opinion. 
 
There is a spectrum of severity in bronchiectasis. In mild bronchiectasis patients can 
be asymptomatic, are not normally chronically colonised when clinically stable, 
have no pathogens in their sputum, have infrequent chest infections (fewer than 
three annually) and mild radiological bronchiectasis. In severe bronchiectasis 
patients are chronically colonised when clinically stable usually with Pseudomonas 
aeruginosa, other enteric gram negative pathogens or Methicillin Resistant 
Staphylococcus aureus, have frequent chest infections (three or more annually) and 
advanced radiological changes with varicose and cystic bronchiectasis3. 
 
This review identifies the current and relevant evidence to guide treatment for 
idiopathic and post-infection bronchiectasis. The treatment goals for clinically 
significant disease include the reduction of cough, sputum volume, sputum 
purulence, number of chest infections and to improve quality of life. The treatment 
differs depending on the severity of disease. The emphasis for milder patients 
concentrates on education, regular chest physiotherapy, keeping up to date with 
influenza and pneumococcal vaccinations and receiving prompt antibiotics for 
infections. For more severe patients, the above is essential with the additional 
consideration of a long-term antibiotic and/or a long term anti-inflammatory agent. 
 
Patients have permanently damaged airways and are prone to having a cough, 
sputum production and recurrent chest infections. There is reasonable consensus that 
antibiotics are required for exacerbations when patients feel a deterioration 
associated with increased sputum volume and purulence. The commonest 
pathogenic organisms are Haemophilus influenzae, Pseudomonas aeruginosa, 
Staphylococcus aureus, Moraxella Catarrhalis and Streptococcus pneumoniae5,6. 
The concept of targeting antibiotics based on the pathogen isolated from sputum 
bacterial culture is sound and will ensure that appropriate antibiotics are given to 
cover the suspected pathogen. It will also allow simplifying antibiotic choice rather 
than using broader spectrum antibiotics for all exacerbations. The British Thoracic 
Society Guidelines recommend 14 days of antibiotics for all exacerbations3. This is 
based on the hypothesis that patients with damaged airways and increased bacterial 
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load require a higher dose and prolonged course of antibiotics to clear an infection. 
Whilst this hypothesis in general is sound, there is a wide spectrum of severity of 
bronchiectasis. Whilst 14 days is pragmatic for more severe exacerbations, a shorter 
course such as 7 days, will likely be effective for milder cases of bronchiectasis. 
Randomised controlled trials are needed to assess the optimum duration of 
antibiotics in mild, moderate and severe bronchiectasis.  
 
The current mode of delivery seems pragmatic- for exacerbations to start off with 
oral antibiotics and to consider intravenous antibiotics if patients are ill and require 
hospital admission, have pathogens resistant to oral antibiotics or have failed to 
respond to an appropriate course of oral antibiotics. The addition of inhaled 
antibiotics to oral antibiotics in the short term did not improve outcomes and led to 
more adverse effects10 and currently is therefore not routinely recommended. Future 
studies addressing whether inhaled antibiotics are additive to intravenous antibiotics 
needs further study and would be of potential benefit in patients with more severe 
bronchiectasis with drug resistant pathogens.  
    
There is some controversy whether to prescribe antibiotics if patients present with a 
viral exacerbation. Patients will often describe starting with a viral infection, which 
subsequently leads to a secondary bacterial infection. Whilst no studies have been 
conducted in bronchiectasis, a recent study performed in both COPD subjects and 
healthy volunteers showed an increase in bacterial burden in the COPD cohort only 
(16% rise in proteobacterial sequences, most notably in Haemophilus influenzae 
from baseline) after inoculation with rhinovirus59. This may be of relevance in 
bronchiectasis also and studies are needed to investigate if viruses alter the 
respiratory microbiome and whether early intervention with antibiotics can reduce 
these secondary bacterial infections or not. In clinical practice, we tend to advise 
patients to keep rescue antibiotics at home and if there is increased sputum volume 
and purulence to start antibiotic therapy at that stage.  
 
Reducing respiratory tract infections is important to reduce the burden of disease. 
Although there is a lack of randomised controlled trials all patients should receive 
the annual influenza vaccination and the pneumococcal vaccination, which may be 
repeated every 5 years3. Another clear recommendation is to advise patients to avoid 
contact, if possible, with people known to have the cold or flu.  
 
The first line therapy for bronchiectasis is to educate the patient about their 
condition. They should know when and how to perform chest physiotherapy and 
when to seek medical help for an infection. There is a national standard that has 
been written for bronchiectasis and this recommends that all patients should see a 
dedicated respiratory physiotherapist and to be taught airway clearance techniques60. 
The standard technique used in current day practice is the acute cycle breathing 
technique (ACBT). There are many other techniques available and another 
commonly used technique is autogenic and postural drainage. Sometimes positive 
expiratory airway pressure devices such as the acapella or flutter valve are used to 
aid sputum clearance. Despite the lack of randomised controlled trials in 
bronchiectasis, there is clear scientific rationale to clear the purulent secretions from 
the airways, which will improve symptoms but may also reduce the incidence of 
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respiratory tract infections. In mild disease, this may only need to be done during 
respiratory tract infections but in patients with severe disease, patients should do this 
at least twice daily.  
 
There has been increasing interest in airway adjuncts to promote airways clearance. 
Large multi-centred randomised controlled trials are needed but there is encouraging 
data that suggests both hypertonic saline and mannitol may promote airway 
clearance17,18,19,25. We do however need studies to show if these treatments can 
ultimately reduce exacerbations. The study investigating DNase by O’Donnell et al, 
is an important landmark study showing that DNase was harmful in bronchiectasis 
and caused increased exacerbations and an accelerated decline in lung function29. 
This was a key study showing that we cannot just adopt treatments that work for 
cystic fibrosis in patients with bronchiectasis. 
    
In addition to chest clearance, patients with bronchiectasis with airflow limitation 
and breathlessness should have a trial of short and long acting bronchodilators. 
Further studies are needed to address which patients may benefit from inhaled 
corticosteroids, as both reducing sputum volume and improving health status are 
important31-35. The studies however have not proven whether long term treatment 
has any impact on exacerbations. In addition, there have been concerns about the 
long-term use of inhaled corticosteroids in patients with COPD with regards to 
pneumonia risk36. Before advocating long term treatments, the benefits must 
outweigh the potential risks. At this current time, the routine use cannot be 
recommended except if there was co-existent asthma or significant COPD3. Large 
randomized controlled studies are needed and in addition, further research is needed 
to address whether inhaled corticosteroids are additive to long term antibiotic and 
mucoactive therapy.  
    
There has been a growing interest in newer therapies for bronchiectasis to break the 
‘vicious cycle’. These include anti-inflammatory and anti-infective therapies. It is 
likely such treatments are not needed for patients with mild bronchiectasis who have 
few symptoms when clinically stable and have few chest infections. The largest anti-
inflammatory therapies studied to date are the macrolides. There is however debate 
whether macrolides are anti-infective, anti-inflammatory or both. There are three 
randomised controlled studies using macrolide therapy for 6 months up to one year. 
All three studies showed in comparison to placebo, macrolide therapy reduced 
exacerbations48-50. It is clear that it was not dependent on the macrolide chosen or 
the frequency of delivery. Reducing exacerbations is key to improving the morbidity 
of bronchiectasis and these studies support the long-term use of macrolides. There 
are however concerns with macrolides concerning their toxicity in a middle age and 
elderly cohort. The concerns are the risk of non-tuberculous mycobacteria, 
cardiovascular mortality and pneumococcal resistance to macrolides61,62. In 
bronchiectasis, macrolide resistance in this group would make the treatment of non-
tuberculous mycobacteria very difficult to treat. This is of major concern because 
non-tuberculous mycobacteria are isolated in 5-10% of cases in Europe but 30-40% 
cases in the US61,62. Recent reviews have shown that macrolide use can increase 
cardiovascular mortality, which would be concern to a middle and elderly aged 
cohort51,63. It has been shown in these studies that there is a significant increase in 
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pneumococcal resistance to macrolides49,50. It is not known however whether this 
has any clinical significance. In the studies to date up to one year, these have not 
been of any clinical significance.  
    
There are many potential new anti-inflammatory treatments in bronchiectasis. The 
aetiology of bronchiectasis is poorly understood and in over 50% there is no 
identified aetiology3. There is growing interest in assessing whether channelopathies 
including CFTR are implicated in bronchiectasis. If identified, this offers a potential 
novel new treatment target. There are a whole host of potential new anti-
inflammatory treatments but in our opinion the following targets would be an 
excellent start. These include airway anti-inflammatories such as inhaled anti-
elastase therapy, alpha-1-antitrypsin or secretory leukoprotease inhibitor, targets to 
reduce neutrophil recruitment such as monoclonal antibodies against interleukin 8, 
leukotriene B4 and C5a, pro-resolution treatments such as lipoxins and resolvins, 
and systemic anti-inflammatory therapies such as statins or anti-tumour necrosis 
factor alpha blockers.       
   
Long term oral antibiotics have been proposed as a treatment for patients with three 
or more exacerbations annually despite other therapy3. These are suitable 
particularly in patients colonised with potential pathogenic organisms, for example 
Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis, 
which have multiple suitable oral antibiotic preparations. In patients with recurrent 
exacerbations a long term oral antibiotic may reduce the bacterial burden and 
improve outcomes42,44,46. The major limiting factor is that such long-term antibiotics 
have side effects and predominantly diarrhoea43,45. We would recommend the 
antibiotic chosen be based on the pathogen and sensitivity testing and continued 
long term. Further studies are needed to address whether such treatments can impact 
on bacterial resistance. 
   
A recent growing area has been in the field of long term inhaled antibiotics. The 
studies to date show exciting preliminary data that long term inhaled antibiotics can 
reduce the bacterial burden and improve clinical outcomes55-58. We need however 
more studies to confirm that long term inhaled antibiotics can reduce exacerbations. 
There has been a longstanding debate whether these treatments should be one month 
on and off or continuous56,58. The theory for the on-off regimen was to reduce the 
development of microbial resistance. The long term antibiotic studies to date have 
not shown that continuous antibiotics lead to bacterial resistance affecting patient 
care55,57,58. In our opinion continuous treatment allows the optimum therapy to 
reduce the bacterial load and ultimately reduce exacerbations. There will be a wide 
spectrum in the future of potential inhaled antibiotics and the agent chosen should be 
based on the pathogen and sensitivity patterns. It is likely that inhaled therapy will 
be predominantly used in patients colonised with more complex pathogens such as 
Pseudomonas aeruginosa where there are limited or no long term suitable oral 
therapies. The limiting factors to date using these therapies are they have significant 
cost to their use and are all currently unlicensed and therefore their use is confined 
to registered clinical trials. In addition, such therapies can cause bronchospasm and 
breathlessness and around 10% of patients will have to discontinue therapy despite 
the addition of inhaled or nebulised bronchodilator therapy53,55,58.  
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An alternative approach in patients with very severe bronchiectasis is the 
consideration for regular planned eight weekly courses of intravenous antibiotic 
therapy. Our open labelled study showed that this treatment improved patients’ 
symptoms with reduced antibiotic burden, cough and improved health status and 
reduction of systemic inflammation64.  Randomised controlled trials are however 
needed to explore this further.  
    
There is an international drive to license both anti-infective and anti-inflammatory 
therapies for this chronic disabling condition using traditional medicines. There will 
likely be novel new therapies in the future attempting to modify the inflammatory or 
host response. The future will evaluate whether anti-inflammatory therapies are 
additive to antibiotic therapies as would be expected in the vicious cycle seen in 
bronchiectasis. The next 10-20 years will see a large expansion in this field, which 
will improve the evidence base for this chronic disease.   
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Author Study N Antibiotic Dose & Duration Microbiology Results Our Interpretation 
Hill et 
al, 19867 
Open label 33 Oral Amoxicillin 
 
 
 
 
 
Oral Amoxicillin 
 
 
Nebulised 
Amoxicillin 
250mg t.d.s 14 day  
 
 
 
 
 
3g b.d 14 days, if failed to 
respond to above 
 
500mg b.d 4 months, if 
failed to respond to above 
Initial responders: 
47% no pathogen 
35% H. influenzae 
12% S. pneumoniae 
6% P. aeruginosa 
 
Those given 2nd line: 
31% no pathogen 
50% H. influenzae 
13% P. aeruginosa 
6% S. aureus 
7/7 mucoid to clear and time to next 
exacerbation 6.5 months 
7/7 mucopurulent to clear and time to next 
exacerbation 9 days 
3/19 purulent to clear and time to next 
exacerbation 4 days 
7/12 (4 patients not entered) purulent to 
clear and time to next exacerbation 14 days 
 
2/3 (2 patients not entered) purulent to 
clear with no relapse at 11 months 
Patients with purulent 
sputum need higher 
dosages of prolonged 
antibiotics. 
Chan et 
al, 19968 
Randomised  42 Ciprofloxacin 
Versus. 
Amoxicillin 
500mg b.d 7 days 
 
1g t.d.s 7 days 
41% P. aeruginosa 100% bacterial clearance 
95% improved sputum purulence 
25% bacterial clearance 
55% improved sputum purulence 
Targeted antibiotics 
improve bacterial 
clearance. 
Lam et 
al, 19899 
Randomised  41 Ofloxacin 
 
Versus. 
 
 
Amoxicillin 
200mg t.d.s 10days 
 
 
 
 
1g t.d.s 10days 
32% P. aeruginosa or 
Klebsiella 
14/20 ‘excellent’ improvement in sputum 
purulence 
1/14 ‘failure’ in improvement 
94% bacterial eradication 
 
8/21 ‘excellent’ improvement 
8/21 ‘poor’ improvement 
45% bacterial eradication 
Targeted antibiotics 
improve bacterial 
clearance. 
Bilton et 
al, 200610 
Randomised  53 Ciprofloxacin + 
inhaled 
tobramycin 
 
 
Ciprofloxacin + 
placebo (quinine 
sulphate) 
750mg oral ciprofloxacin + 
300mg/5ml of Tobramycin 
inhalation solution b.d for 14 
days 
 
750mg oral ciprofloxacin + 
1.25mg/5ml of quinine 
sulphate b.d for 14days 
100% P. aeruginosa No statistically significant difference in 
clinical outcomes at days 14 or 21 despite 
greater microbiological response with the 
addition of inhaled tobramycin. 
Increased wheeze with tobramycin 50% 
vs. 15% (placebo arm). 
The addition of inhaled 
tobramycin to oral 
ciprofloxacin confirmed 
no additional clinical 
benefit but increased 
symptoms related to 
inhaled tobramycin. 
Tsang et 
al, 
199911 
Randomised 35 Levofloxacin 
Versus. 
IV Ceftazidime 
300mg b.d 10 days 
 
1g t.d.s 10 days 
29% P. aeruginosa 
 
41% no pathogen 
57% bacterial clearance 
 
69% bacterial clearance 
Significant improvement in eradication 
rates, sputum volume, purulence, cough 
and dyspnoea scores in both groups. No 
significant difference between groups. 
No difference in 
bacterial clearance 
comparing oral with 
intravenous anti-
pseudomonal 
antibiotics. 
Brambil
la et al, 
199212 
Comparison 512 IV and then oral 
Cefuroxime axetil 
 
IV and then oral 
Amoxicillin plus 
clavulanic acid 
750mg, t.d.s, iv (48-72hr) 
then 500mg, b.d, oral 
(5days) 
1.2g, t.d.s, (48-72hr) then 
625mg, t.d.s, oral (5days) 
Not available 87.1% cured or improved 
72.8% bacterial clearance 
 
85.9% cured or improved 
70% bacterial clearance 
Similar clinical and 
microbiological efficacy 
comparing 
cephalosporins and 
penicillin with 
clavulanic acid therapy. 
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Author Study N Corticosteroid Dose & Duration Results Our Interpretation 
Tsang et 
al, 199831 
Randomised 24  Fluticasone 
Versus 
Placebo  
500micrograms, b.d, 
 4 weeks  
The fluticasone group had a significant decrease in sputum leukocyte 
count, IL-1b, IL8 and LTB4.  
The fluticasone group had one and the placebo group three 
exacerbations (not statistically significant).  
No significant change in spirometry or sputum volume.  
No adverse reactions were reported in either group. 
This proof of concept study showed 
inhaled corticosteroids over 4 weeks 
reduced sputum neutrophilic airways 
inflammation. 
Tsang et 
al, 200532 
Randomised 86 Fluticasone  
Versus  
Placebo 
500micrograms, b.d, 
1 year 
 
The fluticasone group had a significant improvement in 24hr sputum 
volume (OR 2.5, 95% CI 1.1 to 6.0, p = 0.03) but not exacerbation 
frequency, sputum purulence or lung function.  
Patients colonised with Pseudomonas had significant improvements in 
sputum volume (OR 13.5, 95% CI 1.8 to 100.2, p = 0.03) and 
exacerbation frequency (OR 13.3, 95% CI 1.8 to 100.2, p = 0.01). 
This study showed long term inhaled 
corticosteroid over 1 year reduced 
sputum volume and in a subanalyis 
showing benefit particularly in 
patients with Pseudomonas 
aeruginosa. Further confirmatory 
studies are needed. 
Elborn et 
al, 199233 
 Randomised  20 Beclometasone 
dipropionate  
Versus  
Placebo  
750micrograms, b.d,  
6 weeks 
The beclometasone group had a significant (18%) reduction in sputum 
volume (p<0.003). 
This study showed a reduction in 
sputum volume over 6 weeks. 
Martinez 
et al, 
200634 
Randomised  93 High dose Fluticasone   
Versus  
Low dose fluticasone 
Versus 
No treatment 
 
 
 
500micrograms, b.d,  
6 months 
250micrograms, b.d,  
6 months 
No treatment 
6 months 
Only high dose inhaled steroid showed a significant improvement in 
dyspnoea, sputum production, days without cough, short acting b2 
agonist use and quality of life. The SGRQ improved from (45.4 [14.2] 
vs. 40.5 [13.9]; P = 0.01). There were no changes in pulmonary 
function, sputum microbiology or number or severity of exacerbations.  
Increase in adverse effects with high dose ICS, more commonly of dry 
mouth, local irritation and dysphonia.  
Significant reduction in sputum volume with the lower dose steroid 
but not maintained at 6months. 
This study showed only clinical 
benefit with dose inhaled 
corticosteroid. 
Martinez 
et al, 
201235 
Randomised  40 Formoterol-
budesonide 
Versus 
18/640micrograms,  
3 months 
 
In the combination treatment arm there was a significant improvement 
in dyspnoea, increase in cough free days, a reduction in number of 
rescue b2 agonist inhalations and improvement in QofL. The SGRQ in 
The combination therapy improved 
symptoms and had less side effects 
from high dose inhaled 
Mehta 
et al, 
199113 
Comparison 85 Amoxicillin 
 
 
Amoxicillin plus 
clavulanic acid 
 
Amoxicillin plus 
clavulanic acid 
500mg, t.d.s, oral 7-10days 
 
 
750mg, t.d.s, oral 7-10days 
 
 
1.2g, t.d.s, IV 3 days then 
oral as above 
S. pneumoniae (n=12) 
Klebsiella ( n=41) 
P. aeruginosa (n=21) 
E. coli (n=9) 
H. influenzae (n=7) 
S. aureus (n=6) 
66% clinical improvement 
47% radiological improvement 
 
60% clinical improvement 
53% radiological improvement 
 
56% clinical improvement 
44% radiological improvement 
45% bacterial clearance with amoxicillin 
plus clavulanic acid compared with 8% 
bacterial clearance with amoxicillin. 
Targeted antibiotics 
improve bacterial 
clearance. 
Table 1. Antibiotics in bronchiectasis exacerbations  
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Budesonide  1600micrograms,  
3 months 
the combination treatment improved by 5.3 units; P= 0.006).   
No difference in lung function or sputum microbiology.  
More exacerbations in the high dose budesonide group but not 
statistically significant from the combination arm.  
The combination treatment had less inhaled corticosteroid side effects 
such as pharyngeal irritation (5% vs. 35%), dysphonia (0% vs. 25%) 
and mouth dryness (5 vs. 35%). 
corticosteroids. 
Table 2. Inhaled corticosteroids in bronchiectasis  
 
 
Author Study N Antibiotic Dose & 
Duration 
Microbiology Results Our Interpretation 
MRC, 195742 Randomised 122 Penicillin 
 
Tetracycline 
 
Lactulose  
2g 1yr, 2x/week 
 
2g 1yr, 2x/week 
 
2g 1yr, 2x/week 
None recorded Sputum purulence improved by 33% 
26% reduction in volume 
Sputum purulence improved by 50% 
36% reduction in volume 
Sputum purulence improved by 29% 
24% reduction in volume 
First long term 
randomised controlled 
trial showing long term 
tetracycline improved 
clinical outcome. 
Sobel et al, 
196243 
 Randomised  90 Penicillin 
 
Tetracycline 
 
Oleandomycin/ 
penicillin combo 
 
Placebo  
1g, 36months 
 
2g, 36months  
 
2g, 36 months 
 
None available 27% mainly GI upset 
 
27% mainly diarrhoea 
 
20% mainly GI upset 
 
 
10% mainly diarrhoea 
Long term tetracyclines 
lead to gastrointestinal 
side effects in 20-30% of 
cases – predominantly 
diarrhoea. 
Cherniack et al, 
195944 
Randomised 67 Penicillin 
 
Tetracycline 
 
Oleandomycin/ 
penicillin combo 
 
Placebo 
 
1g, 3-22months 
 
2g, 3-22months  
 
2g, 3-22 months 
 
28% H. influenzae 
14% S. pneumoniae 
15% 
Staphylococcus spp 
23% yeasts 
Exacerbations rates were not significantly affected with 
penicillin when compared with placebo. 
Exacerbations rates were lower with tetracyclines - mean 
exacerbation 1.32 ± 0.3 standard error when compared with 
placebo 3.36 ± 0.6 P<0.01. Shorter duration of illness with 
tetracyclines 14.5 ± 2.9 days versus 29.2 ± 5.1 days. 
There was no significant difference in exacerbation rates with 
oleandomycin/penicillin when compared with placebo.  
There was no significant difference in exacerbation rates 
between tetracycline (1.32 ± 0.3) and the combination 
oleandomycin/penicillin 1.92 ± 0.3. 
No significant impact on lung function FEV1 or FVC, sputum 
volume or sputum purulence. 
This study supports that 
long term tetracyclines 
reduce exacerbation 
frequency. 
Dowling et al, 
196045 
Randomised 89 Penicillin 
 
Tetracycline 
1g, 3-31months 
 
2g, 3-31months  
59% H. influenzae 
5% S. pneumoniae 
21% 
Significant increase in Pseudomonas spp with tetracyclines from 
19% pre therapy to 43% post therapy. There was a relative 
reduction in H. influenzae and S. pneumoniae.  
With long term 
tetracyclines there was a 
reduction in conventional 
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Oleandomycin/ 
penicillin 
combination 
 
Placebo 
 
2g, 3-31 months 
 
Staphylococcus spp 
12% Pseudomonas 
spp 
Increase in Klebsiella spp with penicillin from 25% pre therapy 
to 54% post therapy but a relative reduction in S. pneumoniae. 
Increase in Proteus spp from 14% to 43% with combination 
Oleandomycin/penicillin therapy but relative reduction in S. 
pneumoniae. 
bacteria that would 
respond to tetracycline 
e.g. S.pneumoniae, 
H.influenzae, S.aureus but 
an increase in 
P.aeruginosa that does 
not respond to 
tetracyclines. 
Currie et al, 
199046 
Randomised  38 Amoxicillin 
 
 
Placebo 
3g, b.d, 32 
weeks 
 
24% P. aeruginosa The Amoxicillin treated group led to 65% clinical improvement 
vs. 21% in placebo, p=0.02. 
Other positive effects in the amoxicillin treated group were: 
Reduction in 24 hour sputum volume (p<0.05) 
Less time confined to bed and away from work. 
Less severe exacerbations but no effect on frequency. 
Well tolerated apart from two patients intolerant due to drug rash 
and diarrhoea.  
High dose amoxicillin 
over 8 months led to 
significant clinical 
improvement with less 
exacerbations.  
Table 3. Oral antibiotic studies in stable state bronchiectasis  
Author Study N Antibiotic Dose & Duration Microbiology Results Our Interpretation 
Tsang et al, 
199947 
Randomised 21 Erythromycin 
Versus 
Placebo 
500mg, b.d, 8 weeks 
 
76% P. aeruginosa 
14% H. influenzae 
5% K. Pneumoniae 
5% E. coli 
Erythromycin group had improved 
FEV1, FVC & reduced 24hr sputum 
vol. No difference in microbial load or 
pro-inflammatory cytokines 
Proof of concept study that 
macrolide therapy over 8 
weeks has a possible anti-
inflammatory effect. 
Wong et al, 
201248 
Randomised 141 Azithromycin 
Versus 
Placebo 
500mg, 3x/week, 6 
months 
13% P. aeruginosa 
27% H. influenzae 
3% S. aureus 
1% S. pneumoniae 
(Only common 
pathogens reported) 
 
Event-based exacerbations were 
significantly reduced in the 
azithromycin group (0.59) compared 
with the placebo group (1.57), 
p<0.0001. 
Median time to first exacerbation in 1 
year was longer in the azithromycin 
group 239 versus 85 days with placebo. 
First randomised controlled 
trial with azithromycin 500mg, 
three times a week, versus 
placebo reduced exacerbation 
in the azithromycin treated 
group. 
Altenburg 
et al, 201349 
Randomised 83 Azithromycin 
Versus 
Placebo 
250mg, o.d, 1 year 11 % P. aeruginosa 
17 % H. influenzae 
5 % M. Catarrhalis 
7.5 % S. aureus 
4 % A. fumigatus 
1 % H. parainfluenzae 
7.5 % S. pneumoniae 
1 % X. maltophilia 
1.5 % S. marcescens 
1 % E.coli 
1.5 % E. cloacae 
Median number of exacerbations 0 in 
azithromycin group compared with 2 in 
placebo group, p<0.001. 
%Predicted FEV1 increased by 1.03 per 
3m and %predicted FVC by 1.33 in 
azithromycin treated patients. 
GI adverse effects in 40% in the 
azithromycin group and 5% in the 
placebo but no discontinuation needed. 
Macrolide resistance was 88% in the 
azithromycin group versus 26% in the 
Similarly, this study showed 
azithromycin 250mg, once 
daily, over a year reduced 
exacerbations but 
gastrointestinal side effects are 
common. Oropharnygeal 
streptococcus develops 
significant macrolide resistance 
and the long term significance 
of this needs to be explored 
further. 
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Author Study N Antibiotic Dose & Duration Microbiology Results Our Interpretation 
Lin et 
al, 
199752 
Randomised  16 Gentamicin  
Versus 
0.45% saline 
40mg, b.d, 3 days  Not recorded The gentamicin group led to a 
reduction in microbial load, sputum 
Myeloperoxidase (MPO) levels and 
sputum volume. There was improved 
Borg breathlessness score, peak 
expiratory flow rates and 6 min walk.  
Early proof of concept 
study showing inhaled 
antibiotics could reduce 
microbial burden and 
improve clinical 
outcomes. 
Barker 
et al, 
200053 
Randomised  74 Tobramycin  
Versus 
Placebo 
300mg, b.d, 4 weeks on 
treatment then 2 weeks off 
100% P. aeruginosa The tobramycin group at week 4 led 
to a significant reduction of sputum 
bacteria by 4.54 log (10) cfu/g with 
tobramycin with no change in the 
placebo group, p<0.01. 
Tobramycin subjects also showed a 
35% eradication rate at week 6, with 
no eradication in placebo. 
Tobramycin group had increased 
cough, wheeze, chest pain and 
breathlessness. 
Inhaled tobramycin over 4 
weeks can eradicate 
P.aeruginosa in 35% - an 
outcome that is very 
different to the cystic 
fibrosis population. 
Wilson 
et al, 
201354 
Randomised 124 Ciprofloxacin (DPI) 
Versus 
Placebo  
32.5mg, b.d, 28 days 54% P. aeruginosa 
24% H. influenzae 
20% S. aureus 
7% S. pneumoniae 
6% M. catarrhalis 
4% K. pneumoniae 
6% P. mirabilis 
There was a significant reduction in 
bacterial density for those on 
ciprofloxacin DPI with total sputum 
bacterial load at day 28 - end of 
treatment (EOT) (-3.62 log10 CFUg
-1 
(range -9.78–5.02 log10 CFUg
-1)) 
Inhaled ciprofloxacin 
improved bacterial 
clearance over 28 days 
and was well tolerated. 
2.5 % A. xylosoxidans placebo group.  
Serisier et 
al, 201350 
Randomised 117 Erythromycin 
ethysuccinate 
Versus 
Placebo 
400mg, b.d, 48 weeks 35% P. aeruginosa 
20.5% H. influenzae 
45.35% ‘normal flora 
(no pathogens)’ 
Erythromycin significantly reduced 
exacerbations (1.29 vs 1.97/patient/yr 
for placebo, p-0.003). 
Subgroup analysis showed a similar 
trend in patients colonised with P. 
aeruginosa.   
Sputum volume was reduced in the 
erythromycin group. 
% Predicted FEV1 decline was 
attenuated with erythromycin. 
Erythromycin increased the proportion 
of macrolide resistant streptococci 
(28% vs. 0.04%, p<0.001).  
Erythromycin over 48 weeks at 
400mg, twice daily, showed 
similarly a reduction in 
exacerbations but an increased 
the proportion of macrolide 
resistant streptococci. The long 
term significance of this needs 
to be explored further. 
Table 4. Long term macrolide therapy studies in stable bronchiectasis  
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4% K. oxytoca compared with placebo (-0.27 log10 
CFUg-1 (range -7.96–5.25 log10 
CFUg-1)) (p<0.001). The counts 
increased thereafter until they were 
similar at day 84.  
14/40 subjects in the ciprofloxacin 
DPI group reported pathogen 
eradication at EOT vs 4/49 in the 
placebo group (p=0.001). 
3/60 in ciprofloxacin vs 3/64 in 
placebo reported bronchospasm, 0/60 
vs 5/64 reported cough and 1/60 vs 
2/64 reported haemoptysis. No change 
in FEV1 or FVC for either group. No 
significant difference between the 
groups in sputum volume or colour. 
Drobnic 
et al, 
200555 
Randomised 
crossover  
study 
30 Tobramycin 
Versus 
Placebo  
300mg, b.d, 6 months 100% P. aeruginosa No effect on overall number of 
exacerbations, pulmonary function or 
health status. 
The tobramycin treated group had a 
reduced number of and length of 
hospital admissions (p<0.05). 
Significant reduction in P. aeruginosa 
bacterial load (p<0.05) 
Bronchospasm occurred in 10%.  
No significant increase in bacterial 
resistance. 
Inhaled tobramycin in 
patients with 
P.aeruginosa over 6 
months led to a reduction 
in severity of admissions 
and with no impact on 
bacterial resistance. 
Serisier 
et al, 
201356 
Randomised 42 Ciprofloxacin (DRCFI) 
Versus 
Placebo 
150mg ciprofloxacin for 
inhalation + 20mg free 
ciprofloxacin for 
inhalation, o.d, 24 weeks 
(3x 28days on/28days off) 
100% P. aeruginosa There was a mean reduction in 
P.aeruginosa bacterial density at day 
28 of 4.2 log10 CFU/g with DRCFI 
compared to a mean reduction of 0.08 
with placebo (p=0.002). 
Time to first exacerbation was 
significantly delayed by DRCFI (134 
days) when compared with placebo 
(58days). 
DRCFI was well tolerated with fewer 
respiratory related adverse events than 
placebo. Main treatment related 
adverse events included nausea, 
sinusitis, fatigue, headache and 
abnormal taste. 3 subjects in each arm 
In per protocol analysis 
inhaled ciprofloxacin led 
to a delayed first 
exacerbation in this 6 
month study. 
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developed an exacerbation – thought 
not to be related to treatment. 
Orriols  
et al, 
199957 
 Randomised 
open labelled 
study 
15 Ceftazidime + 
tobramycin 
Versus 
Symptomatic treatment  
1g, b.d &  
100mg b.d, 1 year  
100% P. aeruginosa In the active group the mean number 
of admissions and length of admission 
were significantly lower than 
symptomatic treatment. 
No change in FEV1 or FVC for 
overall exacerbation frequency for 
either group. 
No significant increase in bacterial 
resistance. 
This small study supports 
that long term inhaled 
antibiotics reduce the 
severity of exacerbations.  
Murray 
et al, 
201158 
Randomised 
single blinded 
study 
65 Gentamicin  
Versus 
0.9% Saline 
80mg, b.d, 1 year 48.1% P. aeruginosa 
40.7% H. influenzae 
7.4% S. aureus 
3.4% S. pneumoniae 
 
The gentamicin group led to                           
1. Increased ETT 95m 
2. Leicester Cough Questionnaire 
81% had 1.3U improvement or greater 
vs. 20% placebo  
3. SGRQ 82.5% had 4U improvement 
or greater vs. 19.2% placebo  
4. Increased time to next exacerbation 
(Gentamicin 120d (87-162) vs. Saline 
61.5d (20-7-122.7)) 
5. Decreased exacerbations (Gent 0(0-
1) vs. Saline 1.5(1-2)) 
6. No significant effect on 
antimicrobial resistance 
 
There was however in the gentamicin 
group, 
1. No effect 24hr volume, FEV1, 
FVC, FEF25/75 
2. 21.9% (7 of 32 patients) reported 
bronchospasm and received 
adjunctive nebulised β2 agonist 
treatment. Despite this, two patients 
(6%) required withdrawal from the 
study (one at month 3 and one at 
month 6) 
Treatment needs to be continuous for 
its on going efficacy. 
This 1 year study supports 
long term inhaled 
antibiotics reduce total 
number of exacerbations 
and time to first 
exacerbation, Treatment, 
however, has to be 
continuous for its ongoing 
efficacy. 
Table 5. Inhaled antibiotic studies in stable bronchiectasis  
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Abstract 
Introduction: Bronchiectasis is a chronic respiratory condition characterised by 
cough, sputum production and recurrent chest infections. There are multiple 
aetiologies, but in up to 50% of patients the aetiology is unknown. The treatment is 
largely symptomatic with regular chest physiotherapy and antibiotics for infective 
exacerbations. Research is being directed towards breaking the ‘vicious circle’ of 
bronchiectasis with therapies directed at improving mucociliary clearance, treating 
chronic infection and reducing inflammation in the airways.  
Areas covered: This review highlights the current status of bronchiectasis research, 
summarising reported and ongoing studies of potential therapeutic agents not yet 
assessed in large trials or licensed for treatment.  A literature review was performed 
on the PubMed database and upcoming trials were sought on the clinical trials.gov 
website. Only studies from preclinical stages to phase II were included. 
Expert opinion: The trials discussed offer insight into potential therapeutic agents 
for the future and help highlight areas in need of further targeted research. There are 
promising new anti-infective and anti-inflammatory therapies for more advanced 
bronchiectasis but phase III studies are needed to investigate these agents further and 
also to decide at what stage therapy should be implemented.  
Article Highlights  
• Bronchiectasis has become more commonly recognised with the advent of CT of the chest 
• The mainstay of treatment for clinically significant bronchiectasis is chest physiotherapy and 
antibiotics 
• Large randomised controlled trials are lacking in bronchiectasis 
• Encouraging data has been published in mucoactive therapies, long term antibiotics and anti-
inflammatory therapies 
• Larger randomised controlled trials are needed to identify long term effects of such therapies 
and target groups for long term therapy 
1. Introduction 
Bronchiectasis is a chronic respiratory condition first described over a century ago, 
characterised by daily cough and chronic sputum production with a predisposition to 
recurrent chest infections [I]. The prevalence of bronchiectasis is unknown but it is 
being recognised and diagnosed more commonly, perhaps because high resolution 
computer tomography (CT) scanning of the chest, the gold standard for diagnosis, is 
more frequently used in clinical practice. In the United States, the prevalence ranges 
from 4/100,000 in young adults to nearly 300/100,000 in those older than 75years 
[2,3]. Diagnostic CT images show the bronchial diameter to be larger than the 
adjacent pulmonary artery in affected areas (signet ring sign). The degree of 
bronchial dilatation increases with severity from cylindrical or tubular 
bronchiectasis in mild disease to varicose bronchiectasis (focal constrictive areas 
along the dilated airways) to saccular or cystic bronchiectasis in severe disease [4]. 
The spectrum of bronchiectasis ranges from mild, moderate to severe. The 
classification of bronchiectasis is complex and there is a degree of overlap. The 
severity should be classified based on clinical features and not on radiology. In our 
clinical experience mild disease is associated with the following clinical features: 
mucoid sputum production when stable, less than 10mls sputum volume/24hours 
and limited exacerbations (1 or 2 exacerbations a year) which can usually be treated 
with oral antibiotics. Moderate disease is usually associated with mucopurulent or 
purulent sputum when clinically stable but not leading to an excess of exacerbations 
(2 or less exacerbations a year). Patients with severe disease have frankly purulent 
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sputum when clinically stable, produce more than 10mls/day and have more 
frequent exacerbations (≥3/year). These patients can be colonised by more difficult 
pathogens such as Pseudomonas aeruginosa, other enteric Gram negative organisms 
or MRSA. These patients may require intravenous antibiotics and hospital admission 
to treat their exacerbations [1,5]. 
Bronchiectasis has been termed an ‘Orphan disease’ relating to the relative lack of 
research in this field when compared to asthma, lung cancer and chronic obstructive 
pulmonary disease (COPD) [6]. Bronchiectasis is often regarded as a heterogenous 
disease in view of the multiple aetiologies and associated comorbidities. 53% of 
cases are idiopathic and the second most common cause is a past respiratory 
infection (29-42%) [1,7,8]. 
Cole et al coined the phrase ‘the vicious circle’ when describing the pathogenesis of 
bronchiectasis [9]. The colonisation of lower respiratory tracts with pathogenic 
bacteria leads to a predominantly neutrophilic inflammatory response in the airways. 
Despite this host response there is a failure of bacterial clearance [5,10]. The 
neutrophil products in particular neutrophil elastase can further damage the 
mucociliary escalator, predisposing to bacterial colonisation which perpetuates the 
inflammatory response. Thus the vicious circle is established [9]. 
Therapies designed to break this circle can be grouped into anti-infective, anti-
inflammatory and mucoactive agents.  The goals of treatment include reducing 
cough and sputum volume, reducing sputum purulence, reducing the number of 
chest infections and improving quality of life (QofL).  
This review on developing therapies summarises the trials in preclinical to phase II 
stages of new drugs being explored for the treatment of idiopathic and post-infection 
bronchiectasis. It is beyond the scope of this paper to comment on treatment 
strategies for bronchiectasis due to active allergic bronchopulmonary aspergillosis, 
active sarcoid, cystic fibrosis and immunoglobulin deficiencies which all have their 
own disease specific treatments.  
A literature search was performed on PubMed with the following keyword searches: 
‘bronchiectasis’ or ‘non-cystic fibrosis bronchiectasis’ and ‘phase I study’, ‘phase II  
study’, ‘antibiotics’, ‘mucoactive therapy’, ‘anti-inflammatory therapy’.  A keyword 
search on the clinicaltrials.gov website was performed with ‘bronchiectasis.’ 127 
studies were identified, of which 27 were included.  
 
2. Anti-infective treatment 
2.1 Long term antibiotics 
There is chronic colonisation of the lower respiratory tract with bacteria in up to 
70% of patients with bronchiectasis [5,10]. Up to 26% of bronchiectatic patients can 
be colonized with Pseudomonas aeruginosa [10,11]. This bacterium is associated 
with more frequent exacerbations, poorer quality of life, deteriorating lung function 
and increased mortality [12-14].  It has been shown that increasing bacterial load is 
directly proportional to an increase in the number of outpatient exacerbations and 
hospital admissions [5]. This in turn reduces quality of life of patients – an important 
clinical endpoint in bronchiectasis. It is therefore considered to be important to 
attempt to reduce the bacterial load in the stable state with the aim of reducing 
exacerbations and improving QofL. One such method is the introduction of long 
term antibiotics. Current antibiotics in published phase II trials - inhaled 
ciprofloxacin and tobramycin are displayed in table 1. 
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Table 1 - Long term antibiotics 
Intervention/ 
Control 
Patient information Inclusion 
microbiology 
Primary endpoint  Outcome CFU/(MIC) Other outcomes Study 
Ciprofloxacin DPI, 
32.5mg, b.i.d, days 
1-28, n=60 
Placebo, b.i.d, days 
1-28, n=64 
• N=124 
• Stable for 30days 
• 1 hospital admission or 
2 courses of antibiotics 
in the last 12 months 
• Those on long term 
antibacterial therapy 
were excluded 
Culture positive for 
pre-defined 
respiratory pathogens 
(PA, HI, SA, SP, 
MC, KP, PM, KO). 
Total bacterial 
density in sputum 
after 28 days of 
treatment  
Greater mean reduction in 
CFU/ml during treatment and 
at end of treatment (EOT) 
DAY 28 was seen in the 
ciprofloxacin group p<0.001 
 
Bacterial eradication at EOT 
in 35% ciprofloxacin group 
versus 8% placebo group 
p=0.001. 
 
6 subjects had increased MIC 
levels >4mg/L at EOT in the 
ciprofloxacin arm, nil in 
placebo group 
2 treatment emergent  
serious adverse effects 
compared to 3 in placebo 
group 
Wilson et al 
[15] 
Randomised 
double-blind, 
2013 
Ciprofloxacin, Dual 
release for 
Inhalation (DRCFI), 
o.d,  for 3 cycles of 
28days on/28days 
off, n=20 
Placebo, o.d, for 3 
cycles of 28days 
on/28days off, n=22 
• N=42 
• 2 or more 
exacerbations in last 
year 
Ciprofloxacin 
sensitive 
Pseudomonas 
aeruginosa at 
screening in sputum 
Change in P. 
aeruginosa 
bacterial density to 
end of treatment 
cycle 1 (day 28) 
Significant reduction in 
bacterial load at day 28 in 
DRCFI group p<0.001 
(modified intention to treat 
analysis) 
 
Failure to culture PA was 
more frequent in DRCFI 
group (60% versus 14%) 
p=0.003 
 
No significant difference in 
MIC levels 
Prolonged time to next 
exacerbation (134 days 
versus 58) p=0.046 in a 
modified intention to 
treat analysis 
 
No difference between 
the groups at day 28 for 
FEV1, QofL or 6minute 
walk test (6MWT) 
Serisier et al 
[16] 
Randomised 
double-blind, 
2013 
Tobramycin 
(nebulised), 300mg, 
b.i.d, 28 days , n=37 
Placebo (1.25mg 
• N=74 
• No antibiotics within 2 
weeks of screening 
visit 
At least 104 cfu 
Pseudomonas 
aeruginosa per gram 
of sputum 
Change in P. 
aeruginosa 
bacterial density 
from baseline to 
Mean decrease of 4.54log10 
cfu/g sputum of PA in 
Tobramycin solution for 
inhalation(TSI) arm versus a 
Reduction in PA was a 
significant predictor of 
improved medical 
condition (subjective 
Barker et al 
[17] 
Randomised 
Double-blind, 
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quinine sulphate), 
b.i.d, 28 days, n=37 
week 4 mean increase of 0.02log10 
cfu/g with placebo (p<0.01) 
 
Tobramycin resistant strains 
in 11% in TSI arm versus 3% 
in placebo arm (p=0.36) 
 
Eradication of PA in 35% of 
TSI patients at week 6 
analysis: improved or not 
improved) throughout 
treatment (p<0.01) and at 
week 6 (p<0.04) in TSI 
arm 
 
No difference in FEV1 in 
either group but 
incidence of dyspnoea, 
wheeze and chest pain 
significantly greater in 
TSI arm (p=0.01)  
2000 
 
Tobramycin 
(nebulised), 300mg, 
b.i.d, or placebo 
b.i.d, each for 6 
months in a 
crossover fashion 
with a 1 month 
washout period in 
between the cycles 
• N=30 
• An inpatient 2 week 
course of intravenous 
ceftazidime and 
tobramycin prior to 
entry 
At least 3 sputum 
cultures in the last 6 
months identified 
Pseudomonas 
aeruginosa 
No powering 
estimation was 
performed in this 
study. Efficacy 
was primarily 
evaluated by 
means of number 
of exacerbations, 
number and days 
of hospital 
admission 
Significant decrease in 
bacterial density with 
tobramycin (p=0.038) 
 
No change in bacterial 
resistance 
No difference in the 
frequency of pulmonary 
exacerbations 
 
Significant reduction in 
number of hospital 
admissions ((Mean+/- 
SD) 0.15+/- 0.37 in 
tobramycin period versus 
0.75+/-1.16 in placebo 
group) and length of stay 
in tobramycin period 
2.05+/- 5.03 days versus 
12.65 +/- 21.8 days 
(p<0.047) 
 
No change in FEV1, 
FVC or QofL 
 
Bronchospasm in 10% 
tobramycin patients 
(n=3)  
Drobnic et al 
[18] 
Crossover  
Double-blind, 
2005 
Ciprofloxacin, oral, • N=53 Chronic colonization Clinical outcome Significant mean PA density No difference in clinical Bilton et al 
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750mg and 
tobramycin, 
inhaled, 
300mg/5mls, b.i.d, 
14 days, n=26 
Ciprofloxacin, oral, 
750mg and placebo, 
5mls  (1.25mg 
quinine sulphate), 
b.i.d, 14 days, n=27 
• Acute exacerbation with Pseudomonas 
aeruginosa 
assessment at day 
21 (test of cure) 
reduction in the Cip/Tobra 
arm (3.67log10 versus 
1.15log10 on day 7 and by 
3.25log10 versus 0.52log10 on 
day 14 (p<0.001)  
outcomes between the 
groups at day 14 or day 
21 
 
Significant increase in 
frequency of wheeze 
with 50% in cip/tobra 
versus 14.8% in 
cip/placebo (p<0.01) 
[19] 
Randomised 
Double-blind, 
2006 
 
Pseudomonas aeruginosa (PA), Haemophilus influenzae (HI), Staphylococcus aureus (SA),  Streptococcus pneumoniae (SP), Moraxella catarrhalis (MC), Klebsiella 
pneumoniae (KP), Proteus mirabilis (PM) and Klebsiella oxytoca (KO). 
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Further phase 3 studies assessing the time to next exacerbation and frequency of 
exacerbations are underway using inhaled ciprofloxacin. The RESPIRE study 
(NCT01764841) will randomise patients into one of four groups – 28day on/28 days 
off ciprofloxacin dry powder for inhalation (DPI), 28day on/28 days off placebo, 14 
days on/14days off ciprofloxacin DPI and 14 days on/14days off placebo for 48 
weeks. ORBIT-3 (NCT01515007) randomises patients to receiving dual release 
ciprofloxacin for inhalation (DRCFI) once daily for 28 days on/28 days off therapy 
for six cycles or to placebo. These studies are currently ongoing. 
In addition to the studies shown in table 1 there is an open-label phase II trial 
recruiting to assess the efficacy of a dry powder for inhalation form of tobramycin 
(NCT02035488). The main objective of the study is to assess the pharmacokinetics 
of dry powder tobramycin delivered through the ‘Cyclops’ inhaler device at 
different doses and the local tolerability. 8 patients are to be recruited and will be 
given one dose of tobramycin every week. Doses will increment form 30mg to 
60mg then 120mg and finally 240mg. Primary outcome measure includes actual 
dose delivered. 
There is another open label trial ongoing assessing bacterial density as the primary 
endpoint comparing combined inhaled and systemic tobramycin therapy with 
systemic therapy alone (NCT01677403). Patients colonised with Pseudomonas 
aeruginosa will be given either saline or nebulised tobramycin 80mg b.i.d for 14 
days in addition to systemic therapy (no additional details available). The trial is 
currently still recruiting and aims to enrol 120 patients. 
Tobramycin has also been studied as part of a fosfomycin/tobramycin combination 
(4:1 w/w) drug (FTI) [20]. Results show this could be a novel combined inhaled 
antibiotic for patients with bronchiectasis and cystic fibrosis. A phase II study 
assessed the formulation’s activity in vitro and in vivo. Clinical isolates from cystic 
fibrosis and bronchiectasis patients were evaluated for MIC, minimum bactericidal 
content, post antibiotic effect, synergy, spontaneous mutation frequency (SMF), 
time-kill and in a rat pneumonia model [20]. Results showed the combination drug 
to have a potent dose dependent bactericidal action against Pseudomonas 
aeruginosa in the rat pneumonia model but tobramycin alone was found to be more 
active than the combination drug with a lower MIC90 (mg/L). For Pseudomonas 
aeruginosa and Staphylococcus aureus the SMF was lower for FTI than either of the 
single drugs alone. FTI had a lower MIC than either tobramycin or fosfomycin 
against staphylococcus aureus (methicillin resistance detected in 75% of strains) and 
a comparable MIC90 with vancomycin (MIC90 of 2 versus MIC90 of 1). FTI also 
demonstrated high activity against Staphylococcus aureus, Haemophilus influenzae, 
Klebsiella pneumoniae and Escherichia coli but was poor against Stenotrophomonas 
maltophilia and Bukholderia cepacia. Synergy testing did not show any antagonism 
between the two drugs. Dual activity against both Gram positive and Gram negative 
bacteria make it an attractive choice for patients colonised with multiple pathogens 
and may be useful in attenuating the development of drug resistant organisms. 
Another antimicrobial currently being investigated for patients with bronchiectasis is 
inhaled amikacin via nebuliser. A multi-national phase II trial assessing the safety 
and tolerability of Arikace-a liposomal form of amikacin has been completed 
(NCT00775138). Patients chronically colonised with Pseudomonas aeruginosa 
(n=64) were recruited. The double blind trial randomised patients to nebulised once 
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daily dosing of either Arikace 280mg, Arikace 560mg or placebo for 28 days. Co-
primary endpoints assessed treatment emergent adverse events and pulmonary 
function abnormalities. Secondary endpoints included time to next exacerbation, 
quality of life and bacterial density.  An interim analysis reported no concerns 
regarding safety and tolerability but full results have not been published yet [21]. 
 
2.2 Anti-viral therapy for viral exacerbations 
The role of viruses in bronchiectasis exacerbations is poorly understood. The British 
national quality standards for bronchiectasis advise physicians to provide patients 
with a self-management plan to enable them to take ownership and responsibility for 
their condition [22]. They also advise an annual influenza vaccine and to avoid 
contact if possible with people known to have a viral infection to prevent viral 
induced exacerbations [22]. This is based on expert consensus from clinicians 
managing bronchiectasis as there are no completed studies to date investigating the 
role of viruses and anti-viral treatment in bronchiectasis exacerbations. Studies are 
needed to assess the clinical efficacy of antiviral therapy in bronchiectasis 
exacerbations to help guide management. A phase 1 study (NCT01113034) 
assessing the safety of antiviral agent DAS181 in patients with bronchiectasis was 
underway but further information regarding its current status is not available. 
DAS181 is a fusion protein of the sialidase catalytic domain of Actinomyces 
viscosus and the anchoring domain of the human amphiregulin. It’s mechanism of 
action consists of cleaving the sialic acid receptor on the cells surface of  host cells 
which influenza virus requires to infect cells [23,24]. This novel action could make 
it a potent inhibitor of seasonal and emerging influenza strains [25]. 
 
2.3 Preventative therapy for exacerbations 
In addition to the above studies there has been interest in immunostimulating agents. 
These compounds consist of antigens from several bacterial strains and are designed 
to stimulate an immune response. OM-85 (also known as bronchoVaxom) consists 
of extracts of eight different bacterial species (Haemophilus influenzae, 
Streptococcus pneumoniae, Klebsiella pneumoniae and Klebsiella ozaenae, 
Staphylococcus aureus, Streptococcus pyogenes, Streptococcus viridans and 
Neisseria catarrhalis). It is thought to directly activate lung macrophages, enhance 
antigen presentation, and encourage differentiation of CD4 T lymphocytes and B 
lymphocytes [26]. The agent has been studied in COPD and was found to 
significantly reduce exacerbations [27-29]. A randomised double blind multicentre 
placebo-controlled trial is planned looking at the effect on exacerbations in 
bronchiectasis but recruitment has not yet commenced (NCT01968421).  
 
3.0 Mucoactive agents 
Hyperosmolar agents, sometimes referred to as ‘mucoactive’ therapies are designed 
to enhance mucus clearance by altering its physical structure, making it less viscous 
and more mobile. Therapies designed to enable easier expectoration of sputum aim 
to break the vicious circle by preventing the infection of stagnant mucus in the lower 
airways.  
N-acetylcysteine (NAC) has been investigated as a mucolytic therapy in COPD but 
to date no evidence exist in the field of bronchiectasis. NAC is thought to disrupt the 
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mucus gel structure by altering the degree of crosslinking or interactions between 
molecules in the sputum [30]. Zheng et al conducted a randomised trial and propose 
a 600mg twice daily regime can reduce the rate of exacerbations in moderate and 
severe COPD patients [31]. Whilst further work is needed before it is incorporated 
into clinical practice [32], the potential for NAC to be used in other respiratory 
conditions like bronchiectasis should be considered. A randomised control trial is 
currently ongoing where the researchers aim to recruit 120 bronchiectasis patients to 
either NAC 600mg twice daily for 12 months or placebo (NCT02088216). The 
primary endpoint examines exacerbations of bronchiectasis. 
 
4.0 Anti-inflammatory agents 
The inflammation caused by persistent bacterial infection and colonisation further 
propagates the vicious circle. This part of the circle naturally lends itself to being 
targeted by anti-inflammatory therapies.  
Statins have been used in cardiovascular medicine to lower cholesterol and have 
also been associated with reduced mortality rates in patients with influenza virus 
[33]. Their pleotropic effects, in particular, their anti-inflammatory properties have 
made them a potential therapeutic agent in bronchiectasis. Of note there is reduced 
neutrophil inflammation in healthy volunteer studies exposed to lipopolysaccharide 
[34]. Mandal et al recently published a randomised controlled trial of high dose 
atorvastatin (80mg) versus placebo in bronchiectasis (see table 2) [35]. The same 
group have gone on to assess the use of atorvastatin in patients with Pseudomonas 
aeruginosa in a crossover trial assessing cough as the primary endpoint 
(NCT01299194). Patients will receive 80mg atorvastatin or placebo for 3 months 
followed by a 6 week wash out period. They will then crossover to the other arm for 
a further 3 months. The study will also assess the effect on cough. This trial has 
completed recruitment but results have not yet been published. 
Theophylline forms part of the stepwise treatment for asthma as outlined in the 
NICE guidelines [36,37]. The mechanism of action of theophylline is not fully 
understood but it thought to have some anti-inflammatory effects by inhibiting 
phosphodiesterase (inhibits TNFa, inhibits leukotriene synthesis, reduces 
inflammation and innate immunity) in addition to antagonising adenosine receptors 
and inhibiting TGF-beta mediated conversion of pulmonary fibroblasts. 
Theophylline may be useful in patients with steroid resistance as it is able to restore 
histone deacetylase levels and enhance the anti-inflammatory effects of steroids 
[38]. There have not yet been any large trials in bronchiectasis but there are two 
small randomised parallel studies currently recruiting patients in bronchiectasis. The 
first study assesses the safety and efficacy of 24 weeks of theophylline 100mg, twice 
daily against placebo (NCT01684683). A further randomised study investigating the 
role of theophylline with low dose formoterol-budesonide over a 24 weeks period is 
also recruiting for patients with bronchiectasis (NCT01769898). The primary 
outcome for both studies assesses quality of life as measured by the SGRQ.  
Similarly, Roflumilast - a phosphodiesterase type 4 inhibitor has shown some 
efficacy in reducing neutrophilic inflammation in COPD patients but has not yet 
been studied in bronchiectasis [39]. Roflumilast has been licensed in COPD and 
could be a potential anti-inflammatory agent in bronchiectasis but randomised 
controlled trials are required first. A phase II study is planned in symptomatic 
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bronchiectasis patients but status information regarding this trial is not available 
(NCT01580748).  
Non-steroidal anti-inflammatory drugs (NSAIDS) have been investigated for their 
anti-inflammatory effects in bronchiectasis (see table 2). The mechanism of action in 
the study by Llewellyn-jones showed reduced resident neutrophil chemotaxis and 
therefore this agent may be useful in bronchiectasis by reducing airway neutrophil 
inflammation[40].
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Table 2 - Anti-inflammatory therapies 
Intervention/ 
Control 
Patient information Inclusion 
microbiology 
Primary outcome Outcome CFU/(MIC) Other outcomes Study 
Atorvastatin, 80mg, 
o.d. for 6 months, 
n=30 
Placebo, o.d. for 6 
months, n=30 
• Clinically significant 
bronchiectasis 
• 2 or more chest 
infections in preceding 
year 
• Smokers, >15 year 
pack history, ex-
smokers of <1 year 
were all excluded 
Patients with chronic 
colonisation with 
Pseudomonas 
aeruginosa were 
excluded 
Reduction in cough 
from baseline to 6 
months, as 
measured by the 
LCQ 
Chronic colonisation 
increase from 57% to 63% 
with atorvastatin 
 
Chronic colonisation 
remained at 40% in 
placebo group 
 
No significant difference 
in bacterial load at 6 
months in either group 
Significant improvement 
in cough (p=0.01) in the 
atorvastatin group. 
 
33% in atorvastatin group 
had an adverse event 
versus 10% in placebo 
group (p=0.02) 
 
FEV1 and FVC unchanged 
 
Exercise capacity 
improved by 35m in the 
atorvastatin group 
 
Serum interleukin 8 and 
CRP fell from baseline 
levels with atorvastatin 
 
8/24 had ≥2 exacerbations 
and 5/24 had ≥3 
exacerbations with 
atorvastatin versus 16/29 
and 10/29 in placebo group 
respectively 
Mandal et al, 
[35]  
Randomised 
control trial, 
2014 
Indomethacin, 2mls 
of aerosolized 
preparation 
containing 
1.2m g/ml, t.i.d, 14 
days, n=13 
Placebo, t.i.d, 14 
• N=25 
• Bronchorrhoea for 4 
weeks prior to study 
Chronic bronchitis, 
(12) diffuse 
panbronchiolitis (5), 
(17) PA, (3) HI, (1) 
SA 
Primary endpoint 
not specified in 
paper 
• No change in 
total bacterial 
CFU/g or in 
bacterial flora in 
either group 
No significant difference 
in FEV1 or FVC in either 
group 
 
Breathlessness assessed by 
Borg’s score improved 
with indomethacin only 
Tamaoki et al, 
[41] 
Randomised 
controlled trial, 
1992 
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days, n=12 bronchiectasis (8) (from 7.1 ±0.5 to 4.5±0.4, 
p<0.01) 
 
2 patients in the 
indomethacin group 
developed dry mouth but 
hypotension or 
bronchoconstriction was 
not observed 
 
Sputum weight 
significantly reduced from 
189±19g to 95±21g/day at 
day 14 in the indomethacin 
group (p<0.001) 
Indomethacin, 
25mg, t.i.d, 28 days, 
n=9 
Indomethacin, 
25mg, t.i.d, 14 days, 
n=8 
• N=9 clinically stable 
bronchiectasis 
• No inhaled or oral 
steroids in last 3 
months 
• N=8 healthy volunteers 
(7) HI, (5) BC, (3) 
SP, (1) PA, (1) PM 
from the 9 
bronchiectasis 
patients (patients 
grew more than 1 
organism) 
Primary endpoint 
not specified in 
paper (lab based 
study) 
• No significant 
difference in total 
sputum bacterial 
load, no change 
in 12hour sputum 
volume in sputum  
No adverse effects 
recorded, no change in 
sputum characteristics or 
peak flow recorded  and no 
exacerbations during 
treatment 
 
Significant reduction in 
peripheral neutrophil 
chemotaxis to 10nmol/L 
FMLP (p<0.0001) at day 
28, returning to baseline at 
day 63 
 
Significant reduction in 
fibronectin degradation by 
resting and stimulated 
neutrophils in 
bronchiectasis patients at 
day 14 and day 28, 
Llewellyn-
jones et al, 
[40] 
Open labelled, 
1995 
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returning back to baseline 
at day 63 (p<0.001) 
 
Similar neutrophil results 
in healthy controls after 
14day treatment 
 
No change in superoxide 
generation, intracellular 
elastase or 
myeloperoxidase in 
bronchiectasis samples  
AZD9668, 
60mg, b.i.d, 4 
weeks, n=22 
Placebo, b.i.d, n=16 
•  Idiopathic or post-
infective bronchiectasis 
• Clinically stable for 6 
weeks prior to entry 
into study 
9 with non-
Pseudomonas 
organisms, 9 with 
Pseudomonas in 
AZD9668 group 
No powering 
estimation was 
performed for this 
study 
• No information 
supplied 
Significant changes 
defined a priori as P<0.1 
 
No change in sputum 
neutrophils with AZD9668 
 
FEV1 improved by 100mls 
(P=0.006) and slow vital 
capacity improved by 
130mls (P=0.079)with 
AZD9668 
 
Plasma IL-8 reduced with 
AZD9668 (P=0.085) 
 
Post waking sputum IL-6 
reduced with AZD9668 
(P=0.098) 
 
No significant difference 
in QofL, sputum weight or 
other lung function 
parameters 
Stockley et al, 
[42] 
Randomised 
control trial, 
2013 
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AZD9668 was well 
tolerated with commonest 
side effect of headache 
(7/22 in AZD9668 versus 
2/16 in placebo group) 
Beta carotene, oral, 
0.69 ± 0.19 mg kg-1 
t.i.d with meals for 
cystic fibrosis and 
bronchiectasis 
patients only, 6 
months 
• Cystic fibrosis (CF) 
n=18, bronchiectasis 
(BE) n=15, healthy 
children n=15 
• Conditions where 
reactive oxygen 
species have been 
implicated were 
excluded (cirrhosis, 
hepatitis, diabetes 
mellitus, corticosteroid 
therapy or insulin 
therapy 
Not specified No primary 
endpoint specified, 
explorative study 
• Not specified  Vitamin E (VE) levels 
were significantly lower 
than healthy volunteers at 
baseline with CF 
(p=0.001) and BE 
(p=0.0001) 
 
Beta carotene (BC) levels 
were significantly lower in 
CF group than healthy 
volunteers at baseline 
(p=0.008) 
 
CF and BE has 
significantly higher 
malondialdehyde (MDA, 
biomarker of lipid 
peroxidation due to free 
radical oxidation) than 
healthy controls at baseline 
(p=0.0001) 
 
Post treatment VE and BC 
increased in both CF 
(p=0.007, p=0.001) and 
BE (p=0.008, p=0.001) 
 
Post treatment reduction in 
TNFa and MDA in both 
Cobanoglu et 
al, [43] Open 
labelled, 2002 
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CF (p=0.022, p=0.001) and 
BE (p=0.035, p=0.015) 
 
Post treatment vital 
capacity improved in BE 
(P=0.02), FEV1 and FEV25-
75 improved in CF 
(P=0.016, P=0.017 
respectively) 
Haemophilus influenzae (HI), Pseudomonas aeruginosa (PA),  Streptococcus pneumoniae (SP), Haemophilus parainfluenzae (PI), 
Moraxella catarrhalis (MC), Stenotrophomonas maltophilia (SM), Klebsiella pneumoniae (KP) and Candida albicans (CA), 
Staphylococcus aureus (S)A, Branhamella catarrhalis (BC,) Proteus mirabilis (PM). N-formyl-methionyl-leucyl-phenylalanine (FMLP) 
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Neutrophil elastase inhibitors are thought to have potential in reducing the 
inflammatory response seen in the airways of patients with bronchiectasis. In 
bronchiectasis there is excess neutrophilic airways inflammation and free elastase is 
found in patients with more advanced bronchiectasis. Neutrophil elastase inhibition 
offers a potential therapeutic intervention. To date, there has been one phase II trial 
investigating the compound AZD9668 – an oral neutrophil elastase inhibitor (see 
table 2) [42]. 
The generation of oxygen free radicals is a part of the neutrophilic inflammatory 
response and is known to damage airways. It has therefore been postulated that the 
imbalance between oxidants and antioxidants may play a role in bronchiectasis. To 
investigate this further Cobanglu and colleagues explored the effect of beta carotene 
in children with cystic fibrosis (CF), bronchiectasis and healthy controls [43]. 
Novel treatments are being sought to break the ‘vicious circle’ of bronchiectasis and 
some of the newer agents include AZD5069 (CXC chemokine receptor 2 antagonist 
CXCR2). Its mechanism of action includes reducing calcium flux and reducing 
chemotactic response to known chemoattractants. AZD5069 had undergone phase I 
studies to understand its safety and efficacy (NCT00953888) and the change in 
pharmacokinetic profile when co-administered to healthy volunteers with 
ketoconazole (NCT01735240). A subsequent phase II study (NCT01255592) 
enrolled 83 bronchiectasis patients in a randomised placebo controlled trial to 
receive either AZD5069 twice daily for 28 days or placebo. The trial has concluded 
but results have not yet been published. 
 
5.0 Conclusion 
The vicious circle of bronchiectasis needs to be broken in order to improve 
symptoms, prevent recurrent infections and halt any potential progression of the 
disease. A number of new therapies are in the pipeline targeting not only the 
bacterial burden in the lower airways but also the excessive neutrophilic 
inflammatory response seen in patients with bronchiectasis. Ultimately phase III 
trials are needed before these agents can become licensed for routine use in 
bronchiectasis. 
 
6.0 Expert commentary 
Bronchiectasis was first described over a century ago and despite this there is a lack 
of large randomised controlled trials compared to other chronic respiratory 
conditions. The heterogeneity of this condition and associated co-morbidities makes 
managing this condition challenging. We have focused the review on idiopathic and 
post-infective bronchiectasis, the commonest aetiologies found in bronchiectasis, 
which in our opinion is managed similarly. The aims of treatment for patients with 
clinically significant bronchiectasis are to reduce cough, sputum volume, sputum 
purulence, number of exacerbations and to improve quality of life.   
The management of bronchiectasis should be based on the clinical impact for each 
individual patient. For patients with mild disease treatment should be focused on 
prevention of exacerbations. This includes daily chest clearance using the active 
cycle breathing technique or alternatives recommended by the respiratory 
physiotherapist, if unable to carry out the active cycle breathing technique. For 
younger patients we would recommend positive expiratory pressure devices such as 
the Acapella®. We would recommend an annual influenza vaccination and the 
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pneumococcal vaccination every 5 years. The conjugate pneumococcal vaccine in 
our opinion offers potential immunological therapeutic advantages over the 
traditional polysaccharide vaccine but requires further study. Immunostimulating 
agents are an exciting future therapeutic strategy but further studies are needed 
before this can be implemented into clinical practice. This group of patients have 
limited exacerbations and exacerbations should be treated promptly with antibiotics 
as per sputum culture and sensitivities. In our opinion there is no need in this group 
to receive mucoactive therapies or long term anti-inflammatory or anti-infective 
therapies. 
In our view therapy for moderate clinical disease therapy should be targeted at 
improving symptoms and preventing disease progression. In our opinion these 
patients may benefit from muco-active therapies. The strongest evidence exists for 
hypertonic saline [44-46] and mannitol [47-52] which increase sputum expectoration 
and promote airway clearance. We would recommend using hypertonic saline (7%) 
in patients that have difficulty in achieving airways clearance with active cycle 
breathing technique alone. We would recommend reserving the use of inhaled 
mannitol until the results are available from the ongoing phase III studies. Anti-
inflammatory agents are an exciting therapeutic option which may improve 
symptoms and prevent disease progression. Recently, we have seen the publication 
of large trials assessing the use of macrolides as a potential anti-inflammatory 
therapy to reduce exacerbation frequency [53-55]. We believe that the side effect 
profile of macrolides in this group of patients mitigates the potential therapeutic 
advantages of reducing exacerbations. The side effect profile we are concerned with 
are the increased pneumococcal resistance to macrolides, the adverse effects on 
hearing and balance, the gastro-intestinal side effects and the potential risk of 
macrolide resistant non-tuberculous mycobacteria. In patients with bronchiectasis 
there is excess neutrophil airways inflammation with free elastase activity and high 
levels of chemo-attractants such as interleukin 8, leukotriene B4 and Complement 
5A in the airways. Our view is that the neutrophil elastase inhibitors, CXCR2 
antagonists and statins are the most promising therapeutic targets as they target the 
neutrophil airways inflammation. The best evidence exists for statins as they have 
been shown in a preliminary study to improve neutrophil apoptosis and reduce 
cough but is not sufficient currently to put into routine clinical practice [35]. The 
benefit of statins over macrolides is it not being an antibiotic and therefore if it can 
be tolerated it is a safer long term strategy. Ultimately larger randomised controlled 
trials are needed. In our practice anti-inflammatory therapies are not currently used 
for this group but probably should be in the future when more evidence exists. 
For severe bronchiectasis we would recommend long term antibiotics. The rationale 
for long term antibiotic treatment is to reduce bacterial burden in the airways. 
Consequently this would reduce the number of exacerbations and improve quality of 
life. This was shown in the 12 month phase III trial of nebulised gentamicin [56]. 
The study showed gentamicin was efficacious in reducing the number of 
exacerbations, improving quality of life, increasing time to next exacerbation, 
reducing sputum volume, reducing sputum purulence and reducing bacterial load but 
reported all markers returned to baseline after 3 months off treatment [56]. The 
study by Haworth et al [57] showed that nebulised colomycin continuously for 6 
months reduced time to next exacerbation only if patients complied with therapy. 
Studies to date using cyclical therapy (using inhaled aztreonam) on and off have 
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failed to show clinical benefit [58]. In our opinion inhaled antibiotics should be used 
in patients chronically infected with Pseudomonas aeruginosa with 3 or more 
exacerbations per year. In fully sensitive Pseudomonas aeruginosa we would use 
nebulised gentamicin as first line in view of its proven efficacy and low cost. As 
second line we would use colomycin and third line tobramycin. We use these agents 
continuously for life but monitor the gentamicin levels in serum, hearing and renal 
function and sputum sensitivities.  
We use long term oral therapy for patients with severe bronchiectasis (three or more 
exacerbations per year) and chronic infection with other potential pathogenic 
organisms except Pseudomonas aeruginosa. The commonest pathogen is 
Haemophilus influenzae, and we treat with long term amoxicllin if it is a beta 
lactamase negative producing organism. We treat these patients long term but 
monitor side effects, sputum culture and sensitivities and adjust long term treatments 
as required. 
If there is failure despite this treatment we would consider long term anti-
inflammatory treatment in addition. We would use long term azithromycin in view 
that the long term benefits outweigh the disadvantages in this group of patients. We, 
however, send three sputum samples for mycobacterial culture first and only use in 
patients with no evidence of non-tuberculous mycobacteria. This treatment would be 
continued long term as long as there were no side effects that require treatment 
cessation. We would use macrolides before other potential anti-inflammatory 
therapies in view that these are the only treatments that have been shown to be of 
benefit in international trials. 
We reserve regular intravenous antibiotics, administered in 8 weekly cycles, for 
those patients unresponsive or intolerant to the above therapies and have 5 or more 
exacerbations per year. The only study to date on regular intravenous therapy 
reported patients feel better and require less antibiotic therapy overall [59]. 
Originally a lot of therapies were based on those used for cystic fibrosis but we have 
learnt a lot from the inhaled DNase study [60] that treatments that work in cystic 
fibrosis can be harmful in non-cystic fibrosis bronchiectasis. In the next five years 
we hope to see multiple phase III clinical trials using different inhaled antibiotic 
therapies and multiple phase II trials assessing anti-inflammatory therapies so these 
treatments can become licensed for patients with bronchiectasis. The ultimate 
challenge will be to decide when we should institute both anti-inflammatory and 
anti-infective therapies and in which patients. In our opinion if we target people 
earlier with moderate disease we will hopefully improve symptoms and halt disease 
progression. This review has focussed on chronic management but another challenge 
is defining exacerbations and investigating how they should be treated. Currently we 
treat with oral antibiotics as first line and if this fails proceed to intravenous 
antibiotics using therapies based on sputum cultures and sensitivity patterns for 14 
days. There are ongoing studies addressing optimal length of therapy 
(NCT02047773) which is another fertile area for future research. 
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ABSTRACT 
Introduction: Inhaled or nebulised antibiotics are a major topic of ongoing research 
interest in reducing exacerbations in bronchiectasis. There are no licenced inhaled or 
nebulised antibiotics currently in bronchiectasis. 
Areas covered: Inhaled or nebulised ciprofloxacin as a long-term treatment in 
bronchiectasis. 
Expert opinion: Results from the Phase III ongoing trials on inhaled or nebulised 
ciprofloxacin will be key for the outcome of the drugs but additionally, cost-
effectiveness and longer-term studies will be necessary to determine the viability of 
the drug. Head to head studies are needed to decide on the optimum inhaled or 
nebulised antibiotic and their place with or without long term macrolide therapy. It 
is also important to determine what treatment is viable for acute exacerbations due 
to P. aeruginosa. Ciprofloxacin is the only currently available oral agent for 
exacerbations due to P. aeruginosa. The concern is that using inhaled or nebulised 
ciprofloxacin will prevent the use and efficacy of its oral equivalent, by developing 
resistance.  
 
Drug summary 
Drug name: Ciprofloxacin 
Phase: Phase III trials results awaited. 
Indication : For patient with bronchiectasis that suffer multiple exacerbations (3 or 
more a year) chronically infected with Pseudomonas aeruginosa 
Pharmacology: Fluoroquinolone, strongly active against anaerobic, gram-negative 
bacilli e.g. Pseudomonas aeruginosa, some gram-positive action.  
Method of action: inhibits DNA gyrase and topoisomerase IV inhibiting cell 
division. 
Route of administration: Inhaled and nebulised formulations discussed. 
Ciprofloxacin has equal bioavailability orally and intravenously.  
Chemical formula: C17H18FN3O3•HCl•H2O 
Pivotal trials:  Wilson et al, Ciprofloxacin dry powder for inhalation in non-cystic 
fibrosis bronchiectasis: A phase II randomised study. Eur. Respir. J. 
2013;41:1107-1115. 
Serisier et al, Inhaled, dual release liposomal ciprofloxacin in non-
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cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-
blind, placebo-controlled trial. Thorax. 2013;68:812-817. 
Phase III trials results awaited. 
 
1.0 Introduction 
1.1 Bronchiectasis 
Bronchiectasis is an acquired irreversible bronchopulmonary disease where 
bronchial walls in the lung are permanently inflamed and dilated [1]. This leads to 
what is known as a ‘vicious cycle’ [2] between chronic bacterial infection and 
immune dysregulation. The damaged bronchi lead to debilitation of the mucociliary 
apparatus and therefore an accumulation of mucus, a favourable environment for 
bacteria which, in turn, results in increased bacterial infections. This further 
damages the bronchi by eliciting an inflammatory response and the cycle is 
perpetuated [3]. Haemophilus influenzae, Pseudomonas aeruginosa, Staphylococcus 
aureus, Moraxella catarrhalis and Streptococcus pneumoniae are the most 
commonly cultured pathogens in the sputum of patients with bronchiectasis. P. 
aeruginosa is associated with more severe disease, more rapid decline in forced 
expired volume in 1 second, increased hospitalisation and worse quality of life. It 
has also been associated with reduced survival.  
Patients have recurrent cough, sputum production and recurrent respiratory tract 
infections. The mainstream of treatment is chest physiotherapy, annual influenza 
vaccination and prompt treatment of infective exacerbations. Short term antibiotics 
for exacerbations are part of routine practice and prescribed based on recent 
microbiology. Ciprofloxacin is currently the only oral agent active against P. 
aeruginosa. Long-term antibiotics are considered if having three or more 
exacerbations per year but there are no licensed long-term antibiotics to date for use 
in bronchiectasis [4]. Inhaled or nebulised antibiotics are an attractive option as it 
targets high concentration treatment to the airways with the long term aim of chronic 
bacterial suppression and limits systemic toxicity. Phase 3 trials have been 
completed for inhaled or nebulised ciprofloxacin so this review will therefore focus 
on studies to date on inhaled or nebulised ciprofloxacin.  
 
1.2 Overview of the market 
Currently there are no licensed long term inhaled or nebulised antibiotics for use in 
bronchiectasis due to a lack of long-term randomised double blind control trial data. 
Commonly used unlicensed agents include nebulised gentamicin, tobramycin and 
colomycin [5,6]. There are increasing interest in other inhaled/nebulised antibiotics 
such as aztreonam, amikacin and ciprofloxacin [6]. Competitive agents are the long 
term oral macrolides (mainly azithromycin and erythromycin) showing efficacy in 
reducing exacerbations [7-10].  
 
2.0 Introduction of the compound 
Ciprofloxacin is a broad-spectrum antibiotic compound from the fluoroquinolone 
class. It is mainly active against anaerobic Gram-negative bacilli, in particular 
Pseudomonas aeruginosa but weakly active against Gram-positive bacteria [11]. 
Ciprofloxacin is currently available routinely as an oral or intravenous (IV) 
antibiotic as it has equal bioavailability. However, these routes of administration are 
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not as efficient in achieving the desired pulmonary concentration at the site of 
infection as are inhaled or nebulised formulations. Inhaled or nebulised 
ciprofloxacin has been developed and tested to improve intrapulmonary drug 
delivery for long term treatment. This should also minimize systemic exposure to 
the antibiotic, which would subsequently diminish any risk of systemic toxicity [12]. 
 
2.1 Pharmacodynamics 
Ciprofloxacin’s mechanism of action is focussed on the inhibition of DNA gyrase 
and topoisomerase IV, key components involved in the relaxation of positively 
supercoiled DNA [13] and its separation respectively, thereby inhibiting cell 
division [11]. 
 
2.2 Pharmacokinetics and metabolism 
Orally administered ciprofloxacin is well-absorbed and distributed through the body 
fluids and tissues with a bioavailability of 70%. Its half-live is relatively short 
among fluoroquinolones and range between 3 and 5 hours, requiring a dose every 
12h [11]. On the other hand, inhaled formulations using liposomal release provide a 
way of extending the half-life of the compound to 10.5h and thereby supporting 
single dose per day regime [14]. Ciprofloxacin is eliminated by renal excretion and 
therefore dosage adjustment is necessary for patients with creatinine clearances 
lower than 50 ml/min [11].   
 
3.0 Clinical efficacy 
There are two main forms of inhaled or nebulised ciprofloxacin undergoing phase III 
trials for treatment of bronchiectasis patients: dry powder for inhalation (DPI) and as 
dual-release ciprofloxacin for inhalation (DRCFI), respectively [12].  
 
3.1 Dry Powder for Inhalation Ciprofloxacin (DPI) 
Ciprofloxacin DPI refers to aerosolized ciprofloxacin spray dried through the 
PulmoSphere™ drying process [15]. This method coats the ciprofloxacin core with a 
dry phospholipid “shell” that quickly disperses upon entering the lung, exposing 
thereby the ciprofloxacin crystals. Phase I studies of this form of ciprofloxacin 
assessing its pharmacodynamics and pharmacokinetics revealed achievement of high 
pulmonary concentrations along with low systemic exposure [16].  
A phase II randomized, placebo-controlled, double-blind study was conducted. It 
included bronchiectasis patients that were either idiopathic or had post infectious 
bronchiectasis with positive cultures of at least one of the following pathogens: P. 
aeruginosa, H. influenzae, M. catarrhalis. S. aureus, S. pneumoniae, S. maltophilia, 
Enterobacteriaceae or Achromobacter xylosoxidans. They were divided into two 
arms, one received ciprofloxacin DPI 32.5mg (n=60) and the other one, the 
corresponding placebo (n=64) dispensed using a T-326 inhaler twice daily for 28 
days and followed up for another 56 days after treatment [17]. The study met its 
primary outcome showing a statistically significant reduction in bacterial load in the 
ciprofloxacin DPI cohort compared with the placebo one with a reduction equal to 
3.62 log colony forming units/ml at 28 days. There were trends to an improvement 
in quality of life with ciprofloxacin but this improvement did zznot reach statistical 
or clinical significance. The study was too short to show an impact on exacerbations. 
Following the promising outcomes of phase I and II of ciprofloxacin DPI, phase III 
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clinical trials (RESPIRE-1 and RESPIRE-2) have been designed to assess time to 
first exacerbation and mean exacerbations as the primary outcome and results are 
awaited. Both studies are international prospective, parallel-group, randomized, 
double-blind, multicentre, placebo-controlled trials with a timeframe of 48weeks 
and a 8-week follow-up period after end of treatment [18]. These will consist of two 
different cycle patterns of 28 days on/off drug for 6 cycles or 14 days on/off for 14 
cycles with an inhaled twice daily regimen of 32.5mg regimen. The phase II trial 
showed increased levels of resistance towards ciprofloxacin at the end of treatment 
but an improvement in susceptibility after a period off treatment. The on/off design 
of the study is used to reduce the probability of developing resistance with long term 
antibiotics.  
 
3.2 Dual Release Ciprofloxacin for Inhalation (DRCFI) 
While inhaled formulations of ciprofloxacin proved to be efficient to ensure 
localised delivery of the antibiotic, one pitfall is that the residence time is relatively 
low as the compound gets rapidly absorbed in the system [19]. This rationale led to 
the development of a liposomal formulation that allows a reduced frequency of 
dosing. This may increase the likelihood if patient compliance [19].  
Preliminary studies of liposomal ciprofloxacin (Lipoquin) administered to rabbits as 
aerosols showed a half-life of the compound ranging from 8.3 to 10.2h in the lung, 
consistent with results in mice and significantly higher than values obtained through 
intravenous delivery [20]. Based on these results, Lipoquin®, a liposomal 
ciprofloxacin compound developed by Aradigm Corp made of a bilayer composition 
combining HSPC and cholesterol was subjected to clinical trials [21]. Furthermore, 
another compound made up of a 1:1 mixture of Lipoquin (50mg/mL) and free 
ciprofloxacin (FCI, 20mg/mL) called Pulmaquin® also developed by Aradigm Corp. 
was also subjected to clinical trials [21]. 
A first phase I trial involving 20 health volunteer was set up to evaluate the safety, 
tolerability and pharmacokinetics of Lipoquin looking at a daily single dose given to 
the cohort for one week. The compound was generally well tolerated with no serious 
adverse events recorded and showed pharmacokinetics results consistent with the 
expected values. This study set the bases for the use of a once-daily inhaled dose of 
ciprofloxacin in subsequent trials. 
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An initial open-label trial involving 36 patients from multiple centres and carried 
over a 4-week period compared the administration of two different doses of inhaled 
Lipoquin to bronchiectasis patients chronically infected with P. aeruginosa. Results 
demonstrated a significant mean decrease of P. aeruginosa colony forming units/g 
compared to baseline during and one week after the 28-days treatment period. 
However, there was no statistically significant difference between the two groups 
(3mL and 6mL) but the 3mL group did not report any serious drug-related adverse 
reactions whereas one possible drug-related adverse reaction was reported for the 
6mL dose group. There was no difference in the number of respiratory treatment 
emergent adverse events between the active and placebo groups. 
Following the encouraging results, the combinatory formulation of liposomal 
ciprofloxacin with free un-encapsulated ciprofloxacin was also evaluated to 
establish whether any further clinical benefits could be added from a more rapid 
peak of ciprofloxacin concentration. The mixture composed of 3mL of Lipoquin and 
3mL of free ciprofloxacin proved to be safe and well tolerated and was later named 
Pulmaquin. 
Subsequent series of trials were named ORBIT: Once daily Respiratory 
Bronchiectasis Inhalation Treatment. The first one, ORBIT-1 consisted of a Phase 
2b international, double-blind, placebo-controlled trial of Lipoquin that involved a 
total of 95 adult bronchiectasis patients with chronic infection with P. aeruginosa. 
Two doses were included in the study 100mg (2mL) and 150mg (3mL) 
ciprofloxacin as well as their corresponding placebos, respectively. The primary 
end-point of mean change of P. aeruginosa colony forming units/g from baseline to 
day 28 was achieved. Both group showed statistically significant mean reduction 
although there was no significant difference between the 2mL and 3mL Lipoquin 
doses. Therefore, the 3mL dose of Lipoquin was confirmed as the optimal liposomal 
dose [22]. 
The ORBIT-2 clinical trial was a Phase 2b international, double-blind, placebo-
controlled, multi-centre study expanding over 168 days looking at the 6mL (210mg) 
Pulmaquin formulation and involving a total of 42 adult bronchiectasis patients with 
chronic infection with P. aeruginosa.  The primary end-point of statistically 
significant mean reduction of colony forming units/g (28 days) was achieved and 
Pulmaquin was found to be well-tolerated by the cohort [22]. The Pulmaquin treated 
group resulted in a mean (SD) 4.2 (3.7) log10 CFU/g reduction in P aeruginosa 
bacterial density at day 28 (vs -0.08 (3.8) with placebo, p=0.002). There were fewer 
exacerbations requiring antibiotic treatment (40% versus 77%, p=0.027) and longer 
time to first exacerbation (134days versus 58days p=0.046 per protocol or p=0.057 
modified intention to treat analysis) in the Pulmaquin treated group. There was no 
difference in FEV1, SGRQ score or 6minute walk test between the Pulmaquin 
treated and placebo groups. 
Based on the evidence, Phase 3 ORBIT-3 and ORBIT-4 trials have been designed 
and are currently ongoing involving approximately 255 patients each and both are 
randomized, placebo-controlled, international, multi-centre studies. They are 
organised as 6 cycles of 28days on/28days off treatment followed by a final 28 day 
open-label extension with all patients receiving Pulmaquin. The primary end-point 
was determined as the time to first exacerbation with secondary end-points looking 
at further parameters such as number of pulmonary exacerbations, number of severe 
pulmonary exacerbations and quality of life [22,23].  
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Table 1: Summary of completed and ongoing trials of ciprofloxacin in bronchiectasis based on the data available on https://clinicaltrials.gov/ 
 
Intervention 
[Study] Phase 
Primary 
Outcome 
Measures 
Secondary Outcome Measures Arms and assigned interventions Outcome 
Radiolabelled 
Ciprofloxacin Dry 
Powder for 
inhalation (DPI) 
(Cipro Inhale, 
BAYQ3939) 
I 
Ciprofloxacin 
pharmacokinetics, 
including lung 
deposition 
[timeframe: 
within 24h of 
treatment] 
Adverse events collection  
[timeframe: follow-up 2 weeks] 
• Ciprofloxacin	32.5mg	single	powder	
dose	of	99m	Tc	labelled	ciprofloxacin	
PulmoSphere	inhalation	powder	
inhaled	by	healthy	subjects	
• Ciprofloxacin	32.5mg	single	powder	
dose	of	99m	Tc	labelled	ciprofloxacin	
PulmoSphere	inhalation	powder	
inhaled	by	healthy	subjects	under	
charcoal	block	
• Ciprofloxacin	32.5mg	single	powder	
dose	of	99mTc	labelled	ciprofloxacin	
PulmoSphere	inhalation	powder	
inhaled	by	COPD	patients	
• Ciprofloxacin	32.5mg	single	powder	
dose	of	99mTc	labelled	ciprofloxacin	
PulmoSphere	inhalation	powder	
inhaled	by	bronchiectasis	patients	
Single dose 
32.5mg of 
ciprofloxacin DPI 
safe and well 
tolerated; 
systemic 
exposure 
considerably 
smaller than 
parenteral 
treatment, t1/2 
clearance and 
volume of 
distribution 
greater than 
values reported 
for oral and IV 
ciprofloxacin. 
Ciprofloxacin DPI 
(Cipro, 
BAYQ3939)[13] 
II 
Change from 
baseline in total 
bacteria load in 
the sputum at the 
end of treatment 
[day 29] 
Change in FEV1 and FVC from baseline; 
time to exacerbation with antibiotic 
intervention; effect on HRQoL (using 
both the SGRQ and CRQ-SAS); change 
in C-reactive protein and absolute 
neutrophil count from baseline; 24h 
sputum volume and colour; emergence 
of resistance among baseline pathogens 
• Ciprofloxacin	for	inhalation	32.5mg	
twice/day	
• Inhalation	of	matching	placebo	
twice/day	
Well tolerated 
and significantly 
reduced total 
sputum bacterial 
load at the end of 
treatment 
compared with 
placebo (-3.6 Log 
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and emergence of new potential 
respiratory pathogens 
unit reduction) 
Ciprofloxacin DPI 
(BAYQ3939) 
[RESPIRE-1] [14] 
III 
Time to first 
exacerbation over 
48 weeks after 
baseline 
Mean number of exacerbations per 
patient over 48 weeks after baseline, 
pathogens present at baseline and 
eradicated at 48 weeks, change of SGRQ 
score from baseline, new pathogens at 
48 weeks, not present at baseline, 
changes of FEV1 from baseline, adverse 
events: number and extent. 
• Ciprofloxacin	DPI	32.5mg	inhaled	
twice	daily	intermittently	
administered	for	28	days	on/	28	days	
off	for	6	cycles	
• Placebo	inhaled	twice	daily	
intermittently	administered	for	28	
days	on/28	days	off	for	6	cycles	
• Ciprofloxacin	DPI	32.5mg	inhaled	
twice	daily	for	14	days	on/	14	days	
off	for	14	cycles	
• Placebo	inhaled	twice	daily	
intermittently	administered	for	
14days	on/14days	off	for	14	cycles	
Full data not 
published yet 
Ciprofloxacin DPI 
(BAYQ3939)  
[RESPIRE-2]  
III 
Time to fist 
exacerbation over 
48 weeks after 
baseline 
Mean number of exacerbations per 
patient over 48 weeks after baseline, 
pathogens present at baseline and 
eradicated at 48 weeks, change of SGRQ 
score from baseline, new pathogens at 
48 weeks, not present at baseline, 
changes of FEV1 from baseline, adverse 
events: number and extent. 
• Ciprofloxacin	DPI	32.5mg	inhaled	
twice	daily	intermittently	
administered	for	28	days	on/	28	days	
off	for	6	cycles	
• Placebo	inhaled	twice	daily	
intermittently	administered	for	28	
days	on/28	days	off	for	6	cycles	
• Ciprofloxacin	DPI	32.5mg	inhaled	
twice	daily	for	14	days	on/	14	days	
off	for	14	cycles	
• Placebo	inhaled	twice	daily	
intermittently	administered	for	
14days	on/14days	off	for	14	cycles	
Full data not 
published yet 
Ciprofloxacin for 
inhalation 
[ORBIT-1] [19] 
II 
Mean change in 
PA density in 
sputum log10 
Microbiological efficacy; time 
to/number of/severity of/time to resolve 
exacerbations; changes in spirometry; 
• Ciprofloxacin	for	inhalation	3ml/day	
by	inhalation	for	28	days	
• Ciprofloxacin	for	inhalation	2ml/day	
2ml and 3ml 
doses found to be 
equipotent, 
 323 
CFU/g of sputum 
from baseline to 
day 28 
QoL; safety and tolerability. by	inhalation	for	28	days	
• Placebo	3ml/day	by	inhalation	for	28	
days	
• Placebo	2ml/day	by	inhalation	for	28	
days	
significantly 
reducing PA 
density in sputum 
with excellent 
safety and 
tolerability 
Dual Release 
Ciprofloxacin for 
inhalation 
(DRCFI) [ORBIT-
2] [18] 
II 
Mean change in 
PA density in 
sputum log10 
CFU/g of sputum 
from baseline to 
day 28 
[timeframe: 168 
days] 
Microbiological efficacy; time 
to/number of/severity of/time to resolve 
exacerbations; changes in spirometry; 
QoL; safety and tolerability. 
• DRCFI	once	daily	made	up	of	
liposomal	ciprofloxacin	for	inhalation	
150mg	in	3ml	and	free	ciprofloxacin	
60mg	in	3	ml	provided	in	separate	
vials	for	3	cycles	of	28	days	on	/	28	
days	off	
• Placebo	once	daily	made	up	of	control	
liposomes	15mg	in	3ml	and	normal	
saline	0.9%	in	3ml	for	3	cycles	of	28	
days	on	/	28	days	off	
Well tolerated 
and significantly 
reduced total 
sputum bacterial 
load at the end  
(-4.2 log unit 
reduction) of 
treatment 
compared with 
placebo 
Dual Release 
Ciprofloxacin for 
inhalation 
(DRCFI) 
[ORBIT-3] 
III 
Time to first 
exacerbation 
[timeframe: 1 
year] 
Number of exacerbations 
[timeframe: 1 year] 
• DRCFI	once	daily	for	28	days	on	/	28	
days	off	for	six	cycles	
• Placebo	Liposomes	for	inhalation	
(PLI)	once	daily	for	28	days	on	and	28	
days	off	for	six	cycles	
 Full data not 
published yet 
Pulmaquin (liquid 
mixture of liposomally 
encapsulated and un-
encapsulated 
ciprofloxacin) 
[ORBIT-4] 
III 
Time to first 
pulmonary 
exacerbation from 
baseline 
[timeframe: 48 
weeks] 
Number of exacerbations 
[timeframe: 1 year] 
• Pulmaquin	once	daily	28	days	
on/28days	off	for	6	cycles	
• Placebo	(liquid	formulation	of	empty	
liposomes)	once	daily	for	28	days	
on/28	days	off	for	6	cycles	
Full data not 
published yet 
4.0 Safety and Tolerability 
The main side effects are related to oral Ciprofloxacin. The most common side 
effects experienced are nausea, vomiting and diarrhoea. Headache, dizziness, 
insomnia, skin rash or abnormal liver function can be more serious complications 
related to its use. The most concerning side-effects are peripheral neuropathy and 
tendonitis which can cause permanent damage [11]. There is limited data available 
on side effects with inhaled ciprofloxacin but expected side effects will be local side 
effects including oro-pharyngeal thrush and bronchospasm but its tolerability and 
side effect profile will come clearer following publication of the phase 3 trials.    
 
5.0 Regulatory affairs 
There are currently no licensed inhaled or nebulised drugs for use in bronchiectasis. 
The ongoing trials if they meet their primary endpoint will then likely meet 
regulatory approval for licensing for use in bronchiectasis. 
 
 
6.0 COMMENTARY – EXPERT OPINION 
1. What, if any, improvement does the drug hold over other therapies? 
The use of specially formulated preparations of ciprofloxacin is designed to 
achieve optimal deposition in the lungs. Long term treatment is aimed to 
reduce chronic bacterial suppression, although eradication would be the 
preferred outcome. Inhaled or nebulised ciprofloxacin over 28 days achieved 
an excellent log unit reduction in microbial load  (-3.4 to -4.1 log units at 28 
days), similar to aminoglycosides (-4.6 log units) and both superior to the 
microbial load reduction with amikacin (-0.4 log units), colomycin (-1.4 log 
units) and aztreonam (-2.6 log units) [6]. Long term studies are however 
needed to assess whether this impacts on reducing exacerbations, the 
endpoint required by EME and FDA for licensing purposes. 
 
2. What, if any, impact is the drug likely to have on current treatment 
strategies? 
To date, colostin [25] and gentamicin [5] has the most robust data for proven 
effectiveness in bronchiectasis. Nebulised gentamicin is inexpensive and 
reduced exacerbations in a single centred study, but treatment must be 
continuous for its ongoing efficacy. The Colsitin trial showed it prolonged 
the time to first exacerbation but only in patients that complied with 
treatment >80% [25]. Cost-effectiveness studies are important and necessary 
in guiding long term therapy. In addition, there have been no head to head 
trials comparing inhaled or nebulised antibiotics with long term macrolide 
therapy so there is no data available to determine which long term treatment 
strategy (anti-inflammatory or antibiotic) should be instituted first. 
 
Currently inhaled or nebulised ciprofloxacin has no impact on current 
treatment strategies. The two main therapeutic long term antibiotics that 
clinicians currently use are long term macrolide therapy or long term 
nebulised antibiotics. The long term nebulised antibiotics used 
internationally, despite being unlicensed, are nebulised gentamicin, 
colomycin and tobramycin.  
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3. How likely are physicians to prescribe the drug? 
Currently physicians are unlikely to prescribe inhaled/nebulised 
ciprofloxacin as there are suitable alternatives as highlighted above. The 
issue of developing resistance, which may make oral ciprofloxacin 
ineffective for future exacerbations, is an important consideration, especially 
in the more severe P. aeruginosa colonised cohort of patients and so the 
outcome of the phase III studies are eagerly awaited. 
The situation will however change if there is regulatory approval for inhaled 
or nebulised ciprofloxacin. 
 
4. What data is still needed? 
Results from the Phase III ongoing trials will be key for the outcome of the 
drugs but additionally, cost-effectiveness and longer-term studies will be 
necessary to determine the viability of the drug. Head to head studies are 
needed to decide on the optimum inhaled or nebulised antibiotic and their 
place with or without long term macrolide therapy. It is also important to 
determine what treatment is viable for acute exacerbations due to Ps. 
aeruginosa as a fear is that using inhaled or nebulised ciprofloxacin will 
prevent the use and efficacy of oral ciprofloxacin for exacerbations due to P. 
aeruginosa.   
 
5. Where is the drug likely to be in 5 years’ time? 
There are many unanswered questions about long term inhaled or nebulised 
antibiotics. The correct target group needs explored, but in our opinion most 
will focus treatment in patients with chronic infection with P. aeruginosa or 
non-fermenting gram negative organisms. There will be other potential 
agents that may also be licensed such as inhaled or nebulised gentamicin, 
colomycin, tobramycin and perhaps levofloxacin and amikacin. As the 
nebulised aztreonam study failed to reach its primary endpoint [24], it is 
unlikely that this will be available for routine use in bronchiectasis.   The 
outcome of the current phase III trials mentioned above will be instrumental 
in deciding the place of inhaled/nebulised ciprofloxacin amongst the other 
currently used inhaled antibiotic therapies.  
There may be strategies that look at the optimum duration of inhaled 
antibiotic therapy and whether treatment will be on/off for 14 or 28 days or 
continuous treatment. Our belief is that continuous treatment is likely to be 
the optimum regimen to maintain bacterial suppression and therefore have 
greater impact on reducing exacerbations. Whether continuous regimens 
have an adverse impact on subsequent resistance patterns compared with on-
off regimens remains to be seen. The long term impact if resistance does 
develop is not known. 
It will also be interesting to see if there is any added benefit with co-
administration of oral macrolide therapy.  
In our opinion, for those chronically infected with Haemophilus influenzae, 
Streptococcus pneumoniae, Moraxella catarrhalis, long term oral antibiotics 
should be the first line long term treatment. Evidence to date would be that 
such patients with recurrent infections having at least three exacerbations per 
 2 
year will be better to have first line treatment with a long-term macrolide as 
there is a paucity of randomised controlled trials evaluating other long term 
oral targeted antibiotics. An alternative, in our opinion is that such patients 
may also benefit from a targeted long term oral antibiotic such as amoxicillin 
(in beta lactamase negative patients) or amoxicillin with clavulanic acid or 
doxycycline (for beta lactamase producing organisms) but randomised 
controlled trials are needed.  
The next 5 years will likely in our opinion start to provide licenced therapies 
for patients with bronchiectasis. 
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Abbreviations 
 
Incremental Shuttle Walk test (ISWT) 
St George’s Respiratory Questionnaire (SGRQ) 
Leicester Cough Questionnaire (LCQ) 
Quality of life questionnaire-bronchiectasis (QOL-B) 
6minute walk test (6MWT) 
Bronchiectasis Severity Index (BSI) 
Chronic obstructive pulmonary disease (COPD) 
Forced expiratory volume in 1 second (FEV1) 
Forced vital capacity (FVC)  
Pseudomonas. Aeruginosa (PA) 
Potentially pathogenic microorganisms (PPM) 
Mixed normal flora (MNF) 
White cell count (WCC) 
Estimated sedimentation rate (ESR) 
C-reactive protein (CRP) 
 
Abstract 
Rationale: There is a need for a validated clinical endpoint to assess response to 
therapies in bronchiectasis. 
Objective: To assess the reliability, validity and responsiveness of the incremental 
shuttle walk test (ISWT) as a clinical endpoint in bronchiectasis.  
Methods and measurements: Reliability: In clinically stable patients (n=30) the 
ISWT was performed twice; 6months apart. Validity: Correlation between the St 
George’s Respiratory Questionnaire (SGRQ) and ISWT (n=94) was performed. The 
1-year gentamicin study was reanalyzed to assess the area under the curve (percent 
change of ISWT with a 4 or more-unit improvement in total SGRQ). 
Responsiveness: ISWT was performed pre-and post-14 days antibiotics for an 
exacerbation (94 oral and 30 intravenous courses, n=124) and reanalysis of the 1-
year Gentamicin study,n=57. 
Main Results: The ISWT did not significantly change over 6-months whilst 
clinically stable.  
The ISWT correlated inversely with the SGRQ (rs=-0.60, p<0.0001), Bronchiectasis 
Severity Index score (rs=-0.44, p<0.0001) and sedentary time (rs= -0.48, p=0.0007) 
but correlated with physical activity (rs=0.42, p=0.004). The area under the curve for 
% change in ISWT with 4 or more-unit improvement in SGRQ was 0.79 (95% CI 
0.66-0.91), p=0.001. A threshold of 5% improvement ISWT has a 92% sensitivity 
but 50% specificity, and from the responsiveness studies would capture 73% of all 
patients.  
Conclusions: This study has confirmed the ISWT to be reliable, valid and responsive 
to change in patients with bronchiectasis. The authors propose at minimum clinically 
important difference of 5% improvement in ISWT would be a useful objective 
endpoint to assess therapies in bronchiectasis. 
 
Introduction 
There is an urgent need for objective endpoints to assess progression and response to 
treatment in bronchiectasis. To date, 24-hour sputum volume, microbial clearance, 
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C-reactive protein, quality of life assessed by the St George’s Respiratory 
Questionnaire (SGRQ) [1], the Leicester Cough Questionnaire (LCQ) [2], the 
Bronchiectasis health questionnaire [3] & the Quality of life questionnaire-
bronchiectasis (QOL-B) [4, 5] have been found to be useful clinical endpoints [6]. 
Qualitative bacteriology, and not quantitative bacteriology which is only used in 
phase 2 studies, [7] is often used in routine clinical practice and can be difficult to 
interpret in chronically colonised patients [8]. ‘Exacerbation frequency’ or ‘mean 
exacerbations’ are being used only as endpoints in randomised clinical trials, [9-12] 
with recent consensus on the definition of an exacerbation for use in clinical 
research being published [13]. The forced expired volume in 1 change (FEV1) 
change has shown inconsistent results between studies and not thus a useful 
endpoint [6, 9-12]. There are limitations with each of these endpoints. 
 
An endpoint assessing functional capacity may be a useful endpoint which is 
clinically meaningful. The ISWT and 6-minute walk test (6MWT) are used to assess 
functional capacity. The authors chose the objective assessment of functional 
capacity, ISWT as opposed to the self-pacing of the 6MWT. Both may be useful, but 
a study in cystic fibrosis comparing the two tests found patients covered more 
distance with the ISWT and heart rate and dyspnoea scores were significantly higher 
in the recovery phase of the ISWT than with the 6MWT (p<0.05) [14]. In a small 
study (n=37) in patients with bronchiectasis the minimum clinically important 
difference was thought to be 35m using the anchor-based method (AUC 0.88, 95% 
CI 0.73-0.99) and 37m using the distribution-based method [15]. 
The aim of this paper is to assess the use of ISWT as a reliable indicator of disease 
severity, its response to treatment in bronchiectasis as an objective clinical endpoint 
and its minimum clinically important difference (MCID). 
 
Methodology 
 
Ethics 
Ethical approval was granted by the West of Scotland Research ethics service, REC 
reference 13/WS/0230. All patients provided informed written consent and were 
recruited from a single centre. This approval applies to all the studies listed except 
reanalysis of the Gentamicin study by Murray et al [16] which had separate ethical 
approval. – Clinical Trials Registration number NCT00749866. 
 
Study design 
The ISWT was validated by assessing its reliability, validity and responsiveness. 
Each of these parameters was assessed separately by using several sub-studies 
(Figure 1). Every patient in each of the studies had previously performed the ISWT 
as part of routine clinical practice and was familiar with how the test was conducted. 
A practice walk was therefore not necessary. During each sub-study, no changes to 
medications or overall management of the patients (new airway clearance techniques 
or enrolment into pulmonary rehabilitation) was made other than the antibiotic 
described in the sub-study used to treat exacerbations. 
 
1). The reliability of the ISWT was assessed by inviting 30 patients from routine 
outpatient bronchiectasis clinics (varying severity) to complete the incremental 
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shuttle walk test 6 months apart when they were clinically stable, defined as no 
antibiotic use in the last month. There was no change made to their medical 
management of bronchiectasis during this time.  
 
2). The validity of the ISWT was assessed by correlating the distance walked by 
patients with SGRQ score. This has been validated for use in bronchiectasis and 
measures quality of life. 94 different patients with bronchiectasis were recruited 
prospectively over an 18month period. They were seen at three different time points 
to perform both the ISWT and complete the SGRQ: (VO) when clinically stable, 
(VS) start of an exacerbation and (VE) end of exacerbation after treatment with 14 
days of oral antibiotics (VE). ISWT results were also correlated with the 
Bronchiectasis Severity Index (BSI) scores [17] of these patients to assess disease 
severity. In a sub-study, 49 of these patients (mixture of stable and start of 
exacerbation) were asked to wear an activity monitor on their arm during waking 
hours for a period of 14 days. The physical activity time and sedentary time 
recorded was correlated with the ISWT. 
 
To assess the utility of the ISWT, the authors used the anchor method using a 4 or 
more-unit improvement in total SGRQ as a clinically significant important 
improvement in quality of life [1]. The 1-year gentamicin study [16] was reanalyzed 
to assess the area under the curve (percent change of ISWT with a 4 or more-unit 
improvement in total SGRQ). This study was selected as there was significant 
improvement of 1-year nebulised gentamicin compared with the group that received 
nebulised saline. 
  
3). The responsiveness was assessed by analysing the change in ISWT in patients on 
short term antibiotic therapy for exacerbations. Short-term antibiotic therapy is the 
mainstay for treating exacerbations and known to be effective. 94 patients (recruited 
as part of (2)) received 14days oral antibiotics and performed the ISWT at the start 
and end of exacerbation. An additional 30 patients receiving 14days of intravenous 
antibiotic therapy for an exacerbation (as per the British Thoracic Society guidelines 
[18]) were recruited and performed the ISWT pre and post therapy. Patients on oral 
or intravenous short-term therapy also had their spirometry checked, serum 
inflammatory markers, sputum colour [19] and volume recorded at the time of the 
visits. Responsiveness was also assessed in patients on long-term therapy, by 
retrospectively re-analysing a study where a different cohort of patients were given 
either nebulised 0.9% saline or nebulised gentamicin 80mg twice daily for 
12months, n=65 [16]. Again, the ISWT was performed pre- and post therapy.  
 
Incremental shuttle walk test 
The test was performed per standard test procedure [20] and consisted of a 10-metre 
shuttle course on a flat surface with the walking speed controlled using pre-recorded 
audio signals. At the start and end of the ISWT all patients had their heart rate, 
oxygen saturations and dyspnoea score according to the modified BORG dyspnoea 
scale [21] recorded in accordance with standardised guidelines (2002) [22]. The 
successful completion of distance walked in our study was recorded in increments of 
10m. Difference in ISWT walked between visits are presented in groups of 
‘deterioration/no change’, ‘1-29m improvement’, ‘30-59m improvement’, ‘60-89m 
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improvement’ and ‘³90m improvement’. As baseline distance varied amongst 
patients, the percentage change in ISWT distance was also calculated and presented 
in groups of ‘deterioration’, ‘no change’, ‘0-4.99% improvement’, ‘5-9.9% 
improvement’ and ‘³10% improvement’ change. 
 
Activity monitors 
Patients were asked to wear the SenseWear Armband (BodyMedia Inc., Pittsburgh, 
USA) on the right triceps area. The patients were asked to keep it on for 8 days 
minimum and to only remove it during showering or bathing. The handedness of the 
patient was recorded.  
 
Lung function 
We measured pre-bronchodilator forced expiratory volume in 1 second (FEV1), 
forced vital capacity (FVC) and ratio FEV1:FVC by spirometry according to 
standardized guidelines [23].  
 
Sputum 
Sputum colour was recorded according to a visual colour chart rating. Mucoid 
sputum was rated 1, mucopurulent rated as 2 and purulent sputum rated as 3 or 4 
depending on colour [19]. 24hour sputum volume was recorded by asking patients to 
expectorate solely into a universal container for 24hours. Qualitative and 
quantitative microbiology was performed on all samples pre- and post- 14 days of 
antibiotics. 
 
The minimum clinically important difference 
The anchor method was used to determine the minimum clinically important 
difference using a 4 or more unit rise in SGRQ as a clinically significant 
improvement of quality of life.  
 
Statistical analysis 
All data were analysed using Graphpad prism version 5.0a (Graphpad software, San 
Diego, CA, USA). For demographic and clinical variables, data are presented as 
median (interquartile range) for continuous variables and n (%) for categorical 
variables unless specified otherwise. A Bland-Altman test was used to show 
repeatability over time with bias and 95% limits of agreement calculated and 
intraclass correlation coefficient calculated (study 1). Correlations were assessed 
using the Spearman correlation. The area under the curve was calculated using 
SPSS® version 24. A P value <0.05 was considered statistically significant for each 
analysis. Comparison of changes within a group i.e before and after treatment was 
calculated using Wilcoxon signed rank test and we compared categorical data 
between groups with the χ2 test. An unpaired t test was used to calculate the change 
from baseline to 12months in ISWT between patients assigned gentamicin and 
nebulised saline with results displayed as mean difference (95% confidence 
interval). The MCID was calculated using the anchor method. 
 
Results 
 
Reliability 
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The aetiologies of bronchiectasis in the 30 patients recruited were 70% idiopathic, 
13% post infection, 13% autoimmune disease and 3% IgG2 subclass deficiency. 
Patient baseline characteristics are outlined in table 1.  
 
Table 1. Baseline characteristics 
 
Table 1. Baseline characteristics of patients in this study. Results are presented as 
mean (SD) or %. IV: intravenous, FEV1: forced expiratory volume in 1 second, 
FVC: forced vital capacity, PPM: potentially pathogenic microorganisms, COPD: 
chronic obstructive pulmonary disease.  
 
At the first visit, patients walked a median (IQR) distance of 390m (225m - 
462.5m). 6 months’ later patients were recalled and the test was performed again in 
an identical manner. Patients walked a median distance of 400m (260m - 480m) 
p=0.48. The median change in distance walked was 0m (-25m – 50m) with median 
0% change (-4.9% - 18.2%). A Bland-Altman plot showed a bias of 1.38m and 95% 
limits of agreements from -188m to 185m (see figure 2). The intraclass correlation 
coefficient was calculated to be 0.85 (95% CI 0.68-0.93, p<0.001). 
  
Characteristics Reliability  
(n=30) 
Responsiveness 
IV (n=30) 
Responsiveness 
oral (n=94) 
Age (years) 59.1 (11.4) 62.4 (11.4) 65.6 (10.7) 
Female 47% 47% 54% 
Never smoked 
Ex – smoker 
Current 
60% 
40% 
0% 
70% 
30% 
0% 
62% 
36% 
2% 
FEV1 (L) 
Predicted FEV1 (%) 
2.2L (0.9) 
73.9% (24.5) 
1.58 (0.84) 
56.6% (24.9) 
1.90 (0.75) 
75.8% (23.9) 
FVC (L) 
Predicted FVC (%) 
3.2L (1.1) 
86.4% (25.6) 
2.53 (0.9) 
72.7% (23.2) 
2.85 (0.92) 
91.4% (22.3) 
Sputum microbiology Pseudomonas 
0% 
Other PPM 
40% 
Mixed 
normal flora 
57% 
No sputum 
3% 
Pseudomonas 
27% 
Other PPM 60% 
Mixed normal 
flora 17% 
Pseudomonas 
13% 
Other PPM 
76% 
Mixed normal 
flora 20% 
Inhaled corticosteroids 
Long term oral (>28 
days) oral 
corticosteroids 
60% 
 
7% 
80% 
 
10% 
70% 
 
2% 
COPD 0% 7% 14% 
Co-existing asthma 57% 43% 49% 
Long term (>28 days) 
antibiotics 
3% 10% 7% 
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Validity 
We correlated the meters walked in the ISWT in all three visits for the 94 patients 
(282 tests) with the SGRQ (Total and Activity). There was a negative correlation 
with total and activity scores of the SGRQ with ISWT as shown in figure 3 below; 
rs=-0.60 (P<0.0001) and rs=-0.64 (P<0.0001) respectively. In the sub-study of 49 
patients, the ISWT negatively correlated with sedentary time (rs=-0.48 (P=0.0007)) 
and positively correlated with physical activity duration (rs=0.42 (P=0.004)) time 
measured on the activity monitors – see figure 4. The severity of bronchiectasis 
assessed by calculating the bronchiectasis severity index at baseline also negatively 
correlated with the ISWT, rs=-0.44 (P<0.0001). 
 
In the 12-month nebulised antibiotic study, the area under the curve for % change is 
ISWT with 4 or more-unit improvement in SGRQ was 0.79 (95% CI 0.66-0.91), 
p=0.001. The sensitivity and specificity for the threshold of % improvement ISWT 
are: for 2% improvement in ISWT, 92% sensitivity and 42% specificity; for 5% 
improvement in ISWT, 92% sensitivity and 50% specificity; for 7.5% improvement 
in ISWT, 88% sensitivity and 58% specificity; for 10% improvement in ISWT, 83% 
sensitivity and 62% specificity.  
The authors determined that a clinically useful test would be when we could achieve 
at least 50% of patients having a 50% improvement in SGRQ or more – see table 2. 
Using data from exacerbations, a 5% improvement or greater in ISWT would 
represent the MCID. Although all patients receiving antibiotic therapy improved, 
Erythrocyte Sedimentation Rate only improved in the group that had a 5% or more 
improvement in the ISWT (p<0.001). Both groups had improved C reactive protein, 
but the group that had 5% or more improvement had a greater reduction in C 
reactive protein (p=0.007, data not shown). 
 
Table 2. 
% improvement 
in ISWT group 
% of 110 
patients 
% with SGRQ 
improvement 
(³4units) within 
the group 
AVERAGE 
SGRQ CHANGE 
(Units) 
Deterioration 10.9% 25% -2.08 
 
0.1-1% 6.4% 42.8% -1.67 
 
1.1-2.4% 1.8% 50% -5.5 
2.5% - 4.9% 6.4% 42.8% 5.29 
5-9.9% 9% 60% -8.28 
 
10-19.9% 25.5% 53.6% -6.86 
 
> 20% 40% 68.1% -9.86 
 
Table 2: Percentage of patients with different percent improvements in ISWT, after 
treatment with oral and intravenous antibiotics for exacerbations (data not available 
in 14), with their average change in SGRQ score (a reduction of 4 or more units is a 
clinically significant difference). 
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Responsiveness – Intravenous therapy 
30 patients were given intravenous antibiotics for exacerbations of bronchiectasis. 
Their baseline characteristics are presented in table 1. 
 
Patients were assessed at the beginning and end of intravenous therapy to ensure that 
improvement after intravenous therapy had occurred. Patients had reduced sputum 
purulence, reduced sputum volume, improved forced vital capacity, improved white 
cell count and systemic inflammatory markers erythrocyte sedimentation rate, C 
reactive protein and improved sputum bacterial clearance – see online supplement 
table 1. At the start of exacerbation, patients were walking a median distance of 
265m (137.5-395.0). After 14 days of intravenous therapy, the median distance 
walked improved to 335m (190.0-450.0), p=0.004 with the median change 32.5m (-
12.5m – 90m) and percentage change 11.9% (-3.7 – 38.9%). 
 
Responsiveness - Oral therapy 
94 patients attended for exacerbations that were managed on an outpatient basis with 
oral antibiotics. Oral antibiotics reduced sputum purulence and volume, improved 
forced expired volume in 1 second and forced vital capacity, reduced circulating 
white cell count and systemic inflammatory markers erythrocyte sedimentation rate 
and C reactive protein and improved sputum bacterial clearance (online supplement 
table 2). Patients walked a median value of 370m (252.5-540) on the incremental 
shuttle walk test when clinically stable at the baseline visit. At start of exacerbation 
the median distance walked was 330m (180-510) with median change in distance -
40m (-100-0) and median percentage change -11.1% (-33.1% - 0) compared with 
pre-exacerbation whilst patients were clinically stable (P<0.0001). After oral 
antibiotic therapy, the median distance walked was 350m (210-530). The median 
improvement in distance walked was 50m (10m - 85m) with percentage 
improvement of 16.3% (3.1% - 33.3%) compared with the start of the exacerbation 
(P<0.0001). The distance walked at baseline did not differ from the distance walked 
after oral therapy, suggesting patients may have returned to their baseline level of 
function (p=0.8). 
 
Responsiveness - Nebulised therapy 
In a previous study 65 patients were randomly assigned to nebulised gentamicin 
80mg therapy twice daily or nebulised 0.9% saline [16]. They performed an 
incremental shuttle walk test at baseline and repeated it at 12months of therapy. 
There was improved incremental shuttle walk in the gentamicin treated group 
compared with the saline arm with a mean difference 90.4m (95% CI 40.76 – 140m, 
p=0.0006) and a mean % difference 34.7% (95% CI 12.56 – 56.79, p=0.003). 
 
Change in ISWT with antibiotic therapy 
The actual difference in distance walked and percentage change was calculated for 
each of the treatment groups and shown in figures 5 and 6 respectively.  Overall 
there was 20% of patients that had ‘deteriorated/ no change’ in the ISWT, 14% ‘1-
29m’ improvement, 16% ‘30-59m’ improvement; 20% ‘60-89m’ improvement and 
30% ‘³90m’ improvement.  
Overall 14% of patients tested showed a ‘deterioration’ in %ISWT distance walked, 
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6% demonstrated ‘no change’ on the % ISWT distance walked compared with 
baseline, 8% of patients showed a ‘1-4.99%’ improvement, 10% had ‘5-9.99%’ 
improvement and 63% had ‘³10%’ improvement in the ISWT. 
 
A threshold of 30m improvement would capture 66% of all patients (50% that 
received 14d intravenous antibiotics, 64% that received 14d oral antibiotics and 89% 
received 12m nebulised gentamicin). A threshold of 60m would capture 50% (43% 
of those that received 14d intravenous antibiotics, 48% of those that received 14d 
oral antibiotics and 63% that received 12m nebulised gentamicin). If a threshold of 
at least 5% improvement in ISWT is used, this would capture 73% overall (60% of 
those that received 14d intravenous antibiotics, 69% of those that received 14d oral 
antibiotics and 96% of those that received 12m nebulised gentamicin). A threshold 
of at least 10% improvement in ISWT would capture 63% overall (50% of those that 
received 14d intravenous antibiotics, 61% of those that received 14d oral antibiotics 
and 81% of those that received 12m nebulised gentamicin).   
 
SGRQ and at least 5% improvement in ISWT 
SGRQ scores for 110 patients that received antibiotic therapy were analysed 
(complete data from 14 patients not available). 62.2% of patients that had at least a 
5% improvement in their ISWT distance also had a 4 or more unit rise in SGRQ 
score (p=0.02). 62.5% of patients that had at least a 10% improvement in their 
ISWT had a 4 or more unit rise in SGRQ score (p=0.02).  
 
13.2% of patients that had at least a 30m improvement in ISWT distance also had a 
4 or more unit rise in SGRQ (p=0.15) and 14% of those with a 60m improvement or 
more had a significant improvement in SGRQ of 4 units or more (p=0.28). 
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Discussion 
The main findings of this study support the ISWT to be reliable, valid and 
additionally, responsive to therapy (both short-term and long-term) in a large cohort 
of patients with bronchiectasis and therefore supports its use as an objective clinical 
endpoint that represents functional capacity. 
 
The reliability was assessed over a 6-month period as the proposal would be to use 
the ISWT to assess both short or long-term therapies. At each time period, patients 
were stable and had not required antibiotic therapy for at least 28 days. The ISWT 
was found to be repeatable, in line with previously reported findings [24]. 
 
The validity of the ISWT was supported with good negative correlations with both 
the total and activity SGRQ scores. The SGRQ was chosen as it is already validated 
for use in bronchiectasis and specifically measures activity as one of its domains. 
The correlation would never be perfect as the ISWT is an objective measure of 
exercise capacity whilst the SGRQ is a self-filled questionnaire. In a sub group, 
there was a moderate correlation with sedentary and physically active duration time 
measured by activity monitors and further supports the proposal that the ISWT 
correlates well with other markers of exercise capacity. Overall there has been 
demonstration of at least moderate validity with the ISWT.  
 
The authors assessed the response to therapies known to work in bronchiectasis and 
included patients with an exacerbation treated with oral antibiotics and a more 
severe group receiving intravenous antibiotic therapy. Objective assessments 
showed patients did improve with short term antibiotic therapy and similarly there 
were significant improvements in ISWT. The third group chosen was the previously 
published study assessing the effectiveness of nebulised gentamicin over 1 year to 
assess the ISWT with effective long-term therapy. Patients felt better with nebulised 
gentamicin therapy and there was a reduction in overall exacerbations compared 
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with the group that received nebulised 0.9% saline therapy. There was similarly a 
significant improvement in the ISWT (in the gentamicin arm) over 1 year [16]. The 
change in ISWT distance was found to be sensitive to treatment with the above 
therapies and the authors would therefore recommend that the ISWT be used to 
assess changes in functional capacity in a longitudinal manner as opposed to a one-
off measurement which would be biased by a patient’s baseline functional status. 
 
As patients will all have various functional capacities, so in addition to assessing the 
change in ISWT over time in terms of metre change, the authors also analysed a 
percentage change. The authors assessed all the responsiveness studies to see 
whether there was a threshold of improvement in ISWT that could be used for future 
studies. The best improvement was at least a 30m improvement or 5% improvement 
in ISWT capturing 66% and 73% of patients overall respectively. Only the 
percentage improvement group had a clinically significant improvement in SGRQ of 
4 units or more. The area under the curve showed that the % ISWT was at least 
moderate value in predicting a 4 or more-unit improvement in SGRQ. As the cut-off 
rose, the sensitivity fell and specificity improved. For the MCID, the authors 
proposed that at least 50% should have a 4 or more-unit improvement in SGRQ and 
using a threshold of 5% ISWT improvement this was achieved when treating 
exacerbations of bronchiectasis.  The authors would therefore recommend a MCID 
of 5% change in ISWT to be used as an objective endpoint for assessing response to 
new and existing therapies. 
 
Limitations of this single-centre study was that only patients that could perform the 
ISWT were included in this study and although there was a wide spectrum of 
severity in the included studies, the applicability to very severe bronchiectasis merits 
further study. For this entire study, only 2.3% were unable to perform the ISWT out 
of the combined cohort. Another limitation is choosing an anchor that defines a good 
clinical response. The authors used a 4 unit or more improvement in SGRQ as a 
good surrogate marker, but there are limitations as this is a self-filled questionnaire.  
 
Previous research by Carmargo et al in patients with bronchiectasis has shown the 
ISWT to be reliable [24] and the incremental shuttle walk test has previously been 
used to assess the effect of interventions e.g. chest physiotherapy [25] and 
pulmonary rehabilitation [26, 27] on patients with bronchiectasis but to date it has 
not been validated for use as an objective clinical endpoint in bronchiectasis. 
 
In conclusion, this study has confirmed the ISWT to be reliable, valid and 
responsive to change in patients with bronchiectasis. The authors propose at 
minimum clinically important difference of 5% improvement in ISWT would be a 
useful objective endpoint to assess therapies in bronchiectasis. External validation is 
needed for the proposed 5% improvement in ISWT and should be tested in future 
multi-centred studies. 
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Abstract 
Background: The Bronchiectasis Severity Index is a 9 parameter prognostic tool that 
predicts mortality and hospitalisation. There are other clinical endpoints routinely 
used to assess patients with bronchiectasis. 
Aim: To assess the correlation of other markers of severity in bronchiectasis with 
the bronchiectasis severity index that are not in the original scoring system. 
Design and methods: 207 clinically stable patients were stratified according to the 
bronchiectasis severity index. They all performed a variety of tests including The 
Leicester Cough Questionnaire (LCQ), The St George’s Respiratory Questionnaire, 
sputum colour analysis, incremental shuttle walk test (ISWT), provided sputum for 
quantitative bacteriology and inflammatory marker assays, lung function tests and 
provided whole blood for serum inflammation analysis. 
Results: The Bronchiectasis Severity Index correlated well with cough severity as 
assessed by the LCQ (p=0.01), sputum colour (p=0.02), 24hr sputum volume 
(p=0.0008), ISWT (p<0.0001), bacterial load (p=0.03), sputum neutrophil elastase 
(p=0.0025), sputum myeloperoxidase (p=0.01), White cell count (p=0.0046), 
Neutrophil count (p=0.0015), Erythrocyte sedimentation rate (p=0.0065), C-reactive 
protein (p=0.0045) and all lung function parameters including FVC and FEF25-75 
(p<0.0001). 
Conclusions: Clinical parameters of sputum characteristics, cough severity, ISWT, 
sputum and serum inflammatory markers in regular clinical use that are not 
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incorporated in the BSI score correlate with BSI severity and further work is 
required to see if they are additive or independent in predicting hospitalisation and 
mortality. 
 
Introduction 
Bronchiectasis is a chronic respiratory condition where the airways are dilated and 
distorted. This in turn leads to destruction of the mucociliary escalator and a build-
up of stagnant mucus. Chronic infection prompts a neutrophilic inflammatory 
response in the airways which further propagates the ‘vicious circle’ of infection and 
inflammation. There is a broad spectrum of disease severity, which until recently 
was classed as ‘mild’, ‘moderate’ and ‘severe’ with no real accepted criteria for 
classification. 
There is a real need to risk stratify patients to guide the allocation of finite therapies 
in bronchiectasis and also for predicting prognosis. The Bronchiectasis Severity 
Index (BSI) grades patients with bronchiectasis from a minimum score of 0 (very 
mild) to 26 (very severe).i The scores are classified into tertiles where 0-4 is a low 
score, 5-8 as intermediate and 9 is high score. The BSI incorporates 9 variables; 
age, body mass index (BMI), FEV1 % predicted, hospital admission in the previous 
2 years, number of exacerbations in the last year, MRC dyspnoea score, 
Pseudomonas aeruginosa colonisation, colonisation with other microorganisms and 
radiological severity. The BSI has been externally validated and shown to predict 
mortality, hospital admission, risk of future exacerbations and quality of life.  
 
The presence of some comorbidities (not incorporated in the BSI score) have been 
associated with more severe disease and can contribute to hospitalisation. 
McDonnell and colleagues constructed the Bronchiectasis Aetiology Comorbidity 
Index (BACI) designed to predict the 5-year mortality of comorbidity diagnoses. 
The hazard ratio (95% CI) for death conferred by a one point increase in the BACI 
score was 1.18 (1.14 - 1.23), p<0.0001. When the BACI score was used in 
conjunction with the BSI, the combined model was superior overall in predicting 5-
year mortality with AUC (95% CI) 0.83 (0.79 – 0.87).ii  
 
Furthermore, the importance of the neutrophilic inflammatory response in 
bronchiectasis has been recognised with more treatments targeting this part of the 
vicious cycle.iii,iv,v There has been some evidence that bacterial load correlates with 
inflammatory markers and that bacterial load was directly associated with the risk of 
subsequent exacerbations and the severity of exacerbations.vi 
 
The BSI incorporates 9 clinical parameters in its severity score. Components of the 
BSI were picked based on clinical parameters that are routinely measured in clinical 
practice. Many other factors other than these assess disease severity in 
bronchiectasis. The aim of this study is to evaluate whether BSI correlates with 
endpoints not used in the original scoring system. These include cough severity 
assess by the Leicester Cough Questionnaire,vii sputum colour,viii sputum volume, 
ISWT, quantitative bacteriology, sputum and serum inflammation and lung function 
including mid expiratory flows and forced vital capacity. 
 
Methodology 
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Ethics 
Ethical approval was granted by the West of Scotland Research ethics service, REC 
reference 13/WS/0230. All patients provided informed written consent and were 
recruited from a single centre. 
 
Recruitment and study design 
Patients that were clinically stable (no antibiotic therapy for over 6 weeks for an 
exacerbation prior to selection) were recruited from a dedicated outpatient 
bronchiectasis clinic in a tertiary hospital (Royal infirmary of Edinburgh). Patient 
aged 16years and over with radiologically evident bronchiectasis on High 
Resolution Computer Tomography (HRCT) scan were invited to join and attend a 
consultation where the below tests were performed. Bronchiectasis severity score 
(BSI) was calculated for each individual patient according to previous clinical data 
recorded in routine clinic appointments. All patients underwent the tests below and 
results analysed for each of the three severity groups ‘BSI 0-4 mild’, ‘BSI 5-8 
moderate’ and ‘BSI ³9 severe’.  
 
Incremental shuttle walk test 
The test was performed per standard test procedure.ix 
 
Lung function 
We measured pre-bronchodilator forced expiratory volume in 1 second (FEV1), 
forced vital capacity (FVC), mid expiratory flows and ratio FEV1:FVC by 
spirometry according to standardized guidelines.x 
Sputum 
Sputum colour was graded according to a visual colour chart rating.8 24hour sputum 
volume was recorded by asking patients to expectorate solely into a universal 
container for 24hours. Qualitative and quantitative microbiology was performed on 
all samples.xi 
 
Quality of life 
All patients were asked to complete The Leicester Cough Questionnaire7 and the St 
George’s Respiratory Questionnaire.xii 
 
Sputum inflammatory markers 
Whole sputum samples were centrifuged to produce supernatants on which 
myeloperoxidase (MPO), neutrophil elastase (NE) and interleukin – 8 (IL-8) were 
tested. Myeloperoxidase activity was measured with a chromogenic substrate assay 
and free elastase activity by spectrophotometry with a synthetic substrate 
(methoxysuccinyl-Ala-Ala-Pro-Val paranitroanilide; Sigma, Gillingham, UK) and 
interleukin 8 measured using commercially available specific ELISAs (R&D 
Systems, Oxford, UK).xiii 
 
Blood inflammatory markers 
Venous blood sampling was taken to monitor full blood count, urea and electrolytes, 
Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).  
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Statistical analysis 
All data were analysed using Graphpad prism version 5.0a (Graphpad software, San 
Diego, CA, USA). For demographic and clinical variables, data are presented as 
mean (standard deviation) if data was normally distributed and median (interquartile 
range) if not normally distributed for continuous variables and n (%) for categorical 
variables unless specified otherwise. A P value <0.05 was considered statistically 
significant for each analysis. Comparison of changes between groups was performed 
by Analysis of Variance (ANOVA) statistical test or the Kruskal Wallis test if data 
was not normally distributed.  
 
Results 
207 patients were recruited from a tertiary hospital outpatient clinic. Baseline 
characteristics are displayed below in table 1. Aetiology of bronchiectasis is shown 
in table 2. 
 
Quality of life 
The Leicester Cough Questionnaire (LCQ) assesses quality of life based on the 
impact of cough severity across the domains of physical, psychological and social 
items. The St George’s Respiratory Questionnaire (SGRQ) assesses quality of life 
based on symptoms, activity and psychosocial impact. Both quality of life 
assessments correlated with BSI severity; SGRQ: p<0.0001 and the LCQ: p=0.01 – 
see figure 1. The median (IQR) of LCQ results for each BSI tertile were: 19 (16-20), 
18 (14-20) and 16 (13-19) respectively. The median (IQR) for the SGRQ for each 
group was: 26 (17-37), 29 (16-44) and 44 (30-66) respectively. 
 
Figure 1. 
 
 
Figure 1. Quality of life in clinically stable patients with bronchiectasis in ‘mild, 0-
4’ ‘moderate, 5-8’ and ‘severe, ³9’ BSI groups shown as boxplot with median (IQR) 
and 5-95% CI, A: Incremental shuttle walk test (ISWT), p<0.0001, B: Leicester 
Cough Questionnaire (LCQ), p=0.01, C: St George’s Respiratory Questionnaire 
(SGRQ), p<0.0001. The minimal clinical important difference is 1.3 Units for the 
Leicester Cough Questionnaire and 4 Units for the St George’s Respiratory 
Questionnaire. 
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Sputum characteristics 
There were associations with increasing 24hr sputum volume and with increasing 
sputum purulence with higher BSI scores – see Table 3. 
 
Incremental shuttle walk test 
The distance walked in the incremental shuttle walk test was significantly lower in 
the progressive BSI tertiles of severity. In BSI group 0-4 the mean (SD) ISWT 
distance was 484.2m (183.9), for group 5-8 was 372.4m (180.5) and for those with a 
score of 9 and over had deteriorated to 250.1m (179), p<0.0001 – see Figure 1. 
 
Bacteriology 
There was a significant increase in bacterial load with increasing severity of BSI 
from groups 0-4, 5-8 and ³9 with median (IQR) counts of 0 CFU/ml (0 - 9.3x106), 
0.1x105 CFU/ml (0 – 7.4 x106) and 1.27x107 CFU/ml (0.02 x106 – 1.0 x108) 
respectively, p<0.0001 – see Table 3. 
 
Sputum inflammatory markers 
With increasing BSI score, there were increasing levels of sputum free neutrophil 
elastase (p=0.0025) and sputum myeloperoxidase (p=0.01). There was no 
association with Interleukin-8 (p=0.57), see Table 3.  
 
Serum inflammatory markers 
There was a significant association between increasing BSI severity group and white 
cell count (WCC) (p=0.0046), neutrophil count (p=0.0015), Erythrocyte 
sedimentation rate (p=0.0065) and C-reactive protein (p=0.0045) whilst clinically 
stable - see Table 3. 
 
Lung function tests 
Forced expiratory volume in 1 second (FEV1), percent predicted of FEV1 (% FEV1), 
forced vital capacity (FVC), percent predicted FVC (%FVC), mid expiratory flows 
at 25-75% (FEF25-75) and percent predicted of FEF25-75 (%FEF25-75) was tested in all 
patients. All lung function parameters deteriorated with increasing BSI severity 
group, p<0.0001 – see Table 3. Mean (SD) for each BSI group 0-4, 5-8 and ³9 for 
FEV1: 2.42L (0.81), 1.94L (0.63) and 1.61L (0.64); %FEV1: 87.1% (20.1), 80.2% 
(24.7) and 64.2% (21.9); FVC: 3.4L (0.95), 3.0L (0.79) and 2.7L (0.97); %FVC: 
101.5% (20.6), 99.3% (25.0) and 80.4% (23.8); FEF25-75: 1.7L (1.0), 1.2L (0.7) and 
0.9L (0.6); %FEF25-75: 52.8% (29.1), 41.7% (23.6) and 31.1% (20.6) respectively. 
 
Discussion 
The bronchiectasis severity index score is internationally validated for predict 30-
day mortality rate and hospitalisation. The authors have found that in addition the 
BSI links with sputum purulence, 24hr sputum volume, quantitative bacterial load, 
lung function, functional capacity, quality of life, sputum and serum inflammatory 
markers. 
 
These other endpoints have been shown to be of importance previously but have not 
to date been linked with the bronchiectasis severity index.  
 
 24 
Sputum colour was investigated by Murray and colleagues in stable patients with 
bronchiectasis. They reported good reliability of sputum colour between patients and 
clinician and that it was predictive of bacterial colonisation (p<0.0001). They also 
reported independent factors associated with sputum purulence were bacterial 
colonization, radiological severity with varicose or cystic bronchiectasis, FEV1 less 
than 80% predicted and diagnosis of bronchiectasis aged less than 45yrs old.8 
 
Bacterial load has been evaluated with conflicting evidence in the literature. Tunney 
and colleagues reported that bacterial load did not change with exacerbations 
although the sample size was small (n=14) and they did not measure bacterial load 
during clinical stability and during an exacerbation in the same patients.xiv Chalmers 
and colleagues reported there was a direct relationship between bacterial load and 
the severity of exacerbations and risk of subsequent exacerbations. They linked 
bacterial load with airways inflammation and systemic inflammation when assessing 
both inpatients and outpatient exacerbations. Furthermore, they reported the 
reduction of bacterial load with short and long term antibiotic therapy.6  
 
Lung function in bronchiectasis has not been well characterised in bronchiectasis. A 
study by Guan and colleagues have reported in 142 stable patients that the variables 
associated with a 50% or lower FEV1 were radiological severity (p<0.01), presence 
of Pseudomonas aeruginosa (p<0.01) and the presence of symptoms for 10 or more 
years (p=0.01). They also noted differences in FEV1 and FVC between 
exacerbations and convalescence in a small subgroup (p<0.05).xv Martinez-Garcia 
and colleagues also investigated FEV1 decline in 76 stable patients. They also found 
accelerated decline in lung function to be associated with more severe exacerbations, 
the presence of Pseudomonas aeruginosa in sputum and systemic inflammation.xvi  
 
The ISWT is an objective measurement of functional capacity and has been 
previously shown to remain stable in patients with clinical stability i.e. no change to 
medications and no exacerbation 6 months apart.13 It has also been shown to 
improve with long-term nebulised antibiotics11 and anti-inflammatory treatment.13 
The authors demonstrated that the ISWT mean distances deteriorated significantly 
with increasing severity of BSI. A recent study has validated the ISWT as a clinical 
endpoint in bronchiectasis and found a 5% difference in distance walked to be the 
minimum clinically important difference (MCID). They found the ISWT to correlate 
with severity, deteriorate with exacerbations and improve with treatment.xvii 
 
The Leicester Cough Questionnaire (LCQ) (range 3-21, 3 most severe cough 
severity) and the St George’s Respiratory Questionnaire (SGRQ) (range 0-100, 100 
most severe) have both been validated as clinical endpoints for use in 
bronchiectasis.7, 12 The MCID for the LCQ is 1.3units and for the SGRQ is 4units.  
 
The authors believe that severity of bronchiectasis can be due to the degree of 
sputum inflammation present in the airways which drives the destructive 
neutrophilic inflammatory response in the vicious cycle of bronchiectasis. Previous 
studies have shown the importance of airway inflammation and its correlation with 
higher bacterial loads and subsequent increased risk of exacerbation and with severe 
exacerbations.6 Airway inflammatory markers have also been shown to improve 
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with the use of long term antibiotic use.6,11 They also reported on the increased 
airways inflammation present with patients colonised with Pseudomonas aeruginosa 
and in those with more severe radiological bronchiectasis.6 Elevation of Neutrophil 
elastase, a product of activated neutrophils has been investigated by Chalmers and 
colleagues and was found to be associated with the bronchiectasis severity index 
score (r=0.49, p<0.0001) but was not independently associated with mortality rates. 
The authors found neutrophil elastase to rise in exacerbations and have good 
discrimination for severe exacerbations and all-cause mortality.xviii 
 
Relatively little is known about systemic inflammation in patients with 
bronchiectasis due to the paucity of studies in this area. A study by Wilson and 
colleagues in 87 stable bronchiectasis patients investigated the correlation of 
inflammatory markers with radiological severity, lung function, sputum bacteriology 
and health related quality of life as assessed by the SGRQ. They reported patients 
have raised inflammatory markers when clinically stable and that inflammatory 
markers correlate with disease severity; WCC, neutrophil count, ESR and CRP all 
correlated with radiological severity, WCC and CRP correlated with total SGRQ 
scores.xix 
 
Significance 
There have been no prior studies linking the BSI with sputum purulence despite its 
importance in recognising severity. This is the first study to show increasing sputum 
purulence links with increasing severity of BSI. The role of quantitative bacteriology 
has been debated in the literature but this study supports the notion that increasing 
bacterial load is associated with increased severity of bronchiectasis. The most 
commonly research lung function parameter is FEV1 and variables associated with 
its decline have been investigated. The BSI already incorporates percent predicted 
FEV1 as part of its severity scoring system but as this can be affected by other 
respiratory conditions that patients with bronchiectasis might have such as asthma 
and COPD, the authors thought it would be prudent to examine other measures of 
lung function. This is the first study to find all parameters of actual and predicted 
FEV1, FVC and FEF25-75 correlated with worsening severity of bronchiectasis as 
assessed by the BSI. Functional capacity in bronchiectasis has not been well studied 
in bronchiectasis and has only recently been validated in this respiratory condition. 
This study has shown that the ISWT links with BSI severity in stable patients. The 
LCQ and SGRQ are validated clinical endpoints in bronchiectasis. This is the first 
study to show these measurements of quality of life link with BSI severity scoring. 
Lastly, the BSI is a very clinical tool and does not incorporate any laboratory 
endpoints that assess inflammation. This study demonstrates that markers of sputum 
inflammation –MPO and neutrophil elastase and markers of serum inflammation –
WCC, Neutrophil count, ESR and CRP all increase with worsening severity of 
bronchiectasis as assessed by the BSI. 
 
Limitations  
Due to the small number of patients in this study, the authors could not explore the 
added value of these endpoints to BSI to predict 30-day mortality and 
hospitalisation.  
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Conclusion 
The bronchiectasis severity index stratifies patients into tertiles and has been shown 
to predict 30day mortality and hospitalization. The authors have shown the BSI 
scoring of severity to also link with other endpoints of increasing sputum purulence, 
24hr sputum volume, bacterial load, functional capacity as assessed by the ISWT, 
quality of life, lung function parameters of FVC and mid expiratory flows in 
addition to FEV1, sputum and serum inflammatory markers. Further work is needed 
to assess whether these clinical endpoints could be additive or independent to the 
BSI in predicted mortality and hospitalisation. 
 
Funding 
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Table 1. 
Characteristic Total patients 
Number 207 
Mean  (SD) Age (yrs) 65.79 (10.6) 
Female n (%) 110 (53) 
Current smokers 
Ex-smokers 
Never 
9 (4) 
83 (40) 
115 (56) 
Mean (SD) 29.09 (35.54) 
COPD 
Asthma 
Interstitial lung disease 
Lung cancer 
Pulmonary Hypertension 
Inactive ABPA 
35 (17) 
23 (11) 
3 (1) 
2 (1) 
1 (1) 
21 (10) 
IHD 14 (7) 
Other cancers 22 (11) 
Inhaled steroid 
Dose (mean, SD) 
Oral steroid 
Dose (mean, SD) 
Nebulised bronchodilators   
Long-term antibiotics 
Cyclical IV antibiotics 
LTOT 
23 (11) 
211mcg (104.4) 
12 (6) 
7.7mg (5.3) 
7 (3) 
11 (5) 
1 (0.5) 
2 (1) 
Table 1 shows the baseline characteristics of the 207 stable patients recruited. N (%) 
or as otherwise stated. BMI: body mass index, COPD: chronic obstructive 
pulmonary disease, ABPA: allergic bronchopulmonary aspergillosis, IHD: 
ischaemic heart disease, IV: intravenous and LTOT: long term oxygen therapy. 
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Table 2. 
Aetiology Number of patients (%) 
Idiopathic 92 (44.4) 
Post infectious 55 (26.6) 
COPD 9 (4.3) 
Inflammatory bowel disease 7 (3.4) 
Immunoglobulin deficiency 9 (4.3) 
Allergic bronchopulmonary aspergillosis  13 (6.3) 
Connective tissue disease 7 (3.4) 
Aspiration or inhalation or GORD 15 (7.2) 
Table to show the N (%) of patients with different aetiologies of bronchiectasis. 
COPD: chronic obstructive pulmonary disease, GORD: gastric oesophageal reflux 
disease 
 
Table 3. 
Clinical parameter BSI 0-4 BSI 5-8 BSI³9 P value 
Sputum colour 
(units) 
1.8 (0.8) 2.1 (0.8) 2.3 (0.8) 0.0008 
Sputum volume 
(mls) median (IQR) 
2 (0-10) 4 (0-10) 8 (1-15) 0.02 
Bacterial 
load(cfu/ml) median 
(IQR) 
0 (0 - 
9.3x106) 
0.1x105 (0 - 
7.4x106) 
1.27x107 (0.02 
x106 - 1.0 
x108) 
0.03 
FEV1 (L) 2.42 (0.81) 1.94 (0.63) 1.61 (0.64) <0.0001 
FEV1 % predicted 87.1 (20.1) 80.2 (24.7) 64.2 (21.9) <0.0001 
FVC (L) 3.4 (0.95) 3.0 (0.79) 2.7 (0.97) <0.0001 
FVC % predicted 101.5 (20.6) 99.3 (25.0) 80.4 (23.8) <0.0001 
FEF25-75 (L) 1.7 (1.0) 1.2 (0.7) 0.9 (0.6) <0.0001 
FEF25-75 % 
predicted 
52.8 (29.1) 41.7 (23.6) 31.1 (20.6) <0.0001 
Sputum NE (ng/ml) 
median (IQR) 
2569 (1408-
6191) 
2600 (1915-
3404) 
3238 (2013-
11552) 
0.0025 
Sputum 
MPO(ng/ml) 
median (IQR) 
1719 (859-
4718) 
1125 (399-
3096) 
 
2521 (1159-
9544) 
0.01 
Sputum IL-8 
(ng/ml) median 
(IQR) 
14976 
(3815-
26466) 
13257 (6324-
30975) 
11848 (5935 - 
31455) 
0.57 
WCC x109/L 
median (IQR) 
6.3 (5.3-7.9) 6.9 (5.5-8.7) 8.0 (6-10.4) 0.005 
Neutrophils x109/L 
median (IQR) 
3.5 (2.6-4.8) 4.0 (3.2-6.2) 5.2 (3.5-7.5) 0.002 
ESR (mm/hr) 
median (IQR) 
11 (6-17) 12 (7-18) 17 (8-28.8) 0.0065 
CRP (mg/L) 
median (IQR) 
3 (1-7) 3 (1-8.6) 7 (2.5-22.5) 0.0045 
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Comparison of changes between groups was performed by Analysis of Variance 
(ANOVA) statistical test or the Kruskal Wallis test if data was not normally 
distributed. Data presented as mean (standard deviation) unless otherwise specified. 
CFU/ml: colony forming units/millilitre, NE: neutrophil elastase, MPO: 
myeloperoxidase, IL-8: interleukin-8, WCC: white cell count, ESR: erythrocyte 
sedimentation rate, CRP: C-reactive protein. 
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